var images_info;if (!images_info) images_info =[]; images_info["94"]={"94099":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of normal kidney","title":"Ultrasound of a normal kidney","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Ultrasound of a normal kidney</div><div class=\"cntnt\"><img style=\"width:463px; height:335px;\" src=\"images/NEPH/94099_Ultrasound_of_normal_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal kidney with a hypoechoic parenchyma (P) surrounding the echogenic renal sinus. There should be few if any fluid-filled structures with the renal sinus.</div><div class=\"graphic_footnotes\">S: renal sinus.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 94099 Version 3.0</div></div></div>"},"94100":{"type":"graphic_diagnosticimage","displayName":"Ultrasound showing a kidney with hydronephrosis","title":"Ultrasound of a kidney with hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of a kidney with hydronephrosis</div><div class=\"cntnt\"><img style=\"width:406px; height:311px;\" src=\"images/NEPH/94100_US_kidney_hydronephrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of a kidney with hydronephrosis. Dilated calyces (C) appear as fluid-filled structures within the renal sinus.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 94100 Version 1.0</div></div></div>"},"94101":{"type":"graphic_diagnosticimage","displayName":"Ultrasound showing hydronephrosis and dilated ureter","title":"Ultrasound of a kidney with hydronephrosis and a dilated proximal ureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of a kidney with hydronephrosis and a dilated proximal ureter</div><div class=\"cntnt\"><img style=\"width:405px; height:310px;\" src=\"images/NEPH/94101_US_hydroneph_dilated_ureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of a kidney with hydronephrosis and a dilated proximal ureter (arrow).</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 94101 Version 1.0</div></div></div>"},"94105":{"type":"graphic_diagnosticimage","displayName":"CT emphysematous pyelitis","title":"Emphysematous pyelitis on CT","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Emphysematous pyelitis on CT</div><div class=\"cntnt\"><img style=\"width:600px; height:215px;\" src=\"images/RADIOL/94105_CT_emphysema_pyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT through the kidneys (A) shows air within the calyces of the right kidney (arrows). E. Coli was isolated from the urine. Image B shows air in the right renal pelvis (arrow) associated with an air fluid level (arrowhead). The patient had a rectovesical fistula.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 94105 Version 2.0</div></div></div>"},"94106":{"type":"graphic_diagnosticimage","displayName":"CT emphysematous cystitis","title":"Emphysematous cystitis on CT","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Emphysematous cystitis on CT</div><div class=\"cntnt\"><img style=\"width:588px; height:309px;\" src=\"images/RADIOL/94106_CT_emphysemat_cystitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the bladder shows air in the wall of the bladder (arrows), air within the bladder (dashed arrow) and&nbsp;an air fluid level in a Foley catheter (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 94106 Version 2.0</div></div></div>"},"94107":{"type":"graphic_diagnosticimage","displayName":"CT colovesical fistula diverticulitis","title":"Diverticulitis complicated by colovesical fistula on CT","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Diverticulitis complicated by colovesical fistula on CT</div><div class=\"cntnt\"><img style=\"width:588px; height:352px;\" src=\"images/RADIOL/94107_CT_coloves_fist_divert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the bladder shows air within the urinary bladder (dashed arrow) with a fistulous tract (arrowhead) extending from the sigmoid colon (arrow) to the bladder. The patient has diverticulitis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 94107 Version 2.0</div></div></div>"},"94108":{"type":"graphic_picture","displayName":"Crown root fracture","title":"Crown root dental fracture","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Crown root dental fracture</div><div class=\"cntnt\"><img style=\"width:560px; height:518px;\" src=\"images/EM/94108_Crown_root_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The central incisor appears extruded (arrow).<br />(B) Radiograph demonstrates a crown root fracture instead of extrusion (distal horizontal crown fracture line [arrow] and curved apical root fracture line [arrowheads]).<br />(C) Preoperative photograph of the crown root fragment with attached periodontal ligaments (arrows). The pulp canal is also visible (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Dennis McTigue, DDS.</div><div id=\"graphicVersion\">Graphic 94108 Version 1.0</div></div></div>"},"94117":{"type":"graphic_algorithm","displayName":"Algorithm for HD phenocopy cases","title":"Algorithm for the investigation of Huntington disease phenocopy cases","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Algorithm for the investigation of Huntington disease phenocopy cases</div><div class=\"cntnt\"><img style=\"width:674px; height:324px;\" src=\"images/NEURO/94117_AlgorithmHDphenocopycase.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed clinico-genetic algorithm for the workup of Huntington disease (HD) phenocopy patients, highlighting key diagnoses to be considered.</div><div class=\"graphic_footnotes\">DRPLA, dentatorubral-pallidoluysian atrophy; HDL2, Huntington disease-like 2; NBIA, neurodegeneration with brain iron accumulation; SCA, spinocerebellar ataxia.</div><div class=\"graphic_reference\">From: Hensman Moss DJ, Poulter M, Beck J, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 2014; 82:292. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/82/4/292\" target=_blank>10.1212/WNL.0000000000000061</A>. Copyright © 2014 American Academy of Neurology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94117 Version 4.0</div></div></div>"},"94118":{"type":"graphic_table","displayName":"T preparations","title":"Testosterone replacement therapy preparations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Testosterone replacement therapy preparations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Testosterone formulation type</td> <td class=\"subtitle1\">Preparation<br /> (trade name in United States)</td> <td class=\"subtitle1\">Dosage units supplied</td> <td class=\"subtitle1\">Typical dose range</td> <td class=\"subtitle1\">Application site</td> <td class=\"subtitle1\">Disadvantages and toxicity</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Long-acting injections<br /> (intramuscular)</td> <td>Testosterone enanthate<br /> (Delatestryl)</td> <td>200 mg/mL</td> <td>100 to 200 mg every two weeks to 50 to 100 mg weekly</td> <td class=\"divider_bottom\" rowspan=\"3\">Thighs for self injection, buttocks when administered by another person</td> <td class=\"divider_bottom\" rowspan=\"3\">Fluctuating serum testosterone levels, 21-gauge needles needed for long-acting esters</td> </tr> <tr> <td>Testosterone cypionate<br /> (Depo-Testosterone)</td> <td> <p>100 mg/mL</p> 200 mg/mL</td> <td>100 to 200 mg every two weeks to 50 to 100 mg weekly</td> </tr> <tr class=\"divider_bottom\"> <td>Mixture of testosterone esters of propionate, phenylpropionate, isocaproate, and decanoate (Sustanon) not available in United States</td> <td>250 mg/mL</td> <td>250 mg every three weeks, or 100 to 200 mg every two weeks, or 50 to 100 mg weekly</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Extra-long-acting injections<br /> (intramuscular)</td> <td>Testosterone undecanoate (Nebido), not available in United States</td> <td>1000 mg/4 mL</td> <td>1000 mg initially, followed by 1000 mg at six weeks, followed by 1000 mg every 10 to 14 weeks</td> <td>Gluteal medius only</td> <td class=\"divider_bottom\" rowspan=\"2\">Injection-associated pulmonary oil microembolism (POME), restricted access in United States*, trochar needed for extra-long acting esters</td> </tr> <tr class=\"divider_bottom\"> <td>Testosterone undecanoate (Aveed), United States approved preparation</td> <td>250 mg/mL</td> <td>750 mg initially, followed by 750 mg after four weeks, followed by 750 mg every 10 weeks</td> <td>Gluteal medius only</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Transdermal patches</td> <td>Testosterone transdermal 24-hour patch<br /> (Androderm)</td> <td> <p>2 mg/24-hour patch</p> 4 mg/24-hour patch</td> <td>2 to 6 mg/day</td> <td>Dry intact skin of back, abdomen, upper thighs, or arm</td> <td class=\"divider_bottom\" rowspan=\"2\">Skin rash, poor adherence</td> </tr> <tr class=\"divider_bottom\"> <td>Testosterone transdermal 24-hour patch (Andropatch), not available in United States</td> <td> <p>2.5 mg/24-hour patch</p> 5 mg/24-hour patch</td> <td>2.5 to 5 mg/day</td> <td>Dry intact skin of upper arms, back, stomach, or thighs</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Transdermal gels/pumps/solutions</td> <td>Testogel 1% gel</td> <td>50 mg in 5 gram packet</td> <td rowspan=\"3\">50 to 100 mg/day</td> <td rowspan=\"4\">Dry intact skin of back, abdomen, upper thighs, or arm</td> <td class=\"divider_bottom\" rowspan=\"7\">Normal serum testosterone levels not achieved in all hypogonadal males, potential for skin transfer</td> </tr> <tr> <td>Testim 1% gel</td> <td>50 mg in 5 gram packet</td> </tr> <tr> <td>AndroGel 1% gel</td> <td> <p>25 mg in 2.5 gram packet</p> 50 mg in 5 gram packet</td> </tr> <tr> <td>AndroGel 1.62% gel</td> <td> <p>20.25 mg in 1.25 gram packet</p> <p>40.5 mg in 2.5 gram packet</p> Metered dose pump (20.25 mg per actuation)</td> <td>20.25 to 81 mg/day</td> </tr> <tr> <td>Fortesta 2% gel</td> <td>Metered dose pump (10 mg per actuation)</td> <td>10 to 70 mg/day</td> <td>Dry intact skin of front and inner thighs</td> </tr> <tr> <td>Axiron 2% solution</td> <td>Metered dose pump (30 mg per actuation)</td> <td>30 to 120 mg/day</td> <td>Apply using applicator to dry intact skin of axilla</td> </tr> <tr class=\"divider_bottom\"> <td>Tostran 2% gel, not available in United States</td> <td>Metered dose pump (10 mg per actuation)</td> <td>60 to 80 mg/day</td> <td>Dry intact skin of abdomen and inner thighs</td> </tr> <tr class=\"divider_bottom\"> <td>Oral testosterone</td> <td>Testosterone undecanoate (Andriol, Restandol), not available in United States</td> <td>40 mg capsules</td> <td>40 to 80 mg twice a day after breakfast and dinner</td> <td>Oral medication</td> <td>Gastrointestinal side effects</td> </tr> <tr class=\"divider_bottom\"> <td>Testosterone subcutaneous implants<br /> (pellets)</td> <td>Testosterone implant pellets<br /> (Testopel)</td> <td>75 mg pellets</td> <td>150 to 450 mg every three to six months</td> <td>Subcutaneous implant under clean skin in the hips</td> <td>Incision required for insertion, pellet extrusion, infection, fibrosis, no information available on optimal dosing</td> </tr> <tr> <td>Buccal testosterone</td> <td>Buccal testosterone system<br /> (Striant)</td> <td>30 mg per buccal system</td> <td>30 mg twice daily</td> <td>Buccal application</td> <td>Poor adherence, gum irritation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Subject to US Food and Drug Administration (FDA)-required REMS (Risk Evaluation and Mitigation Strategy) program, which includes restricted distribution scheme and certification of healthcare providers and facilities.</div><div class=\"graphic_reference\">Courtesy of Ravi Balasubramanian, MD and Peter Snyder, MD.</div><div id=\"graphicVersion\">Graphic 94118 Version 3.0</div></div></div>"},"94120":{"type":"graphic_picture","displayName":"Escharotomy performed for chest wall burn","title":"Escharotomy performed for chest wall burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Escharotomy performed for chest wall burn</div><div class=\"cntnt\"><img style=\"width:269px; height:287px;\" src=\"images/SURG/94120_Escharotomy_chest_wall_burn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image depicts the&nbsp;depth of an escharatomy performed along&nbsp;the chest wall and abdomen. The subcutaneous tissue&nbsp;became visible as the incisions widened secondary to edema.</div><div id=\"graphicVersion\">Graphic 94120 Version 2.0</div></div></div>"},"94121":{"type":"graphic_diagnosticimage","displayName":"Apical root fracture","title":"Apical root dental fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical root dental fracture</div><div class=\"cntnt\"><img style=\"width:173px; height:446px;\" src=\"images/EM/94121_Apical_root_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph demonstrates an apical root fracture (arrows). These fractures typically do not require specific treatment.</div><div class=\"graphic_reference\">Courtesy of Dennis McTigue, DDS.</div><div id=\"graphicVersion\">Graphic 94121 Version 1.0</div></div></div>"},"94122":{"type":"graphic_diagnosticimage","displayName":"Cervical root fracture","title":"Cervical root dental fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical root dental fracture</div><div class=\"cntnt\"><img style=\"width:190px; height:430px;\" src=\"images/EM/94122_Cervical_root_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph shows a cervical root fracture in a permanent tooth&nbsp;(arrows). This injury requires splinting of the crown of the tooth to prevent mobility and permit healing. However, if the crown remains mobile after splinting, then crown removal followed by extrusion, root canal, and restoration is usually necessary.</div><div class=\"graphic_reference\">Courtesy of Dennis McTigue, DDS.</div><div id=\"graphicVersion\">Graphic 94122 Version 1.0</div></div></div>"},"94132":{"type":"graphic_table","displayName":"Inventory of complicated grief","title":"Inventory of complicated grief","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inventory of complicated grief</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"highlight_gray_text\"> <td class=\"centered\" colspan=\"5\"><strong>TO BE COMPLETED BY OFFICE PERSONNEL</strong></td> </tr> <tr class=\"highlight_gray_text\"> <td colspan=\"5\"><strong>Subject name:</strong></td> </tr> <tr class=\"highlight_gray_text\"> <td colspan=\"3\"><strong>ID number:</strong></td> <td colspan=\"2\"><strong>Today's date:<br /> (year/month/day)</strong></td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"sublist1\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">PLEASE check the box next to the answer which best describes how you feel right now:</td> </tr> <tr> <td colspan=\"5\">1. I think about this person so much that it's hard for me to do the things I normally do...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">2. Memories of the person who died upset me...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">3. I feel I cannot accept the death of the person who died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">4. I feel myself longing for the person who died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">5. I feel drawn to places and things associated with the person who died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">6. I can't help feeling angry about his/her death...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">7. I feel disbelief over what happened...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">8. I feel stunned or dazed over what happened...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">9. Ever since s/he died it is hard for me to trust people...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">10. Ever since s/he died I feel like I have lost the ability to care about other people or I feel distant from people I care about..</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">11. I have pain in the same area of my body or have some of the same symptoms as the person who died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">12. I go out of my way to avoid reminders of the person who died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">13. I feel that life is empty without the person who died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">14. I hear the voice of the person who died speak to me...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">15. I see the person who died stand before me...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">16. I feel that it is unfair that I should live when this person died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">17. I feel bitter over this person's death...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">18. I feel envious of others who have not lost someone close...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> <tr> <td colspan=\"5\">19. I feel lonely a great deal of the time ever since s/he died...</td> </tr> <tr> <td class=\"indent2\"><span class=\"primarybox_left\">&nbsp;</span> Never</td> <td><span class=\"primarybox_left\">&nbsp;</span> Rarely</td> <td><span class=\"primarybox_left\">&nbsp;</span> Sometimes</td> <td><span class=\"primarybox_left\">&nbsp;</span> Often</td> <td><span class=\"primarybox_left\">&nbsp;</span> Always</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Never = 0; Rarely = 1; Sometimes = 2; Often = 3; Always = 4.<br />A score greater than 25 indicates probably complicated grief.<br />A score greater than 30 indicates definite complicated grief.</div><div class=\"graphic_reference\">Reproduced from: Prigerson HG, Maciejewski PK, Reynolds CF 3rd, et al. Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res 1995; 59:65. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94132 Version 2.0</div></div></div>"},"94138":{"type":"graphic_table","displayName":"Pouchitis Disease Activity Index","title":"Pouchitis Disease Activity Index (PDAI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pouchitis Disease Activity Index&nbsp;(PDAI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical criteria</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Stool frequency</td> </tr> <tr> <td class=\"indent2\">Usual post-op stool frequency</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent2\">One to two stools/day &#62; post-op usual</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent2\">Three or more stools/day &#62; post-op usual</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Rectal bleeding</td> </tr> <tr> <td class=\"indent2\">None or rare</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent2\">Present daily</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Fecal urgency/abdominal cramps</td> </tr> <tr> <td class=\"indent2\">None</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent2\">Occasional</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent2\">Usual</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Fever (temperature &#62;100&#176;F)</td> </tr> <tr> <td class=\"indent2\">Absent</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Present</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Endoscopic criteria</td> </tr> <tr> <td class=\"indent1\">Edema</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Granularity</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Friability</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Loss of vascular pattern</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Mucus exudate</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ulceration</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acute histologic criteria</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Polymorph infiltration</td> </tr> <tr> <td class=\"indent2\">Mild</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent2\">Moderate + crypt abscess</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent2\">Severe + crypt abscess</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ulceration per low-power field (average)</td> </tr> <tr> <td class=\"indent2\">&#60;25 percent</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent2\">&#8805;25 to &#8804;50 percent</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent2\">&#62;50 percent</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pouchitis is defined as a total PDAI score &ge;7 points. Remission is defined as a PDAI score &lt;3 points. Improvement is defined as a decrease in the PDAI score of at least 3 points with a total PDAI score &ge;3 points.</div><div class=\"graphic_reference\">From: Pardi DS, D'Haens G, Shen B, et al. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009; 15:1424. DOI: <a href=\"http://journals.lww.com/ibdjournal/pages/articleviewer.aspx?year=2009&amp;issue=09000&amp;article=00026&amp;type=abstract\" target=\"_blank\">10.1002/ibd.21039</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2009 Crohn's &amp; Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94138 Version 3.0</div></div></div>"},"94139":{"type":"graphic_table","displayName":"HbF health and untreated disease","title":"Fetal hemoglobin (HbF) in health and untreated disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal hemoglobin (HbF) in health and untreated disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder/condition</td> <td class=\"subtitle1\">Typical range of HbF<br /> (percent)</td> </tr> <tr> <td>Normal (HbA only)</td> <td>&#60;1</td> </tr> <tr> <td>Sickle cell trait (HbAS)</td> <td>&#60;1 to 2</td> </tr> <tr> <td>Sickle cell anemia (HbSS)</td> <td>1 to 25</td> </tr> <tr> <td>HbSC disease</td> <td>1 to 10</td> </tr> <tr> <td>HbS-beta<sup>0</sup> thalassemia</td> <td>1 to 25</td> </tr> <tr> <td>HbS-beta<sup>+</sup> thalassemia</td> <td>1 to 20</td> </tr> <tr> <td>HbS-delta-beta thalassemia</td> <td>15 to 25</td> </tr> <tr> <td>HbS-gene deletion HPFH</td> <td>30 (age &#62;5 years) or more</td> </tr> <tr> <td>Heterozygous gene deletion HPFH</td> <td>17 to 36</td> </tr> <tr> <td>Non-gene deletion HPFH</td> <td>5 to 35</td> </tr> <tr> <td>Beta-thalassemia trait</td> <td>1 to 10 (mean approximately 1.2)</td> </tr> <tr> <td>Homozygous beta thalassemia</td> <td>10 to 95</td> </tr> <tr> <td>Delta-beta thalassemia trait</td> <td>7 to 10</td> </tr> <tr> <td>HbE-beta<sup>0</sup> thalassemia</td> <td>20 to 70</td> </tr> <tr> <td>HbE-beta<sup>+</sup> thalassemia</td> <td>8 to 60</td> </tr> <tr> <td>HbH disease</td> <td>&#60;1</td> </tr> <tr> <td>Juvenile chronic myeloid leukemia</td> <td>Up to 70</td> </tr> <tr> <td>Erythroleukemia</td> <td>Up to 60</td> </tr> <tr> <td>Hydatidiform mole</td> <td>Sometimes up to 6</td> </tr> <tr> <td>Fanconi anemia</td> <td>2 to 85</td> </tr> <tr> <td>Paroxysmal nocturnal hemoglobinuria</td> <td>5 to 10</td> </tr> <tr> <td>Miscellaneous disorders of bone marrow and some cancers</td> <td>1 to 10</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HbF was measured by different methods including alkali denaturation and high performance liquid chromatography (HPLC). Typical HbF ranges for patients of different ethnicities, ages, and beta thalassemia mutations are provided; for rare mutations, few cases might have been studied. Many of the ranges of values reported were taken from the references.<sup>[1-3]</sup></div><div class=\"graphic_footnotes\">HbF: hemoglobin F; HPFH: hereditary persistence of fetal hemoglobin.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd ed, Blackwell, London 1981.</li>&#xD;&#xA;    <li>Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 4th ed, Blackwell, London 2001.</li>&#xD;&#xA;    <li>Bunn HF, Forget BF. Hemoglobin: Molecular, Genetic and Clinical Aspects, Saunders, Philadelphia 1986.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 94139 Version 1.0</div></div></div>"},"94140":{"type":"graphic_table","displayName":"Acquired disorders increased HbF","title":"Acquired disorders/conditions associated with increased fetal hemoglobin (HbF) levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acquired disorders/conditions associated with increased fetal hemoglobin (HbF) levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Developmental</td> </tr> <tr> <td class=\"indent1\">Trisomy 13</td> </tr> <tr> <td class=\"indent1\">Infants of diabetic mothers</td> </tr> <tr> <td class=\"subtitle1_single\">Bone marrow regeneration</td> </tr> <tr> <td class=\"indent1\">Acute blood loss</td> </tr> <tr> <td class=\"indent1\">Transient erythroblastopenia of childhood</td> </tr> <tr> <td class=\"indent1\">Bone marrow transplantation</td> </tr> <tr> <td class=\"indent1\">Chemotherapy</td> </tr> <tr> <td class=\"indent1\">Following iron treatment in severe iron deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Bone marrow failure syndromes</td> </tr> <tr> <td class=\"indent1\">Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Leukemia</td> </tr> <tr> <td class=\"indent1\">Juvenile myelomonocytic leukemia (JMML)</td> </tr> <tr> <td class=\"indent1\">Erythroleukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Choriocarcinoma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 94140 Version 2.0</div></div></div>"},"94158":{"type":"graphic_picture","displayName":"Becker's nevus 2","title":"Becker's nevus (Becker's melanosis)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Becker's nevus (Becker's melanosis)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94158_Beckers_nevus_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Becker's nevus presenting as a large, slightly hyperpigmented patch on the left shoulder of a boy. Note the hyperpigmented \"islands\" at the periphery of the lesion.</div><div id=\"graphicVersion\">Graphic 94158 Version 2.0</div></div></div>"},"94173":{"type":"graphic_picture","displayName":"Dyschromatosis symmetrica hereditaria","title":"Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi)","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi)</div><div class=\"cntnt\"><img style=\"width:732px; height:527px;\" src=\"images/DERM/94173_Dyschromatossymmtrchrdtr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented and hypopigmented macules over the dorsum of the hands in a 10-year-old boy with dyschromatosis symmetrica hereditaria.</div><div class=\"graphic_reference\">From: Mohana D, Verma U, Amar AJ, Choudhary RK. Reticulate acropigmentation of dohi: A case report with insight into genodermatoses with mottled pigmentation. Indian J Dermatol 2012; 57:42. DOI: <a href=\"http://www.e-ijd.org/article.asp?issn=0019-5154;year=2012;volume=57;issue=1;spage=42;epage=44;aulast=Mohana\" spellcheck=\"true\" target=\"_blank\">10.4103/0019-5154.92676</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Asian Academy of Dermatology and Venereology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94173 Version 3.0</div></div></div>"},"94174":{"type":"graphic_figure","displayName":"Time spent in diastole","title":"Total time spent in diastole","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Total time spent in diastole</div><div class=\"cntnt\"><img style=\"width:462px; height:362px;\" src=\"images/ANEST/94174_Timespentindiastole.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Total time spent in diastole each minute plotted as a function of heart rate in beats per minute. The reduction in diastolic interval leads to diminished left ventricular blood flow as heart rate increases.</div><div class=\"graphic_reference\">Reproduced with permission from: Green MS, Okum GS, Horrow JC. Anesthetic Management of Myocardial Revascularization In: A Practical Approach to Cardiac Anesthesia, 5th ed, Hensley FA, Martin DE, Gravlee GP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 94174 Version 8.0</div></div></div>"},"94175":{"type":"graphic_figure","displayName":"Hematopoietic stem cell niches","title":"Hematopoietic stem cell niches","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Hematopoietic stem cell niches</div><div class=\"cntnt\"><img style=\"width:467px; height:625px;\" src=\"images/HEME/94175_Hematopoietic_stem_cell_niches.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graphic depicts endosteal and perivascular niches for hematopoietic stem cells (HSCs); it is not known whether HSCs migrate between these niches. The niches regulate HSC quiescence, self-renewal, mobilization, and differentiation. Cell-cell contact, secreted cytokines, and extracellular matrix (ECM) factors all play roles. Some of the secreted factors are shown. ECM factors include fibronectin, hyaluronic acid, collagen, laminin, glycosaminoglycans, heparan sulfate, and chondroitin sulfate.</div><div class=\"graphic_footnotes\">CAR: CXCL12-abundant reticular cell.</div><div class=\"graphic_reference\">Based on a figure created by Colin A Sieff, MB, BCh, FRCPath.</div><div id=\"graphicVersion\">Graphic 94175 Version 2.0</div></div></div>"},"94176":{"type":"graphic_table","displayName":"Causes of short stature","title":"Major causes of short stature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of short stature</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Distinguishing features</td> <td class=\"subtitle1\">Typical evaluation</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Bone age</td> <td class=\"subtitle1\">Height velocity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Normal variants of growth</td> </tr> <tr> <td class=\"indent1\">Familal short stature*<br /> </td> <td>Short parent(s), often below the 10th percentile. Adult height short for population, but&nbsp;within the&nbsp;range predicted by parents' height.</td> <td>Hx, PE, bone age</td> <td>None needed. Reassurance; monitor growth.</td> <td>Normal</td> <td> <p>Low-normal </p> <p>eg, from age 6 until puberty:</p> <ul> <li>Girls about 4 to 5 cm/year </li> <li>Boys about 3.5 to 4.5 cm/year </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Constitutional delay of growth and puberty*<br /> </td> <td>Normal height for bone age but not for chronological age. Often family history of delayed growth and/or puberty. Adult height usually normal.</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>Be alert for the possibility of underlying systemic disease </li> <li>Lab screening if height velocity is slow </li> </ul> </td> <td>None needed. Reassurance; monitor growth; +/&ndash; treatment with sex steroids during puberty.</td> <td>Delayed</td> <td>Slow during first three to five years of life; normal during childhood. Pubertal growth spurt is delayed but prolonged, often resulting in normal adult height.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Small for gestational age infant, with catch-up growth<br /> </td> <td>Most SGA infants catch up by two years of age; the remainder have slower or absent catch-up growth that can be considered pathologic</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>For prematurely born infants, adjust height for gestational age (up to&nbsp;1 year of chronological age) </li> </ul> </td> <td>Monitor growth to distinguish from the 10 percent of SGA infants who do not have catch-up growth</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Pathologic causes of growth failure</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Systemic disorders or processes with secondary effects on growth </td> </tr> <tr> <td class=\"indent2\">Undernutrition</td> <td>Low weight-for-height</td> <td>Hx (including dietary and social hx), PE, bone age</td> <td>Reverse nutritional deficit</td> <td>Delayed or normal</td> <td>Slow (eg, &#60;4 cm/year)</td> </tr> <tr> <td class=\"indent2\">Glucocorticoid therapy</td> <td>Growth effects are dose-related, greatest with systemic dosing. Mild effects&nbsp;may occur with long-term use of&nbsp;inhaled glucocorticoids</td> <td>Hx, PE<br /> <ul class=\"decimal_heading\"> <li>Assess contribution of underlying disease to growth deficit </li> </ul> </td> <td>Minimize glucocorticoid dose or give on alternate days if feasible; consider alternate drugs</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Gastrointestinal disease (especially Crohn's disease and celiac disease)</td> <td>GI symptoms (diarrhea, abdominal pain). Crohn's disease may have oral ulcers and anal fissures/skin tags.</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>Screening lab tests including CBC, ESR or CRP, celiac serologies </li> </ul> </td> <td>Diagnose and treat underlying disease, improve nutrition, avoid glucocorticoids</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Rheumatologic disease (especially systemic onset juvenile idiopathic arthritis [JIA])</td> <td>Fever, arthralgias, rash, lymphadenopathy</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>Screening lab tests including CBC and ESR or CRP, ANA, RF </li> </ul> </td> <td>Diagnose and treat underlying disease, improve nutrition, avoid glucocorticoids</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\"> <p>Renal disease <br /> (chronic kidney disease, renal tubular acidosis)</p> </td> <td>Growth impairment may precede the diagnosis of CKD. Other symptoms of CKD may include polyuria, edema, elevated creatinine, tea-colored urine, hypertension.</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>Screening lab tests including BUN, creatinine, and urine analysis </li> </ul> </td> <td>Diagnose and treat underlying disease, maximize nutrition; GH if needed</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Cancer</td> <td> <ul> <li>Any cancer: multiple mechanisms for growth failure, including decreased intake, increased energy needs </li> <li>Brain cancer: direct effects on hypothalamic-pituitary&nbsp;function </li> <li>Cancer treated with CNS radiotherapy or chemotherapy: may have direct effects on GH production, with late effects on growth </li> </ul> </td> <td>Hx, PE, bone age<br /> <p>&nbsp;</p> <p>For children with history of cancer, or with CNS symptoms or hypothalamic-pituitary disease: screening lab tests to assess&nbsp;pituitary&nbsp;function (free T4, IGF-I, IGFBP-3), +/&ndash; head MRI with contrast.&nbsp;</p> </td> <td>Ensure adequate nutrition; treat any secondary pituitary hormone deficiencies (eg, GH deficiency)</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Pulmonary disease (eg, cystic fibrosis, immune deficiencies with recurrent pulmonary infections, or severe asthma)</td> <td>Respiratory symptoms, recurrent infections<br /> <ul class=\"decimal_heading\"> <li>In CF: steatorrhea/GI symptoms, failure to thrive </li> </ul> </td> <td>Hx, PE, bone age. Test for CF and immune deficiencies.</td> <td>Diagnose and treat underlying disease, ensure adequate nutrition, avoid glucocorticoids</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Immunologic disease</td> <td>Recurrent infections (manifestations vary depending on type of immunodeficiency)</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>Workup for immune deficiencies (refer to topic review on children with recurrent infections) </li> </ul> </td> <td>Diagnose and treat underlying disease</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Endocrine causes of growth failure </td> </tr> <tr> <td class=\"indent2\">Hypothyroidism</td> <td>Sluggishness, lethargy, cold intolerance, constipation, decreased reflexes</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>TSH <em>and</em> free T4. If hypothyroidism is central (low TSH and low T4), also assess for other pituitary hormone deficiencies. </li> </ul> </td> <td>Thyroid hormone replacement</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Cushing syndrome</td> <td>Obesity with central fat distribution; buffalo hump; purple striae</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>24 hour urine collection for free cortisol </li> </ul> </td> <td>Diagnose and treat underlying disease</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Growth hormone deficiency</td> <td>Progressive growth failure. May also have symptoms of other pituitary hormone deficiencies.</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>Measurements of GH, IGF-I, and IGFBP-3<sup>&#916;</sup> </li> </ul> </td> <td>rGH</td> <td>Delayed</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Precocious puberty</td> <td>Virilization</td> <td>Hx, PE, bone age<br /> <ul class=\"decimal_heading\"> <li>LH, FSH<sup>&#916;</sup> </li> </ul> </td> <td>Treatment depends on type of precocious puberty</td> <td>Advanced</td> <td>Initially fast, then stops early</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Genetic diseases with primary effects on growth </td> </tr> <tr> <td class=\"indent2\">Turner syndrome</td> <td> <p>Square \"shield\" chest, webbed neck, cubitus valgus<sup>&#9674;</sup>, genu valgum, Madelung deformity<sup>&#167;</sup>. </p> <p>Up to 50 percent have only short stature and absent pubertal development.</p> </td> <td>Karyotype analysis (for 45,X, structural abnormality of X, or mosaic)</td> <td>Estrogen, GH</td> <td>Normal</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">SHOX mutations</td> <td>May have isolated short stature (usually stocky appearance)&nbsp;OR additional features: shorter forearms and lower legs, cubitus valgus<sup>&#9674;</sup>, Madelung deformity<sup>&#167;</sup>, high arched palate</td> <td>Molecular genetic testing for SHOX abnormalities</td> <td>Consider GH</td> <td>Normal</td> <td>Slow</td> </tr> <tr> <td class=\"indent2\">Noonan syndrome</td> <td>Minor facial dysmorphism, heart disease, intellectual disability, webbed neck, pectus excavatum, cryptorchidism</td> <td>Molecular genetic testing for PTPN11, SOS1, and other genes<sup>&#916;</sup></td> <td>Consider GH</td> <td>Normal</td> <td>Low-normal or slow</td> </tr> <tr> <td class=\"indent2\">Silver-Russell syndrome</td> <td>Severe intrauterine growth restriction and postnatal growth retardation. Prominent forehead, triangular face, downturned corners of the mouth, and body asymmetry (hemihypertrophy).</td> <td>Clinical diagnosis, supported by molecular genetic testing<sup>&#916;</sup></td> <td>Consider GH</td> <td>Normal</td> <td>Slow</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Skeletal dysplasias</td> </tr> <tr> <td class=\"indent3\">Achondroplasia </td> <td>Short arms and legs, midface hypoplasia, trident hands. Most cases identified prenatally or in early infancy.</td> <td>Clinical diagnosis<br /> <ul class=\"decimal_heading\"> <li>Genetic testing for FGFR3 mutations is available<sup>&#916;</sup> </li> </ul> </td> <td>Management of complications, which may include craniocervical junction compression, sleep apnea,&nbsp;spinal stenosis.</td> <td>&nbsp;Mildly delayed</td> <td>Slow&nbsp;</td> </tr> <tr> <td class=\"indent3\">Hypochondroplasia</td> <td><span style=\"font-size: 10pt; font-family: verdana,sans-serif;\">Short arms and legs similar to but milder than in achondroplasia; lumbar lordosis.</span>&nbsp;May include macrocephaly, epilepsy.</td> <td> <p>Skeletal survey</p> <ul> <li>Genetic testing for FGFR3 mutations (positive in 70 percent) </li> </ul> </td> <td>Surveillance&nbsp;for spinal stenosis, with surgery as needed.&nbsp;</td> <td>&nbsp;? Normal</td> <td>Slow&nbsp;</td> </tr> <tr> <td class=\"indent3\">Spondyloepiphysial dysplasia&nbsp;</td> <td>Heterogenous manifestations; trunk disproportionately shortened compared with limbs; may develop scoliosis, kyphosis and osteoarthritis.</td> <td>Anthropometrics; skeletal survey&nbsp;</td> <td>Surveillance for spinal disorders and osteoarthritis,&nbsp;with surgery as needed.</td> <td>? Normal</td> <td>Slow</td> </tr> <tr> <td class=\"indent3\">Osteogenesis imperfecta</td> <td>Children with moderate to severe disease are usually recognized by recurrent fractures but also develop short stature. Blue sclerae, scoliosis, and hearing loss may be present.</td> <td>Skeletal survey</td> <td>Bisphosphonates, fracture management&nbsp;</td> <td>Normal&nbsp;</td> <td>Low-normal or slow&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Hx: history; PE: physical examination; CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: c-reactive protein; IGF-I: insulin-like growth factor I; IGFBP-3: insulin-like growth factor binding protein 3; GH: growth hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; SHOX: short stature homoeobox; SGA: small for gestational age; GI: gastrointestinal; CF: cystic fibrosis; CNS: central nervous system; CKD: chronic kidney disease.<br />* Some patients have features of both familial short stature and constitutional delay of growth and puberty (CDGP).<br />Δ Evaluation of patients in whom this disorder is suspected usually is performed by a subspecialist (ie, a Pediatric Endocrinologist, Gastroenterologist, or Geneticist).<br /><FONT class=lozenge>◊</FONT> Cubitus valgus is an increased carrying angle of the arm.<br />§ Madelung deformity is focal dysplasia of the distal radial physis, which can result in a prominent ulna and wrist pain.</div><div id=\"graphicVersion\">Graphic 94176 Version 3.0</div></div></div>"},"94177":{"type":"graphic_table","displayName":"Ablation of skeletal metastases","title":"Ablation of skeletal metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ablation of skeletal metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Ablation type</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Number of tumors</td> <td class=\"subtitle1\">Median follow-up in months</td> <td class=\"subtitle1\">Pain reduction*<br /> (number of patients achieving, mean decrease in pain intensity<sup>&#182;</sup>)</td> <td class=\"subtitle1\">Opioid reduction<br /> (MEDD or&nbsp;% of patients using less opioids)</td> <td class=\"subtitle1\">Number of major complications</td> </tr> <tr> <td>Callstrom M, 2006</td> <td>RFA</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> <td class=\"centered\">6</td> <td>59 of 62, 7.7 to 2.4 over&nbsp;24 weeks<sup>&#916;</sup></td> <td>MEDD reduced from 66 to 44 mg at 214 weeks</td> <td class=\"centered\">4</td> </tr> <tr> <td>Dupuy D, 2009</td> <td>RFA</td> <td class=\"centered\">55</td> <td class=\"centered\">55</td> <td class=\"centered\">3</td> <td>NR, 14.2<sup>&#9674;</sup></td> <td>NR</td> <td class=\"centered\">3</td> </tr> <tr> <td>Bagla S, 2016</td> <td>RFA</td> <td class=\"centered\">50 (spine)</td> <td class=\"centered\">69</td> <td class=\"centered\">NR</td> <td>24 of 34; decrease in pain intensity (numerical pain rating scale<sup>&#916;</sup>) from 5.9 to 2.1 over 3 months&nbsp;</td> <td>NR</td> <td class=\"centered\">NR</td> </tr> <tr> <td>Callstrom M, 2013</td> <td>Cryo</td> <td class=\"centered\">61</td> <td class=\"centered\">69</td> <td class=\"centered\">6</td> <td>42 of 61, 7.1 to 1.4 over 24 weeks<sup>&#916;</sup></td> <td>83%</td> <td class=\"centered\">1</td> </tr> <tr> <td>Tomasian A, 2015<span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\"><sup>&#167;</sup></span></td> <td>Cryo</td> <td class=\"centered\">14</td> <td class=\"centered\">31</td> <td class=\"centered\">10</td> <td>All 14; from 8 to 3 over 12 weeks</td> <td>MEDD reduced from 360 to&nbsp;80 mg per day at 12 weeks</td> <td class=\"centered\">2</td> </tr> <tr> <td>Liberman B, 2009</td> <td>FUS</td> <td class=\"centered\">31</td> <td class=\"centered\">32</td> <td class=\"centered\">3</td> <td>18 of 25, 5.9 to 1.8 over 12 weeks<sup>&#916;</sup></td> <td>67%</td> <td class=\"centered\">0</td> </tr> <tr> <td rowspan=\"2\">Hurwitz M, 2014</td> <td>FUS</td> <td class=\"centered\">112</td> <td class=\"centered\" rowspan=\"2\">NR</td> <td class=\"centered\" rowspan=\"2\">NR</td> <td rowspan=\"2\"><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">72 of 112 versus 7 of 35 control<sup><span>&#165;</span></sup>, mean decrease in pain intensity 7.0 to 3.4 over 12 weeks (versus 6.8 to 6.1 control)</span></td> <td rowspan=\"2\">44% at 12 weeks (versus 14% in control arm)</td> <td class=\"centered\" rowspan=\"2\">3</td> </tr> <tr> <td>Sham control</td> <td class=\"centered\">35</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEDD: morphine equivalent daily dose; RFA: radiofrequency ablation; NR: not reported; Cryo: cryoablation; FUS: focused ultrasound.<br />* Clinically significant pain reduction defined variably;&nbsp;refer to&nbsp;related UpToDate topic.<br />¶ As indicated by a mean decrease in Visual Analog Score for pain.<br />Δ Scale of 1 to 10.<br /><FONT class=lozenge>◊</FONT> 100-point scale, mean difference in pain intensity from baseline.<br />§ Spine lesions only. <br />¥ Patients whose worst numerical rating scale assessment for pain decreased by at least&nbsp;2 points and whose&nbsp;MEDD intake did not increase by more than 25% from baseline to 3 months were considered responders.</div><div id=\"graphicVersion\">Graphic 94177 Version 7.0</div></div></div>"},"94179":{"type":"graphic_figure","displayName":"Chronological age vs bone age for boys","title":"Chronological age versus bone age for boys","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Chronological age versus bone age for boys</div><div class=\"cntnt\"><img style=\"width:658px; height:408px;\" src=\"images/PEDS/94179_Chron_age_vs_bone_age_boys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chart depicts bone age as compared with chronological age in boys. The normal range is represented by 2 standard deviations (SD) above and below the mean (white area on this chart). Bone age is delayed if it is below this threshold (blue area), and advanced if it is above this threshold (green area).&nbsp;In clinical practice, a bone age that is 20 percent below or above the chronological age is considered abnormal.&nbsp;These data are based on the Brush Foundation Study, performed in well-nourished Caucasian children in the 1930s and 1940s.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Edition, Stanford, CA: Stanford University Press and London, UK: Oxford University Press, 1959.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from: Gaskin CM, Kahn SL, Bertozzi JC, Bunch PM. Skeletal development of the hand and wrist. Oxford University Press, New York 2011. p.8.</div><div id=\"graphicVersion\">Graphic 94179 Version 3.0</div></div></div>"},"94180":{"type":"graphic_figure","displayName":"Chronological age vs bone age for girls","title":"Chronological age versus bone age for girls","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Chronological age versus bone age for girls</div><div class=\"cntnt\"><img style=\"width:662px; height:415px;\" src=\"images/PEDS/94180_Chron_age_vs_bone_age_girls.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chart depicts bone age as compared with chronological age in girls. The normal range is represented by 2 standard deviations (SD) above and below the mean (white area on this chart). Bone age is delayed if it is below this threshold (blue area), and advanced if it is above this threshold (green area). In clinical practice, a bone age that is 20 percent below or above the chronological age is considered abnormal. These data are based on the Brush Foundation Study, performed in well-nourished Caucasian children in the 1930s and 1940s.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Edition, Stanford, CA: Stanford University Press and London, UK: Oxford University Press 1959.</LI></OL>Data from: Gaskin CM, Kahn SL, Bertozzi JC, Bunch PM. Skeletal development of the hand and wrist. Oxford University Press, New York 2011. p.8.</div><div id=\"graphicVersion\">Graphic 94180 Version 2.0</div></div></div>"},"94181":{"type":"graphic_algorithm","displayName":"Evaluation occult GI bleeding","title":"Evaluation of occult gastrointestinal bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of occult gastrointestinal bleeding</div><div class=\"cntnt\"><img style=\"width:412px; height:288px;\" src=\"images/GAST/94181_Evaluation_occult_GI_bleed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GI: gastrointestinal.<br />* Occult bleeding refers to hemoccult-positive stool and/or iron deficiency anemia without visible evidence of bleeding (eg, melena or hematochezia).<br />&para; Consider evaluation with a side-viewing duodenoscope if there are risk factors for hemobilia or hemosuccus pancreaticus, or a push enteroscopy in patients at risk for an aortoenteric fistula (though if the suspicion for an aortoenteric fistula is high, the evaluation should also include computed tomographic angiography).<br />&Delta; If the initial colonoscopy was inadequate, a repeat colonoscopy should be performed.</div><div id=\"graphicVersion\">Graphic 94181 Version 2.0</div></div></div>"},"94183":{"type":"graphic_picture","displayName":"Pernio on toes","title":"Pernio","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pernio</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94183_Pernio_on_toes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous edematous macules and papules on the toes.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94183 Version 1.0</div></div></div>"},"94184":{"type":"graphic_picture","displayName":"Pernio fingers","title":"Pernio","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pernio</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94184_Pernio_fingers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous papules and crusts on the fingers of a patient with pernio.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94184 Version 1.0</div></div></div>"},"94185":{"type":"graphic_picture","displayName":"Pernio hands child","title":"Pernio","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pernio</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94185_Pernio_hands_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous papules and plaques with blistering in a child with pernio.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94185 Version 1.0</div></div></div>"},"94186":{"type":"graphic_picture","displayName":"Pernio with ulceration on toes","title":"Pernio","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pernio</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94186_Pernio_ulceration_on_toes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous edematous papules and ulceration on the toes.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94186 Version 1.0</div></div></div>"},"94187":{"type":"graphic_picture","displayName":"Pernio on finger","title":"Pernio","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pernio</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/94187_Pernio_on_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Edematous, erythematous to violaceous papules and papulovesicles on the finger of a patient with pernio.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94187 Version 1.0</div></div></div>"},"94188":{"type":"graphic_picture","displayName":"Pernio on nose","title":"Pernio","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pernio</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94188_Pernio_on_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous, edematous papule on nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94188 Version 2.0</div></div></div>"},"94189":{"type":"graphic_picture","displayName":"Cryofibrinogenemia hand","title":"Cryofibrinogenemia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Cryofibrinogenemia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94189_Cryofibrinogenemia_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Healing acral ulcer and livedo-like changes of the skin in cryofibrinogenemia.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94189 Version 1.0</div></div></div>"},"94193":{"type":"graphic_algorithm","displayName":"Discharge from PACU for patients with OSA","title":"Discharge from PACU for patients with obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Discharge from PACU for patients with obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:604px; height:353px;\" src=\"images/ANEST/94193_Discharge_PACU_patients_OSA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative PACU discharge timing and location for the patient with known or suspected OSA after general anesthesia. Such patients should be monitored for &gt;60 minutes after usual PACU criteria are met.</div><div class=\"graphic_footnotes\">PACU: post-anesthesia care unit; OSA: obstructive sleep apnea; AHI: apnea-hypopnea index; PAP: positive airway pressure.<br />* Positive airway pressure (PAP) therapy, including continuous PAP, bilevel PAP, or automatically adjusting PAP.<br />&Delta; Significant comorbidities (eg, heart failure, arrhythmias, uncontrolled hypertension, cerebrovascular disease, metabolic syndrome, BMI &gt;35 kg/m<sup>2</sup>).<br /><span class=\"lozenge\">&loz;</span> Recurrent post-anesthesia care unit (PACU) respiratory event: repeated occurrence of oxygen saturation &lt;90 percent, or bradypnea &lt;8 breaths/min, or apnea &ge;10 seconds, or pain sedation mismatch (high pain and sedation scores concurrently)<sup>[1]</sup>.<br />&sect; Equianalgesic doses of oral opioids: codeine 120 mg every four hours, oxycodone 10 mg every four hours, hydromorphone 4 mg every four hours.<br />&yen; Monitored bed: environment with continuous oximetry and the possibility of early medical intervention (eg, intensive care unit, step-down unit, or remote pulse oximetry with telemetry in surgical ward).</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Gali B, Whalen FX, Schroeder D, et al. Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and postanesthesia care assessment. Anesthesiology 2009; 110: 869.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Seet E, Chung F. Management of sleep apnea in adults - functional algorithms for the perioperative period: Continuing Professional Development. Can J Anaesth 2010; 57:849.</div><div id=\"graphicVersion\">Graphic 94193 Version 2.0</div></div></div>"},"94195":{"type":"graphic_picture","displayName":"LEOPARD syndrome","title":"LEOPARD syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">LEOPARD syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94195_LEOPARD_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple, disseminated, hyperpigmented macules 2 to 5 mm in diameter in an adolescent girl with LEOPARD syndrome (lentigines, EKG [electrocardiogram]&nbsp;abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, deafness).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94195 Version 2.0</div></div></div>"},"94197":{"type":"graphic_diagnosticimage","displayName":"CT endograft periaortic abscess","title":"Periaortic abscess on CT after aortic endograft","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Periaortic abscess on CT after aortic endograft</div><div class=\"cntnt\"><img style=\"width:586px; height:520px;\" src=\"images/RADIOL/94197_CT_stent_graft_periaortic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan following aortic endografting (A) shows a normal postprocedure appearance. Eight months later (B), the patient presented with fever, and repeat CT scan showed fluid accumulation around the aortic sac (arrow). MRSA grew from the aspirate, and, because the patient was too ill to undergo definitive surgery, a percutaneous drain was placed into the abscess (C, arrow). Three days later, contrast injection into the cavity showed a reduced size of the periaortic abscess cavity (D, arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRSA: methicillin-resistant Staphylococcus aureus.</div><div id=\"graphicVersion\">Graphic 94197 Version 1.0</div></div></div>"},"94199":{"type":"graphic_picture","displayName":"Genicular arteries","title":"Genicular arteries","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Genicular arteries</div><div class=\"cntnt\"><img style=\"width:614px; height:688px;\" src=\"images/EM/94199_Geniculararteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The many arteries making up the peri-articular anastomosis around the knee provide an important collateral circulation for bypassing the popliteal artery when the knee joint has been maintained too long in a fully flexed position or when the vessels are narrowed or occluded.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94199 Version 4.0</div></div></div>"},"94200":{"type":"graphic_picture","displayName":"Neurofibromatosis 1","title":"Neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94200_Neurofibromatosis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Café-au-lait macules, lentigines, and neurofibromas in a patient with neurofibromatosis type 1.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94200 Version 1.0</div></div></div>"},"94201":{"type":"graphic_picture","displayName":"Neurofibromatosis type 1 axillary lentiginosis","title":"Neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/94201_Neurofibromatosis1lentig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Café-au-lait macules and axillary lentiginosis in a patient with neurofibromatosis type 1.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94201 Version 2.0</div></div></div>"},"94202":{"type":"graphic_picture","displayName":"Anterior and posterior patella","title":"Patella: Anterior and posterior surfaces","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Patella: Anterior and posterior surfaces</div><div class=\"cntnt\"><img style=\"width:600px; height:508px;\" src=\"images/EM/94202_Anteriorposteriorpatella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These diagrams show the patella free of all soft tissue attachments. The apex represents the most inferior aspect of this sesamoid bone. The image on the left with the rougher surface depicts the anterior side of the patella; the image on the right with the smoother surface shows the inferior, or articular, side.</div><div class=\"graphic_reference\">Reproduced with permission from: Knee conditions. In: Fundamentals of Sports Injury Management, 3rd Ed, Anderson M, Parr G (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94202 Version 3.0</div></div></div>"},"94203":{"type":"graphic_picture","displayName":"Terra firma dermatosis","title":"Terra firma-forme dermatosis","html":"<div class=\"graphic\"><div style=\"width: 911px\" class=\"figure\"><div class=\"ttl\">Terra firma-forme dermatosis</div><div class=\"cntnt\"><img style=\"width:891px; height:657px;\" src=\"images/DERM/94203_Terrafirmadermatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick, reticulated, brown plaques on the back of a 20-year-old man with terra firma-forme dermatosis. Note the normal-appearing skin in the areas wiped with 70% ethyl alcohol.</div><div class=\"graphic_reference\">From: Erkek E, Sahin S, &Ccedil;etin ED, Sezer E. Terra firma-forme dermatosis. Indian J Dermatol Venereol Leprol 2012; 78:358. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=3;spage=358;epage=360;aulast=Erkek\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.95455</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94203 Version 2.0</div></div></div>"},"94207":{"type":"graphic_algorithm","displayName":"Algorithm for molecular diagnosis of Prader-Willi syndrome","title":"Algorithm for molecular diagnosis of Prader-Willi syndrome","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Algorithm for molecular diagnosis of Prader-Willi syndrome</div><div class=\"cntnt\"><img style=\"width:497px; height:344px;\" src=\"images/PEDS/94207_Algo_molec_diag_PraderWilli.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FISH: fluorescence in situ hybridization; CMA: chromosomal microarray; UPD: uniparental disomy; IC: imprinting center; MLPA: multiplex ligation probe amplification.</div><div class=\"graphic_reference\">Reproduced from: Driscoll DJ, Miller JL, Schwartz S, et al. Prader-Willi Syndrome, 1998 [Updated 2014 Jan 23]. In: Pagon RA, Adam MP, Bird TD, et al. (Eds), GeneReviews&trade; [Internet], University of Washington, Seattle 1993-2014. Available from: <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1330/\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK1330/</a> (Accessed on March 12, 2014). Copyright &copy; 1993-2014, University of Washington, Seattle. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94207 Version 1.0</div></div></div>"},"94208":{"type":"graphic_picture","displayName":"PBC stage 4 trichrome","title":"Primary biliary cholangitis (primary biliary cirrhosis), stage IV","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis), stage IV</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/GAST/94208_PBC_stage_4_trichrome_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain highlighting the irregular nodules, commonly referred to as the \"jigsaw puzzle\" appearance of primary biliary cholangitis. The hepatocytes are surrounded by broad, acellular fibrous bands. The hepatocytes close to the fibrous bands appear lighter in color, giving off a halo effect. This is due to cholate stasis.</div><div id=\"graphicVersion\">Graphic 94208 Version 3.0</div></div></div>"},"94209":{"type":"graphic_picture","displayName":"Acute cholangitis proliferating bile ductules","title":"Acute cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:441px;\" src=\"images/GAST/94209_Acut_cholan_prolif_bile_duc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two portal tracts are shown in this photo, both showing expansion due to edema, mild inflammation, and ductular reaction. Arrows point to proliferating bile ductules (ductular reaction) at the periphery of the portal tract. Note that the bile ducts are damaged.</div><div id=\"graphicVersion\">Graphic 94209 Version 1.0</div></div></div>"},"94210":{"type":"graphic_table","displayName":"US PCC products","title":"PCC products available in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PCC products available in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Unactivated prothrombin complex concentrates (PCC)</td> </tr> <tr> <td class=\"indent1\">4 factor:<br /> <ul class=\"decimal_heading\"> <li>Kcentra </li> </ul> </td> <td>Contain coagulation factors II, VII, IX, and X in inactive forms</td> </tr> <tr> <td class=\"indent1\">3 factor:<br /> <ul class=\"decimal_heading\"> <li>Bebulin VH </li> <li>Profilnine SD </li> </ul> </td> <td>Contain factors II, IX, and X (little to no factor VII)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Activated prothrombin complex concentrates (aPCC)</td> </tr> <tr> <td class=\"indent1\">4 factor:<br /> <ul class=\"decimal_heading\"> <li>FEIBA NF </li> </ul> </td> <td>Contains coagulation factors II, VII, IX, and X; factor VII is mostly activated*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table lists 4 factor and 3 factor (which contain little to no factor VII) PCC products available in the United States. PCCs also contain proteins C and S, and some contain heparin from the purification. Unactivated factors are proenzymes (inactive precursor proteins). Activated factors have higher enzymatic activity. Refer to UpToDate topics on warfarin reversal for use of these products. Kcentra is sold in Canada as Octaplex.</div><div class=\"graphic_footnotes\">PCC: prothrombin complex concentrates; FEIBA NF: factor eight inhibitor bypassing activity, nanofiltered.<br />* A single-factor product containing recombinant activated human factor VII (rFVIIa) is also available.</div><div id=\"graphicVersion\">Graphic 94210 Version 3.0</div></div></div>"},"94211":{"type":"graphic_picture","displayName":"Acute cholangitis ductular reaction","title":"Acute cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/GAST/94211_Acut_cholangitis_duct_react.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ductular reaction (arrows) at the periphery of a portal tract. Ductules are irregular, glandular structures that have similar morphological characteristics as bile ducts. These are not seen in normal liver and are only found when there is liver injury.</div><div id=\"graphicVersion\">Graphic 94211 Version 1.0</div></div></div>"},"94212":{"type":"graphic_picture","displayName":"PBC with ductular reaction","title":"Primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/GAST/94212_PBC_ductular_reaction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to irregular, anastomosing ductal structures that make up the so-called ductular reaction. When this is seen in a biopsy of a patient with primary biliary cholangitis (PBC), this is indicative of at least stage 2 PBC.</div><div id=\"graphicVersion\">Graphic 94212 Version 2.0</div></div></div>"},"94213":{"type":"graphic_table","displayName":"MGUS quick facts","title":"Quick facts: Monoclonal gammopathy of undetermined significance (MGUS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quick facts: Monoclonal gammopathy of undetermined significance (MGUS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td colspan=\"2\"> <p><strong>Definition:</strong> Asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder defined by the presence of a serum monoclonal protein (M-protein) &#60;3 g/dL in a person without end organ damage (lytic bone lesions, anemia, hypercalcemia, renal insufficiency, hyperviscosity) related to the proliferative process and a bone marrow with &#60;10 percent monoclonal plasma cells (if performed).</p> The three main types, in order of decreasing frequency:<br /> <ul> <li>Non-IgM MGUS (IgG, IgA, or IgD MGUS) can progress to smoldering and then symptomatic multiple myeloma. Less frequently, progresses to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder. </li> <li>IgM MGUS can progress to smoldering and then symptomatic Waldenstr&#246;m macroglobulinemia, lymphoma, or AL amyloidosis. Infrequently, IgM MGUS can progress to IgM multiple myeloma. </li> <li>Light chain MGUS can progress to idiopathic Bence Jones proteinuria and to light chain multiple myeloma, AL amyloidosis, or light chain deposition disease.</li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Epidemiology:</strong> 1 to 2 percent of the adult population. Mean age = 70 years. Risk factors: increasing age, male sex, and certain ethnicities (Africans and African Americans &#62; Caucasians).</td> </tr> <tr> <td colspan=\"2\"><strong>Clinical presentation:</strong> No role for screening. M-protein usually detected on SPEP or UPEP performed for one of a wide variety of clinical symptoms and disorders.</td> </tr> <tr> <td colspan=\"2\"><strong>Evaluation:</strong></td> </tr> <tr> <td><span class=\"primarybox_left\">&nbsp;</span> SPEP, UPEP, quantitative immunoglobulins, serum FLC assay &ndash; SPEP and UPEP detect and quantify the M-protein, and immunofixation confirms its presence and determines type (IgG, IgM, IgA, IgD, kappa, lambda). Serum M-protein is always &#60;3 g/dL and usually &#60;1 g/dL.</td> <td rowspan=\"6\">\"Red Flags\"<br /> <ul> <li>Bone pain </li> <li>Fatigue/generalized weakness </li> <li>Constitutional \"B\" symptoms (unintentional weight loss, fever, night sweats) </li> <li>Neurologic symptoms (neuropathy, headache, dizziness, loss of vision/hearing) </li> <li>Bleeding </li> <li>Symptoms suggestive of amyloid (macroglossia, nephrotic range proteinuria, restrictive cardiomyopathy, unexplained elevated NT-proBNP) </li> <li>Lymphadenopathy, hepatomegaly, or splenomegaly </li> <li>Abnormal laboratory findings: anemia, elevated creatinine, hypercalcemia </li> </ul> </td> </tr> <tr> <td><span class=\"primarybox_left\">&nbsp;</span> CBC, chemistries, creatinine &ndash; End organ damage suggested if: hemoglobin &#60;10 g/dL or 2 g/dL below normal; serum creatinine &#62;2 mg/dL [176.8 &#181;mol/liter]; or serum calcium &#62;11.5 mg/dL [2.875 mmol/liter].</td> </tr> <tr> <td><span class=\"primarybox_left\">&nbsp;</span> Metastatic bone survey to exclude lytic bone lesions and severe osteopenia.</td> </tr> <tr> <td><span class=\"primarybox_left\">&nbsp;</span> Bone marrow aspiration and biopsy if: M protein &#8805;1.5 g/dL; non-IgG MGUS; abnormal serum FLC ratio (ie, ratio of kappa to lambda FLC &#60;0.26 or &#62;1.65); or if any abnormality of the CBC, serum creatinine, serum calcium, or radiographic bone survey.</td> </tr> <tr> <td><strong>Diagnosis:</strong> Requires all three: M-protein &#60;3 g/dL; no end organ damage; and &#60;10 percent clonal plasma cells in bone marrow (if performed).</td> </tr> <tr> <td><strong>Clinical course and management:</strong> Reevaluate after six months with SPEP, UPEP, CBC, creatinine, electrolytes, and serum calcium. If M-protein stable and no end organ damage:<br /> <ul> <li>Patients with low-risk MGUS (serum M protein &#8804;1.5 g/dL, IgG subtype, and normal serum free light chain ratio) have a risk of progression of only 5 percent over 20 years and may be followed with history and physical examination alone </li> <li>All other patients are followed with annual SPEP, UPEP, CBC, creatinine, and serum calcium </li> <li>The evolution of MGUS to myeloma can be abrupt. Patients should return promptly if clinical symptoms occur. Emergence of a \"red flag\" symptom requires prompt evaluation.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; CBC: complete blood count; FLC: free light chain.</div><div id=\"graphicVersion\">Graphic 94213 Version 1.0</div></div></div>"},"94240":{"type":"graphic_table","displayName":"Common ingredients cough and cold medications","title":"Common active ingredients of orally administered over-the-counter cough and cold preparations*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common active ingredients of orally administered over-the-counter cough and cold preparations*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ingredient</td> <td class=\"subtitle1\">Typical single adult dose</td> <td class=\"subtitle1\">Typical single pediatric dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antihistamine</td> </tr> <tr> <td class=\"sublist2_start divider_bottom\" colspan=\"3\"><strong>First generation</strong></td> </tr> <tr> <td class=\"indent2\">Brompheniramine</td> <td>4 mg</td> <td>1 mg</td> </tr> <tr> <td class=\"indent2\">Diphenhydramine</td> <td>25 mg</td> <td>1 to 1.25 mg/kg up to 25 mg</td> </tr> <tr> <td class=\"indent2\">Chlorpheniramine</td> <td>2 to 4 mg</td> <td>1 to 2 mg</td> </tr> <tr> <td class=\"indent2\">Doxylamine</td> <td>6.25 to 12.5 mg</td> <td>2.5 to 6.25 mg</td> </tr> <tr> <td class=\"indent2\">Clemastine</td> <td>1 to 2 mg (base)</td> <td>0.5 to 1 mg (base)</td> </tr> <tr> <td class=\"indent2\">Dimenhydrinate</td> <td>50 mg</td> <td>1.25 mg/kg up to 25 mg</td> </tr> <tr> <td class=\"indent2\">Triprolidine</td> <td>2.5 mg</td> <td>1.25 mg</td> </tr> <tr> <td class=\"sublist2_start divider_bottom\" colspan=\"3\"><strong>Second generation</strong></td> </tr> <tr> <td class=\"indent2\">Loratadine</td> <td>5 to 10 mg</td> <td>5 mg</td> </tr> <tr> <td class=\"indent2\">Fexofenadine</td> <td>60 mg (IR); 180 mg (ER)</td> <td>15 to 30 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Cetirizine</td> <td>5 to 10 mg</td> <td>2.5 to 5 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Decongestant</td> </tr> <tr> <td class=\"indent1\">Phenylephrine</td> <td>5 to 10 mg</td> <td>2.5 mg</td> </tr> <tr> <td class=\"indent1\">Pseudoephedrine</td> <td>30 to 60 mg (IR); 120 to 240 mg (ER)</td> <td>1 mg/kg up to 15 mg (IR)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phenylpropanolamine<sup>&#182;</sup></td> <td>25 mg (IR) to 50 mg (ER)</td> <td>6.25 to 12.5 mg (IR)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cough suppressant</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dextromethorphan</td> <td>10 to 20 mg (IR); 60 mg (ER)</td> <td>2.5 to 7.5 mg (IR); 15 mg (ER)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipyretic/analgesic</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (paracetamol)</td> <td>325 to 1000 mg (IR); 1300 mg (ER)</td> <td>10 to 15 mg/kg up to 650 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ibuprofen</td> <td>200 to 400 mg</td> <td>4 to 10 mg/kg up to 300 mg (age &#8805;12 years: up to 400 mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Analgesic</td> </tr> <tr> <td class=\"indent1\">Naprosyn</td> <td>200 mg (base)</td> <td>5 mg/kg up to 200 mg (base)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketoprofen<sup>&#916;</sup></td> <td>12.5 to 25 mg (IR); 100 to 200 mg (ER)</td> <td>0.5 mg/kg up to 25 mg (IR)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Expectorant</td> </tr> <tr> <td class=\"indent1\">Guaifenesin</td> <td>200 to 400 mg (IR); 600 to 1200 mg (ER)</td> <td>50 to 200 mg (IR)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IR: immediate release; ER: extended release.<br />* Over-the-counter (OTC) preparations may contain combinations of several active ingredients. If possible, the clinician should obtain the container with the listed ingredients rather than relying upon the reported brand name because different preparations can have similar or the same brand names. Doses reflect the recommended over-the-counter dose. Higher doses may be approved for patients under medical supervision.<br />¶ Not available in United States.<br />Δ Available OTC in many countries; requires a prescription in the United States.</div><div id=\"graphicVersion\">Graphic 94240 Version 3.0</div></div></div>"},"94241":{"type":"graphic_picture","displayName":"Pseudofolliculitis postinflammatory","title":"Postinflammatory hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:590px; height:213px;\" src=\"images/DERM/94241_Pseudofolliculitis_postinfl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postinflammatory hyperpigmentation secondary to pseudofolliculitis barbae.</div><div id=\"graphicVersion\">Graphic 94241 Version 2.0</div></div></div>"},"94242":{"type":"graphic_picture","displayName":"Burn postinflammatory pigmentation","title":"Postinflammatory hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:590px; height:417px;\" src=\"images/DERM/94242_Burn_postinfl_pigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postinflammatory hyperpigmentation secondary to burn.</div><div id=\"graphicVersion\">Graphic 94242 Version 1.0</div></div></div>"},"94244":{"type":"graphic_picture","displayName":"Laugier-Hunziker","title":"Laugier-Hunziker syndrome","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Laugier-Hunziker syndrome</div><div class=\"cntnt\"><img style=\"width:712px; height:432px;\" src=\"images/DERM/94244_Laugier_hunziker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented gingival maculae in a 38-year-old white woman with Laugier-Hunziker syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94244 Version 1.0</div></div></div>"},"94245":{"type":"graphic_table","displayName":"Genetic syndromes with hyperpigmentation","title":"Genetic syndromes associated with cutaneous hyperpigmentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic syndromes associated with cutaneous hyperpigmentation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Mutated gene</td> <td class=\"subtitle1\">Clinical features related to hyperpigmentation</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Carney syndrome<br> (NAME/LAMB syndrome)</td> <td>Autosomal dominant</td> <td><em>PRKAR1A </em></td> <td>Nevi, ephelides lentigines, blue nevi</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Cronkhite-Canada syndrome</td> <td>Sporadic</td> <td>Unknown, considered to be an idiopathic and acquired disorder</td> <td>Lentigines of buccal mucosa, face, hands/feet</td> <td> <p>Typically affects older men</p> Associated with alopecia, nail dystrophy, intestinal polyposis</td> </tr> <tr class=\"divider_bottom\"> <td>Dowling-Degos</td> <td>Autosomal dominant with variable penetrance</td> <td><em>KRT5 </em></td> <td>Reticulated hyperpigmentation of the flexures</td> <td>Associated with pitted facial scars and comedone-like lesions on the back and neck</td> </tr> <tr class=\"divider_bottom\"> <td>Dyskeratosis congenita</td> <td>X-linked recessive</td> <td><em>DKC1 </em></td> <td>Reticulated hyperpigmentation primarily on the neck, upper chest, and upper arms</td> <td>Associated with bone marrow dysfunction and predisposition to malignancy, in particular mucosal squamous cell carcinoma, leukemia, and Hodgkin's disease</td> </tr> <tr class=\"divider_bottom\"> <td>LEOPARD syndrome</td> <td>Autosomal dominant</td> <td><em>PTPN11 </em></td> <td>Lentigines present in early infancy/childhood</td> <td>Associated with EKG changes, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, growth retardation, deafness</td> </tr> <tr class=\"divider_bottom\"> <td>McCune-Albright syndrome</td> <td>Sporadic</td> <td><em>GNAS1 </em></td> <td>Caf&#233;-au-lait-macules which usually appear in infancy and can overlie bony changes</td> <td>Associated with polyostotic fibrous dysplasia, hyperfunction of endocrine glands, especially the gonads with precocious puberty</td> </tr> <tr class=\"divider_bottom\"> <td>Neurofibromatosis type 1</td> <td>Autosomal dominant</td> <td><em>NF1</em></td> <td> <p>Multiple caf&#233;-au-lait macules</p> <p>Axillary or inguinal&nbsp;freckling</p> </td> <td>Caf&#233;-au-lait macules&nbsp;and freckles usually precede the appearance of neurofibromas&nbsp; </td> </tr> <tr class=\"divider_bottom\"> <td>Peutz-Jeghers syndrome</td> <td>Autosomal dominant</td> <td><em>STK11 </em></td> <td>Lentigines over perioral region, oral mucosa, hands</td> <td>Associated with pancreatic carcinoma, ovarian/testicular tumors</td> </tr> <tr> <td>Reticulate acropigmentation of Kitamura</td> <td>Autosomal dominant</td> <td><em>ADAM10 </em></td> <td>Atrophic, acral, lentigo-like lesions</td> <td>Associated with palmoplantar and dorsal phalangeal pitting</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NAME: nevi, atrial myxoma, myxoid neurofibroma, ephelides; LAMB: lentigines, atrial myxoma, mucocutaneous myxoma, blue nevi; LEOPARD: electrocardiogram abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural&nbsp;deafness; EKG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 94245 Version 3.0</div></div></div>"},"94247":{"type":"graphic_table","displayName":"Incidence S aureus bacteremia","title":"Incidence rates of <EM>Staphylococcus aureus</EM> bloodstream infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence rates of <EM>Staphylococcus aureus</EM> bloodstream infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">First author</td> <td class=\"subtitle1\">Population, year</td> <td class=\"subtitle1\">MRSA incidence per 100,000</td> <td class=\"subtitle1\">MSSA incidence per 100,000</td> <td class=\"subtitle1\">Total incidence per 100,000</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>El Atrouni<sup>[1]</sup></td> <td>United States (adults), 1998 to 2005</td> <td class=\"centered\">12.4</td> <td class=\"centered\">25.4</td> <td class=\"centered\">38.2</td> <td>Overall SAB incidence stable during the study period, but the proportion due to MRSA increased.</td> </tr> <tr class=\"divider_bottom\"> <td>Klevens<sup>[2]</sup></td> <td>United States, 2005</td> <td class=\"centered\">23.9</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td>Most invasive MRSA infections were healthcare associated.</td> </tr> <tr class=\"divider_bottom\"> <td>Kallen<sup>[3]</sup></td> <td>United States (healthcare-associated infections only), 2005 to 2008</td> <td class=\"centered\">25.7</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td>Hospital-onset and healthcare-associated MRSA bacteremia decreased 34 and 20 percent, respectively, over the four-year period.</td> </tr> <tr class=\"divider_bottom\"> <td>Rhee<sup>[4]</sup></td> <td>United States, 2007 to 2013</td> <td class=\"centered\">16.1</td> <td class=\"centered\">29.6</td> <td class=\"centered\">45.7</td> <td>Community-onset MRSA bacteremia incidence stable during the study period and largely due to USA300 strain type.</td> </tr> <tr class=\"divider_bottom\"> <td>Allard<sup>[5]</sup></td> <td>Canada (adults), 1991 to 2005</td> <td class=\"centered\">3.3</td> <td class=\"centered\">24.3</td> <td class=\"centered\">27.6</td> <td>MRSA incidence increased from 0 to 7.4 per 100,000, while MSSA incidence remained stable.</td> </tr> <tr class=\"divider_bottom\"> <td>Mejer<sup>[6]</sup></td> <td>Denmark (adults), 1995 to 2008</td> <td class=\"centered\">0.18</td> <td class=\"centered\">22.5</td> <td class=\"centered\">22.7</td> <td>Overall SAB incidence stable, and 30-day mortality rate improved during the study period.</td> </tr> <tr class=\"divider_bottom\"> <td>Asgeirsson<sup>[7]</sup></td> <td>Iceland (adults), 1995 to 2008</td> <td class=\"centered\">0.15</td> <td class=\"centered\">24.4</td> <td class=\"centered\">24.5</td> <td>SAB incidence increased during the study period, but mortality improved.</td> </tr> <tr class=\"divider_bottom\"> <td>Huggan<sup>[8]</sup></td> <td>New Zealand, 1998 to 2005</td> <td class=\"centered\">0.08</td> <td class=\"centered\">21.4</td> <td class=\"centered\">21.5</td> <td>Rates stable over time.</td> </tr> <tr class=\"divider_bottom\"> <td>Laupland<sup>[9]</sup></td> <td>Multinational (Australia, Canada, Denmark, Finland, Sweden), 2000 to 2008</td> <td class=\"centered\">1.9</td> <td class=\"centered\">24.2</td> <td class=\"centered\">26.1</td> <td>Community-onset MSSA incidence was similar among study regions. Rates of MRSA and hospital MSSA varied considerably by region. No overall change in burden of SAB over time.</td> </tr> <tr class=\"divider_bottom\"> <td>Jacobsson<sup>[10]</sup></td> <td>Sweden, 2003 to 2005</td> <td class=\"centered\">0</td> <td class=\"centered\">27.6</td> <td class=\"centered\">27.6</td> <td>All cases were MSSA.</td> </tr> <tr class=\"divider_bottom\"> <td>Skogberg<sup>[11]</sup></td> <td>Finland, 2004 to 2007</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">20</td> <td>SAB associated with higher case-fatality rate than other pathogens.</td> </tr> <tr class=\"divider_bottom\"> <td>Tong<sup>[12]</sup></td> <td>Australia, 2006 to 2007</td> <td class=\"centered\">16</td> <td class=\"centered\">49</td> <td class=\"centered\">65</td> <td>SAB incidence rate in the indigenous Australian population was 172 per 100,000.</td> </tr> <tr class=\"divider_bottom\"> <td>Tong<sup>[13]</sup></td> <td>Australia, 2007 to 2010</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">11.2</td> <td>SAB rates higher in indigenous Australians, especially for community-associated MRSA.</td> </tr> <tr class=\"divider_bottom\"> <td>Taylor<sup>[14]</sup></td> <td>Canada, 2011 to 2013</td> <td class=\"centered\">3.95</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td>66.9 percent of cases were community acquired and 33.1 percent hospital acquired.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">van Cleef<sup>[15]</sup></td> <td>Netherlands, 2009</td> <td class=\"centered\">0.18</td> <td class=\"centered\">19.1</td> <td class=\"centered\">19.3</td> <td class=\"divider_bottom\" rowspan=\"2\">Cross-border comparison between Netherlands and North Rhine-Westphalia, Germany, showing 32-fold higher MRSA bacteremia incidence in Germany.</td> </tr> <tr class=\"divider_bottom\"> <td>Germany, 2009</td> <td class=\"centered\">5.76</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Rates in specific subpopulations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Landrum<sup>[16]</sup></td> <td>United States (military), 2005 to 2010</td> <td class=\"centered\">2.0</td> <td class=\"centered\">2.7</td> <td class=\"centered\">4.7</td> <td>Rates of both MRSA and MSSA bacteremia decreased during the study period.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Larsen<sup>[17]</sup></td> <td>Denmark (HIV-infected adults), 1995 to 2007</td> <td class=\"centered\">4.9</td> <td class=\"centered\">489</td> <td class=\"centered\">494</td> <td>50 percent of initial episodes of SAB were in IDUs.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Burkey<sup>[18]</sup></td> <td>United States (HIV-infected adults), 2000 to 2004</td> <td class=\"centered\">850</td> <td class=\"centered\">1110</td> <td class=\"centered\">1960</td> <td>74.7 percent of MRSA bacteremia episodes in IDUs.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fitzgerald<sup>[19]</sup></td> <td>Ireland (hemodialysis recipients), 1998 to 2009</td> <td class=\"centered\">5600</td> <td class=\"centered\">11400</td> <td class=\"centered\">17000</td> <td>Intravascular catheters implicated as the source in 83 percent of cases.</td> </tr> <tr> <td class=\"indent1\">Wang<sup>[20]</sup></td> <td>Taiwan (all dialysis recipients), 2003 to 2008</td> <td class=\"centered\">1131</td> <td class=\"centered\">678</td> <td class=\"centered\">1809</td> <td>SAB more common among hemodialysis recipients than peritoneal dialysis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>S. aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>; SAB: <EM>S. aureus</EM> bacteremia; N/A: not applicable; IDU: injection drug user.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>El Atrouni WI, Knoll BM, Lahr BD, et al. Temporal trends in the incidence of Staphylococcus aureus bacteremia in Olmsted County, Minnesota, 1998 to 2005: a population based study. Clin Infect Dis 2009; 49:e130.</LI>&#xD;&#xA;<LI>Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763.</LI>&#xD;&#xA;<LI>Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304:641.</LI>&#xD;&#xA;<LI>Rhee Y, Aroutcheva A, Hota B, et al. Evolving epidemiology of Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2015; 36:1417.</LI>&#xD;&#xA;<LI>Allard C, Carignan A, Bergevin M, et al. Secular changes in incidence and mortality associated with Staphylococcus aureus bacteraemia in Quebec, Canada, 1991-2005. Clin Microbiol Infect 2008; 14:421.</LI>&#xD;&#xA;<LI>Mejer N, Westh H, Schønheyder HC, et al. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis 2012; 12:260.</LI>&#xD;&#xA;<LI>Asgeirsson H, Gudlaugsson O, Kristinsson KG, et al. Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality. Clin Microbiol Infect 2011; 17:513.</LI>&#xD;&#xA;<LI>Huggan PJ, Wells JE, Browne M, et al. Population-based epidemiology of Staphylococcus aureus bloodstream infection in Canterbury, New Zealand. Intern Med J 2010; 40:117.</LI>&#xD;&#xA;<LI>Laupland KB, Lyytikainen O, Sogaard M, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 2013; 19:465.</LI>&#xD;&#xA;<LI>Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39:6.</LI>&#xD;&#xA;<LI>Skogberg K, Lyytikainen O, Ollgren J, et al. Population based burden of bloodstream infections in Finland. Clin Microbiol Infect 2012; 18: E170.</LI>&#xD;&#xA;<LI>Tong SY, Bishop EJ, Lilliebridge RA, et al. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous northern Australia: epidemiology and outcomes. J Infect Dis 2009; 199:1461.</LI>&#xD;&#xA;<LI>Tong SY, van Hal SJ, Einsiedel L, et al. Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in indigenous Australians. BMC Infect Dis 2012; 12:249.</LI>&#xD;&#xA;<LI>Taylor G, Bush K, Leal J, et al. Epidemiology of meticillin-resistant Staphylococcus aureus bloodstream infections in Alberta, Canada. J Hosp Infect 2015; 89:132.</LI>&#xD;&#xA;<LI>van Cleef BA, Kluytmans JA, van Benthem BH, et al. Cross border comparison of MRSA bacteraemia between The Netherlands and North Rhine-Westphalia (Germany): a cross-sectional study. PLoS One 2012; 7:e42787.</LI>&#xD;&#xA;<LI>Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 2012; 308:50.</LI>&#xD;&#xA;<LI>Larsen MV, Harboe ZB, Ladelund S, et al. Major but differential decline in the incidence of Staphylococcus aureus bacteraemia in HIV-infected individuals from 1995 to 2007: a nationwide cohort study. HIV Med 2012; 13:45.</LI>&#xD;&#xA;<LI>Burkey MD, Wilson LE, Moore RD, et al. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med 2008; 9:858.</LI>&#xD;&#xA;<LI>Fitzgerald SF, O’Gorman J, Morris-Downes MM, et al. A 12-year review of Staphylococcus aureus bloodstream infections in haemodialysis patients: more work to be done. J Hosp Infect 2011; 79:218.</LI>&#xD;&#xA;<LI>Wang IK, Chang YC, Liang CC, et al. Bacteremia in hemodialysis and peritoneal dialysis patients. Intern Med 2012; 51:1015.</LI></OL></div><div id=\"graphicVersion\">Graphic 94247 Version 4.0</div></div></div>"},"94248":{"type":"graphic_picture","displayName":"Diabetic dermopathy","title":"Diabetic dermopathy","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Diabetic dermopathy</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/94248_Diabetic_dermopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small brown spots on the shins of a patient with diabetes mellitus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94248 Version 1.0</div></div></div>"},"94250":{"type":"graphic_diagnosticimage","displayName":"Ultrasound medial knee with and without MCL injury","title":"Ultrasound of medial knee joint line with and without MCL injury","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ultrasound of medial knee joint line with and without MCL injury</div><div class=\"cntnt\"><img style=\"width:598px; height:268px;\" src=\"images/EM/94250_US_medial_knee_MCL_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These still images from ultrasound examinations of the knee show a normal medial joint line and a widened medial joint line resulting from a medial collateral injury. Note the increased space between the tibia and fibula in the image of the injured knee. The image of the injured knee was obtained while placing a valgus stress on the joint.</div><div class=\"graphic_reference\">Courtesy of William W Dexter, MD.</div><div id=\"graphicVersion\">Graphic 94250 Version 2.0</div></div></div>"},"94251":{"type":"graphic_movie","displayName":"Ultrasound examination of the MCL","title":"Ultrasound examination of the medial collateral ligament","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Ultrasound examination of the medial collateral ligament</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/94251_USexaminationMCLvid.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:540px; height:345px;\" src=\"images/EM/94251_USexaminationMCLimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William W. Dexter, MD.</div><div id=\"graphicVersion\">Graphic 94251 Version 2.0</div></div></div>"},"94253":{"type":"graphic_table","displayName":"The five-part questionnaire for identifying hypermobility","title":"The five-part questionnaire for identifying hypermobility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The five-part questionnaire for identifying hypermobility</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol class=\"numbers_to_nine\"> <li>Can you now (or could you ever) place your hands flat on the floor without bending your knees? </li> <li>Can you now (or could you ever) bend your thumb to touch your forearm? </li> <li>As a child, did you amuse your friends by contorting your body into strange shapes OR could you do splits? </li> <li>As a child or teenager, did your shoulder or kneecap dislocate on more than one occasion? </li> <li>Do you consider yourself double-jointed? </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients who answer \"yes\" to two or more questions may be suspected of generalized joint hypermobility.</div><div id=\"graphicVersion\">Graphic 94253 Version 1.0</div></div></div>"},"94271":{"type":"graphic_diagnosticimage","displayName":"Fracture of C7 shown by CT and MRI but not plain radiographs","title":"Fracture of 7th cervical vertebra in a patient with ankylosing spondylitis visualized by CT and MRI but not plain radiographs","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Fracture of 7th cervical vertebra in a patient with ankylosing spondylitis visualized by CT and MRI but not plain radiographs</div><div class=\"cntnt\"><img style=\"width:598px; height:274px;\" src=\"images/RHEUM/94271_Fracture_C7_CT_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cervical fracture (7th cervical vertrebra) in a patient with advanced ankylosing spondylitis. The fracture is a complete segment fracture (unstable fracture), extending from the ventral&nbsp;to the dorsal parts of the spine. Bone marrow edema due to the fracture and fracture lines are seen on MRI, while bone destruction&nbsp;is seen more clearly on CT. Arrows indicate the ventral borders of the fracture. The fracture is not seen on the plain radiographs.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 94271 Version 3.0</div></div></div>"},"94303":{"type":"graphic_algorithm","displayName":"Approach to the diagnosis of Raynaud phenomenon","title":"Approach to the diagnosis of Raynaud phenomenon","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of Raynaud phenomenon</div><div class=\"cntnt\"><img style=\"width:720px; height:873px;\" src=\"images/RHEUM/94303_Appr_diag_Raynaud_phenomen.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CTD: connective tissue disease; MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.</div><div class=\"graphic_reference\">Reproduced from: Boin F, Wigley FM. Clinical features and treatment of Scleroderma. In: Kelley's Textbook of Rheumatology, 9th ed, Firestein GS, Budd RC, Gabriel SE, et al (Eds), Elsevier, Philadelphia 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94303 Version 3.0</div></div></div>"},"94323":{"type":"graphic_picture","displayName":"Microscopy - Cestode eggs","title":"Cestode eggs","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Cestode eggs</div><div class=\"cntnt\"><img style=\"width:535px; height:244px;\" src=\"images/ID/94323_Microscopy_Cestode_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common cestode eggs recognized on wet mount include:<br />(A) <em>Taenia solium</em><br />(B) <em>Taenia saginata</em><br />(C) <em>Hymenolepis nana</em><br />(D) <em>Diphyllobothrium latum</em><br />(E) <em>Hymenolepis diminuta</em><br />(F) <em>Dipylidium caninum</em><br />The eggs can be useful for diagnosis, although the primary diagnostic forms are the mature (gravid) proglottids and the scolex. The eggs of <em>Taenia</em> are indistinguishable (A and B).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Available at: <a href=\"http://www.cdc.gov/dpdx/\" target=\"_blank\">http://www.cdc.gov/dpdx/</a> (Accessed March 13, 2014).</div><div id=\"graphicVersion\">Graphic 94323 Version 1.0</div></div></div>"},"94324":{"type":"graphic_picture","displayName":"Microscopy - Cestode proglottids and scolices","title":"Cestode proglottids and scolices","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Cestode proglottids and scolices</div><div class=\"cntnt\"><img style=\"width:535px; height:663px;\" src=\"images/ID/94324_Micro_Cestod_proglot_scolic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common cestodes include <EM>Taenia</EM>, <EM>Diphyllobothrium</EM>, <EM>Hymenolepis</EM>, and <EM>Dipylidium</EM>. The primary diagnostic forms are the mature (gravid) proglottids and the scolex. Proglottids are macroscopic structures passed in the stool; these may be submitted for laboratory examination. Proglottids increase in size as they grow from immature to gravid. Proglottids of <EM>Taenia</EM>, <EM>Dipylidium</EM>, and <EM>Diphyllobothrium</EM> are large (length 0.5 to 1.5 cm), while proglottids of <EM>Hymenolepis</EM> species are much smaller (0.5 mm x 1.0 mm).<br />Distinguishing these species requires careful gross and macroscopic examination. The scolices are quite small (diameter ≤1 mm) but can be examined under a dissecting or light microscope to identify hooklets and suckers for speciation.<br />(A) Gross <EM>Taenia</EM> species (upper panel), with <EM>Taenia saginata</EM> proglottid and scolex (lower left panel) and <EM>Taenia solium</EM> proglottid and scolex (lower right panel). Note the distinct hooklets of <EM>T. solium</EM> seen on the scolex distinguishing it from <EM>T. saginata</EM>.<br />(B) Gross <EM>Diphyllobothrium</EM> species (upper panel), with <EM>Diphyllobothrium latum</EM> proglottid and scolex (lower panel). Note the elongated folded sucker of this species.<br />(C) Gross <EM>Hymenolepis</EM> species (upper panel; maximum width 1 mm width and length 40 mm), with <EM>Hymenolepis nana</EM> (lower left panel) and <EM>Hymenolepis diminuta</EM> (lower right panel). The proglottids and scolex of these species are difficult to distinguish.<br />(D) Gross <EM>Dipylidium</EM> species (upper panel; length 10 to 40 cm) with <EM>Dipylidium caninum</EM> (lower panel). Note the double pored proglottid distinctive of this species.<br />The proglottids of <EM>Taenia</EM> have &gt;14 ovarian branches (<EM>T. saginata</EM>, A) or &lt;14 ovarian branches (<EM>T. solium</EM>, B). <EM>T. solium</EM> also has a scolex with hooklets (A, lower right panel). <EM>Diphyllobothrium latum</EM> has a distinctive proglottid containing a \"central rosette\" that is visible with or without ink infusion preparation (B, upper panel). <EM>Hymenolepis nana</EM> (C, lower left panel) and <EM>H. diminuta</EM> (C, lower right panel) can be distinguished by the presence of polar filaments in the eggs of <EM>H. diminuta</EM>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Available at: <a href=\"http://www.cdc.gov/dpdx/\" target=\"_blank\">http://www.cdc.gov/dpdx/</a> (Accessed March 13, 2014).</div><div id=\"graphicVersion\">Graphic 94324 Version 3.0</div></div></div>"},"94325":{"type":"graphic_diagnosticimage","displayName":"Crowned dens syndrome","title":"Crowned dens syndrome","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Crowned dens syndrome</div><div class=\"cntnt\"><img style=\"width:561px; height:655px;\" src=\"images/RHEUM/94325_Crowned_dens_syndrome_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These neck CT images (A, coronal; B, sagittal; C &amp; D, axial) of a 72-year-old man with CPPD demonstrate the characteristic curvilinear calcifications of the transverse ligament of the atlas (arrows) and crown-shaped calcium deposits (A) surrounding the odontoid process. Crowned dens syndrome is characterized by recurrent neck pain related to deposits of calcium hydroxyapatite or CPPD in ligaments around the odontoid process. The appearance is that of a crown or halo surrounding the odontoid process. Patients may present with severe neck pain and stiffness, fever, and elevated inflammatory markers, mimicking infection. Evidence of CPPD in other joints suggest the diagnosis of this less-common manifestation of CPPD.</div><div class=\"graphic_footnotes\">CT: computed tomography; CPPD: calcium pyrophosphate deposition disease.</div><div class=\"graphic_reference\">Copyright © 2016 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 94325 Version 5.0</div></div></div>"},"94326":{"type":"graphic_figure","displayName":"Calcium and magnesium transport in the thick ascending limb","title":"Calcium and magnesium transport in the thick ascending limb","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Calcium and magnesium transport in the thick ascending limb</div><div class=\"cntnt\"><img style=\"width:537px; height:520px;\" src=\"images/NEPH/94326_Magnesium_thick_ascend_limb.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Na is reabsorbed via the apical Na-K-2Cl cotransporter (NKCC2) and pumped out basolaterally by the Na-K-ATPase, Cl exits via the Cl channel composed of chloride channel Kb (ClC-Kb) and barttin, and K is recycled apically via the inwardly rectifying K channel, ROMK, thereby generating a lumen-positive transtubular voltage. In addition, transcellular reabsorption of NaCl generates a concentration gradient in the late thick ascending limb (TAL) favoring NaCl backflux. In the presence of Na-selective paracellular permeability mediated by a complex of claudin-16 and -19 (CLDN16/19), this generates a NaCl diffusion potential that augments the transepithelial voltage. Ca and Mg are reabsorbed passively across the paracellular pathway, driven by the lumen-positive electrical potential. The identity of the paracellular divalent cation pore may be made up of claudin-16 and possibly -19. Blood Ca levels regulate this process by stimulating the Ca-sensing receptor (CaSR), which negatively regulates calcineurin and nuclear factor of activated T-cells cytoplasmic-1 (NFATc1). NFATc1 increases transcription of the microRNAs, miR-9 and miR-374, which inhibit expression of claudin-14 (CLDN14), a protein that normally binds to and inhibits claudin-16 and -19.</div><div id=\"graphicVersion\">Graphic 94326 Version 3.0</div></div></div>"},"94327":{"type":"graphic_figure","displayName":"Magnesium transport in the distal convoluted tubule","title":"Magnesium transport in the distal convoluted tubule","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Magnesium transport in the distal convoluted tubule</div><div class=\"cntnt\"><img style=\"width:556px; height:337px;\" src=\"images/NEPH/94327_Magnesium_dist_conv_tubule.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnesium enters on the luminal side via the magnesium channel, transient receptor potential cation channel 6 (TRPM6), driven by the hyperpolarized membrane potential generated by the apical potassium channel, Kv1.1. Epidermal growth factor (EGF) stimulates trafficking of TRPM6 to the cell surface. The gamma subunit of the Na-K-ATPase participates in the pumping of sodium out of the cell, facilitated by basolateral potassium recycling by the potassium channel, Kir4.1. Basolateral magnesium exit may occur through cyclin M2 (CNNM2), which acts as a magnesium channel or transporter.</div><div class=\"graphic_footnotes\">EGFR: Epidermal growth factor receptor.</div><div id=\"graphicVersion\">Graphic 94327 Version 1.0</div></div></div>"},"94332":{"type":"graphic_table","displayName":"Causes of vomiting in young infants","title":"Important causes of vomiting in early infancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important causes of vomiting in early infancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Physiologic reflux or GERD</td> </tr> <tr> <td>Pyloric stenosis</td> </tr> <tr> <td>Necrotizing enterocolitis</td> </tr> <tr> <td class=\"sublist1_start\">Obstruction</td> </tr> <tr> <td class=\"sublist1\">Malrotation with midgut volvulus</td> </tr> <tr> <td class=\"sublist1\">Hirschsprung disease</td> </tr> <tr> <td class=\"sublist1\">Intussusception</td> </tr> <tr> <td class=\"sublist1\">Congenital atresias, stenoses or webs</td> </tr> <tr> <td>Gastroenteritis</td> </tr> <tr> <td>Metabolic disorders</td> </tr> <tr> <td>Feeding intolerance (may be associated with cardiac, pulmonary, renal, or neuromotor disorders)</td> </tr> <tr> <td>Adrenal crisis</td> </tr> <tr> <td>Dietary protein intolerance (eg, milk protein enteritis)</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td>Toxic ingestion</td> </tr> <tr> <td>Increased intracranial pressure (eg, subdural hematoma from child abuse, or hydrocephalus)</td> </tr> <tr> <td>Hepatobiliary disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease.</div><div id=\"graphicVersion\">Graphic 94332 Version 1.0</div></div></div>"},"94336":{"type":"graphic_algorithm","displayName":"General approach to obstetrical management of uncomplicated GDM","title":"General approach to obstetrical management of uncomplicated GDM","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">General approach to obstetrical management of uncomplicated GDM</div><div class=\"cntnt\"><img style=\"width:600px; height:435px;\" src=\"images/OBGYN/94336_Gen_appr_obst_manag_GDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm reflects the author's general approach to obstetrical management of patients with uncomplicated gestational diabetes.</div><div class=\"graphic_footnotes\">* When counseling patients, key issues to address include (1) the difficulty in accurately predicting birth weight by any method; (2) estimated fetal growth between ultrasound examination and delivery; (3) the risks of shoulder dystocia and associated complications; (4) the risks of a cesarean delivery in the current pregnancy; and (5) the risks of cesarean delivery in the current pregnancy on management and outcome of future pregnancies.</div><div id=\"graphicVersion\">Graphic 94336 Version 1.0</div></div></div>"},"94339":{"type":"graphic_table","displayName":"Endocrinopathy screening in childhood cancer survivors","title":"Risk-based screening for endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk-based screening for endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Potential late effect</td> <td class=\"subtitle1\">Anatomical location of injury</td> <td class=\"subtitle1\">Cytotoxic&nbsp;therapy</td> <td class=\"subtitle1\">Basic screening tests and frequency*</td> </tr> <tr class=\"divider_bottom\"> <td>GH deficiency</td> <td>Hypothalamic-pituitary axis</td> <td> <p>Radiation to the hypothalamic-pituitary axis (&#8805;18 Gy)</p> Surgery impacting the hypothalamic-pituitary area</td> <td> <p>Plot height on normative growth curves every six months</p> GH stimulation testing, if indicated</td> </tr> <tr class=\"divider_bottom\"> <td>LH/FSH deficiency</td> <td>Hypothalamic-pituitary axis</td> <td> <p>Radiation to the hypothalamic-pituitary axis (&#62;30 to 40 Gy)</p> Surgery impacting the hypothalamic-pituitary area</td> <td> <p>Physical exam with Tanner staging</p> <p>Baseline measurements: In males, LH, FSH, and testosterone&nbsp;at 14 years; In females, LH, FSH, and estradiol at 13 years</p> <p>Repeated measurements when clinically indicated</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Precocious puberty</td> <td>Hypothalamic-pituitary axis</td> <td>Radiation to the hypothalamic-pituitary axis (&#8805;18 Gy)</td> <td>Physical exam with Tanner staging every six months</td> </tr> <tr class=\"divider_bottom\"> <td>Central hypothyroidism</td> <td>Hypothalamic-pituitary axis</td> <td> <p>Radiation to the hypothalamic-pituitary axis (&#62;30 to 40 Gy)</p> Surgery impacting the hypothalamic-pituitary area</td> <td> <p>Annual measurement of TSH and Free T4</p> Consider more frequent screening during periods of rapid growth</td> </tr> <tr class=\"divider_bottom\"> <td>ACTH deficiency</td> <td>Hypothalamic-pituitary axis</td> <td> <p>Radiation to the hypothalamic-pituitary axis (&#62;30 to 40 Gy)</p> Chronic glucocorticoids therapy (transient deficiency)</td> <td>Annual measurement of 8 AM&nbsp;cortisol level or appropriate&nbsp;stimulation testing</td> </tr> <tr class=\"divider_bottom\"> <td>Diabetes insipidus</td> <td>Hypothalamic-pituitary axis</td> <td> <p>Surgery impacting the hypothalamic-pituitary area</p> Infiltrative tumors in the hypothalamic-pituitary area</td> <td> <p>If clinically indicated, measurement of serum and urine sodium and osmolality</p> Water deprivation testing, if indicated</td> </tr> <tr class=\"divider_bottom\"> <td>Thyroid dysfunction</td> <td>Thyroid gland</td> <td> <p>Radiation impacting the thyroid, including I-131</p> Drug therapy with tyrosine kinase inhibitors</td> <td> <p>Annual measurement of TSH and Free T4</p> Consider more frequent screening during periods of rapid growth</td> </tr> <tr class=\"divider_bottom\"> <td>Gonadal dysfunction<br /> (female)</td> <td>Ovaries</td> <td> <p>Radiation to the gonads</p> Side effect of drug therapy due to:<br /> <ul class=\"decimal_heading\"> <li>Alkylating agents </li> <li>Nitrosoureas </li> <li>Cisplatin </li> </ul> </td> <td> <p>Physical exam with Tanner staging</p> Baseline measurement of LH and FSH at 13 years of age and then as clinically indicated</td> </tr> <tr class=\"divider_bottom\"> <td>Gonadal dysfunction<br /> (male)</td> <td>Testes</td> <td> <p>Radiation to the gonads</p> Side effect of drug therapy due to:<br /> <ul class=\"decimal_heading\"> <li>Alkylating agents </li> <li>Nitrosoureas </li> <li>Cisplatin </li> </ul> </td> <td> <p>Physical exam with Tanner staging</p> Baseline measurement of LH and FSH at 14 years of age and then as clinically indicated</td> </tr> <tr class=\"divider_bottom\"> <td>Skeletal dysplasia</td> <td>Spine</td> <td>Radiation to the spine</td> <td>Annual measurement of sitting height</td> </tr> <tr class=\"divider_bottom\"> <td>Impaired bone mineral density</td> <td>Other</td> <td> <p>Cranial radiation</p> Side effect of drug therapy due to methotrexate and/or glucocorticoids</td> <td>Baseline DXA scan or other method (eg, quantitative computed tomography) at entry into long-term follow-up</td> </tr> <tr> <td>Diabetes mellitus</td> <td>Other</td> <td>Abdominal or total body irradiation</td> <td>Annual measurement of serum glucose</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GH: growth hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; TSH: thyroid-stimulating hormone; ACTH: adrenocorticotropic hormone; DXA: dual energy x-ray absorptiometry.<br />* All screening testing recommendations adapted from the Children's Oncology Group Long-Term Follow-Up Guidelines, which are available at <A href=\"http://www.survivorshipguidelines.org/\" target=_blank>www.survivorshipguidelines.org</A>.</div><div id=\"graphicVersion\">Graphic 94339 Version 3.0</div></div></div>"},"94340":{"type":"graphic_picture","displayName":"Bakri tamponade balloon catheter","title":"Bakri tamponade balloon catheter","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Bakri tamponade balloon catheter</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/OBGYN/94340_BT_Cath.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana.</div><div id=\"graphicVersion\">Graphic 94340 Version 2.0</div></div></div>"},"94341":{"type":"graphic_figure","displayName":"Adipocyte differentiation lipodystrophies","title":"Differentiation of adipocytes in relation to acquired and congenital lipodystrophies","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Differentiation of adipocytes in relation to acquired and congenital lipodystrophies</div><div class=\"cntnt\"><img style=\"width:548px; height:572px;\" src=\"images/ENDO/94341_Adipocyte_dffrntt_lpdystrph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differentiation of adipocytes, demonstrating gene activation and signaling pathways, in relation to acquired lipodystrophies: lipodystrophy genes and their associated protein products are bolded. Mesenchymal stem cells have the pluripotent ability to differentiate into osteocytes, myocytes, chondrocytes, stromal cells, or adipocytes. Wnt signal transduction pathways and other transcription factors lead to the development of a committed pre-adipocyte. Subsequently, adipogenic stimuli, such as insulin, glucocorticoids, IGF-1, and prostaglandins, initiate cell changes to differentiate into an adipocyte. Current data suggests that the BSCL-2 gene, coding for seipin, and AKT-2 play a role in adipocyte differentiation, and their mutations are involved in congenital generalized lipodystrophy (CGL) 2 and familial partial lipodystrophy (FPLD) 4, respectively. CCAAT-enhancer-binding proteins (C-EBP) b/d transcription factors stimulate factors PPARg, C-EBPa, and sterol regulatory element-binding protein (SREBP)1c, which are upregulated in this process; PPARg mutations are associated with FPLD3. Intracellular lipid accumulation in an adipocyte is dependent on substrate availability. In response to a variety of lipogenic signals, an adipocyte matures as the size of the lipid droplets are increased. Fatty acid synthase (FAS), acetyl coenzyme A carboxylase, and diacylglycerol acyltransferase (DGAT) expression is upregulated, necessary for the biosynthesis of phospholipids and triglycerides. AGPAT2 is responsible for acylating phosphatidic acid to synthesize triglycerides and phospholipids, and its mutation is involved in CGL1. PTRF regulates caveolae intracellularly and its functional loss results in CGL4. Apoptosis of adipocytes is influenced by LMNA, encoding for nuclear lamina proteins, and ZMPSTE24 required for post-translational lamina processing. Mutations in these genes lead to mandibuloacral dysplasia via premature nucleus disruption.</div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor 1.</div><div class=\"graphic_reference\">Reproduced from: Tsoukas MA, Mantzoros CS. Chapter 37: Lipodystrophy Syndromes. In: Endocrinology Adult and Pediatric, 7th Ed, Jameson JL, and DeGroot LJ (Eds). Saunders, 2016. Copyright &copy; 2016. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94341 Version 1.0</div></div></div>"},"94342":{"type":"graphic_picture","displayName":"ebb Complete Tamponade System ","title":"ebb Complete Tamponade System  designed by Belfort-Dildy ","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">ebb Complete Tamponade System&nbsp; designed by Belfort-Dildy </div><div class=\"cntnt\"><img style=\"width:501px; height:590px;\" src=\"images/OBGYN/94342_Belfort_Dildy_OTS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; 2014 Clinical Innovations. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 94342 Version 2.0</div></div></div>"},"94343":{"type":"graphic_figure","displayName":"Belfort-Dildy duel balloon tamponade system ","title":"Belfort-Dildy duel balloon tamponade system ","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Belfort-Dildy duel balloon tamponade system </div><div class=\"cntnt\"><img style=\"width:524px; height:590px;\" src=\"images/OBGYN/94343_Belfort_Dildy_system_insitu.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &copy; 2014 Clinical Innovations. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 94343 Version 2.0</div></div></div>"},"94345":{"type":"graphic_picture","displayName":"Cervicitis in a woman with gonorrhea","title":"Cervicitis in a woman with gonorrhea","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Cervicitis in a woman with gonorrhea</div><div class=\"cntnt\"><img style=\"width:528px; height:353px;\" src=\"images/ID/94345_Cervicitis_gonorrhea.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Diseases: STD Clinical Slides. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/std/training/clinicalslides/slides-dl.htm\" target=\"_blank\">http://www.cdc.gov/std/training/clinicalslides/slides-dl.htm</a> (Accessed on April 24, 2014).</div><div id=\"graphicVersion\">Graphic 94345 Version 1.0</div></div></div>"},"94346":{"type":"graphic_picture","displayName":"Gonococcal conjunctivitis in an adult","title":"Gonococcal conjunctivitis in an adult","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Gonococcal conjunctivitis in an adult</div><div class=\"cntnt\"><img style=\"width:532px; height:348px;\" src=\"images/ID/94346_Gonococcal_ophthalmia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Diseases: STD Clinical Slides. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/std/training/clinicalslides/slides-dl.htm\" target=\"_blank\">http://www.cdc.gov/std/training/clinicalslides/slides-dl.htm</a> (Accessed on April 24, 2014).</div><div id=\"graphicVersion\">Graphic 94346 Version 1.0</div></div></div>"},"94365":{"type":"graphic_figure","displayName":"Mechanism of action of antiviral therapies","title":"Mechanism of action of direct acting antivirals for hepatitis C virus","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Mechanism of action of direct acting antivirals for hepatitis C virus</div><div class=\"cntnt\"><img style=\"width:645px; height:350px;\" src=\"images/ID/94365_Mech_action_antiviral_thera.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NS5A: nonstructural protein 5A; NS5B: nonstructural protein 5B; NNPI: non-nucleoside polymerase inhibitor.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Clinical Pharmacology &amp; Therapeutics. Au J, Pockros PJ. Novel Therapeutic Approaces for Hepatitis C. Clin Pharmacol Ther 2014; 95:78. Copyright &copy; 2014. <a href=\"http://www.nature.com/clpt\" target=\"_blank\">www.nature.com/clpt</a>.</div><div id=\"graphicVersion\">Graphic 94365 Version 1.0</div></div></div>"},"94370":{"type":"graphic_table","displayName":"Capecitabine and bevacizumab elderly mCRC","title":"Capecitabine and bevacizumab for elderly patients with metastatic colorectal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine and bevacizumab for elderly patients with metastatic colorectal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bevacizumab</td> <td>7.5 mg/kg IV</td> <td>Dilute into a total volume of 100 mL normal saline.* Administer the first dose over 90 minutes. If well tolerated, the second infusion may be administered over 60 minutes. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#182;</sup></td> <td>1000 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily (total dose 2000 mg/m<sup>2</sup> daily). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#916;</sup></td> <td>Days 1 to 14</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Capecitabine: LOW (10 to 30%). </li> <li>Bevacizumab: MINIMAL (&#60;10%). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Bevacizumab is neither a vesicant nor an irritant. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not indicated (reported rate of any grade neutropenia was 5% in the original study<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Bevacizumab does not require dosage adjustments for liver or renal dysfunction. Lower starting doses of capecitabine may be needed for patients with renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count at baseline then every three weeks prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes, liver, and renal function at baseline then every three weeks prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in blood pressure, urine protein concentration, neurologic function, signs of GI perforation, and risk for bleeding and/or blood clots prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea and palmar-plantar erythrodysesthesia during treatment. </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The treatment cycle should be delayed one week if the total white blood cell count is &#60;3000 cells/microL, absolute neutrophil count is &#60;1500 cells/microL, or the platelet count is &#60;75,000/microL on day 1. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce dose of capecitabine. For grade 4 neutropenia or thrombocytopenia of febrile neutropenia during therapy, interrupt capecitabine until resolves to grade 0 or 1, then reduce dose by 25% for the next treatment.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nonhematologic toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, dose modifications of capecitabine were allowed for the occurrence and resolution of any NCI-CTC grades 2 to 4 nonhematologic toxicity during the prior cycle.<sup>[1]</sup> For grade 2 or higher toxicity, interrupt capecitabine until resolved to grade 0 or 1. Recommended dose modification guidelines for capecitabine based upon toxicity are available in the United States Prescribing Information.<sup>[2]</sup> <ul> <li>Grade 2: For the first, second, and third occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75% of the starting dose; third occurrence, 50% of the starting dose).<sup>[2]</sup> For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. </li> <li>Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75% of the starting dose; second occurrence, 50% of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. </li> <li>Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50% of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for fist recurrence of grade 4 toxicity. </li> </ul> </li> <li>Doses of capecitabine that are omitted for toxicity are not replaced. The patient should resume planned treatment cycles at the modified dose. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> <li>Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS).<sup>[3]</sup> Bevacizumab should not be administered within 28 days of surgery, and it should be suspended prior to elective surgery. Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; INR: international normalized ratio; NCI-CTC: National Cancer Institute Common Toxicity Criteria.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />¶ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />Δ Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cunningham D, et al. Lancet Oncol 2013; 14:1077.</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Bevacizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 94370 Version 15.0</div></div></div>"},"94372":{"type":"graphic_diagnosticimage","displayName":"Remodeling after DDH treatment","title":"Remodeling after treatment for developmental dysplasia of the hip","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Remodeling after treatment for developmental dysplasia of the hip</div><div class=\"cntnt\"><img style=\"width:485px; height:728px;\" src=\"images/PEDS/94372_Remodel_after_DDH_treatment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This girl was diagnosed with dislocated left hip shortly after birth. She failed Pavlik harness treatment as well as an attempted closed reduction.<br />(A) Antero-posterior (AP) radiograph of pelvis at age 10 months, just before open reduction. Note lack of acetabular development and failure of ossific nucleus to form.<br />(B) AP of pelvis three months after open reduction (age 13 months). Note early acetabular formation.<br />(C) Frog lateral of pelvis three months after open reduction. Note appearance of ossific nucleus (arrow) and early acetabular formation.<br />(D) AP of pelvis at age one year, six months. Ossific nucleus remains small.<br />(E) AP radiograph of pelvis at age two years, six months. Ossific nucleus catching up to opposite side and acetabulum continues to normalize.<br />(F) AP radiograph of pelvis at age four years, four months. The femoral heads are equal in size and shape. The left acetabulum remains slightly dysplastic.<br />(G) AP radiograph of pelvis at age seven years (six years and two months after open reduction). Except for postsurgical changes along the ilium, the hips appear similar. She has full pain-free motion and function. She will continue to be monitored until skeletal maturity.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 94372 Version 3.0</div></div></div>"},"94373":{"type":"graphic_figure","displayName":"Meta-analysis of breast cancer mortality in screening trials","title":"Meta-analysis of breast cancer mortality after 13 years of follow-up in breast cancer screening trials","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Meta-analysis of breast cancer mortality after 13 years of follow-up in breast cancer screening trials</div><div class=\"cntnt\"><img style=\"width:612px; height:306px;\" src=\"images/PC/94373_Mt_br_cnc_mrt_aft_13yr_Edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malmö II is excluded because follow-up of about 13 years was not available; the Swedish Two Count (Kopparberg and Östergötland) and Canada I and II trials are split into their component parts; the Edinburgh trial is excluded because of severe imbalances between randomised groups. Weights are from random-effects analysis.</div><div class=\"graphic_footnotes\">RR: relative risk.</div><div class=\"graphic_reference\">Reproduced from: Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380:1778. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94373 Version 2.0</div></div></div>"},"94376":{"type":"graphic_table","displayName":"MRI sequences for dementia evaluations","title":"MRI sequences for dementia evaluations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MRI sequences for dementia evaluations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Routine</td> </tr> <tr> <td class=\"subtitle2_left\">Sequence</td> <td class=\"subtitle2_left\">Purpose</td> </tr> <tr> <td class=\"indent1\">1. 3D T1-weighted gradient echo or contiguously sliced oblique coronal T1</td> <td>Visualize anatomy, atrophy patterns</td> </tr> <tr> <td class=\"indent1\">2. T2-weighted with fluid attenuation (FLAIR)</td> <td>Vascular, infectious and other structural pathology</td> </tr> <tr> <td class=\"indent1\">3. Diffusion tensor or diffusion weighted</td> <td>Recent ischemic changes, hydrocephalus</td> </tr> <tr> <td class=\"indent1\">4. Spoiled gradient recall echo or other susceptibility weighted</td> <td>Microhemorrhage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Supplemental sequences</td> </tr> <tr> <td class=\"indent1\">5. Post-contrast T1</td> <td>Demyelinating lesions, infections, neoplasms and vascular malformations</td> </tr> <tr> <td class=\"indent1\">6. Phase contrast</td> <td>CSF flow</td> </tr> <tr> <td class=\"indent1\">7. Arterial spin label (ASL)</td> <td>Regional cerebral perfusion</td> </tr> <tr> <td class=\"indent1\">8. Magnetic resonance angiogram</td> <td>Large vessel integrity</td> </tr> <tr> <td class=\"indent1\">9. Resting state function MRI</td> <td>Assessing resting network or functional systems</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 94376 Version 3.0</div></div></div>"},"94377":{"type":"graphic_table","displayName":"Regional atrophy patterns in neurodegenerative dementias","title":"Regional atrophy patterns in neurodegenerative dementias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Regional atrophy patterns in neurodegenerative dementias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Dementia syndrome</td> <td class=\"subtitle1\">Atrophy pattern</td> </tr> <tr> <td>Alzheimer dementia</td> <td>Temporal (including hippocampal), parietal, prefrontal atrophy, sparing sensorimotor strip and occiput</td> </tr> <tr> <td>Behavioral variant frontotemporal dementia</td> <td>Prefrontal, anterior temporal</td> </tr> <tr> <td>Huntington disease</td> <td>Head of the caudate</td> </tr> <tr> <td>Nonfluent variant primary progressive aphasia</td> <td>Dominant perisylvian</td> </tr> <tr> <td>Posterior cortical atrophy</td> <td>Bilateral superior parietal-occipital junction</td> </tr> <tr> <td>Progressive supranuclear palsy</td> <td>Diminished midbrain anteroposterior diameter</td> </tr> <tr> <td>Semantic variant primary progressive aphasia</td> <td>Dominant anterior temporal</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 94377 Version 4.0</div></div></div>"},"94388":{"type":"graphic_algorithm","displayName":"MGUS diagnosis algorithm","title":"Algorithm for the diagnosis of monoclonal gammopathy of undetermined significance (MGUS)","html":"<div class=\"graphic\"><div style=\"width: 1211px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of monoclonal gammopathy of undetermined significance (MGUS)</div><div class=\"cntnt\"><img style=\"width:1191px; height:1169px;\" src=\"images/HEME/94388_MGUSDXalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; FLC: free light chain; MM: multiple myeloma; FISH: fluorescence in situ hybridization; LDH: lactate dehydrogenase; CRP: C-reactive protein; CRAB: hyper<STRONG>c</STRONG>alcemia, <STRONG>r</STRONG>enal insufficiency, <STRONG>a</STRONG>nemia, <STRONG>b</STRONG>one lesions; IgG: immunoglobulin G; IgA: immunoglobulin A; IgD: immunoglobulin D; IgM: immunoglobulin M; CT: computed tomography; MRI: magnetic resonance imaging; AL: amyloid light-chain; PET: positron emission tomography.<br />* The serum FLC assay can be used in place of urine studies; however, if a M-protein is seen on serum studies or if the serum FLC ratio is abnormal, urine electrophoresis and immunofixation need to be performed.<br />¶ Imaging should be performed using whole body low-dose CT, whole body PET/CT, whole body MRI, or MRI of the spine and pelvis (depending upon availability and institutional preference).</div><div id=\"graphicVersion\">Graphic 94388 Version 7.0</div></div></div>"},"94393":{"type":"graphic_picture","displayName":"Ashy dermatosis arm","title":"Erythema dyschromicum perstans (ashy dermatosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema dyschromicum perstans (ashy dermatosis)</div><div class=\"cntnt\"><img style=\"width:396px; height:590px;\" src=\"images/DERM/94393_Ashy_dermatosis_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous light blue-gray, \"ashy\" macules on the arm of a patient with erythema dyschromicum perstans.</div><div id=\"graphicVersion\">Graphic 94393 Version 3.0</div></div></div>"},"94394":{"type":"graphic_figure","displayName":"Persistence of HbF in adults","title":"Persistence of HbF in adults","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">Persistence of HbF in adults</div><div class=\"cntnt\"><img style=\"width:659px; height:457px;\" src=\"images/HEME/94394_Persistence_HbF_in_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased production of HbF in adults can be acquired or inherited, the latter as a primary condition or secondary to various anemias. The primary increases caused by deletions and the <em>HBG1</em> or <em>HBG2</em> promoter mutations are identifiable by significant increases in HbF (8 to 40 percent) in heterozygotes, and the HbF is homogeneously distributed among the red blood cells (pancellular HPFH). Common variants in <em>Xmn1‑HBG2</em>, <em>HBS1L-MYB</em>, and <em>BCL11A</em> contribute to the common variation in HbF persistence in adults and underlie the common HbF variation observed in all the conditions. These HbF QTL form the genetic determinants of the historically known heterocellular HPFH.</div><div class=\"graphic_footnotes\">HbF: fetal hemoglobin; HPFH: hereditary persistence of HbF; QTL: quantitative trait loci.</div><div id=\"graphicVersion\">Graphic 94394 Version 2.0</div></div></div>"},"94395":{"type":"graphic_figure","displayName":"F cells sickle cell anemia","title":"F cells and sickle cell anemia","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">F cells and sickle cell anemia</div><div class=\"cntnt\"><img style=\"width:560px; height:618px;\" src=\"images/HEME/94395_F_cells_sickle_cell_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distribution of concentrations of HbF/F cell might be the critical determinant for some of the complications of sickle cell anemia. In the figure, some F cells, depicted in bright red and orange, have sufficiently high HbF concentration so that under physiologic O<sub>2</sub> saturations their HbS will contain little or no polymer. In the dark and light blue F cells with lesser amounts of HbF, HbS polymerization will occur at venous O<sub>2</sub> saturations. Some of the F cells and other sickle erythrocytes with little or no HbF will hemolyze intravascularly and by releasing their hemoglobin and arginase into the blood, can deplete bioavailable nitric oxide, leading to a number of vascular complications shown here.</div><div id=\"graphicVersion\">Graphic 94395 Version 1.0</div></div></div>"},"94396":{"type":"graphic_picture","displayName":"Harlequin ichthyosis","title":"Harlequin ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Harlequin ichthyosis</div><div class=\"cntnt\"><img style=\"width:598px; height:449px;\" src=\"images/DERM/94396_Harlequin_ichthyosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Infant with Harlequin ichthyosis due to compound heterozygous mutations in ABCA12 shortly after birth.<br />(B) At 30 days, marked clinical improvement was evident with supportive care including topical retinoids, emollients, and daily baths.</div><div id=\"graphicVersion\">Graphic 94396 Version 1.0</div></div></div>"},"94397":{"type":"graphic_picture","displayName":"Lichen planus pigmentosus","title":"Lichen planus pigmentosus","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Lichen planus pigmentosus</div><div class=\"cntnt\"><img style=\"width:715px; height:453px;\" src=\"images/DERM/94397_Lichen_planus_pigmentosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented macules on the back and abdomen of a patient with lichen planus pigmentosus.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94397 Version 1.0</div></div></div>"},"94399":{"type":"graphic_table","displayName":"Transfusion reactions findings","title":"Distinguishing findings in the evaluation of suspected transfusion reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing findings in the evaluation of suspected transfusion reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reaction</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Laboratory findings</td> <td class=\"subtitle1\">Implicated products and findings</td> </tr> <tr> <td>Acute hemolytic reaction</td> <td>Fever, chills, hypotension, back pain,&nbsp;DIC</td> <td>Hemoglobinemia, hemoglobinuria, positive direct anti-globulin (Coombs) test (may be negative if all cell have hemolyzed), findings of DIC (prolonged PT, prolonged aPTT, low fibrinogen, thrombocytopenia)</td> <td> <p>RBCs, plasma (much less common), rarely platelets</p> Intended recipient does not match actual recipient</td> </tr> <tr> <td>Anaphylactic reaction</td> <td>Hypotension, angioedema, wheezing, respiratory distress</td> <td>Hypoxemia, IgA deficiency, anti-IgA</td> <td>RBCs, platelets, plasma products</td> </tr> <tr> <td>Acute lung injury (TRALI)</td> <td>Respiratory distress, hypotension</td> <td>Abnormal&nbsp;chest radiography, hypoxemia, transient leukopenia, anti-neutrophil or anti-HLA antibodies (if tested)</td> <td>RBCs, platelets, plasma products</td> </tr> <tr> <td>Circulatory overload (TACO)</td> <td>Respiratory distress, rales</td> <td>Abnormal chest radiography, hypoxemia, increased BNP or NT-proBNP</td> <td>RBCs, platelets, plasma products</td> </tr> <tr> <td>Sepsis/bacterial infection</td> <td>Fever, chills, hypotension, DIC</td> <td>Bacteremia, leukocytosis, findings of DIC</td> <td> <p>Platelets most commonly implicated, but can be any product</p> Product may show bacterial contamination</td> </tr> <tr> <td>Febrile non-hemolytic reaction</td> <td>Fever</td> <td>None</td> <td>All blood products, but plasma is much rarer</td> </tr> <tr> <td>Urticarial reaction</td> <td>Hives</td> <td>None unless specific investigation is made</td> <td>All blood products</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table includes some common findings, but is not comprehensive and does not substitute for clinical judgment in the patient evaluation. Not all of the findings listed under each reaction will be present in every case. Refer to UpToDate topics on transfusion reactions for details of evaluation, diagnosis, and management.</div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation; PT: prothrombin time; aPTT: activated partial thromboplastin time; RBCs: red blood cells; TRALI: transfusion-related acute lung injury; TACO: transfusion-associated volume/circulatory overload; BNP: brain natriuretic peptide; NT-proBNP: N-terminal piece of BNP.</div><div class=\"graphic_reference\">Adapted from: Sazama K, DeChristopher PJ, Dodd R, et al. Practice parameter for the recognition, management, and prevention of adverse consequences of blood transfusion. College of American Pathologists. Arch Pathol Lab Med 2000; 124:61.</div><div id=\"graphicVersion\">Graphic 94399 Version 4.0</div></div></div>"},"94419":{"type":"graphic_picture","displayName":"Madelung deformity","title":"Madelung deformity of the forearm","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Madelung deformity of the forearm</div><div class=\"cntnt\"><img style=\"width:597px; height:380px;\" src=\"images/PEDS/94419_Madelung_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Clinical photographs of a patient with Madelung deformity. Note the seemingly prominent ulnar head and apparent volar subluxation of the wrist on the forearm.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Bae DS. Pediatric Hand and Upper Limb Surgery. Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94419 Version 3.0</div></div></div>"},"94420":{"type":"graphic_diagnosticimage","displayName":"Madelung deformity radiographs","title":"Madelung deformity radiographs","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Madelung deformity radiographs</div><div class=\"cntnt\"><img style=\"width:609px; height:444px;\" src=\"images/PEDS/94420_Madelung_deformity_radiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographs of a Madelung deformity.<br />(A) Anteroposterior view.<br />(B) Lateral view.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Bae DS. Pediatric Hand and Upper Limb Surgery. Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 94420 Version 3.0</div></div></div>"},"94426":{"type":"graphic_picture","displayName":"Acanthosis nigricans neck 3","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:590px; height:454px;\" src=\"images/DERM/94426_Acanthosis_nigricans_neck_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyperpigmented, velvety plaque is present on the neck of this patient with acanthosis nigricans.</div><div id=\"graphicVersion\">Graphic 94426 Version 1.0</div></div></div>"},"94427":{"type":"graphic_picture","displayName":"Terra firma-forme dermatosis","title":"Terra firma-forme dermatosis","html":"<div class=\"graphic\"><div style=\"width: 895px\" class=\"figure\"><div class=\"ttl\">Terra firma-forme dermatosis</div><div class=\"cntnt\"><img style=\"width:875px; height:342px;\" src=\"images/DERM/94427_Terrafirmaformedermatosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Brown-gray pigmented patches on the abdomen with islands of normal skin.<br />(B) Remarkable response to wiping of pigmented patches with a gauze pad saturated with isopropyl alcohol.</div><div class=\"graphic_reference\">From: Erkek E, Sahin S, &Ccedil;etin ED, Sezer E. Terra firma-forme dermatosis. Indian J Dermatol Venereol Leprol 2012; 78:358. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=3;spage=358;epage=360;aulast=Erkek\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.95455</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94427 Version 2.0</div></div></div>"},"94428":{"type":"graphic_picture","displayName":"Erythema ab igne dark skin","title":"Erythema ab igne","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Erythema ab igne</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94428_Erythema_ab_igne_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticular hyperpigmentation on the back of a patient who used to sit with his back in proximity of a heating source.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94428 Version 1.0</div></div></div>"},"94431":{"type":"graphic_picture","displayName":"Schisto egg microscopy","title":"Schistosomiasis egg morphology","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Schistosomiasis egg morphology</div><div class=\"cntnt\"><img style=\"width:557px; height:572px;\" src=\"images/ID/94431_Schisto_egg_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human schistosomiasis eggs:<br />(A) <em>S. mansoni</em>.<br />(B) <em>S. hematobium</em>.<br />(C) <em>S. intercalatum</em>.<br />(D) <em>S. japonicum</em>.<br />(E) <em>S. mekongi</em>.</div><div class=\"graphic_reference\">Reproduced from: Clerinx J, Van Gompel A. Schistosomiasis in travelers and migrants. Travel Med Infect Dis 2011; 9:6. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94431 Version 1.0</div></div></div>"},"94432":{"type":"graphic_table","displayName":"Catch-up schedule Hib US","title":"Catch-up schedule for <em>Haemophilus influenzae</em> type b (Hib) immunization for children (<5 years) in the United States who are not at high-risk of invasive Hib disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Catch-up schedule for <em>Haemophilus influenzae</em> type b (Hib) immunization for children (&lt;5 years) in the United States who are not at high-risk of invasive Hib disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Current age</td> <td class=\"subtitle1\">Catch-up regimen</td> </tr> <tr> <td>&#60;6 months</td> <td>Up to three doses of PRP-T* or two doses of PRP-OMP &#8805;4 weeks apart before age 12 months and one dose of Hib conjugate vaccine at 12 through 15 months of age at least 8 weeks after the previous dose</td> </tr> <tr> <td>7 through 11 months</td> <td>Up to two doses of PRP-T* or PRP-OMP &#8805;4 weeks apart before age 12 months and one dose of Hib conjugate vaccine at 12 through 60 months of age at least 8 weeks after the previous dose</td> </tr> <tr> <td>12 through 14 months</td> <td>Two doses of Hib conjugate vaccine &#8805;8 weeks apart, up to 60 months of age</td> </tr> <tr> <td>15 through&nbsp;59 months</td> <td>Single dose of Hib conjugate vaccine up to 60 months of age</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; PRP-OMP: polyribosylribitol phosphate conjugated to the outer membrane protein complex of <EM innerHtml>Neisseria meningitides</EM>; DTaP: diphtheria tetanus-toxoid-acellular pertussis vaccine; IPV: inactivated polio vaccine.<br />* PRP-T Hib conjugate vaccines approved for this age group include ActHIB, Hiberix, and&nbsp;DTaP-IPV/Hib.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <A href=\"http://www.cdc.gov/mmwr/pdf/rr/rr6301.pdf\" target=_blank>MMWR Recomm Rep 2014; 63:1</A>.&nbsp;</LI>&#xD;&#xA;<LI>Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. Available at: <A spellcheck=true href=\"http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html\" target=_blank>www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html</A>. Accessed on February 14, 2018.</LI></OL></div><div id=\"graphicVersion\">Graphic 94432 Version 7.0</div></div></div>"},"94433":{"type":"graphic_table","displayName":"Predictors of difficult endotracheal intubation","title":"Predictors of difficult endotracheal intubation (by direct laryngoscopy)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of difficult endotracheal intubation (by direct laryngoscopy)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Prior difficult intubation </li> </ul> </td> </tr> <tr> <td> <ul> <li>Interincisor (intergingival edentulous patients) gap (&#60;4 cm) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Thyromental distance (&#60;6 cm) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sternomental distance (&#60;12 cm)* </li> </ul> </td> </tr> <tr> <td> <ul> <li>Head and neck extension (&#60;30 degrees from neutral) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Mallampati oropharyngeal classification (class 3 or 4) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Mandibular protrusion (inability to prognath)* </li> </ul> </td> </tr> <tr> <td> <ul> <li>Neck circumference (&#62;40 cm)* </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sub-mental compliance (hard and noncompliant)* </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Physical findings predictive of difficult endotracheal intubation. The greater the number of positive findings, the more likely intubation by direct laryngoscopy will be difficult. The highest positive predictive value comes from a history of difficulty with intubation, or findings of a short thyromental distance or decreased range of motion of the neck.</div><div class=\"graphic_footnotes\">cm: centimeters.<br />* Also predicts difficult video laryngoscopy (in addition to large tonsils and epiglottis and history of Cormack and Lehane grade 3 or 4 at direct laryngoscopy).</div><div class=\"graphic_reference\">Information from:<br /><ol>&#xD;&#xA;    <li>Tremblay MH, Williams S, Robitaille A, Drolet P. Poor visualization during direct laryngoscopy and high upper lip bite test score are predictors of difficult intubation with the GlideScope videolaryngoscope Anesth Analg 2008; 106:1495.</li>&#xD;&#xA;    <li>Aziz MF, Healy D, Kheterpal S, et al. Routine clinical practice effectiveness of the Glidescope in difficult airway management: an analysis of 2,004 Glidescope intubations, complications, and failures from two institutions. Anesthesiology 2011; 114:34.</li>&#xD;&#xA;    <li>Hung OR, Pytka S, Morris I, et al. Clinical trial of a new lightwand device (Trachlight) to intubate the trachea. Anesthesiology 1995; 83:509.</li>&#xD;&#xA;    <li>Hung OR, Pytka S, Morris I, et al. Lightwand intubation: II--Clinical trial of a new lightwand for tracheal intubation in patients with difficult airways. Can J Anaesth 1995; 42:826.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 94433 Version 4.0</div></div></div>"},"94434":{"type":"graphic_table","displayName":"Predictors of difficult mask ventilation","title":"Predictors of difficult mask ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of difficult mask ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Older age (adult) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Male gender </li> </ul> </td> </tr> <tr> <td> <ul> <li>Obesity (BMI &#62;26 kg/m<sup>2</sup>) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Edentulous </li> </ul> </td> </tr> <tr> <td> <ul> <li>Facial hair (especially beard) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Mallampati oropharyngeal grade 3 or 4 </li> </ul> </td> </tr> <tr> <td> <ul> <li>Mandibular protrusion (inability to protrude) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Thyromental distance (short) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Snoring (indication of OSA) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Abnormal neck anatomy&nbsp;</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Risk of difficult mask ventilation increases with greater number of predictors.</div><div class=\"graphic_footnotes\">BMI: body mass index; kg: kilograms; m: meters; OSA: obstructive sleep apnea.</div><div class=\"graphic_reference\">Information from:<br /><ol>&#xD;&#xA;    <li>Langeron O, Masso E, Huraux C, et al. Prediction of difficult mask ventilation. Anesthesiology 2000; 92:1229.</li>&#xD;&#xA;    <li>Kheterpal S, Healy D, Aziz MF, et al. Incidence, predictors, and outcome of difficult mask ventilation combined with difficult laryngoscopy: a report from the multicenter perioperative outcomes group. Anesthesiology 2013; 119:1360.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 94434 Version 3.0</div></div></div>"},"94435":{"type":"graphic_table","displayName":"Facility requirements PCI without on-site surgery","title":"Facility requirements for PCI programs without on-site surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Facility requirements for PCI programs without on-site surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Source</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General recommendations</td> </tr> <tr> <td class=\"indent1\">Requisite support equipment must be available and in good working order to respond to emergency situations.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>PCI-CS</p> ML</td> </tr> <tr> <td class=\"indent1\">Should demonstrate appropriate planning for program development and should complete both a primary PCI development program and an elective PCI development program. Program developments to include routine care process and case selection review.</td> <td class=\"centered\"> <p>AHA</p> D2B</td> </tr> <tr> <td class=\"indent1\">Full support from hospital administration in fulfilling the necessary institutional requirements, including appropriate support services such as intensive care, advanced imaging (CT, MR and other vascular imaging), respiratory care, blood bank and nephrology consultation with access to dialysis.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>PCI-CS</p> ECD</td> </tr> <tr> <td class=\"indent1\">The institution should have systems for credentialing and governing the PCI program. On-site data collection, quality assessment, quality improvement and error management are essential. Each institution must establish an ongoing mechanism for valid and continuous peer review of its quality and outcomes. A quality improvement program should routinely 1) review quality and outcomes of the entire program; 2) review results of individual operators; 3) include risk adjustment; 4) provide peer review of difficult or complicated cases; and 5) perform random case reviews. The review process should assess the appropriateness of the interventional procedures. Evaluation should include the clinical indications for the procedure, technical performance and the quality and interpretation of the coronary angiograms.</td> <td class=\"centered\"> <p>PCI-CS</p> <p>AHA</p> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Written agreements for emergency transfer of patients to a facility with cardiac surgery must exist. Transport protocols should be tested a minimum of two times per year involving both the referring and receiving facility. Develop agreements with a ground or air ambulance service capable of advanced life support and IABP transfer that guarantees a transport vehicle will be on-site to begin transport in &#8804;30 min <em>and arrival at the surgical hospital within 60 min of the decision to declare the need for emergency surgery</em>. Tertiary facility must agree to accept emergent and nonemergent transfers for additional medical care, cardiac surgery, or intervention. <em>Tertiary centers should be able to establish cardiopulmonary bypass on emergency transfer patients within &#60;120 min of an urgent referral.</em></td> <td class=\"centered\"> <p>PCI-GL</p> <p>AHA</p> <p>PCI-CS</p> <p>ECD</p> <em>New</em></td> </tr> <tr> <td class=\"indent1\">Well-equipped and maintained cardiac catheterization laboratory with high-resolution digital imaging capability. The capability for real-time transfer of images and hemodynamic data [via T-1 transmission line] as well as audio and video images to review terminals for consultation at the facility providing surgical backup support is highly recommended.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>PCI-CS</p> ML</td> </tr> <tr> <td class=\"indent1\">Appropriate inventory of interventional equipment, including guide catheters, balloons and stents in multiple sizes; thrombectomy and distal protection devices; covered stents; temporary pacemakers; and pericardiocentesis trays. <em>Access to other diagnostic modalities such as intravascular ultrasound and fractional flow reserve is required.</em> Rotational or other atherectomy devices and the treatment of CTOs should not be performed in facilities without on-site surgery.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>PCI-CS</p> <em>New</em></td> </tr> <tr> <td class=\"indent1\">Meticulous clinical and angiographic selection criteria for PCI.</td> <td class=\"centered\"> <p>PCI-GL</p> AHA</td> </tr> <tr> <td class=\"indent1\">Participation in a national data registry, such as the ACC NCDR in the United States, is required. This allows benchmarking, risk adjustment, and facilitates outcomes analysis of local data.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>ECD</p> AHA</td> </tr> <tr> <td class=\"indent1\">A program should be in place to track and ensure treatments with ACC/AHA guideline-based Class I therapies, both acutely and at discharge.</td> <td class=\"centered\"> <p>PCI-CS</p> ML</td> </tr> <tr> <td class=\"indent1\">Full service laboratories [both primary and elective PCI, with and without on-site cardiac surgery] performing &#60;200 cases annually must have stringent systems and process protocols with close monitoring of clinical outcomes and additional strategies that promote adequate operator and catheterization laboratory staff experience through collaborative relationships with larger volume facilities. Both physicians and staff should have the opportunity to work at a high volume center to enhance their skills. The continued operation of laboratories performing &#60;200 procedures annually that are not serving isolated or underserved populations should be questioned and any laboratory that cannot maintain satisfactory outcomes should be closed.</td> <td class=\"centered\">PCI-CS</td> </tr> <tr> <td class=\"indent1\"><em>Geographic isolation exists if the emergency transport time to another facility is &#62;30 min.</em></td> <td class=\"centered\"><em>New</em></td> </tr> <tr> <td class=\"indent1\">Satisfactory outcomes should be defined by each local facility as part of their quality review process and should be based on national or regional benchmarks. Programs that fail to meet their established criteria for satisfactory performance for two consecutive quarters must undertake efforts to improve engaging outside experts if necessary. Failure to improve quality metrics should also be grounds for program closure regardless of the location.</td> <td class=\"centered\"> <p>ML</p> <p>PCI-CS</p> D2B</td> </tr> <tr> <td class=\"indent1\">As part of the local continuous quality improvement program, there should be a regular review of all patients transferred for emergency surgery with the outcome of surgery and identification of improvement opportunities.</td> <td class=\"centered\">PCI-GL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">STEMI treatment recommendations</td> </tr> <tr> <td class=\"sublist2_start\">Each community should develop a STEMI system of care that follows standards at least as strong as those developed for Mission Lifeline, including:</td> <td class=\"centered\">2009<br /> PCI-GL</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Performance of primary PCI as the first-choice treatment for STEMI to ensure streamlined care paths and increased case volumes. </li> </ul> </td> <td class=\"centered\" rowspan=\"2\">2011<br /> PCI-GL</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>A process for prehospital identification and activation. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Protocols for triage, diagnosis, and cardiac catheterization laboratory activation should be established within the primary PCI hospital/STEMI-Receiving Center. </li> </ul> </td> <td class=\"centered\">ML</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>A single activation phone call should alert the STEMI team. Criteria for EMS activation of the cardiac catheterization laboratory should be established in conjunction with EMS providers. </li> </ul> </td> <td class=\"centered\" rowspan=\"2\">D2B</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Transfer protocols for patients who arrive at STEMI referral centers who are in cardiogenic shock and/or are primary PCI candidates ineligible for fibrinolytic drugs. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">STEMI receiving centers should be available and on-call 24 hours/7 days a week (no diversion) to perform primary PCI. Primary PCI should not be performed at facilities unless it is provided on a 24/7 schedule.* The cardiac catheterization laboratory staff and interventional cardiologist should arrive within 30 min of a STEMI activation call. Facilities should have a plan for triage and treatment of simultaneous presentation of STEMI patients.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>AHA</p> ML</td> </tr> <tr> <td class=\"indent1\">STEMI receiving centers should perform a minimum of 36 primary PCI procedures annually, and these procedures should ideally be performed at facilities that perform a minimum of 200 total PCI procedures annually.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>PCI-CS</p> ML</td> </tr> <tr> <td class=\"indent1\">Facilities performing only primary PCI should perform a minimum of 36 primary PCIs annually and work in collaboration with a high volume PCI facility to ensure good outcomes.</td> <td class=\"centered\"> <p>PCI-GL</p> PCI-CS</td> </tr> <tr> <td class=\"indent1\">There should be a recognized STEMI-Receiving Center liaison/system coordinator to the system and a recognized physician champion.</td> <td class=\"centered\">ML</td> </tr> <tr> <td class=\"indent1\">The STEMI-Receiving Centers should participate in the Mission Lifeline-approved data collection tool, ACTION Registry-Get with the Guidelines&#8482;.</td> <td class=\"centered\"> <p>ML</p> D2B</td> </tr> <tr> <td class=\"indent1\">They should also participate in the regional Mission Lifeline Stakeholder group (if available) to contribute to the development of a regional STEMI System of Care Plan.</td> <td class=\"centered\">ML</td> </tr> <tr> <td class=\"sublist2_start\">Monthly multidisciplinary team meetings to evaluate outcomes and quality improvement data. Operational issues should be reviewed, problems identified, and solutions implemented. The following measurements should be evaluated on an ongoing basis:</td> <td class=\"centered\" rowspan=\"11\">ML</td> </tr> <tr> <td class=\"indent2\">a. Door-to-first device time, nontransfer patients</td> </tr> <tr> <td class=\"indent2\">b. STEMI Referral Hospital ED door-to-balloon [first device used] time</td> </tr> <tr> <td class=\"indent2\">c. First medical contact to balloon inflation [first device used] time, nontransfer patients</td> </tr> <tr> <td class=\"indent2\">d. First medical contact to balloon inflation [first device used] time, transfer patients</td> </tr> <tr> <td class=\"indent2\">e. Proportion of eligible patients receiving reperfusion therapy</td> </tr> <tr> <td class=\"indent2\">f. Proportion of eligible patients administered guideline-based class I therapies</td> </tr> <tr> <td class=\"indent2\">g. Proportion of patients with field diagnosis of STEMI and activation of the Cardiac Catheterization Laboratory for intended primary PCI who</td> </tr> <tr> <td class=\"indent3\">i. Do not undergo acute catheterization because of misdiagnosis</td> </tr> <tr> <td class=\"indent3\">ii. Undergo acute catheterization and found to have no elevation in cardiac biomarkers and no revascularization in the first 24 h</td> </tr> <tr> <td class=\"indent2\">h. In-hospital mortality</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><em>Italics font:</em> New or modified recommendation in the document.</div><div class=\"graphic_footnotes\">ACC: American College of Cardiology; AHA: American Heart Association; CT: computed tomography; CTO: chronic total occlusion; D2B: door-to-balloon alliance; ECD: 2012 expert consensus document; EMS: emergency medical systems; GL: guidelines; IABP: intraaortic balloon pump; IVUS: intravascular ultrasound; ML: Mission Lifeline; MR: magnetic resonance; New: new recommendation in this document; NCDR: National Cardiovascular Data Registry; PCI-CS: 2013 PCI Competency Statement; PCI-GL: 2011 ACCF/AHA/SCAI PCI guidelines; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions; STEMI: ST-segment elevation myocardial infarction.<br />* Required for United States facilities but might not be possible for all facilities worldwide.</div><div class=\"graphic_reference\">Reproduced from: Dehmer GJ, Blankenship JC, Cilingiroglu M, et al. SCAI/ACC/AHA expert consensus document: 2014 update on percutaneous coronary intervention without on-site surgical backup. J Am Coll Cardiol 2014 Mar 17. DOI: 10.1016/j.jacc.2014.03.002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94435 Version 3.0</div></div></div>"},"94436":{"type":"graphic_table","displayName":"Predictors of difficult SGA ventilation","title":"Predictors of difficult supraglottic airway ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of difficult supraglottic airway ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Male gender </li> </ul> </td> </tr> <tr> <td> <ul> <li>Obesity (BMI &#62;30 kg/m<sup>2</sup>) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Poor dentition or large incisors </li> </ul> </td> </tr> <tr> <td> <ul> <li>Neck radiation history </li> </ul> </td> </tr> <tr> <td> <ul> <li>Reduced mouth opening </li> </ul> </td> </tr> <tr> <td> <ul> <li>Reduced cervical spine motion </li> </ul> </td> </tr> <tr> <td> <ul> <li>Tonsillar hypertrophy </li> </ul> </td> </tr> <tr> <td> <ul> <li>Glottic, hypopharyngeal, and subglottic pathology </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Factors that predict difficulty with ventilation using a supraglottic airway such as the LMA.</div><div class=\"graphic_footnotes\">BMI: body mass index; kg: kilograms; m: meters; LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Ramachandran SK, Mathis MR, Tremper KK, et al. Predictors and clinical outcomes from failed Laryngeal Mask Airway Unique™: a study of 15,795 patients. Anesthesiology 2012; 116:1217.</LI>&#xD;&#xA;<LI>Law JA, Broemling N, Cooper RM, et al. The difficult airway with recommendations for management--part 2--the anticipated difficult airway. Can J Anaesth 2013; 60:1119.</LI></OL></div><div id=\"graphicVersion\">Graphic 94436 Version 5.0</div></div></div>"},"94437":{"type":"graphic_table","displayName":"Personnel requirements for PCI programs without on-site surgery","title":"Personnel requirements for PCI programs without on-site surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Personnel requirements for PCI programs without on-site surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Source</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Personnel recommendations</td> </tr> <tr> <td class=\"indent1\">Experienced nursing and technical laboratory staff with training in interventional laboratories. Personnel must be comfortable treating acutely ill patients with hemodynamic and electrical instability.</td> <td class=\"centered\"> <p>PCI-GL</p> PCI-CS</td> </tr> <tr> <td class=\"indent1\">Coronary care unit nursing staff must be experienced and comfortable with invasive hemodynamic monitoring, operation of temporary pacemaker, management of IABP, <em>management of in-dwelling arterial/venous sheaths and identifying potential complications such as abrupt closure, recurrent ischemia, and access site complications</em>.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>PCI-CS</p> <em>New</em></td> </tr> <tr> <td class=\"indent1\">Personnel should be capable of endotracheal intubation and ventilator management both on-site and during transfer if necessary.</td> <td class=\"centered\">PCI-GL</td> </tr> <tr> <td class=\"indent1\">Operators should have ABIM board certification in interventional cardiology and maintain certification, with the exception of operators who have gone through equivalent training outside the United States and are ineligible for ABIM certification and recertification exams.</td> <td class=\"centered\">PCI-CS</td> </tr> <tr> <td class=\"indent1\">Interventional cardiologists should perform a minimum of 50 coronary interventional procedures per year [averaged over a two-year period] to maintain competency.</td> <td class=\"centered\">PCI-CS</td> </tr> <tr> <td class=\"indent1\">Primary PCI should be performed by experienced operators who perform a minimum of 50 elective PCI procedures per year and, ideally, at least 11 primary PCI procedures per year. Ideally, these procedures should be performed in institutions that perform more than 200 elective PCIs per year and more than 36 primary PCI procedures for STEMI per year.</td> <td class=\"centered\"> <p>PCI-CS</p> ML</td> </tr> <tr> <td class=\"indent1\">Facilities should develop internal review processes to assess operators performing &#60;50 PCIs annually. Individual operator level volume is one of several factors that should be considered in assessing operator competence, which include lifetime experience, institutional volume, individual operator's other cardiovascular interventions, and quality assessment of the operator's ongoing performance.</td> <td class=\"centered\">PCI-CS</td> </tr> <tr> <td class=\"indent1\"><em>It is unwise for a newly trained interventional cardiologist to start a new PCI program. Newly trained interventional cardiologists joining an established PCI program should be mentored by existing physicians until it is determined their skills, judgment, and outcomes are acceptable.</em></td> <td class=\"centered\"><em>New</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><em>Italics font:</em> New or modified recommendation in the document.</div><div class=\"graphic_footnotes\">ABIM: American Board of Internal Medicine; ML: Mission Lifeline; PCI-CS: 2013 PCI Competency Statement; PCI-GL: 2011 ACCF/AHA/SCAI PCI guidelines; IABP: intraaortic balloon pump; New: new recommendation in this document; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.</div><div class=\"graphic_reference\">Reproduced from: Dehmer GJ, Blankenship JC, Cilingiroglu M, et al. SCAI/ACC/AHA expert consensus document: 2014 update on percutaneous coronary intervention without on-site surgical backup. J Am Coll Cardiol 2014 Mar 17. DOI: 10.1016/j.jacc.2014.03.002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94437 Version 1.0</div></div></div>"},"94438":{"type":"graphic_table","displayName":"Recommendations for off-site surgical backup and case selection","title":"Recommendations for off-site surgical backup and case selection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for off-site surgical backup and case selection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Source</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Recommendations - Cardiologist - Cardiac surgeon interactions</td> </tr> <tr> <td class=\"indent1\">Interventional cardiologists must establish a working relationship with cardiac surgeons at the receiving facility.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Cardiac surgeons should have privileges at the referring facility to allow review of treatment options as time allows.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Ideally, face-to-face meetings between cardiothoracic surgeons and cardiologists involved should occur on a regular basis <em>(Heart Team approach) especially for the discussion of management of patients undergoing nonprimary PCI who have left main, three-vessel CAD or two-vessel CAD with involvement of the LAD or comorbidities such as diabetes, depressed LV function, or complex anatomy</em>.</td> <td class=\"centered\"> <p>PCI-GL</p> <p>ECD</p> <em>New</em></td> </tr> <tr> <td class=\"indent1\">Cardiac surgeon and receiving hospital agree to provide cardiac surgical backup for urgent cases at all hours and for elective cases at mutually agreed hours.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Surgeon and receiving facility ensure that patients will be accepted based on medical condition, capacity of surgeon to provide services at the time of request, and availability of resources. If this cannot be ensured before the start of an elective procedure, the case should not be done at that time.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Interventional cardiologists must review with surgeons the immediate needs and status of any patient transferred for urgent surgery.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Interventional cardiologist should be familiar with and have immediate access to appropriate life support devices, such an intraaortic balloon pumps, and should be qualified for handling emergencies such as pericardial tamponade and embolization.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Hospital administrations from both facilities endorse the transfer agreement.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Transferring physicians obtain consent for surgery from patients or appropriate surrogates.</td> <td class=\"centered\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\">Initial informed consent for PCI discloses that the procedure is being performed without on-site surgical backup and acknowledges the possibility of risks related to transfer. The consent process should include the risk of urgent surgery and state that a written plan for transfer exists. <em>Consent for PCI should be obtained before the procedure and before any sedatives are given. Consent for PCI obtained while the patient is on the table is not informed consent and is unacceptable in nonemergency situations.</em></td> <td class=\"centered\"> <p>PCI-GL</p> <p>ECD</p> <em>New</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Recommendations - Case selection and management</td> </tr> <tr> <td class=\"sublist2_start\">Avoid intervention in patients with:</td> <td class=\"centered\" rowspan=\"8\"> <p>PCI-GL</p> <p>ECD</p> <em>New</em></td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>&#62;50 percent diameter stenosis of left main artery proximal to infarct-related lesion, especially if the area in jeopardy is relatively small and overall LV function is not severely impaired </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Long, calcified, or severely angulated target lesions at high risk for PCI failure with TIMI flow grade 3 present during initial diagnostic angiography </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Lesions in areas other than the infarct artery (unless they appeared to be flow limiting in patients with hemodynamic instability or ongoing symptoms) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Lesions with TIMI flow grade 3 in patients with left main or three-vessel disease where bypass surgery is likely a superior revascularization strategy compared with PCI </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Culprit lesions in more distal branches that jeopardize only a modest amount of myocardium when there is more proximal disease that could be worsened by attempted intervention </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Chronic total occlusion </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><em>The management of patients with STEMI resuscitated from sudden cardiac death is complex, and decisions about the need for immediate PCI with or without therapeutic hypothermia or possible transfer to a tertiary facility for treatment should be individualized.</em></td> </tr> <tr> <td class=\"sublist2_start\">Emergency transfer for coronary bypass surgery patients with:</td> <td class=\"centered\" rowspan=\"3\"> <p>PCI-GL</p> ECD</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>High-grade left main or three-vessel coronary disease with clinical or hemodynamic instability after successful or unsuccessful PCI of an occluded vessel and preferably with IABP support </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Failed or unstable PCI result and ongoing ischemia, with IABP support during transfer </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><em>Italics font:</em> New or modified recommendation in the document.</div><div class=\"graphic_footnotes\">CTO: chronic total occlusion; ECD: 2012 Expert Consensus Document on Cardiac Catheterization Standards; PCI-GL: 2011 ACCF/AHA/SCAI PCI Guidelines; IABP: intraaortic balloon pump; LV: left ventricle; New: new recommendation in this document; PCI: percutaneous coronary intervention; TIMI: thrombolysis in myocardial infarction.</div><div class=\"graphic_reference\">Reproduced from: Dehmer GJ, Blankenship JC, Cilingiroglu M, et al. SCAI/ACC/AHA expert consensus document: 2014 update on percutaneous coronary intervention without on-site surgical backup. J Am Coll Cardiol 2014 Mar 17. DOI: 10.1016/j.jacc.2014.03.002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94438 Version 2.0</div></div></div>"},"94439":{"type":"graphic_figure","displayName":"Hib incidence US","title":"Estimated annual incidence* of invasive <em>Haemophilus influenzae</em> type b (Hib) disease in children aged <5 years - United States 1980 to 2012","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Estimated annual incidence* of invasive <em>Haemophilus influenzae</em> type b (Hib) disease in children aged <5 years - United States 1980 to 2012</div><div class=\"cntnt\"><img style=\"width:581px; height:363px;\" src=\"images/PEDS/94439_Hib_incidence_US.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Per 100,000 population.</div><div class=\"graphic_reference\">Reproduced from: Briere EC, Rubin L, Moro PL, et al. Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1.</div><div id=\"graphicVersion\">Graphic 94439 Version 1.0</div></div></div>"},"94440":{"type":"graphic_table","displayName":"Unsuitable characteristics without on-site surgery","title":"Patient and lesion characteristics that could be unsuitable for nonemergency procedures at facilities without on-site cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient and lesion characteristics that could be unsuitable for nonemergency procedures at facilities without on-site cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Source</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High-risk patients</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Decompensated congestive heart failure [Killip Class &#8805;3] without evidence for active ischemia. </li> </ul> </td> <td class=\"centered\">PCI-GL</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recent [&#60;8 weeks] cerebrovascular accident. </li> </ul> </td> <td class=\"centered\">AHA</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Advanced malignancy. </li> </ul> </td> <td class=\"centered\">ECD</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Known clotting disorders. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>LVEF &#8804;30 percent. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Chronic kidney disease [creatinine &#62;2.0 mg/dL or creatinine clearance &#60;60 mL/min]. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Serious ongoing ventricular arrhythmias. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients with left main stenosis [&#62;50 percent diameter] or three-vessel disease unprotected by prior bypass surgery [&#62;70 percent stenoses in the proximal or mid segments of all major epicardial coronary arteries], treatment of any or all stenoses. Scoring systems, such as SYNTAX, may be useful in defining the extent of disease and type of revascularization procedure. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients with a single-target lesion that jeopardizes an extensive amount of myocardium. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients undergoing intervention on the last remaining conduit to the heart. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High-risk lesions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Unprotected left main stenosis. </li> </ul> </td> <td class=\"centered\">PCI-GL</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Diffuse disease [&#62;20 mm in length]. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Extremely angulated segment [&#62;90 percent] or excessive proximal or in-lesion tortuosity. </li> </ul> </td> <td class=\"centered\">ECD</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>More than moderate calcification of a stenosis or proximal segment. </li> </ul> </td> <td class=\"centered\"><em>New</em></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Inability to protect major side branches. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Degenerated older vein grafts with friable lesions. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Substantial thrombus in the vessel or at the lesion site. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Any other feature that could, in the operator's judgment, impede successful stent deployment. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Anticipated need for rotational or other atherectomy device, cutting balloon, or laser. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><em>The characteristics listed above identify high-risk patient and lesion features but are not absolute contraindications to performing PCI at a facility without on-site surgery. For example, an elevated creatinine level increases the procedure risk for the patient, but this is not unique to facilities without on-site surgery and treatments to mitigate this complication can be used at all facilities. Ultimately, the operator should consider all factors and make a decision about the suitability of the patient for PCI at the facility.</em></td> <td class=\"centered\"><em>New</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Strategy for surgical backup based on lesion and patient risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>High-risk patients with high-risk lesions should not undergo nonemergency PCI at a facility without on-site surgery. </li> </ul> </td> <td class=\"centered\">PCI-GL</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>High-risk patients with non-high-risk lesions: Nonemergency patients with this profile may undergo PCI, but confirmation that a cardiac surgeon and operating room are immediately available is necessary. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Non-high-risk patients with high-risk lesions require no additional precautions. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Non-high-risk patients with non-high-risk lesions require no additional precautions. Best scenario for PCI without on-site surgery. </li> </ul> </td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><em>Italics font:</em> New or modified recommendation in the document.</div><div class=\"graphic_footnotes\">CTO: chronic total occlusion; ECD: 2012 Expert Consensus Document on Cardiac Catheterization Standards; PCI-GL: 2011 ACCF/AHA/SCAI PCI Guidelines; LVEF: left ventricular ejection fraction; New: new recommendation; PCI: percutaneous coronary intervention; SYNTAX: Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.</div><div class=\"graphic_reference\">Reproduced from: Dehmer GJ, Blankenship JC, Cilingiroglu M, et al. SCAI/ACC/AHA expert consensus document: 2014 update on percutaneous coronary intervention without on-site surgical backup. J Am Coll Cardiol 2014 Mar 17. DOI: 10.1016/j.jacc.2014.03.002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94440 Version 2.0</div></div></div>"},"94441":{"type":"graphic_table","displayName":"Hib vaccine for high-risk groups","title":"Guidance for Haemophilus influenzae type b (Hib) vaccination in high-risk groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidance for Haemophilus influenzae type b (Hib) vaccination in high-risk groups</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">High-risk group*</td> <td class=\"subtitle1\">Hib vaccine guidance</td> </tr> <tr class=\"divider_bottom\"> <td>Patients aged &#60;12 months</td> <td>Follow routine Hib vaccination recommendations</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Patients aged 12 to 59 months</td> <td>If unimmunized or received 0 or 1 dose before age 12 months: 2 doses, 8 weeks apart</td> </tr> <tr> <td>If received &#8805;2 doses before age 12 months: 1 dose, 8 weeks after last dose</td> </tr> <tr class=\"divider_bottom\"> <td>If completed a primary series and received a booster dose at age &#8805;12 months: No additional doses</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Patients aged &#60;60 months undergoing chemotherapy or radiation therapy<sup>&#182;</sup></td> <td>If routine Hib doses administered &#8805;14 days before starting therapy: Revaccination not required</td> </tr> <tr class=\"divider_bottom\"> <td>If dose administered within 14 days of starting therapy or given during therapy: Repeat doses starting at least 3 months following therapy completion</td> </tr> <tr class=\"divider_bottom\"> <td>Patients aged &#8805;15 months undergoing elective splenectomy</td> <td>If unimmunized<sup>&#916;</sup>: 1 dose prior to procedure<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Asplenic patients aged &#62;59 months and adults</td> <td>If unimmunized<sup>&#916;</sup>: 1 dose</td> </tr> <tr class=\"divider_bottom\"> <td>HIV-infected children aged &#8805;60 months</td> <td>If unimmunized<sup>&#916;</sup>: 1 dose</td> </tr> <tr class=\"divider_bottom\"> <td>HIV-infected adults</td> <td>Hib vaccination is not recommended</td> </tr> <tr> <td>Recipients of hematopoietic stem cell transplant, all ages</td> <td>Regardless of Hib vaccination history: 3 doses (at least 4 weeks apart) beginning 6 to 12 months after transplant</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Persons with functional or anatomic asplenia, HIV infection, immunoglobulin deficiency including immunoglobulin G2 subclass deficiency, or early component complement deficiency; recipients of a hematopoietic stem cell transplant; and those receiving chemotherapy or radiation therapy for malignant neoplasms.<br />¶&nbsp;Some experts suggest conducting serologic testing for these patients.<br />Δ Patients who have not received a primary series and booster dose or at least&nbsp;1 dose of Hib vaccine after 14 months are considered unimmunized.<br /><FONT class=lozenge>◊</FONT> Some experts suggest vaccination at least 14 days before the procedure. Some experts suggest administering a dose prior to elective splenectomy regardless of prior vaccination history.</div><div class=\"graphic_reference\">Reproduced from: Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1.</div><div id=\"graphicVersion\">Graphic 94441 Version 4.0</div></div></div>"},"94444":{"type":"graphic_picture","displayName":"Standard retinal photo 2A","title":"Standard retinal photograph #2A","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Standard retinal photograph #2A</div><div class=\"cntnt\"><img style=\"width:590px; height:548px;\" src=\"images/ENDO/94444_Standard_photo_2A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard photograph from the Early Treatment of Diabetic Retinopathy Study (ETDRS), which is used as the gold standard for grading severity in the clinical and research arena. Photograph #2A shows retinal hemorrhages and microaneurysms.</div><div class=\"graphic_reference\">Reproduced with permission from: Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991; 98:786. Copyright &copy; 1991 Fundus Photograph Reading Center Department of Ophthalmology &amp; Visual Sciences University of Wisconsin &ndash; Madison.</div><div id=\"graphicVersion\">Graphic 94444 Version 2.0</div></div></div>"},"94445":{"type":"graphic_picture","displayName":"Standard retinal photo 8A","title":"Standard retinal photograph #8A","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Standard retinal photograph #8A</div><div class=\"cntnt\"><img style=\"width:586px; height:549px;\" src=\"images/ENDO/94445_standard_photo_8a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard photograph from the Early Treatment of Diabetic Retinopathy Study (ETDRS), which is used as the gold standard for grading severity in the clinical and research arena. Photograph #8A show intraretinal microvascular abnormalities (eg, dilated capillaries).</div><div class=\"graphic_reference\">Reproduced with permission from: Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991; 98:786. Copyright &copy; 1991 Fundus Photograph Reading Center Department of Ophthalmology &amp; Visual Sciences University of Wisconsin &ndash; Madison.</div><div id=\"graphicVersion\">Graphic 94445 Version 2.0</div></div></div>"},"94447":{"type":"graphic_algorithm","displayName":"ASA difficult airway algorithm","title":"American Society of Anesthesiologists difficult airway algorithm","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists difficult airway algorithm</div><div class=\"cntnt\"><img style=\"width:820px; height:934px;\" src=\"images/ANEST/94447_ASAdifficultairwayalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SGA: supraglottic airway; LMA: laryngeal mask airway; ILMA: intubating laryngeal mask airway.<br />* Confirm ventilation, tracheal intubation, or SGA placement with exhaled CO<sub>2</sub>.<br />&para; Invasive airway access includes surgical or percutaneous airway, jet ventilation, and retrograde intubation.<br />&Delta; Other options include (but are not limited to): surgery utilizing face mask or supraglottic airway (SGA) anesthesia (eg, LMA, ILMA, laryngeal tube), local anesthesia infiltration, or regional nerve blockade. Pursuit of these options usually implies that mask ventilation will not be problematic. Therefore, these options may be of limited value if this step in the algorithm has been reached via the Emergency Pathway.<br /><span class=\"lozenge\">&loz;</span> Alternative difficult intubation approaches include (but are not limited to): video-assisted laryngoscopy, alternative laryngoscope blades, SGA (eg, LMA or ILMA) as an intubation conduit (with or without fiberoptic guidance), fiberoptic intubation, intubating stylet or tube changer, light wand, and blind oral or nasal intubation.<br />&sect; Emergency noninvasive airway ventilation consists of a SGA.<br />&yen; Consider re-preparation of the patient for awake intubation or canceling surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Apfelbaum JL, Hagberg CA, Caplan RA, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology 2013; 118:251. DOI: <a href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918684\" target=\"_blank\">10.1097/ALN.0b013e31827773b2</a>. Copyright &copy; 2013 by the American Society of Anesthesiologists, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94447 Version 8.0</div></div></div>"},"94449":{"type":"graphic_table","displayName":"Gestational age by MSD","title":"Determination of gestational age based on mean sac diameter","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determination of gestational age&nbsp;based on&nbsp;mean sac diameter</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Mean sac diameter (mm)</td> <td class=\"subtitle1\" rowspan=\"2\">Mean gestational age (weeks)</td> <td class=\"subtitle1\" colspan=\"3\">Gestational age (days)</td> </tr> <tr> <td class=\"subtitle2\">Mean</td> <td class=\"subtitle2\">95% confidence interval</td> <td class=\"subtitle2\">95% prediction interval</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">5</td> <td class=\"centered\">34.5</td> <td class=\"centered\">34.2-35.5</td> <td class=\"centered\">31.6-38.2</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">5.1</td> <td class=\"centered\">35.8</td> <td class=\"centered\">35.2-36.3</td> <td class=\"centered\">32.5-39.1</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">5.2</td> <td class=\"centered\">36.6</td> <td class=\"centered\">36.1-37.2</td> <td class=\"centered\">33.3-39.9</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">5.4</td> <td class=\"centered\">37.5</td> <td class=\"centered\">37-38</td> <td class=\"centered\">34.2-40.8</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">5.5</td> <td class=\"centered\">38.4</td> <td class=\"centered\">37.9-38.9</td> <td class=\"centered\">35.1-41.7</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">5.6</td> <td class=\"centered\">39.3</td> <td class=\"centered\">38.9-39.7</td> <td class=\"centered\">36-42.6</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">5.7</td> <td class=\"centered\">40.2</td> <td class=\"centered\">39.8-40.6</td> <td class=\"centered\">36.9-43.5</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">5.9</td> <td class=\"centered\">41.1</td> <td class=\"centered\">40.7-41.4</td> <td class=\"centered\">37.8-44.3</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">6</td> <td class=\"centered\">41.9</td> <td class=\"centered\">41.6-42.3</td> <td class=\"centered\">38.7-45.2</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">6.1</td> <td class=\"centered\">42.8</td> <td class=\"centered\">42.5-43.2</td> <td class=\"centered\">39.5-46.1</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">6.2</td> <td class=\"centered\">43.7</td> <td class=\"centered\">43.4-44</td> <td class=\"centered\">40.4-47</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">6.4</td> <td class=\"centered\">44.6</td> <td class=\"centered\">44.3-44.9</td> <td class=\"centered\">41.3-47.9</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">6.5</td> <td class=\"centered\">45.5</td> <td class=\"centered\">45.2-45.8</td> <td class=\"centered\">42.2-48.7</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">6.6</td> <td class=\"centered\">46.3</td> <td class=\"centered\">46-46.6</td> <td class=\"centered\">43.1-49.6</td> </tr> <tr> <td class=\"centered\">16</td> <td class=\"centered\">6.7</td> <td class=\"centered\">47.2</td> <td class=\"centered\">46.9-47.5</td> <td class=\"centered\">44-50.5</td> </tr> <tr> <td class=\"centered\">17</td> <td class=\"centered\">6.9</td> <td class=\"centered\">48.1</td> <td class=\"centered\">47.8-48.4</td> <td class=\"centered\">44.8-51.4</td> </tr> <tr> <td class=\"centered\">18</td> <td class=\"centered\">7</td> <td class=\"centered\">49</td> <td class=\"centered\">48.6-49.4</td> <td class=\"centered\">45.7-52.3</td> </tr> <tr> <td class=\"centered\">19</td> <td class=\"centered\">7.1</td> <td class=\"centered\">49.9</td> <td class=\"centered\">49.5-50.3</td> <td class=\"centered\">46.6-53.2</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">7.3</td> <td class=\"centered\">50.8</td> <td class=\"centered\">50.3-51.2</td> <td class=\"centered\">47.5-54</td> </tr> <tr> <td class=\"centered\">21</td> <td class=\"centered\">7.4</td> <td class=\"centered\">51.6</td> <td class=\"centered\">51.2-52.1</td> <td class=\"centered\">48.3-54.9</td> </tr> <tr> <td class=\"centered\">22</td> <td class=\"centered\">7.5</td> <td class=\"centered\">52.5</td> <td class=\"centered\">52-53</td> <td class=\"centered\">49.2-55.8</td> </tr> <tr> <td class=\"centered\">23</td> <td class=\"centered\">7.6</td> <td class=\"centered\">53.4</td> <td class=\"centered\">52.9-53.9</td> <td class=\"centered\">50.1-56.7</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">7.8</td> <td class=\"centered\">54.3</td> <td class=\"centered\">53.7-54.8</td> <td class=\"centered\">51-57.6</td> </tr> <tr> <td class=\"centered\">25</td> <td class=\"centered\">7.9</td> <td class=\"centered\">55.2</td> <td class=\"centered\">54.6-55.7</td> <td class=\"centered\">51.9-58.5</td> </tr> <tr> <td class=\"centered\">26</td> <td class=\"centered\">8</td> <td class=\"centered\">56</td> <td class=\"centered\">55.4-56.7</td> <td class=\"centered\">52.7-59.4</td> </tr> <tr> <td class=\"centered\">27</td> <td class=\"centered\">8.1</td> <td class=\"centered\">56.9</td> <td class=\"centered\">56.3-57.6</td> <td class=\"centered\">53.6-60.3</td> </tr> <tr> <td class=\"centered\">28</td> <td class=\"centered\">8.3</td> <td class=\"centered\">57.8</td> <td class=\"centered\">57.1-58.5</td> <td class=\"centered\">54.5-61.1</td> </tr> <tr> <td class=\"centered\">29</td> <td class=\"centered\">8.4</td> <td class=\"centered\">58.7</td> <td class=\"centered\">58-59.4</td> <td class=\"centered\">55.4-62</td> </tr> <tr> <td class=\"centered\">30</td> <td class=\"centered\">8.5</td> <td class=\"centered\">59.6</td> <td class=\"centered\">58.8-60.4</td> <td class=\"centered\">56.2-62.9</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Mean diameter of gestational sac and corresponding estimates of gestational age.</div><div class=\"graphic_reference\">Reproduced with permission from: Daya S, Woods S, Ward S, et al. Early pregnancy assessment with transvaginal ultrasound scanning. CMAJ 1991; 144:441. Copyright © 1991 Canadian Medical Association. This work is protected by copyright and the making of this copy was with the permission of Access Copyright. Any alteration of its content or further copying in any form whatsoever is strictly prohibited, except as otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 94449 Version 3.0</div></div></div>"},"94472":{"type":"graphic_figure","displayName":"Growth in constitutional delay of growth","title":"Constitutional delay of growth and puberty","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Constitutional delay of growth and puberty</div><div class=\"cntnt\"><img style=\"width:618px; height:811px;\" src=\"images/PEDS/94472_Growth_in_CDGP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical growth curve in a male with constitutional delay of growth and puberty (CDGP). The growth velocity is slow from mid-infancy through late childhood. The pubertal growth spurt is delayed, and the pubertal growth rate may be slightly diminished as compared with normally-growing children. However, the pre-pubertal growth also continues for longer than normal, resulting in an adult height that is within the normal range. The height prediction (target height) for this child also was within the normal adult range, after adjustment for his delayed bone age.</div><div id=\"graphicVersion\">Graphic 94472 Version 2.0</div></div></div>"},"94476":{"type":"graphic_table","displayName":"Models estimating individual risk for BRCA mutations","title":"Models estimating individual risk for BRCA mutations to guide referrals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Models estimating individual risk for BRCA mutations to guide referrals</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"11\" width=\"9%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Model</td> <td class=\"subtitle1\" rowspan=\"2\">Data collection and calculation*</td> <td class=\"subtitle1\" rowspan=\"2\">Relatives with breast or ovarian cancer</td> <td class=\"subtitle1\" rowspan=\"2\">Additional risk factors in model</td> <td class=\"subtitle1\" colspan=\"7\">Accuracy studies</td> </tr> <tr> <td class=\"subtitle2\">Study, year<br /> (reference)</td> <td class=\"subtitle2\">Population</td> <td class=\"subtitle2\">Reference standard</td> <td class=\"subtitle2\">Sensitivity<br /> (%)</td> <td class=\"subtitle2\">Specificity<br /> (%)</td> <td class=\"subtitle2\">PPV</td> <td class=\"subtitle2\">NPV</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">FHAT</td> <td class=\"divider_bottom\" rowspan=\"3\">Clinical scoring tool; referral threshold of 10 is equivalent to a twofold increase in risk for breast or ovarian cancer.</td> <td class=\"divider_bottom\" rowspan=\"3\">First-, second-, and third-degree</td> <td class=\"divider_bottom\" rowspan=\"3\">Age at diagnosis, bilateral breast cancer, breast and ovarian cancer in the same person, breast cancer in men, colon and prostate cancer</td> <td>Gilpin et al, 2000<sup>[1]</sup></td> <td>35 carriers and 149 noncarriers</td> <td>10% threshold</td> <td>94</td> <td>51</td> <td>0.31</td> <td>0.97</td> </tr> <tr> <td>Parmigiani et al,<br /> 2007<sup>[2]</sup></td> <td>33 carriers and 559 noncarriers</td> <td>10% threshold</td> <td>94</td> <td>32</td> <td>&#182;</td> <td>&#916;</td> </tr> <tr class=\"divider_bottom\"> <td>Panchal et al, 2008<sup>[3]</sup></td> <td>200 carriers and 100 noncarriers</td> <td>10% threshold</td> <td>70</td> <td>63</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Manchester scoring system</td> <td class=\"divider_bottom\" rowspan=\"4\">Clinical scoring tool; referral threshold of 10 for <em>BRCA1</em>- or <em>BRCA2</em>-specific scores or 15 combined. Not intended for Ashkenazi Jewish persons.</td> <td class=\"divider_bottom\" rowspan=\"4\">First-, second-, and third-degree</td> <td class=\"divider_bottom\" rowspan=\"4\">Type of cancer (breast, ovarian, pancreatic, or prostate), affected family members, age at diagnosis</td> <td>Evans et al, 2004<sup>[4]</sup></td> <td>23 carriers and 235 noncarriers</td> <td>10% threshold</td> <td>87</td> <td>66</td> <td>0.20</td> <td>0.98</td> </tr> <tr> <td>Barcenas et al, 2006<sup>[5]</sup></td> <td>69 carriers and 306 noncarriers</td> <td>10%&nbsp;threshold</td> <td>93</td> <td>41</td> <td>0.28</td> <td>0.96</td> </tr> <tr> <td>Panchal et al, 2008<sup>[3]</sup></td> <td>200 carriers and 100 noncarriers</td> <td>15%&nbsp;threshold</td> <td>58</td> <td>71</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Antoniou et al, 2008<sup>[6]</sup></td> <td>365 carriers and 1569 noncarriers</td> <td>15%&nbsp;threshold</td> <td>92</td> <td>33</td> <td>0.24</td> <td>0.95</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">RST</td> <td class=\"divider_bottom\" rowspan=\"4\">Clinical checklist of 13 items; referral threshold of&nbsp;two positive responses.</td> <td class=\"divider_bottom\" rowspan=\"4\">First- and second-degree</td> <td class=\"divider_bottom\" rowspan=\"4\">Breast cancer in women &#8804;50 years (self or relatives), ovarian cancer at any age (self or relatives), &#8805;2 cases of breast cancer in women aged &#62;50 years on the same side of the family; breast cancer in men; Jewish ancestry</td> <td class=\"divider_bottom\" rowspan=\"4\">Bellcross et al, 2009<sup>[7]</sup></td> <td class=\"divider_bottom\" rowspan=\"4\">296 women randomly selected from 2462 tested while having screening mammography</td> <td class=\"divider_bottom\" rowspan=\"4\">Correctly assigns to high mutation probability compared with BOADICEA, BRCAPRO, and Myriad II models at 10% thresholds</td> <td>BOADICEA: 89</td> <td>BOADICEA: 77</td> <td>BOADICEA: 0.28</td> <td>BOADICEA: 0.99</td> </tr> <tr> <td>BRCAPRO: 91</td> <td>BRCAPRO: 76</td> <td>BRCAPRO: 0.24</td> <td>BRCAPRO: 0.98</td> </tr> <tr> <td>Myriad II: 91</td> <td>Myriad II: 78</td> <td>Myriad II: 0.34</td> <td>Myriad II: 0.99</td> </tr> <tr class=\"divider_bottom\"> <td>Overall: 81<sup>&#9674;</sup></td> <td>Overall: 92<sup>&#9674;</sup></td> <td>Overall: 0.80<sup>&#9674;</sup><sup>&#167;</sup></td> <td>Overall: 0.92<sup>&#9674;</sup><sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>PAT</td> <td>Clinical scoring tool; optimum referral threshold of 8.</td> <td>First-, second-, and third-degree</td> <td>Breast cancer in women aged &#8804;50 years or &#62;50 years, ovarian cancer at any age, breast cancer in men, Ashkenazi Jewish ancestry</td> <td>Hoskins et al, 2006<sup>[8]</sup></td> <td>737 women identified at potentially increased risk from 3906 tested while having screening mammography<sup>&#135;</sup></td> <td>Correctly assigns to high mutation probability compared with the Myriad II model at the 10% threshold</td> <td>100</td> <td>93</td> <td>0.63</td> <td>1.00</td> </tr> <tr> <td>FHS-7</td> <td>Clinical checklist of&nbsp;seven items; referral threshold of&nbsp;one positive response.</td> <td>First-degree</td> <td>Any relatives with breast cancer at age &#8804;50 years, bilateral breast cancer, breast and ovarian cancer in the same person, breast cancer in men, &#8805;2 relatives with breast and/or ovarian cancer, &#8805;2 relatives with breast and/or colon cancer</td> <td>Ashton-Prolla et al, 2009<sup>[9]</sup></td> <td>885 women with &#8805;1 positive response and 910 with no positive responses from 9218 women tested in primary care clinics</td> <td>Correctly assigns to high mutation probability compared with genetic evaluation<sup>&#134;</sup></td> <td>88</td> <td>56</td> <td>0.63</td> <td>1.00</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value; FHAT: Ontario Family History Assessment Tool; RST: referral screening tool; BOADICEA: Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; PAT: pedigree assessment tool; FHS-7: Family History Screen-7.<br />* Referral threshold indicates estimated probability to initiate a referral, most set at 10%.<br />¶ Positive likelihood ratio of 1.38.<br />Δ Negative likelihood ratio of 0.18.<br /><FONT class=lozenge>◊</FONT> Defined as high-risk by any of the models.<br />§ Corrected for general populations: 0.39.<br />¥ Corrected for general populations: 0.78.<br />‡ Defined as potentially at increased risk by the Gail model for&nbsp;five-year risk for breast cancer of 6.7%, lifetime risk of 15%, or ≥1 case of breast or ovarian cancer in any family member.<br />† Evaluation included kindred analysis, breast cancer risk estimates, Penn II <EM>BRCA1</EM> and <EM>BRCA2</EM> Mutation Risk Evaluation Model mutation risk estimate, and American Society of Clinical Oncology criteria.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gilpin CA, et al. Clin Genet 2000; 58:299.</LI>&#xD;&#xA;<LI>Parmigiani G, et al. Ann Intern Med 2007; 147:441.</LI>&#xD;&#xA;<LI>Panchal SM, et al. BMC Med Genet 2008; 9:116.</LI>&#xD;&#xA;<LI>Evans DG, et al. J Med Genet 2004; 41:474.</LI>&#xD;&#xA;<LI>Barcenas CH, et al. J Clin Oncol 2006; 24:354.</LI>&#xD;&#xA;<LI>Antoniou AC, et al. J Med Genet 2008; 45:425.</LI>&#xD;&#xA;<LI>Bellcross CA, et al. Genet Med 2009; 11:783.</LI>&#xD;&#xA;<LI>Hoskins KF, et al. Cancer 2006; 107:1769.</LI>&#xD;&#xA;<LI>Ashton-Prolla P, et al. BMC Cancer 2009; 9:283.</LI></OL>From <EM>Annals of Internal Medicine</EM>, Nelson HD, Pappas MA, Zakher B, et al, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation, Vol 160, Pg 255. Copyright © 2014 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 94476 Version 8.0</div></div></div>"},"94477":{"type":"graphic_table","displayName":"Skin findings and recluse spider bites","title":"Positive and negative examination features for evaluation of possible brown recluse envenomations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Positive and negative examination features for evaluation of possible brown recluse envenomations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Positive exam features</td> <td class=\"subtitle1\">Negative exam features</td> </tr> <tr> <td>Lesion has small central blister without pus</td> <td>Pus observed in lesion</td> </tr> <tr> <td>Pale area in center of the lesion</td> <td>Center raised and red</td> </tr> <tr> <td>Purpura/bruising</td> <td>Drainage present before 1 week*</td> </tr> <tr> <td>Purpura spread in a direction consistent with gravity (gravitational spread)</td> <td> <p>Tender enlarged lymph node present<sup>&#182;</sup></p> Ulcer present before 1 week</td> </tr> <tr> <td>Outer part of lesion is red and either pale area in center or purpura is present</td> <td>Ulcer &#62;10 cm in diameter or more than 0.5 cm deep</td> </tr> <tr> <td>Central pale area with some surrounding purpura; outer part of lesion is red (red, white, and blue sign)</td> <td> <p>More than 2 separate lesions</p> Lesion present more than 3 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Ignore this negative feature for some body sites: periorbital region, hands, feet.<br />¶ Adenopathy is observed in approximately 1% of brown recluse spider bite cases.</div><div class=\"graphic_reference\">Reproduced from: Rader RK, Stoecker WV, Malters JM, et al. Seaonality of brown recluse populations is reflected by numbers of brown recluse envenomations. Toxicon 2012; 60:1. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94477 Version 3.0</div></div></div>"},"94478":{"type":"graphic_table","displayName":"Ontario family history assessment tool","title":"Ontario family history assessment tool (for BRCA1/BRCA2 risk assessment)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ontario family history assessment tool (for BRCA1/BRCA2 risk assessment)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Breast and ovarian cancer</td> </tr> <tr> <td class=\"indent1\">Mother</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"indent1\">Sibling</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">Second-/third-degree relative</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Breast cancer relative</td> </tr> <tr> <td class=\"indent1\">Parent</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Sibling</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Second-/third-degree relative</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Male relative (add to above)</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Breast cancer characteristics</td> </tr> <tr> <td class=\"indent1\">Onset at age 20 to 29 years</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">Onset at age 30 to 39 y</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Onset at age 40 to 49 years</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Pre-/perimenopausal</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Bilateral/multifocal</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ovarian cancer relative</td> </tr> <tr> <td class=\"indent1\">Mother</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">Sibling</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Second-/third-degree relative</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age at ovarian cancer onset</td> </tr> <tr> <td class=\"indent1\">&#60;40 years</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">40 to 60 years</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">&#62;60 years</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age at prostate cancer onset</td> </tr> <tr> <td class=\"indent1\">&#60;50 years</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age at colon cancer onset</td> </tr> <tr> <td class=\"indent1\">&#60;50 years</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family total</td> </tr> <tr> <td class=\"indent1\">Referral*</td> <td class=\"centered\">&#8805;10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Referral with a score of ≥10 corresponds to doubling of lifetime risk for breast cancer (22%).</div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine,</EM> Moyer VA, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement, vol. 160, p. 271. Copyright © 2014 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 94478 Version 7.0</div></div></div>"},"94479":{"type":"graphic_table","displayName":"Manchester scoring system","title":"Manchester scoring system* (for BRCA1/BRCA2 risk assessment)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manchester scoring system* (for BRCA1/BRCA2 risk assessment)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\"><em>BRCA1</em> score</td> <td class=\"subtitle1\"><em>BRCA2</em> score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age at onset of female breast cancer<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">&#60;30 years</td> <td class=\"centered\">6</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">30 to 39 years</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">40 to 49 years</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">50 to 59 years</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;60 years</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age at onset of male breast cancer<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">&#60;60 years</td> <td class=\"centered\">5<sup>&#916;</sup></td> <td class=\"centered\">8<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;60 years</td> <td class=\"centered\">5<sup>&#916;</sup></td> <td class=\"centered\">5<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age at onset of ovarian cancer<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">&#60;60 years</td> <td class=\"centered\">8</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;60 years</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pancreatic cancer</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age at onset of prostate cancer<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">&#60;60 years</td> <td class=\"centered\">0</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">&#8805;60 years</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Developed so that a score of 10 in either column or a combined score of 15 for both columns would be equivalent to a 10% chance of identifying a <EM>BRCA1</EM> or <EM>BRCA2</EM> mutation.<br />¶ For relatives in direct lineage.<br />Δ If <EM>BRCA2</EM> tested.<br /><FONT class=lozenge>◊</FONT> If <EM>BRCA1</EM> tested.</div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine,</EM> Moyer VA, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement, vol. 160, p. 271. Copyright © 2014 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 94479 Version 7.0</div></div></div>"},"94480":{"type":"graphic_table","displayName":"Referral screening tool","title":"Referral screening tool (for BRCA1/BRCA2 risk assessment)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Referral screening tool (for BRCA1/BRCA2 risk assessment)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Breast cancer at age &#8804;50</td> <td class=\"subtitle1\">Ovarian cancer at any age</td> </tr> <tr> <td>Yourself</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Mother</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Sister</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Daughter</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Mother's side</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Grandmother</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Aunt</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Father's side</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Grandmother</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Aunt</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"3\">&#8805;2 cases of breast cancer after age 50&nbsp;on the same side of the family</td> </tr> <tr> <td colspan=\"3\">Male breast cancer at any age in any relative</td> </tr> <tr> <td colspan=\"3\">Jewish ancestry</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A patient completes the checklist if she has a family history of breast or ovarian cancer and receives a referral if she checks &ge;2 items.</div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine,</EM> Moyer VA, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement, vol. 160, p. 271. Copyright © 2014 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 94480 Version 7.0</div></div></div>"},"94481":{"type":"graphic_table","displayName":"Pedigree assessment tool*","title":"Pedigree assessment tool* (for BRCA1/BRCA2 risk assessment)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pedigree assessment tool* (for BRCA1/BRCA2 risk assessment)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Score<sup>&#182;</sup></td> </tr> <tr> <td>Breast cancer at age &#8805;50 years</td> <td class=\"centered\">3</td> </tr> <tr> <td>Breast cancer at age &#60;50 years</td> <td class=\"centered\">4</td> </tr> <tr> <td>Ovarian cancer at any age</td> <td class=\"centered\">5</td> </tr> <tr> <td>Male breast cancer at any age</td> <td class=\"centered\">8</td> </tr> <tr> <td>Ashkenazi Jewish heritage</td> <td class=\"centered\">4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A score of &ge;8 is the optimum referral threshold.<br />&para; For every family member with a diagnosis of breast or ovarian cancer, including second- or third-degree relatives.</div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine,</EM> Moyer VA, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement, vol. 160, p. 271. Copyright © 2014 American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 94481 Version 8.0</div></div></div>"},"94482":{"type":"graphic_table","displayName":"Family history screen-7*","title":"Family history screen-7* (for BRCA1/BRCA2 risk assessment)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Family history screen-7* (for BRCA1/BRCA2 risk assessment)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Did any of your first-degree relatives have breast or ovarian cancer?</td> </tr> <tr> <td>Did any of your relatives have bilateral breast cancer?</td> </tr> <tr> <td>Did any man in your family have breast cancer?</td> </tr> <tr> <td>Did any woman in your family have breast and ovarian cancer?</td> </tr> <tr> <td>Did any woman in your family have breast cancer before age 50?</td> </tr> <tr> <td>Do you have&nbsp;two or more relatives with breast and/or ovarian cancer?</td> </tr> <tr> <td>Do you have&nbsp;two or more relatives with breast and/or bowel cancer?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* One positive response initiates referral.</div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine</EM>, Moyer VA, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement, Vol 160, Pg 271. Copyright © 2014 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 94482 Version 8.0</div></div></div>"},"94485":{"type":"graphic_table","displayName":"Laboratory testing eosinophilia","title":"Initial laboratory testing to determine the cause of unexplained peripheral blood eosinophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial laboratory testing to determine the cause of unexplained peripheral blood eosinophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">All patients</td> </tr> <tr> <td class=\"indent1\">Complete blood count with differential</td> <td>Abnormal increases or decreases in cell numbers may suggest a primary hematologic condition</td> </tr> <tr> <td class=\"indent1\">Review of the peripheral blood smear</td> <td>Abnormalities of RBC morphology or immature or dysplastic WBCs may suggest a primary hematologic condition</td> </tr> <tr> <td class=\"indent1\">Serum chemistries, creatinine, urinalysis</td> <td>Abnormalities may suggest a potential cause of eosinophilia or presence of organ involvement</td> </tr> <tr> <td class=\"indent1\">Liver function tests</td> <td>Abnormalities may suggest a potential cause of eosinophilia or presence of organ involvement</td> </tr> <tr> <td class=\"indent1\">Serum troponin</td> <td>Elevated troponin suggests cardiac involvement and should be followed up by ECG and possibly echocardiography</td> </tr> <tr> <td class=\"indent1\">Serum vitamin B12 level</td> <td>May be elevated in myeloproliferative neoplasms</td> </tr> <tr> <td class=\"indent1\">Serology for strongyloides</td> <td>Positive result requires treatment prior to corticosteroid administration; however, strongyloidiasis may not be the cause of eosinophilia</td> </tr> <tr> <td class=\"indent1\">Flow cytometry for lymphocyte subsets</td> <td>Patients with lymphocytic forms of hypereosinophilic syndrome may have abnormal lymphocyte surface markers, even if lymphocyte numbers are normal and adenopathy is absent</td> </tr> <tr> <td class=\"indent1\">Chest radiography</td> <td>Abnormalities may suggest a potential cause of eosinophilia or pulmonary involvement</td> </tr> <tr> <td class=\"indent1\">Serum tryptase (total)</td> <td>Unexplained allergic reactions or anaphylaxis, urticaria pigmentosa on skin examination; elevation may suggest mastocytosis or myeloid forms of hypereosinophilic syndrome&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Selected patients</td> </tr> <tr> <td class=\"indent1\">Molecular testing for hematologic disorders</td> <td>Suspected hematologic disorder, usually done on bone marrow but can be done on peripheral blood</td> </tr> <tr> <td class=\"indent1\">Immunoglobulin isotypes (IgG, IgA, IgM)</td> <td>Signs of autoimmune disease or frequent infections to suggest immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Antineutrophil cytoplasmic antibodies</td> <td>Signs of rhinosinusitis, asthma, and/or vasculitis; sensitivity is low</td> </tr> <tr> <td class=\"indent1\">Cortisol testing (morning or dynamic)</td> <td>Signs of adrenal dysfunction&nbsp;</td> </tr> <tr> <td class=\"indent1\">Stool studies for ova and parasites</td> <td>If appropriate, exposure history or watery stools; this testing is neither sensitive nor specific, and several helminths cannot be identified reliably&nbsp;by stool studies</td> </tr> <tr> <td class=\"indent1\">Viral serologies (HIV, HTLV-I and II)&nbsp;</td> <td>If appropriate, exposure history</td> </tr> <tr> <td class=\"indent1\">Toxocara serology</td> <td>Children who may have ingested contaminated soil</td> </tr> <tr> <td class=\"indent1\">Serologies for filaria, trypanosomes, trichinella, schistosomes (along with urine sediment for schistosomes)</td> <td>If appropriate, exposure history</td> </tr> <tr> <td class=\"indent1\">Computed tomography</td> <td>Suspected systemic disorders such as lymphoma; with biopsy of an appropriate lymph node</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table describes the laboratory evaluation for patients with unexplained eosinophilia. Refer to UpToDate topics on eosinophilia and associated conditions&nbsp;including helminthic infections, hematologic conditions, autoimmune diseases, rheumatologic conditions, mastocytosis, and adrenal dysfunction&nbsp;for details.</div><div class=\"graphic_footnotes\">RBC: red blood cell; WBCs: white blood cells; ECG: electrocardiogram; IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus.</div><div id=\"graphicVersion\">Graphic 94485 Version 3.0</div></div></div>"},"94489":{"type":"graphic_picture","displayName":"Leukocytoclastic vasculitis of lower extremities with histology","title":"Leukocytoclastic vasculitis of lower extremities with histology","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Leukocytoclastic vasculitis of lower extremities with histology</div><div class=\"cntnt\"><img style=\"width:728px; height:449px;\" src=\"images/ALLRG/94489_Leukocytoclastvasculhisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous vasculitis most often presents as palpable purpura that is typically a manifestation of benign, localized, self-limited cutaneous disease, often triggered by preceding infection or drug ingestion. Histologically, it is identified by a neutrophilic infiltrate surrounding and disrupting small vessels (postcapillary venules) associated with fibrin deposits and nuclear debris (leukocytoclasia). Extravasated red blood cells, purpura, will be found in the adjacent dermis.</div><div class=\"graphic_reference\">From: Carlson JA, Chen KR. Cutaneous vasculitis update: Small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 2006; 28:486. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94489 Version 4.0</div></div></div>"},"94490":{"type":"graphic_table","displayName":"Sedative drugs for awake intubation","title":"Sedative drugs for awake intubation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sedative drugs for awake intubation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Sedative dose</td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td>Midazolam</td> <td>Benzodiazepine</td> <td>1-2 mg IV, repeated prn (0.025-0.1 mg/kg)</td> <td>Frequently used in combination with fentanyl</td> </tr> <tr class=\"divider_bottom\"> <td>Fentanyl</td> <td>Opioid</td> <td>25-200 mcg IV (0.2-2 mcg/kg), in divided doses at 5-minute intervals, titrated to effect</td> <td>Usually used in combination with other agents (eg, midazolam, propofol)</td> </tr> <tr class=\"divider_bottom\"> <td>Alfentanil</td> <td>Opioid</td> <td>500-1500 mcg IV (10-30 mcg/kg)</td> <td>Faster onset, shorter duration than fentanyl</td> </tr> <tr class=\"divider_bottom\"> <td>Remifentanil</td> <td>Opioid</td> <td>Bolus 0.5 mcg/kg IV followed by an infusion of 0.1 mcg/kg/min</td> <td>Infusion can subsequently be titrated by 0.025 mcg/kg/min to 0.05 mcg/kg/min in 5-minute intervals to achieve adequate sedation</td> </tr> <tr class=\"divider_bottom\"> <td>Propofol</td> <td>Hypnotic</td> <td> <p>0.25 mg/kg IV, in intermittent boluses</p> <p class=\"indent1\">or</p> Continuous IV infusion of 25-75 mcg/kg/min, titrated to effect</td> <td>Can also be used in combination with remifentanil (decrease dose of both drugs)</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine</td> <td>Hypnotic</td> <td>0.2-0.8 mg/kg IV</td> <td> <p>Pretreat with antisialagogue</p> Consider administration of midazolam to attenuate undesirable psychological effects</td> </tr> <tr> <td>Dexmedetomidine</td> <td>Alpha<sub>2</sub> agonist</td> <td>Bolus 1 mcg/kg IV over 10 minutes, followed by an infusion of 0.2-0.7 mcg/kg/hr</td> <td>Reduce dose in older adults and in patients with depressed cardiac function</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Typical sedative regimens used during awake fiberoptic bronchoscopic intubation.</div><div class=\"graphic_footnotes\">mg: milligram; IV: intravenous; prn: as needed; kg: kilogram; mcg: microgram.</div><div id=\"graphicVersion\">Graphic 94490 Version 2.0</div></div></div>"},"94491":{"type":"graphic_algorithm","displayName":"Algorithm for approaching contingent suicidal ideation","title":"Algorithm for approaching contingent suicidal ideation","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Algorithm for approaching contingent suicidal ideation</div><div class=\"cntnt\"><img style=\"width:547px; height:563px;\" src=\"images/PSYCH/94491_Algoapprsuicidalideation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original figure modified for this publication. Peteet JR, Maytal G, Rokni H. Unimaginable loss: contingent suicidal ideation in family members of oncology patients. Psychosomatics 2010; 51:166. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94491 Version 2.0</div></div></div>"},"94492":{"type":"graphic_table","displayName":"Communication with and caring for bereaved patients","title":"Strategies for communication with and caring for bereaved patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for communication with and caring for bereaved patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Things to say...</td> <td class=\"subtitle1\">Because...</td> </tr> <tr> <td>I'm sorry, or I'm sorry she/he's gone.</td> <td>Acknowledges the loss and lets the bereaved person know you feel for them. Not saying this much is often perceived as a lack of respect or concern.</td> </tr> <tr> <td>I can't imagine what you're going through.</td> <td>Bereaved patients are often frustrated by people who minimize or assume they know how they are feeling. No one can fully understand another's loss and admitting this is appreciated.</td> </tr> <tr> <td>What are you remembering about [the deceased] today?</td> <td>Bereaved patients are always remembering the deceased. Don't worry about bringing up sad memories&#8212;they are there. Help them to express their thoughts and they will feel like you care. They will apppreciate your interest.</td> </tr> <tr> <td>Say [deceased's] name</td> <td>Bereaved patients will never forget the deceased. Let them know you won't forget him/her either by mentioning his/her name.</td> </tr> <tr> <td>Talk about the deceased. Depending on your relationship to the deceased, you may want to say it was an honor to know him/her and that you will miss him/her.</td> <td>Bereaved patients worry that others, and even they, will forget the uniqueness of the deceased. Talking about the deceased helps keep everyone remembering. If you did not know the deceased person, acknowledge that and express regret.</td> </tr> <tr> <td>Do you have any questions about the final illness and treatment?</td> <td>Most bereaved people are extremely interested to know about the events leading up to the death and many have unanswered questions that have bothered them. Providing a response may help to provide closure.</td> </tr> <tr> <td>How are you feeling since [the deceased's death]? How has [the deceased's death] affected you?</td> <td>Bereaved patients will appreciate the concern and this may save time by getting to the reason or need for the visit.</td> </tr> <tr> <td class=\"subtitle1\">Things not to say...</td> <td class=\"subtitle1\">Because...</td> </tr> <tr> <td>Call me.</td> <td>Passive effort puts the burden on the bereaved person. A sincere effort is to make a personal call to the bereaved patient.</td> </tr> <tr> <td>How are you? (Causally)</td> <td>Only if you have time to listen. If not, don't ask.</td> </tr> <tr> <td>I know how you feel.</td> <td>It seems presumptuous for anyone to claim to know how another person feels.</td> </tr> <tr> <td>It was probably for the best.</td> <td>A bereaved person does not view it this way.</td> </tr> <tr> <td>[She/he's] happy now.</td> <td>You have no way of knowing this and the patient may resent your presuming to know.</td> </tr> <tr> <td>It is God's will.</td> <td>Those who are in mourning typically protest. Saying God wanted it this way may confuse the religious and offend the nonreligious.</td> </tr> <tr> <td>It was his (or her) time to go.</td> <td>Bereaved patients have trouble seeing it this way. Those in mourning protest their loved one's departure and almost never think the time was \"right.\" However, if you see that they are tormented by what they did or did not do to prevent the loss, it may be in order to say that there are things that are not within anyone's control.</td> </tr> <tr> <td>I'm sorry I brought it up.</td> <td>Don't be sorry; bring it up. Bereaved patients want you to know about their loss.</td> </tr> <tr> <td>Let's change the subject.</td> <td>Don't change the subject. Bereaved patients want to talk with you about their loss.</td> </tr> <tr> <td>You should work toward getting over this by now.</td> <td>Bereaved people never \"get over\" their loss, but learn to live with it. Putting pressure on them to \"move on\" is, in a sense, blaming them for their continued grief, may instill guilt, and add to their concerns. If grief is prolonged, it may be time for a referral for expert help.</td> </tr> <tr> <td>I had another patient who had the same illness [as the deceased] and he suffered for a long time. You should be glad [the deceased] passed away quickly.</td> <td>Though some may find comfort in this comparision, others will not because they feel that it doesn't matter how long a loved one suffered, it matters that she/he did. Safer to avoid these sorts of comparisons.</td> </tr> <tr> <td>You're strong enough to deal with it.</td> <td>Mourning is about the loss and not about the mourner's strength. A more appropriate response might be to say to the breaved, \"I hope you find the strength to bear your loss.\"</td> </tr> <tr> <td class=\"subtitle1\">Practices to implement</td> <td class=\"subtitle1\">How...</td> </tr> <tr> <td>Death notification</td> <td>Try to establish a system whereby you are notified of patient deaths, recent losses, and deaths within patient's families. Encourage patients, colleagues, and funeral directors to notify you if there has been a death in the family, and/or have patients complete a brief form while in the waiting room that asks about recent losses.</td> </tr> <tr> <td>Outreach&#8212;express sorrow, invite discussion, schedule visit, and monitor symptoms</td> <td>Once notified of a death, have staff contact bereaved patients to acknowledge loss, see how they are doing, and encourage a scheduled visit.</td> </tr> <tr> <td>Have useful information available</td> <td>Provide a list of resources for bereaved patients. Make available information on literature and Web sites, support groups, clergy, mental health professionals, lawyers, and financial planners.</td> </tr> <tr> <td class=\"subtitle1\">Practices to avoid</td> <td class=\"subtitle1\">Because...</td> </tr> <tr> <td>Passivity</td> <td>Try not to be passive, vague, or insincere. Refrain from asking bereaved patients to take the initiative, thereby putting the burden on them.</td> </tr> <tr> <td>Avoidance</td> <td>Bereaved patients want you to know that they recently lost a significant person in their life. They typically want you to know how this upsets them and want to talk about it with you. To avoid their grief denies them an opportunity to express and address their concerns, and may obscure the real reason for their visit.</td> </tr> <tr> <td>Making comparisons with other losses</td> <td>Try not to compare one person's loss with other patient deaths or deaths in your family. If handled well, empathy may provide some solace and acknowledging that it could be worse may minimize regrets, but comparisons run the risk of minimizing the significance of an individual's loss.</td> </tr> <tr> <td>Pressure and inappropriate positivity</td> <td>Avoid encouraging them to put the past behind them. Try not to imply that they should be making larger strides towards moving forward with their life. Do not try to locate them on a linear grief trajectory, place them in a stage of grief, or suggest that their outlook be more positive.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Prigerson HG, Jacobs SC. Perspectives on care at the close of life. Caring for bereaved patients: \"All the doctors just suddenly go\". JAMA 2001; 286:1369. Copyright &copy; 2001 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94492 Version 5.0</div></div></div>"},"94493":{"type":"graphic_table","displayName":"Brief grief questionnaire","title":"Brief grief questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Brief grief questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td colspan=\"2\">1. How much are you currently having trouble accepting the death of <sub>______________</sub>?</td> </tr> <tr> <td class=\"indent1\">Not at all</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Somewhat</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A lot</td> <td class=\"centered\">2</td> </tr> <tr> <td colspan=\"2\">2. How much does your grief interfere with your life now?</td> </tr> <tr> <td class=\"indent1\">Not at all</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Somewhat</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A lot</td> <td class=\"centered\">2</td> </tr> <tr> <td colspan=\"2\">3. How much are you bothered by images or thoughts of <sub>_____________</sub> when s/he died or other thoughts about the death that really bother you?</td> </tr> <tr> <td class=\"indent1\">Not at all</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Somewhat</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A lot</td> <td class=\"centered\">2</td> </tr> <tr> <td colspan=\"2\">4. Are there things you used to do when <sub>______</sub> was alive that you don't feel comfortable doing anymore, that you avoid? Like going somewhere you went with him/her, or doing things you used to enjoy together? Or avoiding looking at pictures or talking about <sub>_________</sub>? How much are you avoiding these things?</td> </tr> <tr> <td class=\"indent1\">Not at all</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Somewhat</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A lot</td> <td class=\"centered\">2</td> </tr> <tr> <td colspan=\"2\">5. How much are you feeling cut off or distant from other people since <sub>_________</sub> died, even people you used to be close to like family or friends?</td> </tr> <tr> <td class=\"indent1\">Not at all</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Somewhat</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A lot</td> <td class=\"centered\">2</td> </tr> <tr> <td><strong>Total:</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Screen positive: Total score ≥4.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Shear MK, Simon N, Wall M, et al. Complicated grief and related bereavement issues for DSM-5. Depress Anxiety 2011; 28:103.</li>&#xD;&#xA;</ol>&#xD;&#xA;Questionnaire reproduced with permission from: Katherine Shear, MD.</div><div id=\"graphicVersion\">Graphic 94493 Version 1.0</div></div></div>"},"94495":{"type":"graphic_figure","displayName":"Coronary stenoses diameter reduction","title":"Coronary stenoses diameter reduction","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Coronary stenoses diameter reduction</div><div class=\"cntnt\"><img style=\"width:610px; height:461px;\" src=\"images/CARD/94495_Coronary_stnss_dmtr_rdct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary stenoses of 50, 70, and 90 percent&nbsp;diameter reduction are showing in longitudinal and cross section. The corresponding reductions in cross-sectional area are indicated in parentheses.</div><div class=\"graphic_reference\">Reproduced with permission from: Moscucci M. Coronary Angiography. In: Grossman and Baim's Cardiac Catheterization, Angiography, and Intervention, 8th ed, Moscucci M (Ed), Lippincott Williams &amp; Wilkins, Philadelphia, 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94495 Version 3.0</div></div></div>"},"94497":{"type":"graphic_table","displayName":"Benefit-harm of annual screen, by age","title":"Benefit-harm trade-off for a 10-year course of annual screening mammography for women starting at age 40, 50, and 60 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benefit-harm trade-off for a 10-year course of annual screening mammography for women starting at age 40, 50, and 60 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"> <p>Benefits</p> (lower- and upper-bound estimates)</td> <td class=\"subtitle1\"> <p>Harms</p> <span class=\"sublist1_start\">(lower- and upper-bound estimates)</span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Among 1000 <em>40-year-old</em> women undergoing annual mammography for 10 years:</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">0.1&nbsp;to 1.6 women will avoid dying from breast cancer</td> <td>510 to 690 women will have at least&nbsp;one \"false alarm\" (60&nbsp;to 80 of whom will undergo a biopsy)</td> </tr> <tr> <td>?&nbsp;to 11 women will be overdiagnosed and treated needlessly with surgery, radiation, and/or chemotherapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Among 1000 <em>50-year-old</em> women undergoing annual mammography for 10 years:</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">0.3&nbsp;to 3.2 women will avoid dying from breast cancer</td> <td>490&nbsp;to 670 women will have at least&nbsp;one \"false alarm\" (70&nbsp;to 100 of whom will undergo a biopsy)</td> </tr> <tr> <td>3&nbsp;to 14 women will be overdiagnosed and treated needlessly with surgery, radiation, and/or chemotherapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Among 1000 <em>60-year-old</em> women undergoing annual mammography for 10 years:</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">0.5&nbsp;to 4.9 women will avoid dying from breast cancer</td> <td>390&nbsp;to 540 women will have at least&nbsp;one \"false alarm\" (50&nbsp;to 70 of whom will undergo a biopsy)</td> </tr> <tr> <td>6&nbsp;to 20 women will be overdiagnosed and treated needlessly with surgery, radiation, and/or chemotherapy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Reducing the frequency from annual to every&nbsp;two years has been demonstrated to substantially reduce the harm of false alarms and would be expected to reduce the harm of overdiagnosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Welch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med 2014; 174:448. Copyright &copy; 2014 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94497 Version 6.0</div></div></div>"},"94501":{"type":"graphic_figure","displayName":"Estrogen target tissues","title":"Estrogen target tissues: Biological effects and associated clinical disorders","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Estrogen target tissues: Biological effects and associated clinical disorders</div><div class=\"cntnt\"><img style=\"width:754px; height:667px;\" src=\"images/ENDO/94501_Estrogen_target_tissues.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sexually chimeric illustration of male (blue) and female (pink) tissues and organ systems shown to be responsive to estrogens. Examples of some clinical conditions, disorders, and diseases associated with females (pink boxes) or males (blue boxes) or conditions common to both sexes (gray boxes).</div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; PCOS: polycystic ovary syndrome; BPH: benign prostatic hyperplasia.</div><div class=\"graphic_reference\">Courtesy of Lois Wyrick, National Institute of Environmental Health Sciences.</div><div id=\"graphicVersion\">Graphic 94501 Version 1.0</div></div></div>"},"94503":{"type":"graphic_table","displayName":"Water contaminants able to cause dialysis symptoms","title":"Common symptoms during dialysis and water contaminants capable of causing them","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common symptoms during dialysis and water contaminants capable of causing them</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Water contaminant</td> </tr> <tr> <td>Anemia</td> <td>Aluminum, chloramine, nitrate, lead, copper, zinc, silicon</td> </tr> <tr> <td>Bone disease</td> <td>Aluminum, fluoride, silicon</td> </tr> <tr> <td>Hypertension</td> <td>Calcium, magnesium, sodium</td> </tr> <tr> <td>Hypotension</td> <td>Bacteria, endotoxin, nitrate</td> </tr> <tr> <td>Acidosis</td> <td>Low pH, sulfate</td> </tr> <tr> <td>Muscle weakness</td> <td>Calcium, magnesium</td> </tr> <tr> <td>Nausea/vomiting</td> <td>Bacteria, endotoxin, chloramine, low pH, nitrate, sulfate, calcium, magnesium, copper, zinc</td> </tr> <tr> <td>Neurologic disturbances</td> <td>Aluminum, lead, calcium, magnesium</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Hoenich NA, Levin R. The implications of water quality in hemodialysis. Semin Dial 2003; 16:492. <a href=\"http://onlinelibrary.wiley.com/doi/10.1046/j.1525-139X.2003.16106.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1046/j.1525-139X.2003.16106.x/abstract</a>. Copyright &copy; 2003 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 94503 Version 1.0</div></div></div>"},"94507":{"type":"graphic_figure","displayName":"Change in IPSS and Impact Index with tadalafil and tamsulosin","title":"Changes from baseline in (A) total International Prostate Symptom Score and (B) Benign Prostatic Hyperplasia Impact Index with tadalafil and tamsulosin","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Changes from baseline in (A) total International Prostate Symptom Score and (B) Benign Prostatic Hyperplasia Impact Index with tadalafil and tamsulosin</div><div class=\"cntnt\"><img style=\"width:672px; height:272px;\" src=\"images/PC/94507_Changes_baseline_IPSS_BPH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data represent the least squares mean change plus or minus standard error.</div><div class=\"graphic_footnotes\">LS: least squares; EP: endpoint; ANCOVA: analysis of covariance.<br />* p&lt;0.05 versus placebo based on ANCOVA.</div><div class=\"graphic_reference\">Reproduced from: Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61:917. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94507 Version 3.0</div></div></div>"},"94508":{"type":"graphic_table","displayName":"Dyspnea questions for chronic SCD","title":"Sample dyspnea questions for patients with chronic sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample dyspnea questions for patients with chronic sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1) Do you get short of breath at rest?</td> </tr> <tr> <td>2) Do you get short of breath with minimal exertion? (eg, walking across a room, doing light housework, putting on your shoes, talking on the telephone)</td> </tr> <tr> <td>3) How far can you walk before stopping due to shortness of breath?</td> </tr> <tr> <td>4) How far can you walk on an incline before stopping?</td> </tr> <tr> <td>5) How many flights of stairs can you climb before stopping?</td> </tr> <tr> <td>6) For how long have you felt short of breath?</td> </tr> <tr> <td>7) Do you have chest pain with exertion?</td> </tr> <tr> <td>8) Do you have any trouble breathing while you sleep or lie flat in bed?</td> </tr> <tr> <td>9) Have you ever passed out?</td> </tr> <tr> <td>10) Have you ever felt you were about to pass out?</td> </tr> <tr> <td>11) Do you have any dizziness or light-headedness at rest or with exertion?</td> </tr> <tr> <td>12) Do you have swelling in your legs?</td> </tr> <tr> <td>13) Do you have swelling in your abdomen?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Klings ES, Machado RF, Barst RJ, et al, 2014. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. American Journal of Respiratory and Critical Care Medicine; 189:727. Official Journal of the American Thoracic Society. Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 94508 Version 1.0</div></div></div>"},"94509":{"type":"graphic_algorithm","displayName":"Evaluation of pulmonary hypertension in SCD","title":"Algorithm for evaluation of pulmonary hypertension related to sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of pulmonary hypertension related to sickle cell disease</div><div class=\"cntnt\"><img style=\"width:625px; height:417px;\" src=\"images/PULM/94509_Eval_pulm_hypertension_SCD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed algorithm for evaluation of pulmonary hypertension related to sickle cell disease.</div><div class=\"graphic_footnotes\">TRV: tricuspid regurgitant jet velocity; SCD: sickle cell disease; PH: pulmonary hypertension; 6MWD: 6-minute walk distance; NT-pro-BNP: N-terminal pro-brain natriuretic peptide; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance;&nbsp;ANA: anti-nuclear antibody; HIV: human immunodeficiency virus; LFTs: liver function tests; CXR: chest radiograph; EKG: electrocardiogram.<br />* The use of the term screening refers to mortality risk assessment. Echocardiography should be performed while patients are clinically stable. Patients with an mPAP between 20 and 25 mmHg need further study as they may be at increased mortality risk. NOTE: PAH therapy is to be considered on the basis of a weak recommendation and very low-quality evidence.</div><div class=\"graphic_reference\">Klings ES, Machado RF, Barst RJ, et al, 2014. An official american thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. American journal of respiratory and critical care medicine; 189:727. Official Journal of the American Thoracic Society. Reprinted with permission of the American Thoracic Society. Copyright &copy; 2014 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 94509 Version 1.0</div></div></div>"},"94511":{"type":"graphic_table","displayName":"Impairments associated with OHS","title":"Medical impairments associated with obesity hypoventilation syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical impairments associated with obesity hypoventilation syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Central nervous system</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cognitive deficit </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Decrease neuronal drive </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Upper airway</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obstructive sleep apnea </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Increased intubation risk </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Restrictive lung function </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pulmonary hypertension </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hypercapnia/hypoxemia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Central obesity </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Metabolic syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Chronic inflammation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>IGF-1 deficit </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Endothelial dysfunction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Coronary artery disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Chronic heart failure </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Peripheral edema </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Increased morbi-mortality </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Decreased physical activity </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 94511 Version 1.0</div></div></div>"},"94512":{"type":"graphic_algorithm","displayName":"Mechanisms of sleep disordered breathing","title":"Mechanisms of sleep disordered breathing in obesity hypoventilation","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Mechanisms of sleep disordered breathing in obesity hypoventilation</div><div class=\"cntnt\"><img style=\"width:621px; height:540px;\" src=\"images/PULM/94512_Mech_sleep_disord_breathing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schema outlining the potential sources of respiratory abnormality that can occur in morbid obesity and the complex interaction between these factors that may ultimately lead to the development of hypoventilation.</div><div class=\"graphic_reference\">Reproduced from: Piper AJ. Obesity hypoventilation syndrome - the big and the breathless. Sleep Med Rev 2011; 15:79. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94512 Version 1.0</div></div></div>"},"94513":{"type":"graphic_figure","displayName":"Accumulation of carbon dioxide in OHS","title":"Role of obstructive events and carbon dioxide accumulation in obesity hypoventilation syndrome","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Role of obstructive events and carbon dioxide accumulation in obesity hypoventilation syndrome</div><div class=\"cntnt\"><img style=\"width:754px; height:646px;\" src=\"images/PULM/94513_Accum_carbon_dioxide_OHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic illustration of the primary end-point data obtained in the present study.<br />(A) Spirometry tracing illustrating a postevent increase in ventilation to levels above control periods with stable ventilation. The immediate postevent ventilation was assessed by summing the tidal volumes for all breaths initiated within the first 10 seconds of the interevent period.<br />(B) Graph illustrating the calculation of CO<sub>2</sub> load during respiratory events. Thin line, average metabolic CO<sub>2</sub> production over time; thick line, varying breath-by-breath CO<sub>2</sub> excretion measured during changes in ventilation. CO<sub>2</sub> load during event (shaded areas) is calculated by integrating the difference between breath-by-breath CO<sub>2</sub> excretion and average metabolic CO<sub>2</sub> production during the event.</div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide.</div><div class=\"graphic_reference\">Reproduced with permission from: Berger KI, Ayappa I, Sorkin IB, et al. Postevent ventilation as a function of CO(2) load during respiratory events in obstructive sleep apnea. J Appl Physiol 2002; 93:917. Copyright &copy; 2002 The American Physiological Society.</div><div id=\"graphicVersion\">Graphic 94513 Version 4.0</div></div></div>"},"94515":{"type":"graphic_table","displayName":"ACP discussions","title":"Facilitating advance care planning discussion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Facilitating advance care planning discussion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Step</td> <td class=\"subtitle1\">Purpose</td> <td class=\"subtitle1\">Question/comment</td> </tr> <tr class=\"divider_bottom\"> <td>Permission</td> <td>Invites the patient to discuss their current condition and desires regarding future medical care</td> <td>\"Would you like to talk about what might happen in the future, and how we could make sure your wishes are followed?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Preference</td> <td>Allows patient to determine how involved in planning, and whether he or she wants others involved</td> <td>\"Would you like to talk about this by yourself, or are there others you would like to join us?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Establish the baseline</td> <td>To determine what the patient's understanding is regarding his or her medical situation at the present time</td> <td> <p>\"What is your understanding about your medical situation?\"</p> \"What have your doctors told you?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Provide information</td> <td>To provide clear information about the choices that may be faced in the future, individualized to the patient's own current medical condition</td> <td>For a patient with recurrent cancer, for example: \"Because your cancer came back, it is not curable. You will be living with this disease for the rest of your life, like a chronic disease.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Introduce dilemmas at hand</td> <td>To determine if the patient has thought about the medical care they would like to receive in the future</td> <td>\"Has someone close to you had to face end of life decisions, like deciding about withdrawing a ventilator or going on hospice? What would you have wanted in that situation?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Explore values and beliefs</td> <td>To help the patient define what it means to \"live well\"</td> <td> <p>\"What is most important to you in life?\"</p> <p>\"What are your main worries about your situation?\"</p> \"When you think about your future, what do you hope for?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Elicit ACP preferences</td> <td>To guide the patient to state specific preferences about ACP, including cardiopulmonary resuscitation, life prolonging treatment, and inpatient hospitalization</td> <td>\"If you were to stop breathing, would you want to be on a machine that breathes for you?\" <em>NOTE: if the patient is interesed in a trial of life support, the clinician should ask them to specify the parameters of the trial (how long? Criteria to decide when to stop treatment).</em></td> </tr> <tr class=\"divider_bottom\"> <td>Identify a surrogate decision-maker</td> <td>To specifically name someone who will carry out his or her wishes in the case he or she is unable to in the future</td> <td>\"If you became unable to tell your clinicians what kind of care they should provide you, who would you want to make medical decisions for you?\" <em>NOTE: If the patient names multiple persons, aim to estabish a primary surrogate.</em></td> </tr> <tr class=\"divider_bottom\"> <td>Educate about the role of a surrogate</td> <td>To ensure understanding on how the surrogate decision maker would function in the future</td> <td>\"If you became unable to participate in discussions about your care, your surrogate would be called in to tell us what should be done.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Encourage dissemination among family</td> <td>To ensure that the ACP decisions of the patient are known to their loved ones, and specifically, to the surrogate(s)</td> <td>\"It would be important to let your family know of your wishes and desires for the future. This includes letting everyone know who you have chosen as your surrogate decision maker.\"</td> </tr> <tr class=\"divider_bottom\"> <td>Document</td> <td>Encourages the patient to complete ACP forms, which will increase the chances their wishes are followed in the future</td> <td>\"These are important decisions that will impact your care in the future. We should make sure to get them in writing.\"</td> </tr> <tr> <td>Review</td> <td>Review of these plans on a regular basis ensures that ACP decisions accurately reflect their decisions</td> <td>\"Would you like to revisit your advance care plans? I just want to make sure they still reflect your wishes today, compared to when we did it the last time.\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACP: Advance care planning</div><div class=\"graphic_reference\">Based on information provided by Karen Detering, MD and Maria J Silveira, MD, MA, MPH.</div><div id=\"graphicVersion\">Graphic 94515 Version 1.0</div></div></div>"},"94516":{"type":"graphic_table","displayName":"Peds MH physical findings and lab values","title":"Physical findings and laboratory values for pediatric malignant hyperthermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings and laboratory values for pediatric malignant hyperthermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic, N</td> <td class=\"subtitle1\" colspan=\"2\">Youngest<br /> (n = 35)</td> <td class=\"subtitle1\" colspan=\"2\">Middle<br /> (n = 163)</td> <td class=\"subtitle1\" colspan=\"2\">Oldest<br /> (n = 66)</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Physical exam findings</strong></td> <td class=\"centered\"><strong>n</strong></td> <td class=\"centered\"><strong>%</strong></td> <td class=\"centered\"><strong>n</strong></td> <td class=\"centered\"><strong>%</strong></td> <td class=\"centered\"><strong>n</strong></td> <td class=\"centered\"><strong>%</strong></td> <td class=\"centered\"><strong>P</strong></td> </tr> <tr> <td class=\"indent1\">Elevated temperature</td> <td class=\"centered\">21</td> <td class=\"centered\">60.0</td> <td class=\"centered\">71</td> <td class=\"centered\">43.6</td> <td class=\"centered\">36</td> <td class=\"centered\">54.5</td> <td class=\"centered\">0.1</td> </tr> <tr> <td class=\"indent1\">Rapidly increasing temperature</td> <td class=\"centered\">13</td> <td class=\"centered\">37.1</td> <td class=\"centered\">51</td> <td class=\"centered\">31.3</td> <td class=\"centered\">44</td> <td class=\"centered\">66.7</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Sweating</td> <td class=\"centered\">0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">11</td> <td class=\"centered\">6.7</td> <td class=\"centered\">17</td> <td class=\"centered\">25.8</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Masseter spasm</td> <td class=\"centered\">5</td> <td class=\"centered\">14.3</td> <td class=\"centered\">74</td> <td class=\"centered\">45.4</td> <td class=\"centered\">7</td> <td class=\"centered\">10.6</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Generalized muscular rigidity</td> <td class=\"centered\">6</td> <td class=\"centered\">17.1</td> <td class=\"centered\">53</td> <td class=\"centered\">32.5</td> <td class=\"centered\">25</td> <td class=\"centered\">37.9</td> <td class=\"centered\">0.96</td> </tr> <tr> <td class=\"indent1\">Dark urine</td> <td class=\"centered\">2</td> <td class=\"centered\">5.7</td> <td class=\"centered\">24</td> <td class=\"centered\">14.7</td> <td class=\"centered\">6</td> <td class=\"centered\">9.1</td> <td class=\"centered\">0.26</td> </tr> <tr> <td class=\"indent1\">Tachypnea</td> <td class=\"centered\">12</td> <td class=\"centered\">34.3</td> <td class=\"centered\">43</td> <td class=\"centered\">26.4</td> <td class=\"centered\">21</td> <td class=\"centered\">31.8</td> <td class=\"centered\">0.52</td> </tr> <tr> <td class=\"indent1\">Hypercarbia</td> <td class=\"centered\">27</td> <td class=\"centered\">77.1</td> <td class=\"centered\">95</td> <td class=\"centered\">58.3</td> <td class=\"centered\">59</td> <td class=\"centered\">89.4</td> <td class=\"centered\">&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Cyanosis</td> <td class=\"centered\">2</td> <td class=\"centered\">5.7</td> <td class=\"centered\">16</td> <td class=\"centered\">9.8</td> <td class=\"centered\">7</td> <td class=\"centered\">10.6</td> <td class=\"centered\">0.75</td> </tr> <tr> <td class=\"indent1\">Skin mottling</td> <td class=\"centered\">5</td> <td class=\"centered\">14.3</td> <td class=\"centered\">8</td> <td class=\"centered\">4.9</td> <td class=\"centered\">7</td> <td class=\"centered\">10.6</td> <td class=\"centered\">0.07</td> </tr> <tr> <td class=\"indent1\">Sinus tachycardia</td> <td class=\"centered\">26</td> <td class=\"centered\">74.3</td> <td class=\"centered\">110</td> <td class=\"centered\">67.5</td> <td class=\"centered\">57</td> <td class=\"centered\">86.4</td> <td class=\"centered\">0.01</td> </tr> <tr> <td class=\"indent1\">Ventricular tachycardia</td> <td class=\"centered\">2</td> <td class=\"centered\">5.7</td> <td class=\"centered\">9</td> <td class=\"centered\">5.5</td> <td class=\"centered\">3</td> <td class=\"centered\">4.5</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ventricular fibrillation</td> <td class=\"centered\">0</td> <td class=\"centered\">0.0</td> <td class=\"centered\">5</td> <td class=\"centered\">3.1</td> <td class=\"centered\">4</td> <td class=\"centered\">6.1</td> <td class=\"centered\">0.27</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vital sign and laboratory data</strong></td> <td class=\"centered\"><strong>Mean</strong></td> <td class=\"centered\"><strong>SD</strong></td> <td class=\"centered\"><strong>Mean</strong></td> <td class=\"centered\"><strong>SD</strong></td> <td class=\"centered\"><strong>Mean</strong></td> <td class=\"centered\"><strong>SD</strong></td> <td class=\"centered\"><strong>P</strong></td> </tr> <tr> <td class=\"indent1\">Maximum temperature (&#176;C)</td> <td class=\"centered\">38.4</td> <td class=\"centered\">(1.4)</td> <td class=\"centered\">38.2</td> <td class=\"centered\">(1.7)</td> <td class=\"centered\">40.2</td> <td class=\"centered\">(8.3)</td> <td class=\"centered\">0.0006</td> </tr> <tr> <td class=\"indent1\">Time to maximum temperature (minutes)</td> <td class=\"centered\">181.7</td> <td class=\"centered\">(282.3)</td> <td class=\"centered\">137.1</td> <td class=\"centered\">(191.3)</td> <td class=\"centered\">146.9</td> <td class=\"centered\">(183.0)</td> <td class=\"centered\">0.07</td> </tr> <tr> <td class=\"indent1\">Maximum end-tidal CO<sub>2</sub> (mmHg)</td> <td class=\"centered\">75.9</td> <td class=\"centered\">(23.0)</td> <td class=\"centered\">62.8</td> <td class=\"centered\">(23.9)</td> <td class=\"centered\">75.2</td> <td class=\"centered\">(16.8)</td> <td class=\"centered\">0.0001</td> </tr> <tr> <td class=\"indent1\">Time to maximum etCO<sub>2</sub> (min)</td> <td class=\"centered\">640.8</td> <td class=\"centered\">(205.6)</td> <td class=\"centered\">682.1</td> <td class=\"centered\">(228.9)</td> <td class=\"centered\">861.7</td> <td class=\"centered\">(329.7)</td> <td class=\"centered\">0.0001</td> </tr> <tr> <td class=\"indent1\">Time to first blood gas (min)</td> <td class=\"centered\">183.6</td> <td class=\"centered\">(253.5)</td> <td class=\"centered\">151.2</td> <td class=\"centered\">(219.3)</td> <td class=\"centered\">176.2</td> <td class=\"centered\">(212.3)</td> <td class=\"centered\">0.18</td> </tr> <tr> <td class=\"indent1\">Fio<sub>2</sub></td> <td class=\"centered\">0.75</td> <td class=\"centered\">(0.35)</td> <td class=\"centered\">0.78</td> <td class=\"centered\">(0.32)</td> <td class=\"centered\">0.82</td> <td class=\"centered\">(0.28)</td> <td class=\"centered\">0.51</td> </tr> <tr> <td class=\"indent1\">pH</td> <td class=\"centered\">7.16</td> <td class=\"centered\">(0.19)</td> <td class=\"centered\">7.23</td> <td class=\"centered\">(0.14)</td> <td class=\"centered\">7.2</td> <td class=\"centered\">(0.13)</td> <td class=\"centered\">0.06</td> </tr> <tr> <td class=\"indent1\">Pco<sub>2</sub> (mmHg)</td> <td class=\"centered\">65.3</td> <td class=\"centered\">(39.4)</td> <td class=\"centered\">53.2</td> <td class=\"centered\">(24.1)</td> <td class=\"centered\">61.6</td> <td class=\"centered\">(18.9)</td> <td class=\"centered\">0.0008</td> </tr> <tr> <td class=\"indent1\">Po<sub>2</sub> (mmHg)</td> <td class=\"centered\">157.6</td> <td class=\"centered\">(142.4)</td> <td class=\"centered\">236.5</td> <td class=\"centered\">(176.1)</td> <td class=\"centered\">275.5</td> <td class=\"centered\">(162.2)</td> <td class=\"centered\">0.002</td> </tr> <tr> <td class=\"indent1\">Base excess (mEq/L)</td> <td class=\"centered\">&ndash;6.6</td> <td class=\"centered\">(5.4)</td> <td class=\"centered\">&ndash;5.6</td> <td class=\"centered\">(6.2)</td> <td class=\"centered\">&ndash;4.9</td> <td class=\"centered\">(5.7)</td> <td class=\"centered\">0.19</td> </tr> <tr> <td class=\"indent1\">Bicarbonate (mEq/L)</td> <td class=\"centered\">21.69</td> <td class=\"centered\">(4.58)</td> <td class=\"centered\">21.34</td> <td class=\"centered\">(4.91)</td> <td class=\"centered\">22.75</td> <td class=\"centered\">(3.98)</td> <td class=\"centered\">0.052</td> </tr> <tr> <td class=\"indent1\">Peak lactic acid (mmol/L)</td> <td class=\"centered\">5.2</td> <td class=\"centered\">(5.8)</td> <td class=\"centered\">1.7</td> <td class=\"centered\">(3.4)</td> <td class=\"centered\">3.8</td> <td class=\"centered\">(2.3)</td> <td class=\"centered\">0.003</td> </tr> <tr> <td class=\"indent1\">Peak potassium (mEq/L)</td> <td class=\"centered\">5.07</td> <td class=\"centered\">(1.30)</td> <td class=\"centered\">5</td> <td class=\"centered\">(1.68)</td> <td class=\"centered\">5.44</td> <td class=\"centered\">(1.24)</td> <td class=\"centered\">0.004</td> </tr> <tr> <td class=\"indent1\">Peak creatinine kinase (U/L)</td> <td class=\"centered\">17,843.5</td> <td class=\"centered\">(58,940.6)</td> <td class=\"centered\">32,895.8</td> <td class=\"centered\">(70,279.5)</td> <td class=\"centered\">20,527.8</td> <td class=\"centered\">(61,000.7)</td> <td class=\"centered\">0.0001</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">etCO<sub>2</sub>: end-tidal carbon dioxide.</div><div class=\"graphic_reference\">From: Nelson P, Litman RS. Malignant Hyperthermia in Children: An Analysis of the North American Malignant Hyperthermia Registry. Anesth Analg 2014; 118:369. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2014&amp;issue=02000&amp;article=00018&amp;type=abstract\" target=\"_blank\">10.1213/ANE.0b013e3182a8fad0</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 International Anesthesia Research Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94516 Version 4.0</div></div></div>"},"94517":{"type":"graphic_figure","displayName":"Chlamydia rates by age and sex in the United States 2016","title":"Chlamydia: Rates of reported cases by age and sex, United States, 2016","html":"<div class=\"graphic\"><div style=\"width: 868px\" class=\"figure\"><div class=\"ttl\">Chlamydia: Rates of reported cases by age and sex, United States, 2016</div><div class=\"cntnt\"><img style=\"width:848px; height:429px;\" src=\"images/ID/94517_ChlamydiaagesexUS2016.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Disease Surveillance 2016. Centers for Disease Control and Prevention. Available at: <A href=\"https://www.cdc.gov/std/stats16/chlamydia.htm\" target=_blank>https://www.cdc.gov/std/stats16/chlamydia.htm</A> (Accessed on October 26, 2017).</div><div id=\"graphicVersion\">Graphic 94517 Version 4.0</div></div></div>"},"94546":{"type":"graphic_movie","displayName":"Kernig sign","title":"Kernig sign","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Kernig sign</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/94546_Kernigsignvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:501px; height:377px;\" src=\"images/PEDS/94546_Kernigsignimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kernig sign is present if the patient, in the supine position with the hip and knee flexed at 90&deg;, cannot extend the knee more than 135&deg;, has pain with extension of the knee, and/or there is flexion of the opposite knee. In this video, the infant cries as the knee is extended.</div><div id=\"graphicVersion\">Graphic 94546 Version 1.0</div></div></div>"},"94547":{"type":"graphic_movie","displayName":"Brudzinski sign","title":"Brudzinski sign","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Brudzinski sign</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/94547_Brudzinskisignvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:385px; height:361px;\" src=\"images/PEDS/94547_Brudzinskisignimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brudzinski sign is present if the patient, while in the supine position, flexes the lower extremities during attempted passive flexion of the neck.</div><div id=\"graphicVersion\">Graphic 94547 Version 1.0</div></div></div>"},"94548":{"type":"graphic_algorithm","displayName":"Diagn algorithm suspected inflammatory brain diseases children","title":"Diagnostic algorithm for suspected inflammatory brain diseases in children","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for suspected inflammatory brain diseases in children</div><div class=\"cntnt\"><img style=\"width:498px; height:558px;\" src=\"images/ALLRG/94548_Susp_inflm_brain_disea_chld.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnostic algorithm for suspected inflammatory brain diseases in children. All patients need an initial evaluation, including laboratory tests and MRI or angiography. If initial evaluation does not reveal a definitive diagnosis, a targeted evaluation should be performed. Patients not diagnosed after the targeted evaluations require a brain biopsy to confirm diagnosis.</div><div class=\"graphic_footnotes\">CNS: central nervous system; CRP: C‑reactive protein; ESR: erythrocyte-sedimentation rate; vWF: von Willebrand factor; CBC: complete blood count; IgG: immunoglobulin G; MRI: magnetic resonance imaging; FLAIR: fluid-attenuarted inversion recovery; DWI: diffision-weighted imaging; ADC: apparent diffusion coefficients; PACNS: primary angiitis of the central nervous system; NMO: neuromyelitis optica; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology. Twilt M, Benseler S. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol 2012; 8:97. Copyright © 2012. <A href=\"http://www.nature.com/nrrheum\" target=_blank>www.nature.com/nrrheum</A>.</div><div id=\"graphicVersion\">Graphic 94548 Version 2.0</div></div></div>"},"94549":{"type":"graphic_table","displayName":"CNS vasculitis - Spectrum and differential diagnosis","title":"CNS vasculitis: Spectrum and differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CNS vasculitis: Spectrum and differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary CNS vasculitis</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Evidence of vasculitis exclusively on angiography: Children, progressive angiography-positive childhood PACNS and nonprogressive angiography-positive childhood PACNS subtypes; adults, PACNS (51% in Mayo clinic cohort) </li> <li>Evidence of vasculitis exclusively on brain biopsy: Children, small-vessel childhood PACNS; adults, PACNS (25% in Mayo clinic cohort) </li> <li>Evidence of vasculitis on angiography and brain biopsy: Children, single cases of childhood PACNS; adults, PACNS (24% in Mayo clinic cohort) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Childhood secondary CNS vasculitis</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Active infections or postinfectious states: Viral (VZV, HIV, EBV, CMV); bacterial (<em>Mycobacterium tuberculosis</em>, <em>Mycoplasma pneumonia</em>, <em>Streptococcus pneumoniae</em>); fungal (<em>Aspergillus</em> spp, <em>Candida albicans</em>, <em>Actinomyces</em> spp) </li> <li>Systemic rheumatic diseases: SLE, systemic vasculitis, scleroderma, dermatomyositis, plus others </li> <li>Systemic inflammatory diseases: Inflammatory bowel disease, hemophagocytic lymphohistiocytosis, Kawasaki syndrome </li> <li>Other systemic diseases or exposures: Graft-versus-host disease, radiation, malignancies </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Adult secondary CNS vasculitis</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Active infections or postinfectious states: Viral (VZV, HIV, CMV, HBV, HCV, HSV); bacterial (<em>Borrelia burgdorferi</em> [Lyme disease], <em>Treponema pallidum</em> [syphilis], <em>M. tuberculosis</em>, <em>Salmonella typhi</em>, <em>Streptococcus pneumoniae</em>); fungal (<em>Aspergillus</em>, <em>Coccidoides</em>, <em>Mycomycoses</em>, <em>Histoplasma capsulatum</em>, <em>Toxoplasma</em>); protozoa (<em>Toxoplasma</em>, <em>Plasmodium</em> [malaria]) </li> <li>Systemic rheumatic diseases: Beh&#231;et syndrome, systemic vasculitis (giant cell arteritis, Takayasu arteritis, polyarteritis nodosa and ANCA-associated vasculitis), SLE, sarcoidosis or neurosarcoid, RA, Sj&#246;gren syndrome, scleroderma </li> <li>Systemic inflammatory diseases: Inflammatory bowel disease, hemophagocytic lymphohistiocytosis, cryoglobulinemia </li> <li>Other systemic diseases or exposures: Graft-versus-host diseases, radiation, drugs (cocaine, amphetamines, among others), malignancies (Hodgkin and non-Hodgkin lymphoma, among others) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; PACNS: primary angiitis of the CNS; VZV: varicella-zoster virus; HIV: human immunodeficiency virus; EBV: Epstein-Barr virus; CMV: cytomegalovirus; SLE: systemic lupus erythematosus; HBV: hepatitis B virus; HCV: hepatitis C virus; HSV: herpes simplex virus; ANCA: antineutrophil cytoplasmic antibody; RA: rheumatoid arthritis.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology. Twilt M, Benseler S. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol 2012; 8:97. Copyright &copy; 2012. <a href=\"http://www.nature.com/nrrheum\" target=\"_blank\">www.nature.com/nrrheum</a>.</div><div id=\"graphicVersion\">Graphic 94549 Version 3.0</div></div></div>"},"94550":{"type":"graphic_table","displayName":"Mimics of CNS vasculitis in adults and children","title":"Mimics of CNS vasculitis in adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mimics of CNS vasculitis in adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mimics of angiography-positive CNS vasculitis in children</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Noninflammatory CNS vasculopathies: Dissection, thrombembolic disease, hemoglobin disorders, aPL syndrome, fibromuscular dyplasia, collagen vascular disorders, focal cerebral angiopathy (Marfan syndrome, Ehlers-Danlos syndrome, among others), Moyamoya disease (idiopathic) </li> <li>Conditions associated with cerebral vasospasms: Channelopathies including familiar hemiplegic migraine and calcium channelopathy, reversible vasoconstrictive syndrome </li> <li>Genetic syndromes with associated vasculopathy: Neurofibromatosis type 1, Down syndrome, PHACES, CADASIL, Fabry disease, homocysteinuria </li> <li>Other syndromes with associated cerebral vasculopathy: Cogan syndrome (vasculopathy plus inflammatory eye disease [interstitial keratitis] and vestibularauditory dysfunction), Susac syndrome (noninflammatory vasculopathy resulting in retinopathy, hearing loss and encephalopathy) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mimics of angiography-negative CNS vasculitis in children</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Nonvasculitic inflammatory brain diseases: Demyelinating diseases (acute demyelinating encephalomyelitis, MS, optic neuritis), antibody-mediated inflammatory brain diseases (anti-NMDAR encephalitis, antibody-mediated limbic encephalitis, neuromyelitis optica, Hashimoto encephalitis, postmycoplasma encephalitis, celiac disease-associated encephalitis, PANDAS), T cell-mediated inflammatory brain diseases (Rasmussen encephalitis), granulomatous inflammatory brain diseases (neurosarcoidosis, ANCA-associated vasculitis) </li> <li>Infections: Tuberculosis, JC virus </li> <li>Metabolic diseases with associated inflammatory or ischemic brain lesions: MELAS, ROME, polymerase gamma deficiency </li> <li>Malignancies: Angiocentric lymphoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mimics of angiography-positive CNS vasculitis in adults</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Arteriosclerosis </li> <li>Vasospastic diseases: Reversible vasoconstriction syndrome; migraines; vasospasms secondary to hypertension, drug exposure, subarachnoid hemorrhage, eclapsia, pheochromocytoma </li> <li>Thrombembolic disease, bacterial endocarditis </li> <li>Hemoglobin disorders </li> <li>Antiphospholipid antibody syndrome </li> <li>Fibromuscular dyplasia </li> <li>Genetic diseases associated with obliterating cerebral vasulopathies: Degos disease, retinocerebral vasculopathy with cerebral leucodystrophy </li> <li>Other syndromes with associated cerebral vasculopathy: Cogan syndrome, Susac syndrome, Sneddon syndrome (progressive noninflammatory cerebral arteriopathy and livedo) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mimics of angiography-negative CNS vasculitis in adults</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Demyelinating diseases (MS, optic neuritis) </li> <li>Antibody-mediated inflammatory brain diseases: Anti-NMDAR encephalitis, antibody-mediated limbic encephalitis, neuromyelitis optica, Hashimoto encephalitis, postmycoplasma encephalitis, celiac disease-associated encephalitis </li> <li>T cell-mediated inflammatory brain diseases: Rasmussen encephalitis </li> <li>Granulomatous inflammatory brain diseases: Neurosarcoidosis, ANCA-associated vasculitis </li> <li>Infections: Tuberculosis; JC virus, syphilis </li> <li>Autoinflammatory syndromes: FMF </li> <li>Malignancies </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; aPL: antiphospholipid antibody; PHACES: posterior fossa malformations-hemangiomas-arterial anomalies-cardiac defects-eye abnormalities-sternal cleft and supraumbilical raph syndrome; CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy; MS: multiple sclerosis; NMDAR: <em>N</em>‑methyl d‑aspartate receptor; PANDAS: pediatric autoinflammatory neuropsychiatric disorder associated with streptococcal infections; ANCA: antineutrophil cytoplasmic antibody; MELAS: mitochondrial encephalopathy lactic acidosis and stroke-like episodes; ROME: rolandic mitochondrial encephalomyopathy; FMF: familial Mediterranean fever.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology. Twilt M, Benseler S. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol 2012; 8:97. Copyright © 2012. <A href=\"http://www.nature.com/nrrheum\" target=_blank>www.nature.com/nrrheum</A>.</div><div id=\"graphicVersion\">Graphic 94550 Version 1.0</div></div></div>"},"94551":{"type":"graphic_picture","displayName":"Unilateral laterothoracic exanthem","title":"Unilateral laterothoracic exanthem (asymmetric periflexural exanthem of childhood)","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Unilateral laterothoracic exanthem (asymmetric periflexural exanthem of childhood)</div><div class=\"cntnt\"><img style=\"width:713px; height:532px;\" src=\"images/DERM/94551_Unltrllaterothoraccexnthm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules coalescing in the left axilla and ipsilateral hemithorax and arm in a one-year-old girl.</div><div class=\"graphic_reference\">From: Duarte AF, Cruz MJ, Baudrier T, et al. Unilateral laterothoracic exanthem and primary Epstein-Barr virus infection: case report. Pediatr Infect Dis J 2009; 28:549. DOI: <a href=\"http://journals.lww.com/pidj/pages/articleviewer.aspx?year=2009&amp;issue=06000&amp;article=00023&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/INF.0b013e318193eca7</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 European Society for Paediatric Infectious Diseases. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94551 Version 2.0</div></div></div>"},"94552":{"type":"graphic_table","displayName":"Drug-induced hyperpigmentation","title":"Classes of drugs and chemicals associated with skin and mucous membrane hyperpigmentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classes of drugs and chemicals associated with skin and mucous membrane hyperpigmentation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drug or chemical</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Chemotherapeutic agents</td> <td>Bleomycin</td> <td> <ul> <li>Linear, flagellate bands </li> <li>Hyperpigmentation over joints, striae, and/or palmar creases </li> </ul> </td> </tr> <tr> <td>Busulfan, cyclophosphamide, procarbazine</td> <td> <ul> <li>Diffuse hyperpigmentation of the skin and mucous membranes </li> <li>Pigment localized to the nails, palms/soles, or teeth </li> </ul> </td> </tr> <tr> <td>Cisplatin, docetaxel, doxorubicin, idarubicin</td> <td> <ul> <li>Hyperpigmentation overlying the small joints of the hands and involving the palmar creases, palms/soles, and oral mucosa including the tongue </li> </ul> </td> </tr> <tr> <td>Fluorouracil</td> <td> <ul> <li>Hyperpigmentation in sun-exposed areas </li> <li>Pigmentation along veins used for infusions* </li> </ul> </td> </tr> <tr> <td>Hydroxyurea</td> <td> <ul> <li>Hyperpigmentation over pressure points and on the back </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Methotrexate</td> <td> <ul> <li>Hyperpigmentation in sun-exposed areas and hair </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antimalarials</td> <td>Aminoquinolines</td> <td> <ul> <li>Gray-blue pigmentation on pretibial surfaces and also the face, hard palate, sclerae, and subungual areas </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hormones</td> <td>Oral contraceptives</td> <td> <ul> <li>Hyperpigmentation of the nipples </li> <li>Increased pigmentation of nevi </li> <li>Hyperpigmented patches of the face (melasma) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Heavy metals</td> <td>Arsenic</td> <td> <ul> <li>Areas of bronze hyperpigmentation </li> </ul> </td> </tr> <tr> <td>Gold (chrysiasis)</td> <td> <ul> <li>Permanent blue-gray pigmentation in sun-exposed areas, especially periorbital </li> </ul> </td> </tr> <tr> <td>Iron</td> <td> <ul> <li>Permanent brown pigment at injection or application sites </li> </ul> </td> </tr> <tr> <td>Lead</td> <td> <ul> <li>Pigmentation at gingival margin </li> </ul> </td> </tr> <tr> <td>Mercury</td> <td> <ul> <li>Slate-gray discoloration, especially in skin folds </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Silver (argyria)</td> <td> <ul> <li>Generalized slate-gray discoloration, increased in sun-exposed areas, nails, sclerae, oral mucosa, or application sites </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"divider_bottom\">Prostaglandin agonists</td> <td>Bimatoprost, latanoprost, tafluprost, travoprost, unoprostone</td> <td> <ul> <li>Increased brown pigmentation of iris, eyelids, eyelashes, and periorbital skin </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"divider_bottom\">Smoking</td> <td>Nicotine and other substances in tobacco smoke</td> <td> <ul> <li>Brown hyperpigmented lesions of oral mucosa, lips, and gingiva (smoker's melanosis) </li> </ul> </td> </tr> <tr> <td rowspan=\"9\">Miscellaneous</td> <td>Amiodarone</td> <td> <ul> <li>Slate-gray discoloration in sun-exposed areas, especially face </li> </ul> </td> </tr> <tr> <td>Clofazimine</td> <td> <ul> <li>Diffuse red-brown discoloration of the skin </li> <li>Blue-brown to violaceous discoloration in lesional skin </li> </ul> </td> </tr> <tr> <td>Diltiazem</td> <td> <ul> <li>Slate-gray-brown pigmentation of sun-exposed areas, especially in darker skin types, may have perifollicular accentuation and reticulated pattern </li> </ul> </td> </tr> <tr> <td>Ezogabine</td> <td> <ul> <li>Blue-gray discoloration of skin, nails, conjunctivae, and oral mucosa </li> </ul> </td> </tr> <tr> <td>Minocycline<sup>&#182;</sup></td> <td> <ul> <li>Generalized \"muddy\" brown discoloration </li> <li>Blue-black discoloration in old acne scars or sites of inflammation as well as lower extremities </li> <li>Pigmentation may also involve the nails, sclerae, oral mucosa, bones, thyroid, and teeth </li> </ul> </td> </tr> <tr> <td>Psoralens</td> <td> <ul> <li>Increased skin pigmentation after exposure to ultraviolet A light </li> </ul> </td> </tr> <tr> <td>Psychotropic drugs (amitriptyline, chlorpromazine, desipramine, imipramine, thioridazine)</td> <td> <ul> <li>Slate-gray pigmentation in sun-exposed areas </li> </ul> </td> </tr> <tr> <td>Tacrolimus, topical</td> <td> <ul> <li>Brown pigmented macules at application sites </li> </ul> </td> </tr> <tr> <td>Zidovudine</td> <td> <ul> <li>Mucocutaneous hyperpigmentation that can be widespread/diffuse, acral, or on oral mucosa </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Drug and chemical exposures associated with skin hyperpigmentation. Drug-associated skin hyperpigmentation generally affects sun-exposed areas and may also involve mucous membranes. Clinical features vary; pigmentation often fades slowly and incompletely following withdrawal of the offending agent.</div><div class=\"graphic_footnotes\">* Pigmentation along veins for infusion is also associated with vinorelbine, cisplatin, docetaxel, and other chemotherapeutic infusions.<br />&para; Skin discoloration is described less frequently with use of tetracyclines other than minocycline; this may be due to more frequent prolonged courses of treatment and higher cumulative doses in use of minocycline (eg, in acne treatment) relative to the other tetracyclines.</div><div class=\"graphic_reference\">Adapted from: Kang S, Lerner EA, Sober AJ, Levine N. Pigmentary disorders from exogenous causes. In: Pigmentation and Pigmentary Disorders, Levine N (Ed), CRC Press, 1993. Updated with data from Krause W. Drug-induced hyperpigmentation: A systematic review; J Dtsch Dermatol Ges 2013; 11:644.</div><div id=\"graphicVersion\">Graphic 94552 Version 8.0</div></div></div>"},"94553":{"type":"graphic_picture","displayName":"Hand-foot-and-mouth disease generalized","title":"Generalized hand-foot-and-mouth disease (HFMD)","html":"<div class=\"graphic\"><div style=\"width: 691px\" class=\"figure\"><div class=\"ttl\">Generalized hand-foot-and-mouth disease (HFMD)</div><div class=\"cntnt\"><img style=\"width:671px; height:722px;\" src=\"images/DERM/94553_Handfootmouthdssgnrlz.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-C) Generalized HFMD related to CV-A16 in a 13-month-old boy;<br />(D) generalized HFMD related to CV-A6 in a 12-month-old boy;<br />(E) grouped vesicles in a 23-month-old boy with HFMD related to CV-A16; and<br />(F) grouped vesicles in an 18-month-old boy with HFMD related to CV-A6.</div><div class=\"graphic_reference\">From: Hubiche T, Schuffenecker I, Boralevi F, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J 2014; 33:e92. DOI: <a href=\"http://journals.lww.com/pidj/pages/articleviewer.aspx?year=2014&amp;issue=04000&amp;article=00010&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/INF.0000000000000120</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 European Society for Paediatric Infectious Diseases. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94553 Version 2.0</div></div></div>"},"94554":{"type":"graphic_figure","displayName":"fMRI in SS patients with chronic ocular pain","title":"fMRI in Sjögren's syndrome patients with chronic ocular pain","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">fMRI in Sjögren's syndrome patients with chronic ocular pain</div><div class=\"cntnt\"><img style=\"width:488px; height:674px;\" src=\"images/RHEUM/94554_fMRI_SS_chronic_ocular_pain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cortical regions that activate with ocular pain signal at \"benign stimuli levels\" occur only in chronic&nbsp;Sjögren's syndrome patients with severe pain.</div><div class=\"graphic_reference\">Reproduced from: Moulton EA, Becerra L, Rosenthal P, Borsook D. An approach to localizing corneal pain representation in human primary somatosensory cortex. PloS One 2012; 7:e44643. Copyright &copy; 2012 Moulton et al.</div><div id=\"graphicVersion\">Graphic 94554 Version 2.0</div></div></div>"},"94579":{"type":"graphic_table","displayName":"Maternal cause specific mortality in cardiac arrest","title":"Maternal cause-specific mortality in cardiac arrest","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal cause-specific mortality in cardiac arrest</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"3\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Potential proximate etiology of maternal cardiac arrest,<br /> n (%)</td> <td class=\"subtitle1\">Cause-specific cardiac arrest frequency per 1000 women with each condition</td> <td class=\"subtitle1\">Survival to hospital discharge,*<br /> n (%)</td> </tr> <tr> <td><strong>Postpartum hemorrhage</strong></td> <td class=\"centered\">1349 (27.9)</td> <td class=\"centered\">0.8</td> <td class=\"centered\">739 (55.1)</td> </tr> <tr> <td><strong>Antepartum hemorrhage</strong></td> <td class=\"centered\">813 (16.8) </td> <td class=\"centered\">0.9</td> <td class=\"centered\">433 (53.2)</td> </tr> <tr> <td><strong>Heart failure</strong></td> <td class=\"centered\">645 (13.3)</td> <td class=\"centered\">15.6</td> <td class=\"centered\">458 (71.1)</td> </tr> <tr> <td><strong>Amniotic fluid embolism</strong></td> <td class=\"centered\">645 (13.3)</td> <td class=\"centered\">252.7</td> <td class=\"centered\">337 (52.5)</td> </tr> <tr> <td><strong>Sepsis</strong></td> <td class=\"centered\">544 (11.2)</td> <td class=\"centered\">2.1</td> <td class=\"centered\">256 (46.9)</td> </tr> <tr> <td><strong>Anesthesia complication</strong></td> <td class=\"centered\">379 (7.8)</td> <td class=\"centered\">29.5</td> <td class=\"centered\">310 (81.9)</td> </tr> <tr> <td><strong>Aspiration pneumonitis</strong></td> <td class=\"centered\">346 (7.1)</td> <td class=\"centered\">20.3</td> <td class=\"centered\">287 (82.9)</td> </tr> <tr> <td><strong>Venous thromboembolism</strong></td> <td class=\"centered\">346 (7.1)</td> <td class=\"centered\">43.9</td> <td class=\"centered\">144 (41.5)</td> </tr> <tr> <td><strong>Eclampsia</strong></td> <td class=\"centered\">296 (6.1)</td> <td class=\"centered\">6.2</td> <td class=\"centered\">226 (76.5)</td> </tr> <tr> <td><strong>Puerperal cerebrovascular disorder</strong></td> <td class=\"centered\">212 (4.4)</td> <td class=\"centered\">13.6</td> <td class=\"centered\">85 (40)</td> </tr> <tr> <td><strong>Trauma</strong></td> <td class=\"centered\">125 (2.6)</td> <td class=\"centered\">3.9</td> <td class=\"centered\">29 (23.3)</td> </tr> <tr> <td><strong>Pulmonary edema</strong></td> <td class=\"centered\">118 (2.4)</td> <td class=\"centered\">11.2</td> <td class=\"centered\">83 (70.9)</td> </tr> <tr> <td><strong>Acute myocardial infarction</strong></td> <td class=\"centered\">150 (3.1)</td> <td class=\"centered\">89.8</td> <td class=\"centered\">85 (56.3)</td> </tr> <tr> <td><strong>Magnesium toxicity</strong></td> <td class=\"centered\">66 (1.4)</td> <td class=\"centered\">5.2</td> <td class=\"centered\">57 (85.9)</td> </tr> <tr> <td><strong>Status asthmaticus<sup>&#182;</sup></strong></td> <td class=\"centered\">54 (1.1)</td> <td class=\"centered\">12.6</td> <td class=\"centered\">29 (53.7)</td> </tr> <tr> <td><strong>Anaphylaxis<sup>&#182;</sup></strong></td> <td class=\"centered\">15 (0.3)</td> <td class=\"centered\">10.8</td> <td class=\"centered\">15 (100)</td> </tr> <tr> <td><strong>Aortic dissection/rupture<sup>&#182;</sup></strong></td> <td class=\"centered\">14 (0.3)</td> <td class=\"centered\">31</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Distribution of Maternal Cardiac Arrests (n = 4843), the Nationwide Inpatient Sample (NIS) 1998-2011. Numbers of arrests from local anesthetic toxicity cannot be reported due to restrictions on reporting small cell sizes.</div><div class=\"graphic_footnotes\">%: percent.<br />* Survival is missing for 0.2% of those with cardiopulmonary arrest.<br />¶ Estimates with a relative standard error (ie, standard error/weighted estimate) &gt;0.30 may not be reliable.</div><div class=\"graphic_reference\">Reproduced with permission from: Mhyre JM, Tsen LC, Einav S, et al. Cardiac Arrest during Hospitalization for Delivery in the United States, 1998-2011. Anesthesiology 2014; 120:810. DOI: <A spellcheck=true href=\"http://journals.lww.com/anesthesiology/pages/articleviewer.aspx?year=2014&amp;issue=04000&amp;article=00016&amp;type=abstract\" target=_blank>10.1097/ALN.0000000000000159</A>. Copyright&nbsp;© 2014 American Society of Anesthesiologists, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94579 Version 4.0</div></div></div>"},"94597":{"type":"graphic_table","displayName":"Genes associated with SS in GWAS","title":"Selected genes with polymorphisms associated with Sjögren's syndrome in genome-wide association studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected genes with polymorphisms associated with Sjögren's syndrome in genome-wide association studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene name or region</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Human leukocyte antigen (HLA)</td> <td>The HLA region has&nbsp;the strongest signal in&nbsp;genome-wide association studies (GWAS), particularly the ancestral haplotype of DRB1*0201, DQB1*0201, and DQA1*0501. However, the recognition of <em>RFX5</em>, a key transcriptional regulator of the HLA class II loci, extended previous HLA associations.</td> </tr> <tr class=\"divider_bottom\"> <td><em>IRF5</em></td> <td><em>IRF5</em> is a member of the interferon regulatory factor (IRF) family, a group of transcription factors with diverse roles including virus-mediated activation of interferon and modulation of cell growth, differentiation, apoptosis, and immune system activity.</td> </tr> <tr class=\"divider_bottom\"> <td><em>STAT4</em></td> <td><em>STAT4</em> genes lie next to the&nbsp;<em>STAT1</em> gene locus, suggesting that the genes arose by gene duplication. STAT proteins have several functional domains, including an N-terminal interaction domain, a central DNA-binding domain, an SH2 domain, and the C-terminal trans-activation domain.</td> </tr> <tr class=\"divider_bottom\"> <td><em>IL12A</em></td> <td>Two chains of the interleukin (IL)-12 receptor form&nbsp;a heterodimer after IL-12 binding and activate the receptor-associated Janus kinases, termed <em>JAK2</em> and <em>TYK2</em>. <em>STAT4</em> is phosphorylated by these tyrosine kinases, homodimerizes via its SH2 domain, and translocates into the nucleus to activate gene transcription.</td> </tr> <tr class=\"divider_bottom\"> <td><em>BLK</em></td> <td>Tyrosine-protein kinase, also known as B lymphocyte kinase.</td> </tr> <tr class=\"divider_bottom\"> <td><em>TNIP1</em></td> <td><em>TNIP1</em> has been shown to interact with <em>TNFAIP3</em> and <em>MAPK</em> that are both rapidly induced by tumor necrosis factor (TNF) and inhibit NF-kappa B activation as well as TNF-mediated apoptosis. Knockout studies of a similar gene in mice suggested that this gene is critical for limiting inflammation by terminating TNF-induced NF-kappa B responses.</td> </tr> <tr> <td><em>CXCR5</em></td> <td>Also known as Burkitt lymphoma receptor 1 (<em>BLR1</em>). The&nbsp;<em>CXCR5</em> gene is specifically expressed in follicles in lymph nodes. The gene plays an essential role in B-cell migration.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These results highlight the importance of genes that promote innate immunity (type 1 interferon signature) and acquired immunity (HLA-linked recognition of antigen by T and B cells through traditional antigen-presenting pathways). One interesting observation is that CXCR5, a homing receptor, was not found in GWAS of systemic lupus erythematosus (SLE) patients. This is one of the few examples where SLE and Sjögren's syndrome (SS) can be differentiated on a genetic basis and helps explain the relative organ specificity and lymphoproliferative nature of SS.</div><div class=\"graphic_reference\">Source: Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sj&ouml;gren's syndrome. Nat Rev Rheumatol 2013; 9:544.</div><div id=\"graphicVersion\">Graphic 94597 Version 2.0</div></div></div>"},"94602":{"type":"graphic_picture","displayName":"Proliferative nodules histology","title":"Histologic features of proliferative nodules in giant congenital melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Histologic features of proliferative nodules in giant congenital melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:551px; height:654px;\" src=\"images/DERM/94602_Proliferativenoduleshisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low magnification, the benign proliferative nodule (A, 40x; C, 100x) lacks the sharp demarcation seen in an atypical one (B, 40x; D, 100x). In addition, the benign proliferative nodule (E, 400x) does not possess the nuclear pleomorphism and mitotic figure seen in the atypical counterpart (F, 400x).</div><div class=\"graphic_reference\">From: Phadke PA, Rakheja D, Le LP, et al. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am J Surg Pathol 2011; 35:656. DOI: <a href=\"http://journals.lww.com/ajsp/pages/articleviewer.aspx?year=2011&amp;issue=05000&amp;article=00004&amp;type=abstract\" target=\"_blank\">10.1097/PAS.0b013e31821375ea</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2011 The Arthur Purdy Stout Society of Surgical Pathologists and The Gastrointestinal Pathology Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94602 Version 4.0</div></div></div>"},"94607":{"type":"graphic_picture","displayName":"Facial features FAS","title":"Characteristic facial features in a child with fetal alcohol spectrum disorder","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Characteristic facial features in a child with fetal alcohol spectrum disorder</div><div class=\"cntnt\"><img style=\"width:656px; height:232px;\" src=\"images/PEDS/94607_Facial_features_FASD_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of the fetal alcohol syndrome facial phenotype across three races: Caucasian, Native American, and African American. Characteristic facial features include short palpebral fissure length, smooth philtrum, and a thin upper lip.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Susan Astley PhD, University of Washington.</div><div id=\"graphicVersion\">Graphic 94607 Version 2.0</div></div></div>"},"94608":{"type":"graphic_picture","displayName":"Lip-philtrum ranking guide","title":"University of Washington Lip-Philtrum guide","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">University of Washington Lip-Philtrum guide</div><div class=\"cntnt\"><img style=\"width:748px; height:638px;\" src=\"images/PEDS/94608_Lip_philtrum_ranking_guide.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lip-Philtrum Guides 1 and 2 are used to rank upper lip thinness and philtrum smoothness. The philtrum is the vertical groove between the nose and upper lip. The guides reflect the full range of lip and philtrum shapes with Rank 3 representing the population mean. Ranks 4 and 5 reflect the thin lip and smooth philtrum that characterize the fetal alcohol syndrome (FAS) facial phenotype. Guide 1 is used for Caucasians and all other races with lips like Caucasians. Guide 2 is used for African Americans and all other races with lips as full as African Americans.<br />(B) The lips and philtrum should be assessed with the lips gently closed and no smile. As depicted above, smiling causes the lips and philtrum to appear thinner and smoother, respectively, than they truly are.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Susan Astley PhD, University of Washington.</div><div id=\"graphicVersion\">Graphic 94608 Version 1.0</div></div></div>"},"94609":{"type":"graphic_figure","displayName":"Ear anomalies FASD","title":"Ear anomalies in fetal alcohol spectrum disorders","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ear anomalies in fetal alcohol spectrum disorders</div><div class=\"cntnt\"><img style=\"width:331px; height:416px;\" src=\"images/PEDS/94609_Ear_anomalies_FASD_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Railroad track\" ear is a minor anomaly common among children with fetal alcohol spectrum disorders. Note the upper curve of the outer ear is underdeveloped, folded over, and parallel to the curve beneath it, giving the appearance of a railroad track.</div><div class=\"graphic_reference\">Reproduced with permission: from Darryl Leja.</div><div id=\"graphicVersion\">Graphic 94609 Version 1.0</div></div></div>"},"94610":{"type":"graphic_figure","displayName":"Hand anomalies FASD","title":"Hand anomalies in fetal alcohol spectrum disorders","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand anomalies in fetal alcohol spectrum disorders</div><div class=\"cntnt\"><img style=\"width:331px; height:531px;\" src=\"images/PEDS/94610_Hand_anomalies_FASD_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinodactyly of the fifth finger and a \"hockey stick\" configuration of the upper palmar crease. Note that the upper palmar crease widely curves and terminates between the index and middle fingers.</div><div class=\"graphic_reference\">Reproduced with permission from: Darryl Leja.</div><div id=\"graphicVersion\">Graphic 94610 Version 1.0</div></div></div>"},"94613":{"type":"graphic_picture","displayName":"Granuloma faciale on forehead","title":"Granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma faciale</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/RHEUM/94613_Granuloma_faciale_forehead.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown plaque with prominent follicular orifices on the forehead.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 94613 Version 2.0</div></div></div>"},"94614":{"type":"graphic_picture","displayName":"Lupus tumidus on jawline","title":"Lupus tumidus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lupus tumidus</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/RHEUM/94614_Lupus_tumidus_jawline.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaque without overlying&nbsp;scale on the face.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 94614 Version 1.0</div></div></div>"},"94615":{"type":"graphic_picture","displayName":"Lupus tumidus","title":"Lupus tumidus","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Lupus tumidus</div><div class=\"cntnt\"><img style=\"width:468px; height:352px;\" src=\"images/RHEUM/94615_Lupus_tumidus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Round, erythematous plaques on the upper arm.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 94615 Version 2.0</div></div></div>"},"94616":{"type":"graphic_table","displayName":"Normal ABP for boys based on height","title":"24-hour ambulatory blood pressure (BP) levels for boys based on height","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">24-hour ambulatory blood pressure (BP) levels for boys based on height</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22%\"></colgroup><colgroup span=\"12\" width=\"6.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Height (cm)</td> <td class=\"subtitle1\" colspan=\"4\">Average 24-hour BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average day BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average night BP (percentile)</td> </tr> <tr> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> </tr> <tr> <td class=\"centered\">120</td> <td class=\"centered\">105/66</td> <td class=\"centered\">109/70</td> <td class=\"centered\">114/74</td> <td class=\"centered\">117/77</td> <td class=\"centered\">111/72</td> <td class=\"centered\">116/77</td> <td class=\"centered\">122/80</td> <td class=\"centered\">125/82</td> <td class=\"centered\">94/54</td> <td class=\"centered\">99/58</td> <td class=\"centered\">103/61</td> <td class=\"centered\">106/63</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">125</td> <td class=\"centered\">105/66</td> <td class=\"centered\">110/70</td> <td class=\"centered\">115/74</td> <td class=\"centered\">118/77</td> <td class=\"centered\">111/72</td> <td class=\"centered\">117/76</td> <td class=\"centered\">122/80</td> <td class=\"centered\">125/82</td> <td class=\"centered\">95/55</td> <td class=\"centered\">100/58</td> <td class=\"centered\">105/61</td> <td class=\"centered\">108/63</td> </tr> <tr> <td class=\"centered\">130</td> <td class=\"centered\">106/66</td> <td class=\"centered\">111/70</td> <td class=\"centered\">116/74</td> <td class=\"centered\">119/77</td> <td class=\"centered\">112/72</td> <td class=\"centered\">117/76</td> <td class=\"centered\">122/80</td> <td class=\"centered\">126/82</td> <td class=\"centered\">96/55</td> <td class=\"centered\">101/59</td> <td class=\"centered\">106/62</td> <td class=\"centered\">110/64</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">135</td> <td class=\"centered\">107/66</td> <td class=\"centered\">112/70</td> <td class=\"centered\">117/74</td> <td class=\"centered\">120/77</td> <td class=\"centered\">112/72</td> <td class=\"centered\">117/76</td> <td class=\"centered\">123/80</td> <td class=\"centered\">126/82</td> <td class=\"centered\">97/56</td> <td class=\"centered\">102/59</td> <td class=\"centered\">108/63</td> <td class=\"centered\">111/65</td> </tr> <tr> <td class=\"centered\">140</td> <td class=\"centered\">108/67</td> <td class=\"centered\">113/71</td> <td class=\"centered\">118/75</td> <td class=\"centered\">121/77</td> <td class=\"centered\">113/72</td> <td class=\"centered\">118/76</td> <td class=\"centered\">123/80</td> <td class=\"centered\">126/82</td> <td class=\"centered\">98/56</td> <td class=\"centered\">104/60</td> <td class=\"centered\">109/63</td> <td class=\"centered\">113/65</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">145</td> <td class=\"centered\">110/67</td> <td class=\"centered\">115/71</td> <td class=\"centered\">120/75</td> <td class=\"centered\">123/77</td> <td class=\"centered\">114/72</td> <td class=\"centered\">119/76</td> <td class=\"centered\">124/79</td> <td class=\"centered\">127/81</td> <td class=\"centered\">99/56</td> <td class=\"centered\">105/60</td> <td class=\"centered\">111/64</td> <td class=\"centered\">114/66</td> </tr> <tr> <td class=\"centered\">150</td> <td class=\"centered\">111/67</td> <td class=\"centered\">116/71</td> <td class=\"centered\">121/75</td> <td class=\"centered\">124/77</td> <td class=\"centered\">115/72</td> <td class=\"centered\">120/76</td> <td class=\"centered\">125/79</td> <td class=\"centered\">128/81</td> <td class=\"centered\">100/56</td> <td class=\"centered\">106/60</td> <td class=\"centered\">112/64</td> <td class=\"centered\">116/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">155</td> <td class=\"centered\">113/67</td> <td class=\"centered\">118/71</td> <td class=\"centered\">123/75</td> <td class=\"centered\">126/77</td> <td class=\"centered\">117/72</td> <td class=\"centered\">122/76</td> <td class=\"centered\">127/79</td> <td class=\"centered\">130/81</td> <td class=\"centered\">101/56</td> <td class=\"centered\">107/60</td> <td class=\"centered\">113/64</td> <td class=\"centered\">117/66</td> </tr> <tr> <td class=\"centered\">160</td> <td class=\"centered\">114/67</td> <td class=\"centered\">120/71</td> <td class=\"centered\">124/75</td> <td class=\"centered\">127/77</td> <td class=\"centered\">119/72</td> <td class=\"centered\">124/76</td> <td class=\"centered\">129/79</td> <td class=\"centered\">133/81</td> <td class=\"centered\">103/56</td> <td class=\"centered\">108/60</td> <td class=\"centered\">114/64</td> <td class=\"centered\">118/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">165</td> <td class=\"centered\">116/68</td> <td class=\"centered\">121/71</td> <td class=\"centered\">126/75</td> <td class=\"centered\">129/78</td> <td class=\"centered\">121/72</td> <td class=\"centered\">126/76</td> <td class=\"centered\">132/80</td> <td class=\"centered\">135/82</td> <td class=\"centered\">104/57</td> <td class=\"centered\">110/60</td> <td class=\"centered\">116/64</td> <td class=\"centered\">119/66</td> </tr> <tr> <td class=\"centered\">170</td> <td class=\"centered\">118/68</td> <td class=\"centered\">123/72</td> <td class=\"centered\">128/75</td> <td class=\"centered\">131/78</td> <td class=\"centered\">123/73</td> <td class=\"centered\">128/77</td> <td class=\"centered\">134/80</td> <td class=\"centered\">138/82</td> <td class=\"centered\">106/57</td> <td class=\"centered\">112/61</td> <td class=\"centered\">117/64</td> <td class=\"centered\">121/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">175</td> <td class=\"centered\">120/68</td> <td class=\"centered\">125/72</td> <td class=\"centered\">130/75</td> <td class=\"centered\">133/78</td> <td class=\"centered\">124/73</td> <td class=\"centered\">130/77</td> <td class=\"centered\">136/81</td> <td class=\"centered\">140/83</td> <td class=\"centered\">107/57</td> <td class=\"centered\">113/61</td> <td class=\"centered\">119/64</td> <td class=\"centered\">122/66</td> </tr> <tr> <td class=\"centered\">180</td> <td class=\"centered\">122/68</td> <td class=\"centered\">127/72</td> <td class=\"centered\">131/76</td> <td class=\"centered\">134/78</td> <td class=\"centered\">126/73</td> <td class=\"centered\">132/77</td> <td class=\"centered\">138/81</td> <td class=\"centered\">142/83</td> <td class=\"centered\">109/57</td> <td class=\"centered\">115/61</td> <td class=\"centered\">120/64</td> <td class=\"centered\">124/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">185</td> <td class=\"centered\">123/68</td> <td class=\"centered\">128/72</td> <td class=\"centered\">133/76</td> <td class=\"centered\">136/78</td> <td class=\"centered\">128/73</td> <td class=\"centered\">134/78</td> <td class=\"centered\">140/81</td> <td class=\"centered\">144/84</td> <td class=\"centered\">110/57</td> <td class=\"centered\">116/61</td> <td class=\"centered\">122/64</td> <td class=\"centered\">125/66</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The values are in mmHg and are the average BP based on 24-hour ambulatory BP monitoring.</div><div class=\"graphic_reference\">From: Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34:1887. DOI: <A href=\"http://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2016&amp;issue=10000&amp;article=00002&amp;type=abstract\" target=_blank>10.1097/HJH.0000000000001039</A>. Copyright © 2016 International Society of Hypertension and European Society of Hypertension. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94616 Version 2.0</div></div></div>"},"94617":{"type":"graphic_table","displayName":"Normal ABP for girls based on height","title":"24-hour ambulatory blood pressure (BP) levels for girls based on height","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">24-hour ambulatory blood pressure (BP) levels for girls based on height</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22%\"></colgroup><colgroup span=\"12\" width=\"6.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Height (cm)</td> <td class=\"subtitle1\" colspan=\"4\">Average 24-hour BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average day BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average night BP (percentile)</td> </tr> <tr> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> </tr> <tr> <td class=\"centered\">120</td> <td class=\"centered\">104/66</td> <td class=\"centered\">108/69</td> <td class=\"centered\">112/71</td> <td class=\"centered\">114/72</td> <td class=\"centered\">110/73</td> <td class=\"centered\">114/77</td> <td class=\"centered\">118/80</td> <td class=\"centered\">120/82</td> <td class=\"centered\">95/55</td> <td class=\"centered\">99/60</td> <td class=\"centered\">103/63</td> <td class=\"centered\">106/65</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">125</td> <td class=\"centered\">105/66</td> <td class=\"centered\">109/69</td> <td class=\"centered\">113/71</td> <td class=\"centered\">116/73</td> <td class=\"centered\">111/73</td> <td class=\"centered\">115/77</td> <td class=\"centered\">119/80</td> <td class=\"centered\">121/82</td> <td class=\"centered\">96/55</td> <td class=\"centered\">100/60</td> <td class=\"centered\">104/63</td> <td class=\"centered\">107/66</td> </tr> <tr> <td class=\"centered\">130</td> <td class=\"centered\">106/66</td> <td class=\"centered\">110/69</td> <td class=\"centered\">114/72</td> <td class=\"centered\">117/73</td> <td class=\"centered\">111/72</td> <td class=\"centered\">116/76</td> <td class=\"centered\">120/80</td> <td class=\"centered\">122/82</td> <td class=\"centered\">96/55</td> <td class=\"centered\">101/59</td> <td class=\"centered\">106/63</td> <td class=\"centered\">108/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">135</td> <td class=\"centered\">107/66</td> <td class=\"centered\">111/70</td> <td class=\"centered\">115/72</td> <td class=\"centered\">118/74</td> <td class=\"centered\">112/72</td> <td class=\"centered\">116/76</td> <td class=\"centered\">120/80</td> <td class=\"centered\">123/82</td> <td class=\"centered\">97/55</td> <td class=\"centered\">102/59</td> <td class=\"centered\">107/63</td> <td class=\"centered\">109/66</td> </tr> <tr> <td class=\"centered\">140</td> <td class=\"centered\">108/66</td> <td class=\"centered\">112/70</td> <td class=\"centered\">116/73</td> <td class=\"centered\">119/75</td> <td class=\"centered\">112/72</td> <td class=\"centered\">117/76</td> <td class=\"centered\">121/80</td> <td class=\"centered\">124/82</td> <td class=\"centered\">98/55</td> <td class=\"centered\">103/59</td> <td class=\"centered\">108/63</td> <td class=\"centered\">110/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">145</td> <td class=\"centered\">109/66</td> <td class=\"centered\">113/70</td> <td class=\"centered\">117/73</td> <td class=\"centered\">120/75</td> <td class=\"centered\">113/72</td> <td class=\"centered\">118/76</td> <td class=\"centered\">123/80</td> <td class=\"centered\">125/82</td> <td class=\"centered\">98/54</td> <td class=\"centered\">103/59</td> <td class=\"centered\">109/63</td> <td class=\"centered\">112/66</td> </tr> <tr> <td class=\"centered\">150</td> <td class=\"centered\">110/67</td> <td class=\"centered\">115/70</td> <td class=\"centered\">119/74</td> <td class=\"centered\">121/76</td> <td class=\"centered\">114/72</td> <td class=\"centered\">119/76</td> <td class=\"centered\">124/80</td> <td class=\"centered\">127/82</td> <td class=\"centered\">99/54</td> <td class=\"centered\">104/59</td> <td class=\"centered\">110/63</td> <td class=\"centered\">113/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">155</td> <td class=\"centered\">111/67</td> <td class=\"centered\">116/71</td> <td class=\"centered\">120/74</td> <td class=\"centered\">123/76</td> <td class=\"centered\">116/72</td> <td class=\"centered\">121/76</td> <td class=\"centered\">125/80</td> <td class=\"centered\">128/82</td> <td class=\"centered\">100/54</td> <td class=\"centered\">106/59</td> <td class=\"centered\">111/63</td> <td class=\"centered\">114/66</td> </tr> <tr> <td class=\"centered\">160</td> <td class=\"centered\">112/67</td> <td class=\"centered\">117/71</td> <td class=\"centered\">121/74</td> <td class=\"centered\">123/76</td> <td class=\"centered\">117/72</td> <td class=\"centered\">122/76</td> <td class=\"centered\">126/80</td> <td class=\"centered\">129/82</td> <td class=\"centered\">101/55</td> <td class=\"centered\">106/59</td> <td class=\"centered\">111/63</td> <td class=\"centered\">114/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">165</td> <td class=\"centered\">114/67</td> <td class=\"centered\">118/71</td> <td class=\"centered\">122/74</td> <td class=\"centered\">124/76</td> <td class=\"centered\">118/73</td> <td class=\"centered\">123/77</td> <td class=\"centered\">127/80</td> <td class=\"centered\">130/82</td> <td class=\"centered\">102/55</td> <td class=\"centered\">107/59</td> <td class=\"centered\">112/63</td> <td class=\"centered\">114/66</td> </tr> <tr> <td class=\"centered\">170</td> <td class=\"centered\">115/68</td> <td class=\"centered\">119/71</td> <td class=\"centered\">123/74</td> <td class=\"centered\">125/76</td> <td class=\"centered\">120/74</td> <td class=\"centered\">124/77</td> <td class=\"centered\">128/80</td> <td class=\"centered\">131/82</td> <td class=\"centered\">103/55</td> <td class=\"centered\">108/61</td> <td class=\"centered\">112/67</td> <td class=\"centered\">115/71</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">175</td> <td class=\"centered\">116/69</td> <td class=\"centered\">120/72</td> <td class=\"centered\">124/75</td> <td class=\"centered\">126/76</td> <td class=\"centered\">121/75</td> <td class=\"centered\">125/78</td> <td class=\"centered\">129/81</td> <td class=\"centered\">131/82</td> <td class=\"centered\">105/55</td> <td class=\"centered\">109/59</td> <td class=\"centered\">113/63</td> <td class=\"centered\">115/66</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The values are in mmHg and are the average BP based on 24-hour ambulatory BP monitoring.</div><div class=\"graphic_reference\">From: Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34:1887. DOI: <a href=\"http://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2016&amp;issue=10000&amp;article=00002&amp;type=abstract\" target=\"_blank\">10.1097/HJH.0000000000001039</a>. Copyright &copy; 2016 International Society of Hypertension and European Society of Hypertension. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94617 Version 2.0</div></div></div>"},"94618":{"type":"graphic_table","displayName":"Normal ABP for boys based on age","title":"24-hour ambulatory blood pressure (BP) levels for boys based on age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">24-hour ambulatory blood pressure (BP) levels for boys based on age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22%\"></colgroup><colgroup span=\"12\" width=\"6.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"4\">Average 24-hour BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average day BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average night BP (percentile)</td> </tr> <tr> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">105/65</td> <td class=\"centered\">109/69</td> <td class=\"centered\">113/72</td> <td class=\"centered\">116/74</td> <td class=\"centered\">111/72</td> <td class=\"centered\">116/76</td> <td class=\"centered\">120/79</td> <td class=\"centered\">123/81</td> <td class=\"centered\">95/55</td> <td class=\"centered\">99/59</td> <td class=\"centered\">103/62</td> <td class=\"centered\">106/65</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">6</td> <td class=\"centered\">106/66</td> <td class=\"centered\">110/69</td> <td class=\"centered\">115/73</td> <td class=\"centered\">118/75</td> <td class=\"centered\">112/72</td> <td class=\"centered\">116/76</td> <td class=\"centered\">121/79</td> <td class=\"centered\">124/81</td> <td class=\"centered\">96/55</td> <td class=\"centered\">100/59</td> <td class=\"centered\">105/63</td> <td class=\"centered\">108/66</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">106/66</td> <td class=\"centered\">111/70</td> <td class=\"centered\">116/73</td> <td class=\"centered\">119/75</td> <td class=\"centered\">112/73</td> <td class=\"centered\">117/76</td> <td class=\"centered\">122/80</td> <td class=\"centered\">125/82</td> <td class=\"centered\">96/56</td> <td class=\"centered\">101/60</td> <td class=\"centered\">106/64</td> <td class=\"centered\">110/67</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">8</td> <td class=\"centered\">107/66</td> <td class=\"centered\">112/70</td> <td class=\"centered\">117/73</td> <td class=\"centered\">120/75</td> <td class=\"centered\">112/73</td> <td class=\"centered\">117/76</td> <td class=\"centered\">122/80</td> <td class=\"centered\">125/82</td> <td class=\"centered\">97/56</td> <td class=\"centered\">102/60</td> <td class=\"centered\">108/64</td> <td class=\"centered\">111/67</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">108/67</td> <td class=\"centered\">113/70</td> <td class=\"centered\">118/73</td> <td class=\"centered\">121/75</td> <td class=\"centered\">113/72</td> <td class=\"centered\">118/76</td> <td class=\"centered\">123/80</td> <td class=\"centered\">126/82</td> <td class=\"centered\">97/56</td> <td class=\"centered\">103/60</td> <td class=\"centered\">109/64</td> <td class=\"centered\">112/67</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">10</td> <td class=\"centered\">109/67</td> <td class=\"centered\">114/70</td> <td class=\"centered\">119/73</td> <td class=\"centered\">123/75</td> <td class=\"centered\">113/72</td> <td class=\"centered\">119/76</td> <td class=\"centered\">124/80</td> <td class=\"centered\">127/82</td> <td class=\"centered\">98/56</td> <td class=\"centered\">104/60</td> <td class=\"centered\">110/64</td> <td class=\"centered\">113/67</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">110/67</td> <td class=\"centered\">116/71</td> <td class=\"centered\">121/74</td> <td class=\"centered\">125/76</td> <td class=\"centered\">115/72</td> <td class=\"centered\">121/76</td> <td class=\"centered\">126/80</td> <td class=\"centered\">129/82</td> <td class=\"centered\">99/56</td> <td class=\"centered\">105/60</td> <td class=\"centered\">111/64</td> <td class=\"centered\">115/67</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">12</td> <td class=\"centered\">113/67</td> <td class=\"centered\">118/71</td> <td class=\"centered\">124/74</td> <td class=\"centered\">127/76</td> <td class=\"centered\">117/72</td> <td class=\"centered\">123/76</td> <td class=\"centered\">128/80</td> <td class=\"centered\">132/82</td> <td class=\"centered\">101/56</td> <td class=\"centered\">107/60</td> <td class=\"centered\">113/64</td> <td class=\"centered\">116/67</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">115/67</td> <td class=\"centered\">121/71</td> <td class=\"centered\">126/74</td> <td class=\"centered\">130/76</td> <td class=\"centered\">120/72</td> <td class=\"centered\">126/76</td> <td class=\"centered\">131/80</td> <td class=\"centered\">135/82</td> <td class=\"centered\">103/56</td> <td class=\"centered\">109/60</td> <td class=\"centered\">115/64</td> <td class=\"centered\">119/67</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">14</td> <td class=\"centered\">118/68</td> <td class=\"centered\">124/71</td> <td class=\"centered\">129/75</td> <td class=\"centered\">133/77</td> <td class=\"centered\">122/73</td> <td class=\"centered\">129/77</td> <td class=\"centered\">134/80</td> <td class=\"centered\">138/82</td> <td class=\"centered\">106/57</td> <td class=\"centered\">112/61</td> <td class=\"centered\">118/64</td> <td class=\"centered\">121/67</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">121/68</td> <td class=\"centered\">127/72</td> <td class=\"centered\">132/75</td> <td class=\"centered\">136/77</td> <td class=\"centered\">125/73</td> <td class=\"centered\">132/77</td> <td class=\"centered\">137/81</td> <td class=\"centered\">141/83</td> <td class=\"centered\">108/57</td> <td class=\"centered\">114/61</td> <td class=\"centered\">120/64</td> <td class=\"centered\">123/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">16</td> <td class=\"centered\">123/69</td> <td class=\"centered\">129/72</td> <td class=\"centered\">135/76</td> <td class=\"centered\">138/78</td> <td class=\"centered\">128/74</td> <td class=\"centered\">135/78</td> <td class=\"centered\">140/81</td> <td class=\"centered\">144/84</td> <td class=\"centered\">111/57</td> <td class=\"centered\">117/61</td> <td class=\"centered\">123/64</td> <td class=\"centered\">126/66</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The values are in mmHg and are the average BP based on 24-hour ambulatory BP monitoring.</div><div class=\"graphic_reference\">From: Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34:1887. DOI: <a href=\"http://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2016&amp;issue=10000&amp;article=00002&amp;type=abstract\" target=\"_blank\">10.1097/HJH.0000000000001039</a>. Copyright &copy; 2016 International Society of Hypertension and European Society of Hypertension. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94618 Version 2.0</div></div></div>"},"94619":{"type":"graphic_table","displayName":"Normal ABP for girls based on age","title":"24-hour ambulatory blood pressure (BP) levels for girls based on age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">24-hour ambulatory blood pressure (BP) levels for girls based on age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22%\"></colgroup><colgroup span=\"12\" width=\"6.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"4\">Average 24-hour BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average day BP (percentile)</td> <td class=\"subtitle1\" colspan=\"4\">Average night BP (percentile)</td> </tr> <tr> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> <td class=\"subtitle2\">50th</td> <td class=\"subtitle2\">75th</td> <td class=\"subtitle2\">90th</td> <td class=\"subtitle2\">95th</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">103/66</td> <td class=\"centered\">108/69</td> <td class=\"centered\">112/72</td> <td class=\"centered\">115/74</td> <td class=\"centered\">108/73</td> <td class=\"centered\">114/77</td> <td class=\"centered\">118/80</td> <td class=\"centered\">121/82</td> <td class=\"centered\">95/56</td> <td class=\"centered\">100/61</td> <td class=\"centered\">105/66</td> <td class=\"centered\">108/69</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">6</td> <td class=\"centered\">104/66</td> <td class=\"centered\">109/69</td> <td class=\"centered\">114/72</td> <td class=\"centered\">116/74</td> <td class=\"centered\">110/73</td> <td class=\"centered\">115/77</td> <td class=\"centered\">120/80</td> <td class=\"centered\">122/82</td> <td class=\"centered\">96/56</td> <td class=\"centered\">101/61</td> <td class=\"centered\">106/65</td> <td class=\"centered\">110/68</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">105/66</td> <td class=\"centered\">110/69</td> <td class=\"centered\">115/72</td> <td class=\"centered\">118/74</td> <td class=\"centered\">111/72</td> <td class=\"centered\">116/77</td> <td class=\"centered\">121/80</td> <td class=\"centered\">123/82</td> <td class=\"centered\">96/56</td> <td class=\"centered\">102/60</td> <td class=\"centered\">107/65</td> <td class=\"centered\">111/67</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">8</td> <td class=\"centered\">107/66</td> <td class=\"centered\">112/69</td> <td class=\"centered\">116/72</td> <td class=\"centered\">119/74</td> <td class=\"centered\">112/72</td> <td class=\"centered\">117/76</td> <td class=\"centered\">122/80</td> <td class=\"centered\">124/82</td> <td class=\"centered\">97/55</td> <td class=\"centered\">103/60</td> <td class=\"centered\">108/64</td> <td class=\"centered\">112/67</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">108/66</td> <td class=\"centered\">113/70</td> <td class=\"centered\">117/73</td> <td class=\"centered\">120/74</td> <td class=\"centered\">112/72</td> <td class=\"centered\">118/76</td> <td class=\"centered\">122/80</td> <td class=\"centered\">125/82</td> <td class=\"centered\">98/55</td> <td class=\"centered\">103/59</td> <td class=\"centered\">109/64</td> <td class=\"centered\">112/67</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">10</td> <td class=\"centered\">109/66</td> <td class=\"centered\">114/70</td> <td class=\"centered\">118/73</td> <td class=\"centered\">121/75</td> <td class=\"centered\">113/72</td> <td class=\"centered\">119/76</td> <td class=\"centered\">123/79</td> <td class=\"centered\">126/81</td> <td class=\"centered\">98/55</td> <td class=\"centered\">104/59</td> <td class=\"centered\">110/64</td> <td class=\"centered\">113/67</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">110/66</td> <td class=\"centered\">115/70</td> <td class=\"centered\">119/73</td> <td class=\"centered\">122/75</td> <td class=\"centered\">114/72</td> <td class=\"centered\">120/76</td> <td class=\"centered\">124/79</td> <td class=\"centered\">127/81</td> <td class=\"centered\">99/54</td> <td class=\"centered\">105/59</td> <td class=\"centered\">110/63</td> <td class=\"centered\">114/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">12</td> <td class=\"centered\">111/67</td> <td class=\"centered\">116/70</td> <td class=\"centered\">120/74</td> <td class=\"centered\">123/76</td> <td class=\"centered\">115/72</td> <td class=\"centered\">121/76</td> <td class=\"centered\">125/80</td> <td class=\"centered\">128/82</td> <td class=\"centered\">100/54</td> <td class=\"centered\">105/59</td> <td class=\"centered\">110/63</td> <td class=\"centered\">114/66</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">112/67</td> <td class=\"centered\">117/71</td> <td class=\"centered\">121/74</td> <td class=\"centered\">124/76</td> <td class=\"centered\">116/72</td> <td class=\"centered\">122/77</td> <td class=\"centered\">126/80</td> <td class=\"centered\">129/82</td> <td class=\"centered\">101/54</td> <td class=\"centered\">106/59</td> <td class=\"centered\">111/63</td> <td class=\"centered\">114/66</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">14</td> <td class=\"centered\">113/67</td> <td class=\"centered\">118/71</td> <td class=\"centered\">122/74</td> <td class=\"centered\">125/76</td> <td class=\"centered\">118/73</td> <td class=\"centered\">123/77</td> <td class=\"centered\">127/80</td> <td class=\"centered\">130/82</td> <td class=\"centered\">101/55</td> <td class=\"centered\">106/59</td> <td class=\"centered\">111/63</td> <td class=\"centered\">114/65</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">114/68</td> <td class=\"centered\">118/71</td> <td class=\"centered\">123/75</td> <td class=\"centered\">125/77</td> <td class=\"centered\">119/73</td> <td class=\"centered\">124/77</td> <td class=\"centered\">128/80</td> <td class=\"centered\">130/82</td> <td class=\"centered\">102/55</td> <td class=\"centered\">107/59</td> <td class=\"centered\">111/63</td> <td class=\"centered\">114/65</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">16</td> <td class=\"centered\">115/68</td> <td class=\"centered\">119/71</td> <td class=\"centered\">123/75</td> <td class=\"centered\">126/77</td> <td class=\"centered\">120/74</td> <td class=\"centered\">124/77</td> <td class=\"centered\">129/80</td> <td class=\"centered\">131/82</td> <td class=\"centered\">103/55</td> <td class=\"centered\">107/59</td> <td class=\"centered\">111/63</td> <td class=\"centered\">114/65</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The values are in mmHg and are the average BP based on 24-hour ambulatory BP monitoring.</div><div class=\"graphic_reference\">From: Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34:1887. DOI: <a href=\"http://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2016&amp;issue=10000&amp;article=00002&amp;type=abstract\" target=\"_blank\">10.1097/HJH.0000000000001039</a>. Copyright &copy; 2016 International Society of Hypertension and European Society of Hypertension. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94619 Version 2.0</div></div></div>"},"94621":{"type":"graphic_table","displayName":"Oral antibiotics for acute cystitis in children","title":"Antibacterial agents for oral treatment of acute cystitis in children older than two years and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibacterial agents for oral treatment of acute cystitis in children older than two years and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Maximum single dose</td> </tr> <tr> <td>Amoxicillin*<sup>&#182;</sup></td> <td>13.3 mg/kg three times per day</td> <td>500 mg</td> </tr> <tr> <td>Amoxicillin-clavulanate*</td> <td>22.5 mg amoxicillin/kg twice per day</td> <td>875 mg amoxicillin</td> </tr> <tr> <td>Cefdinir</td> <td>14 mg/kg once per day</td> <td>600 mg</td> </tr> <tr> <td>Cefixime</td> <td>4 mg/kg twice per day</td> <td>200 mg</td> </tr> <tr> <td>Cefpodoxime</td> <td>5 mg/kg twice per day</td> <td>200 mg</td> </tr> <tr> <td>Cefprozil</td> <td>15 mg/kg twice per day</td> <td>500 mg</td> </tr> <tr> <td>Ceftibuten</td> <td>9 mg/kg once per day</td> <td>400 mg</td> </tr> <tr> <td>Cefuroxime</td> <td>15 mg/kg twice per day</td> <td>500 mg</td> </tr> <tr> <td>Nitrofurantoin<sup>&#916;</sup></td> <td>1.25 to 1.75 mg/kg four times per day</td> <td>100 mg</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (TMP-SMX)*<sup>&#916;</sup></td> <td>4 to 6 mg trimethoprim/kg twice per day</td> <td>160 mg TMP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* <EM>Escherichia coli</EM> strains may be resistant to amoxicillin, amoxicillin-clavulanate, and trimethoprim-sulfamethoxazole; therapy should be determined based on local susceptibility patterns.<br />¶ May be indicated if <EM>Enterococcus</EM> is suspected based on Gram stain, culture, or clinical features (eg, underlying genitourinary abnormality, recurrent urinary tract infection).<br />Δ May be indicated if <EM>Staphylococcus saprophyticus</EM> is suspected based on Gram stain, culture or clinical features (sexually active female adolescent).</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.884.</LI>&#xD;&#xA;<LI>Wald ER. Cystitis and pyelonephritis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.535. </LI></OL></div><div id=\"graphicVersion\">Graphic 94621 Version 4.0</div></div></div>"},"94622":{"type":"graphic_table","displayName":"Examination cystitis children","title":"Important aspects of the examination in child (≥2 years) or adolescent with suspected acute cystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the examination in child (≥2 years) or adolescent with suspected acute cystitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination finding</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td>Fever (temperature &#8805;38&#176;C [100.4&#176;F])</td> <td>May suggest upper UTI</td> </tr> <tr> <td>Blood pressure</td> <td>Hypertension may be&nbsp;an early sign of chronic kidney disease</td> </tr> <tr> <td>Growth parameters</td> <td>Poor weight gain may be an indication of chronic or recurrent UTI</td> </tr> <tr> <td>Abdominal palpation</td> <td>Enlarged bladder or kidney suggestive of anatomic abnormality</td> </tr> <tr> <td>Suprapubic or costovertebral angle tenderness</td> <td>Suprapubic tenderness is suggestive of lower UTI; costovertebral angle tenderness is suggestive of upper UTI</td> </tr> <tr> <td>Lower back for signs of occult myelodysplasia (eg, midline pigmentation, lipoma, vascular lesions, sinus, tuft of hair)</td> <td>May be associated with neurogenic bladder</td> </tr> <tr> <td>External genitalia</td> <td>May reveal anatomic abnormalities that predispose to UTI (eg, phimosis, labial adhesions) or signs of considerations in the differential diagnosis (eg, vulvovaginitis, vaginal foreign body, sexually transmitted infection)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UTI: urinary tract infection.</div><div id=\"graphicVersion\">Graphic 94622 Version 2.0</div></div></div>"},"94623":{"type":"graphic_table","displayName":"History cystitis children","title":"Important aspects of the history in child (≥2 years) or adolescent with suspected acute cystitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in child (≥2 years) or adolescent with suspected acute cystitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">History of acute illness</td> </tr> <tr> <td class=\"indent1\">Fever (temperature &#8805;38&#176;C [100.4&#176;F])</td> <td>May suggest upper UTI</td> </tr> <tr> <td class=\"indent1\">Vomiting</td> <td>Suggests upper UTI or other cause of symptoms</td> </tr> <tr> <td class=\"indent1\">Recent illness</td> <td>May suggest adenovirus or be associated with interstitial nephritis</td> </tr> <tr> <td class=\"indent1\">Recent antibiotics</td> <td>May be associated with resistant pathogens or acute interstitial nephritis</td> </tr> <tr> <td class=\"indent1\">Sexual activity</td> <td>Expands the potential pathogens (eg, <em>Staphylococcus saprophyticus</em>, <em>Trichomonas vaginalis</em>) and the differential diagnosis (eg, cervicitis, pelvic inflammatory disease)</td> </tr> <tr> <td class=\"indent1\">If sexually active, use of spermicidal agents</td> <td>Predisposes to urinary tract infection by altering vaginal flora</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Past history</td> </tr> <tr> <td class=\"indent1\">Chronic urinary symptoms (eg, incontinence, poor stream, frequency, urgency, withholding maneuvers)</td> <td>May be associated with anatomic or physiologic abnormalities of the urinary tract (eg, bladder dysfunction, posterior urethral valves), increasing the risk of resistant pathogens or recurrent UTI</td> </tr> <tr> <td class=\"indent1\">Chronic constipation</td> <td>May be associated with urinary stasis and recurrent UTI</td> </tr> <tr> <td class=\"indent1\">Previous UTI or undiagnosed febrile illnesses (which may have been UTI)</td> <td>Recurrent UTI is associated with progression of renal scarring</td> </tr> <tr> <td class=\"indent1\">Vesicoureteral reflux</td> <td>May be a marker of abnormal renal development and possibly associated with renal scarring</td> </tr> <tr> <td class=\"indent1\">Medications</td> <td>May be associated with interstitial nephritis or urinary retention</td> </tr> <tr> <td class=\"indent1\">Family history of frequent UTI, VUR, or other genitourinary abnormalities</td> <td>May be associated with undiagnosed anatomic or physiologic abnormalities of the urinary tract</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; VUR: vesicoureteral reflux.</div><div id=\"graphicVersion\">Graphic 94623 Version 2.0</div></div></div>"},"94624":{"type":"graphic_figure","displayName":"ER-mediated response","title":"Mechanisms of estrogen receptor-mediated response","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Mechanisms of estrogen receptor-mediated response</div><div class=\"cntnt\"><img style=\"width:618px; height:578px;\" src=\"images/ENDO/94624_ER_mediated_response.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ERs within the nucleus of estrogen-responsive cells receive signals from extracellular estrogen (E2), which can pass through cell and nuclear membranes due to its lipophilic character. GFs, such as IGF-1 or EGF, bind and activate membrane receptors (GF receptor), which triggers a cascade of intracellular phosphorylation mediated signaling that activates the ER. Pioneer factors, such as FoxA1, facilitate ER access to ERE motifs in chromatin (steps 1 and 2). Estrogen- or GF-activated ER then recruits co-activators and chromatin remodelers (step 2). The activities of the chromatin remodelers allow RNA polymerase II (RNA Pol II) to access the TSS (steps 3 and 4), resulting in the initiation of RNA transcription.</div><div class=\"graphic_footnotes\">ER: estrogen receptor; GF: growth factor; IGF-1: insulin-like growth factor 1; EGF: epidermal growth factor; ERE: estrogen responsive element; TSS: transcription start site.</div><div id=\"graphicVersion\">Graphic 94624 Version 1.0</div></div></div>"},"94625":{"type":"graphic_figure","displayName":"Survival in patients with anticoagulant-related nephropathy","title":"Survival in patients with presumptive anticoagulant-related nephropathy","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Survival in patients with presumptive anticoagulant-related nephropathy</div><div class=\"cntnt\"><img style=\"width:552px; height:428px;\" src=\"images/NEPH/94625_Surviv_warfarin_nephropathy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival rate and CKD progression in patients with and without presumptive ARN. A Kaplan-Meier plot for patients with presumptive ARN and no presumptive ARN, stratified by CKD, no-CKD status. Patients with presumptive ARN and CKD (black line, n = 305) had the lowest survival rate. Patients with presumptive ARN but no CKD had better survival rates (green line, n = 516). Patients without presumptive ARN, but with CKD had better survival rates, compared with presumptive ARN patients with CKD (blue line, n = 605). Patients without both presumptive ARN and CKD had the best survival rate (red line, n = 2580).</div><div class=\"graphic_footnotes\">ARN: anticoagulant-related nephropathy; CKD: chronic kidney disease; INR: international normalized ratio.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80:181. Copyright &copy; 2011. <a href=\"http://www.nature.com/ki\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 94625 Version 1.0</div></div></div>"},"94626":{"type":"graphic_table","displayName":"Schisto lab tests","title":"Diagnostic tests for schistosomiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for schistosomiasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"34%\"></colgroup><colgroup span=\"6\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"><em>Schistosoma mansoni</em></td> <td class=\"subtitle1\"><em><em>Schistosoma </em>haematobium</em></td> <td class=\"subtitle1\">Cost</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Nonspecific tests</td> </tr> <tr> <td class=\"indent1\">Fecal occult blood test</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Urine dipstick test (for blood)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td>Low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Specific tests</td> </tr> <tr> <td class=\"indent1\">Serology</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Antigen detection (CAA, CCA) in urine</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td>Low to moderate</td> </tr> <tr> <td class=\"indent1\">Ova detection in urine (filtration method)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Ova detection in stool (Kato-Katz)</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Ova detection in stool (concentration method)</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Ova detection in rectal snips</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">PCR in stool or urine (28S-rRNA)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td>High</td> </tr> <tr> <td class=\"indent1\">PCR serum (Sm 1-7)</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td>High</td> </tr> <tr> <td class=\"indent1\">PCR serum (dra-1)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td>High</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+ High sensitivity<br />+/- Moderate sensitivity<br />- Low sensitivity</div><div class=\"graphic_footnotes\">CAA: circulating anodic antigen; CCA: circulating cathodic antigen; PCR: polymerase chain reaction</div><div id=\"graphicVersion\">Graphic 94626 Version 4.0</div></div></div>"},"94628":{"type":"graphic_table","displayName":"Nonrespiratory indications for PSG in children with parasomnias","title":"Non-respiratory indications for polysomnography in children with parasomnias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-respiratory indications for polysomnography in children with parasomnias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Rationale</td> </tr> <tr> <td>Occurrence at random time of the night (rather than first third of the night as in parasomnias associated with arousal from NREM sleep*)</td> <td class=\"divider_bottom\" rowspan=\"4\"> <ul> <li>These features suggest the possibility of nocturnal seizures, rather than parasomnias.&nbsp; </li> <li>For children with these symptoms, we recommend including a 16-channel electroencephalogram (EEG)&nbsp;with the polysomnogram, to investigate the possibility of nocturnal seizures. </li> </ul> </td> </tr> <tr> <td>Very frequent occurrence (&#62;2&nbsp;or 3 nights per week)</td> </tr> <tr> <td>Hypermotor thrashing behavior during nocturnal event</td> </tr> <tr class=\"divider_bottom\"> <td>Short&nbsp;duration of event (seconds, rather than minutes as in arousal parasomnias)</td> </tr> <tr> <td>Fatigue upon awakening</td> <td>This feature suggests obstructive sleep apnea, or possibly nocturnal seizures.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The most common parasomnias in children are sleepwalking, confusional arousals, and sleep terrors, which occur upon partial arousal from non-rapid eye movement (NREM) sleep.</div><div class=\"graphic_reference\">Based upon recommendations described in Kotagal S, Nichols CD, Grigg-Damberger MM, et al. Non-respiratory indications for polysomnography and related procedures in children: an evidence-based review. Sleep 2012; 35:1451.</div><div id=\"graphicVersion\">Graphic 94628 Version 3.0</div></div></div>"},"94629":{"type":"graphic_picture","displayName":"Sacral dimple","title":"Sacral dimple","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Sacral dimple</div><div class=\"cntnt\"><img style=\"width:484px; height:725px;\" src=\"images/NEURO/94629_Sacral_dimple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sacral dimples occur in about 5 percent of neonates and are the most common cutaneous sign of spinal dysraphism (incomplete closure of the neural tube during early embryogenesis, leading to spinal or bony abnormalities). Simple dimples are defined as midline depressions in the dermis that are less than 5 mm in diameter and within 2.5 cm of the anus. Larger lesions (\"atypical dimples\") and those above the gluteal cleft have been associated with spinal dysraphism. Both sexes are equally affected. There are no differences reported among ethnic groups.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94629 Version 1.0</div></div></div>"},"94630":{"type":"graphic_table","displayName":"Brain abscess causes","title":"Brain abscess causes in a meta-analysis of 9699 patients from 123 studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Brain abscess causes in a meta-analysis of 9699 patients from 123 studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">All patients</td> <td class=\"subtitle1\">Children</td> </tr> <tr> <td class=\"sublist1_start\">Positive culture</td> <td class=\"centered\">4543/6663 (68)</td> <td class=\"centered\">631/1093 (63)</td> </tr> <tr> <td class=\"indent1\">Monomicrobial</td> <td class=\"centered\">3067 (77)</td> <td class=\"centered\">325 (73)</td> </tr> <tr> <td class=\"indent1\">Polymicrobial</td> <td class=\"centered\">902 (23)</td> <td class=\"centered\">117 (27)</td> </tr> <tr> <td class=\"sublist1_start\">Cultured microorganisms</td> <td class=\"centered\">5894</td> <td class=\"centered\">724</td> </tr> <tr> <td class=\"sublist2_start\"><em>Streptococcus</em> spp</td> <td class=\"centered\">2000 (34)</td> <td class=\"centered\">260 (36)</td> </tr> <tr> <td class=\"indent2\">Viridans streptococci</td> <td class=\"centered\">755 (13)</td> <td class=\"centered\">58 (6)</td> </tr> <tr> <td class=\"indent2\"><em>S. pneumoniae</em></td> <td class=\"centered\">139 (2)</td> <td class=\"centered\">27 (4)</td> </tr> <tr> <td class=\"indent2\"><em>Enterococcus</em></td> <td class=\"centered\">49 (0.8)</td> <td class=\"centered\">2 (0.3)</td> </tr> <tr> <td class=\"indent2\">Other/not specified</td> <td class=\"centered\">1057 (18)</td> <td class=\"centered\">173 (24)</td> </tr> <tr> <td class=\"sublist2_start\"><em>Staphylococcus</em> spp</td> <td class=\"centered\">1076 (18)</td> <td class=\"centered\">128 (18)</td> </tr> <tr> <td class=\"indent2\"><em>S. aureus</em></td> <td class=\"centered\">782 (13)</td> <td class=\"centered\">80 (11)</td> </tr> <tr> <td class=\"indent2\"><em>S. epidermidis</em></td> <td class=\"centered\">148 (3)</td> <td class=\"centered\">31 (4)</td> </tr> <tr> <td class=\"indent2\">Not specified</td> <td class=\"centered\">146 (2)</td> <td class=\"centered\">16 (2)</td> </tr> <tr> <td class=\"sublist2_start\">Gram-negative enteric</td> <td class=\"centered\">861 (15)</td> <td class=\"centered\">114 (16)</td> </tr> <tr> <td class=\"indent2\"><em>Proteus</em> spp</td> <td class=\"centered\">417 (7)</td> <td class=\"centered\">60 (8)</td> </tr> <tr> <td class=\"indent2\"><em>Klebsiella pneumoniae</em></td> <td class=\"centered\">135 (2)</td> <td class=\"centered\">11 (2)</td> </tr> <tr> <td class=\"indent2\"><em>Escherichia coli</em></td> <td class=\"centered\">126 (2)</td> <td class=\"centered\">18 (2)</td> </tr> <tr> <td class=\"indent2\"><em>Enterobacteriae</em></td> <td class=\"centered\">101 (2)</td> <td class=\"centered\">9 (1)</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas</em> spp</td> <td class=\"centered\">122 (2)</td> <td class=\"centered\">13 (2)</td> </tr> <tr> <td class=\"sublist2_start\"><em>Actinomycetales</em></td> <td class=\"centered\">148 (3)</td> <td class=\"centered\">16 (2)</td> </tr> <tr> <td class=\"indent2\"><em>Nocardia</em></td> <td class=\"centered\">57 (1)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent2\"><em>Corynebacterium</em></td> <td class=\"centered\">49 (0.8)</td> <td class=\"centered\">7 (1)</td> </tr> <tr> <td class=\"indent2\"><em>Actinomyces</em></td> <td class=\"centered\">48 (0.8)</td> <td class=\"centered\">8 (1)</td> </tr> <tr> <td class=\"indent2\"><em>Mycobacterium tuberculosis</em></td> <td class=\"centered\">41 (0.7)</td> <td class=\"centered\">1 (0.2)</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus</em> spp</td> <td class=\"centered\">124 (2)</td> <td class=\"centered\">41 (6)</td> </tr> <tr> <td class=\"indent1\"><em>Peptostreptococcus</em> spp</td> <td class=\"centered\">165 (3)</td> <td class=\"centered\">45 (6)</td> </tr> <tr> <td class=\"indent1\"><em>Bacteroides</em> spp</td> <td class=\"centered\">370 (6)</td> <td class=\"centered\">33 (5)</td> </tr> <tr> <td class=\"indent1\"><em>Fusobacterium</em> spp</td> <td class=\"centered\">119 (2)</td> <td class=\"centered\">17 (2)</td> </tr> <tr> <td class=\"indent1\">Parasites</td> <td class=\"centered\">5 (0.1)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Fungi</td> <td class=\"centered\">83 (1)</td> <td class=\"centered\">8 (1)</td> </tr> <tr> <td class=\"indent1\">Other</td> <td class=\"centered\">821 (13)</td> <td class=\"centered\">49 (7)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data are reported as number of cases (percent).</div><div class=\"graphic_reference\">From: Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess: Systematic review and meta-analysis. Neurology 2014; 82:806. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/82/9/806\" target=_blank>10.1212/WNL.0000000000000172</A>. Copyright © 2014 American Academy of Neurology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94630 Version 11.0</div></div></div>"},"94631":{"type":"graphic_picture","displayName":"Dermal sinus tract","title":"Dermal sinus tract","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Dermal sinus tract</div><div class=\"cntnt\"><img style=\"width:486px; height:727px;\" src=\"images/NEURO/94631_Dermal_sinus_tract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midline dermal sinus tracts, a type of spinal dysraphism (defective fusion of the neural tube leading to spinal or bony abnormalities), result from incomplete closure of the embryonic neuroectoderm early in embryonic development. The midline lesion with a central pit may be an important clue to the connection of the skin surface to the spinal canal, which occurs in approximately 50 percent of dermal sinuses. Meningeal infections, sometimes with an unusual organism(s), can also be a clue to the presence of this lesion. Dermal sinus tracks can leak spinal fluid, and neurologic deficits may be present. Lesions are most frequent in the lumbosacral region but can be anywhere along the midline of the back. They may be associated with other skin lesions. They are generally above the gluteal cleft.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94631 Version 1.0</div></div></div>"},"94634":{"type":"graphic_table","displayName":"Vag radical trachelectomy outcomes","title":"Outcomes of vaginal radical trachlectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of vaginal radical trachlectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Fertility not preserved</td> <td class=\"subtitle1\">Recurrences</td> <td class=\"subtitle1\">Deaths</td> </tr> <tr> <td>Lanowska et al. (2011)<sup>[1]</sup></td> <td class=\"centered\">225</td> <td class=\"centered\">13 (6%)</td> <td class=\"centered\">8 (3.8%)</td> <td class=\"centered\">4 (1.9%)</td> </tr> <tr> <td>Shepherd et al. (2012)<sup>[2]</sup></td> <td class=\"centered\">208</td> <td class=\"centered\">24 (11.5%)</td> <td class=\"centered\">8 (3.8%)</td> <td class=\"centered\">5 (2.4%)</td> </tr> <tr> <td>Covens et al. (2013)*</td> <td class=\"centered\">180</td> <td class=\"centered\">17 (9.4%)</td> <td class=\"centered\">9 (2.7%)</td> <td class=\"centered\">2 (1.1%)</td> </tr> <tr> <td>Plante et al. (2011)<sup>[3]</sup></td> <td class=\"centered\">140</td> <td class=\"centered\">15 (10.7%)</td> <td class=\"centered\">6 (4.8%)</td> <td class=\"centered\">2 (1.6%)</td> </tr> <tr> <td>Marchiole et al. (2007)<sup>[4]</sup></td> <td class=\"centered\">135</td> <td class=\"centered\">17 (12.6%)</td> <td class=\"centered\">7 (5.7%)</td> <td class=\"centered\">5 (4.2%)</td> </tr> <tr class=\"divider_bottom\"> <td>Kim et al. (2012)<sup>[5]</sup></td> <td class=\"centered\">51</td> <td class=\"centered\">9 (17.6%)</td> <td class=\"centered\">2 (3.9%)</td> <td class=\"centered\">1 (1.9%)</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>924</strong></td> <td class=\"centered\"><strong>95 (10.2%)</strong></td> <td class=\"centered\"><strong>40 (4.4%)</strong></td> <td class=\"centered\"><strong>19 (2.1%)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Personal communication, updated information, January 2013.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lanowska M, Mangler M, Spek A, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: Prospective study of 225 patients with early-stage cervical cancer. Int J Gynecol Cancer 2011; 21:1458. </LI>&#xD;&#xA;<LI>Shepherd JH. Cervical cancer. Best Pract Res Clin Obstet Gynaecol 2012; 26:293. </LI>&#xD;&#xA;<LI>Plante M, Gregoire J, Renaud MC, et al. The vaginal radical trachelectomy: An update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011; 121:290. </LI>&#xD;&#xA;<LI>Marchiole P, Benchaib M, Buenerd A, et al. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): A comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol Oncol 2007; 106:132. </LI>&#xD;&#xA;<LI>Kim CH, Abu-Rustum NR, Chi DS, et al. Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer. Gynecol Oncol 2012; 125:585.</LI></OL>From: Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: Radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy. Int J Gynecol Cancer 2013; 23:982. DOI: <A href=\"http://journals.lww.com/ijgc/pages/articleviewer.aspx?year=2013&amp;issue=07000&amp;article=00004&amp;type=abstract\" target=_blank>10.1213/ANE.0b013e3182a8fad0</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2013 International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94634 Version 3.0</div></div></div>"},"94635":{"type":"graphic_table","displayName":"Abd radical trachelectomy outcomes","title":"Outcomes of abdominal radical trachelectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of abdominal radical trachelectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"3\" width=\"16%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Fertility not preserved</td> <td class=\"subtitle1\">Recurrence</td> <td class=\"subtitle1\">No. pregnant/no. attempting</td> </tr> <tr> <td><strong>Wethington et al. (2012)*<sup>[1]</sup></strong></td> <td class=\"centered\">101</td> <td class=\"centered\">30 (30%)</td> <td class=\"centered\">4 (4%)<sup>&#182;</sup></td> <td class=\"centered\"> <p>28 of 38 (74%)</p> T1: 3 (10%); T2: 6 (19%); T3: 16 (52%)</td> </tr> <tr> <td><strong>Nishio et al. (2009)<sup>[2]</sup></strong></td> <td class=\"centered\">71</td> <td class=\"centered\">10 (14%)</td> <td class=\"centered\">6 (10%)<sup>&#916;</sup><sup>&#9674;</sup></td> <td class=\"centered\">4 of 29 (14%)</td> </tr> <tr> <td><strong>Li et al. (2011)<sup>[3]</sup></strong></td> <td class=\"centered\">64</td> <td class=\"centered\">12 (19%)</td> <td class=\"centered\">0</td> <td class=\"centered\">2 of 10 (20%)</td> </tr> <tr> <td><strong>Muraji et al. (2012)<sup>[4]</sup></strong></td> <td class=\"centered\">23</td> <td class=\"centered\">3 (13%)</td> <td class=\"centered\">0</td> <td class=\"centered\">1 of 10 (10%)</td> </tr> <tr> <td><strong>Saso et al. (2012)<sup>[5]</sup></strong></td> <td class=\"centered\">30</td> <td class=\"centered\">0</td> <td class=\"centered\">3 (10%)<sup>&#167;</sup></td> <td class=\"centered\">3 of 10 (30%)</td> </tr> <tr> <td><strong>Pareja et al. (2008)<sup>[6]</sup></strong></td> <td class=\"centered\">15</td> <td class=\"centered\">1 (6%)</td> <td class=\"centered\">0</td> <td class=\"centered\">3 of 6 (50%)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ungar et al. (2005)<sup>[7]</sup></strong></td> <td class=\"centered\">33</td> <td class=\"centered\">3 (10%)</td> <td class=\"centered\">0</td> <td class=\"centered\">3 of 10 (30%)</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\">337</td> <td class=\"centered\">59 (17%)</td> <td class=\"centered\">13 (3.7%)</td> <td class=\"centered\">44 of 113 (39%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes series already published from Memorial Sloan-Kettering Cancer Center (Abu-Rustum), the Czech Republic (Cibula), and the Massachusetts General Hospital (Duska).<br />¶ Two patients alive with disease, two with no evidence of disease (NED).<br />Δ Three patients NED, three lost to follow-up.<br /><FONT class=lozenge>◊</FONT> Five of six recurrences: Lesions ≥2 cm.<br />§ Two patients died of disease, one NED.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Wethington SL, Cibula D, Duska LR, et al. An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies. Int J Gynecol Cancer 2012; 22:1251.</LI>&#xD;&#xA;<LI>Nishio H, Fujii T, Kameyama K, et al. Abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer in a series of 61 women. Gynecol Oncol 2009; 115:51.</LI>&#xD;&#xA;<LI>Li J, Li Z, Wang H, et al. Radical abdominal trachelectomy for cervical malignancies: Surgical, oncological and fertility outcomes in 62 patients. Gynecol Oncol 2011; 121:565.</LI>&#xD;&#xA;<LI>Muraji M, Sudo T, Nakagawa E, et al. Type II versus type III fertility-sparing abdominal radical trachelectomy for early-stage cervical cancer: A comparison of feasibility of surgical outcomes. Int J Gynecol Cancer 2012; 22:479.</LI>&#xD;&#xA;<LI>Saso S, Ghaem-Maghami S, Chatterjee J, et al. Abdominal radical trachelectomy in West London. BJOG 2012; 119:187.</LI>&#xD;&#xA;<LI>Pareja FR, Ramirez PT, Borrero FM, et al. Abdominal radical trachelectomy for invasive cervical cancer: A case series and literature review. Gynecol Oncol 2008; 111:555.</LI>&#xD;&#xA;<LI>Ungar L, Palfalvi L, Hogg R, et al. Abdominal radical trachelectomy: A fertility-preserving option for women with early cervical cancer. BJOG 2005; 112:366.</LI></OL>From: Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: Radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy. Int J Gynecol Cancer 2013; 23:982. DOI: <A spellcheck=true href=\"http://journals.lww.com/ijgc/pages/articleviewer.aspx?year=2013&amp;issue=07000&amp;article=00004&amp;type=abstract\" target=_blank>10.1213/ANE.0b013e3182a8fad0</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2013 International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94635 Version 3.0</div></div></div>"},"94641":{"type":"graphic_table","displayName":"Fasting guidelines of international anesthesia societies","title":"Fasting guidelines of international anesthesia societies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fasting guidelines of international anesthesia societies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Country, year</td> <td class=\"subtitle1\">Fasting requirements at time of induction</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>American Society of Anesthesiologists, 2017<sup>[1]</sup></td> <td> <ul> <li>2 hours clear liquids, not including alcohol&nbsp; </li> <li>4 hours breast milk </li> <li>6 hours nonhuman milk, infant formula, light meal </li> <li>8 hours or more fried or fatty food or meat </li> </ul> </td> <td> <ul> <li>Healthy patients, elective surgery, pregnant patients not in labor </li> <li>Light meal defined as toast or cereal with clear liquid </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>European Society of Anesthesiology, 2011<sup>[2]</sup></td> <td> <ul> <li>2 hours clear liquids </li> <li>4 hours breast milk </li> <li>6 hours milk, infant formula, solid food </li> <li>Chewing gum and sucking hard candy allowed up until time of induction </li> </ul> </td> <td> <ul> <li>Applies to patients with obesity, diabetes, GERD, nonlaboring pregnant patients </li> <li>Encourages oral fluid up to 2 hours prior to induction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Canadian Anesthesiologists' Society, 2014<sup>[3]</sup></td> <td> <ul> <li>2 hours clear liquids </li> <li>4 hours breast milk </li> <li>6 hours light meal, infant formula, and nonhuman milk </li> <li>8 hours meat, fried, or fatty food </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Association of Anaesthetists in Great Britain and Ireland, 2010<sup>[4]</sup></td> <td> <ul> <li>2 hours clear liquids </li> <li>4 hours breast milk </li> <li>6 hours solid food, infant formula, and cow's milk </li> </ul> </td> <td> <ul> <li>Gum chewing should be treated as clear </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Scandinavian Society of Anaesthesiology and Intensive Care Medicine, 2005<sup>[5]</sup></td> <td> <ul> <li>2 hours clear liquids </li> <li>4 hours breast milk and infant formula </li> <li>6 hours solid food and cow's milk </li> <li>2 hours chewing gum and any form of tobacco </li> <li>Up to 1 hour prior to induction, 150 mL water </li> </ul> </td> <td> <ul> <li>2 hours for preoperative carbohydrate drinks intended for preoperative nutrition </li> </ul> </td> </tr> <tr> <td>German Society of Anesthesiology and Intensive Care, 2004<sup>[6]</sup></td> <td> <ul> <li>2 hours clear liquids </li> <li>4 hours breast milk and infant formula </li> <li>6 hours meal </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td> <p>Australian and New Zealand College of Anaesthetists, 2016<sup>[7]</sup></p> </td> <td> <ul> <li>2 hours clear liquids, all ages </li> <li>3 hours breast milk for infants &#60;6 months of age </li> <li>4 hours formula for infants &#60;6 months of age </li> <li>6 hours breast milk, formula, limited solid food for children &#62;6 months of age and adults </li> </ul> </td> <td> <ul> <li>Encourages oral fluid up to 2 hours prior to induction </li> <li>Up to 200 mL clear liquids per hour up until two hours prior to induction for adults </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. Anesthesiology 2017; 126:376.</LI>&#xD;&#xA;<LI>Smith I, Kranke P, Murat I, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2011; 28:556.</LI>&#xD;&#xA;<LI>Merchant R, Chartrand D, Dain S, et al. Guidelines to the Practice of Anesthesia--Revised Edition 2014. Can J Anaesth 2014; 61:46.</LI>&#xD;&#xA;<LI>Association of anaesthetists of Great Britain and Ireland. Peroperative Assessment and Patient Preparation. Available at: <A href=\"http://www.aagbi.org/sites/default/files/preop2010.pdf\">http://www.aagbi.org/sites/default/files/preop2010.pdf</A>&nbsp;(accessed 2/1/18).</LI>&#xD;&#xA;<LI>Søreide E, Eriksson LI, Hirlekar&nbsp;G, et al. Pre-operative fasting guidelines: an update. Acta Anaesthesiol Scand 2005; 49:1041.</LI>&#xD;&#xA;<LI>Praoperaives Nuchternheitsdebot bei Elektiven Eingriffen AU Verbankdmitteilung DGAI SO Anesthesiol Intensivmed. 2004;12:722</LI>&#xD;&#xA;<LI>Australian and New Zealand College of Anaesthetists. Guidelines on Pre-Anaesthesia Consultation and Patient Preparation. Available at <A href=\"https://www.anzca.edu.au/getattachment/resources/professional-documents/ps07_guidelines_pre-anaesthesia_consultation_patient_preparation.pdf\">https://www.anzca.edu.au/getattachment/resources/professional-documents/ps07_guidelines_pre-anaesthesia_consultation_patient_preparation.pdf</A> (accessed 2/1/18).</LI></OL></div><div id=\"graphicVersion\">Graphic 94641 Version 5.0</div></div></div>"},"94645":{"type":"graphic_table","displayName":"Focal seizure semiology descriptors","title":"Common descriptors of behaviors during focal seizures (alphabetically)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common descriptors of behaviors during focal seizures (alphabetically)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Cognitive</td> <td class=\"subtitle1_left\">Automatisms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Acalculia </li> <li>Aphasia </li> <li>Attention impairment </li> <li>D&#233;j&#224; vu or jamais vu </li> <li>Dissociation </li> <li>Dysphasia </li> <li>Hallucinations </li> <li>Illusions </li> <li>Memory impairment </li> <li>Neglect </li> <li>Forced thinking </li> <li>Responsiveness impairment </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Aggression </li> <li>Eye-blinking </li> <li>Head-nodding </li> <li>Manual </li> <li>Oral-facial </li> <li>Pedaling </li> <li>Pelvic thrusting </li> <li>Perseveration </li> <li>Running (cursive) </li> <li>Sexual </li> <li>Undressing </li> <li>Vocalization/speech </li> <li>Walking </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Emotional or affective</td> <td class=\"subtitle1_left\">Motor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Agitation </li> <li>Anger </li> <li>Anxiety </li> <li>Crying (dacrystic) </li> <li>Fear </li> <li>Laughing (gelastic) </li> <li>Paranoia </li> <li>Pleasure </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Dysarthria </li> <li>Dystonic </li> <li>Fencer's posture (figure-of-4) </li> <li>Incoordination </li> <li>Jacksonian </li> <li>Paralysis </li> <li>Paresis </li> <li>Versive </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Autonomic</td> <td class=\"subtitle1_left\">Sensory</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"> <ul> <li>Asystole </li> <li>Bradycardia </li> <li>Erection </li> <li>Flushing </li> <li>Gastrointestinal </li> <li>Hyper/hypoventilation </li> <li>Nausea or vomiting </li> <li>Pallor </li> <li>Palpitations </li> <li>Piloerection </li> <li>Respiratory changes </li> <li>Tachycardia </li> </ul> </td> <td class=\"indent1 divider_bottom\"> <ul> <li>Auditory </li> <li>Gustatory </li> <li>Hot-cold sensations </li> <li>Olfactory </li> <li>Somatosensory </li> <li>Vestibular </li> <li>Visual </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\">Laterality</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Left </li> <li>Right </li> <li>Bilateral </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Fisher RS, Cross JH, D'Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017. DOI: 10.1111/epi.13671. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.13671/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.13671/abstract</A>. Copyright © 2017 The International League Against Epilepsy. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 94645 Version 2.0</div></div></div>"},"94650":{"type":"graphic_picture","displayName":"Nevus spilus","title":"Speckled lentiginous nevus (nevus spilus)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Speckled lentiginous nevus (nevus spilus)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94650_Nevus_spilus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large hyperpigmented patch resembling a caf&eacute;-au-lait macule with multiple superimposed hyperpigmented macular or papular foci on the shoulder of a patient with a speckled lentiginous nevus (nevus spilus).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94650 Version 1.0</div></div></div>"},"94653":{"type":"graphic_picture","displayName":"Schisto mucosal polyps","title":"Mucosal polyps in schistosomiasis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Mucosal polyps in schistosomiasis</div><div class=\"cntnt\"><img style=\"width:598px; height:191px;\" src=\"images/ID/94653_Schisto_mucosal_polyps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pseudopolyps of <em>Schistosoma hematobium</em> in bladder of 38-year-old traveler with hematuria four months after returning from Dogon Valley, Mali.<br />(B) Pseudopolyps of <em>Schistosoma</em> spp in rectocolon.</div><div class=\"graphic_reference\">(A) Courtesy of Patrick Soentjens, MD.<br />(B) Courtesy of Eric Libby, MD.</div><div id=\"graphicVersion\">Graphic 94653 Version 1.0</div></div></div>"},"94662":{"type":"graphic_figure","displayName":"Beta-globin cluster deletions","title":"Deletions of the beta-globin cluster","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Deletions of the beta-globin cluster</div><div class=\"cntnt\"><img style=\"width:763px; height:517px;\" src=\"images/HEME/94662_Beta_globin_cluster_delet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deletions of the &beta;-globin cluster causing hereditary persistence of HbF (HPFH), <SUP>G</SUP>γ(<SUP>A</SUP>γ&delta;&beta;)<SUP>0</SUP> thalassemia, and <SUP>G</SUP>γ<SUP>A</SUP>(γ&delta;&beta;)<SUP>0</SUP> thalassemia. Arrows in the cluster at the top of the diagram indicate DNase1 hypersensitive sites; those to the left of the &epsilon; gene define the lower LCR. The inverted region in the two double-deletion/inversion cases are shown as a dashed line.</div><div class=\"graphic_footnotes\">* This deletion has only been found in <em>trans</em> to the HbS.</div><div class=\"graphic_reference\">From: Thein SL, Wood WG. The molecular basis of β thalassemia, δβ thalassemia, and hereditary persistence of fetal hemoglobin. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed, Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (Eds). Cambridge University Press, Cambridge 2009. p.323. Copyright © 2009 Cambridge University Press. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 94662 Version 1.0</div></div></div>"},"94664":{"type":"graphic_picture","displayName":"Chickenpox","title":"Chickenpox (varicella-zoster infection)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chickenpox (varicella-zoster infection)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94664_Chickenpox.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous vesicles, some of which are&nbsp;hemorrhagic, on the face of a child with chickenpox.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94664 Version 2.0</div></div></div>"},"94666":{"type":"graphic_picture","displayName":"Leksell frame","title":"Leksell frame","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Leksell frame</div><div class=\"cntnt\"><img style=\"width:590px; height:409px;\" src=\"images/ANEST/94666_Leksell_frame.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Lashmi Venkatraghavan.</div><div id=\"graphicVersion\">Graphic 94666 Version 2.0</div></div></div>"},"94667":{"type":"graphic_figure","displayName":"Nailfold capillaroscopy in systemic sclerosis","title":"Nailfold capillaroscopy in systemic sclerosis (scleroderma)","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Nailfold capillaroscopy in systemic sclerosis (scleroderma)</div><div class=\"cntnt\"><img style=\"width:472px; height:644px;\" src=\"images/RHEUM/94667_Nailfold_capilla_syst_scler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>(A) Normal hairpin-shaped capillaries in a healthy subject. No relevant variation in the thickness of the capillary loops is evident.</li>&#xD;&#xA;</ul>&#xD;&#xA;Systemic sclerosis. Representative examples of architectural disorganization of the nailfold microvascular bed:&#xD;&#xA;<ul>&#xD;&#xA;    <li>(B) Striking shape heterogeneity characterized by enlarged loops (*).</li>&#xD;&#xA;    <li>(C) Heterogeneity with tortuous capillaries, slightly dilated capillary loops (*), and capillary hemorrhages.</li>&#xD;&#xA;    <li>(D) Architectural derangement dominated by extremely enlarged loops (*) and neoformation of capillaries (arrow).</li>&#xD;&#xA;    <li>(E) Architectural disorganization characterized by irregular distribution of capillaries that shows a high degree of heterogeneity without loop enlargement.</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Reproduced from: Walter G, Medico PD, Izzo F, Cervini C. Microvascular involvement in systemic sclerosis: capillaroscopic findings. Semin Arthritis Rheum 2001; 30:397. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94667 Version 2.0</div></div></div>"},"94718":{"type":"graphic_diagnosticimage","displayName":"Hereditary multiple osteochondromas","title":"Hereditary multiple osteochondromas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hereditary multiple osteochondromas</div><div class=\"cntnt\"><img style=\"width:187px; height:638px;\" src=\"images/PEDS/94718_Hereditary_mult_osteochondr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower extremity radiograph of child with hereditary multiple osteochondromas (some of which are indicated with arrows), also known as&nbsp;multiple hereditary exostosis. The osteochondromas&nbsp;have resulted in an apparent (false) limb length discrepancy due to inability to adduct the right hip causing pelvic obliquity.</div><div id=\"graphicVersion\">Graphic 94718 Version 1.0</div></div></div>"},"94730":{"type":"graphic_picture","displayName":"Lichen striatus trunk","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/DERM/94730_Lichen_striatus_3_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flat-topped erythematous papules coalescing in a narrow curvilinear band on the abdomen.</div><div id=\"graphicVersion\">Graphic 94730 Version 3.0</div></div></div>"},"94731":{"type":"graphic_picture","displayName":"Lichen striatus albus","title":"Lichen striatus albus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen striatus albus</div><div class=\"cntnt\"><img style=\"width:394px; height:590px;\" src=\"images/DERM/94731_Lichen_striatus_4_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented macules and patches following lines of Blaschko on the leg.</div><div id=\"graphicVersion\">Graphic 94731 Version 2.0</div></div></div>"},"94732":{"type":"graphic_picture","displayName":"Lichen striatus arm","title":"Lichen striatus","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Lichen striatus</div><div class=\"cntnt\"><img style=\"width:498px; height:362px;\" src=\"images/DERM/94732_Lichen_striatus_5_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, flat-topped papules grouped in a narrow linear band along the arm.</div><div id=\"graphicVersion\">Graphic 94732 Version 3.0</div></div></div>"},"94743":{"type":"graphic_algorithm","displayName":"Algorithm for evaluation of short stature","title":"Algorithm for the evaluation of a child with short stature*","html":"<div class=\"graphic\"><div style=\"width: 1066px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of a child with short stature*</div><div class=\"cntnt\"><img style=\"width:1046px; height:674px;\" src=\"images/PEDS/94743_Algo_evaluat_short_stature.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm describes the detailed evaluation of a child with short stature. Some components of the evaluation can reasonably be performed in the primary care setting, including initial interpretation and height velocity, and initial laboratory screening for an underlying systemic disease, if suspected based on symptoms. Other components of the evaluation, including bone age interpretation and the detailed evaluation for causes of short stature, are typically performed by a pediatric endocrinologist, if available.</div><div class=\"graphic_footnotes\">GDPP: gonadotropin-dependent precocious puberty (central sexual precocity); GIPP: gonadotropin-independent precocious puberty (peripheral sexual precocity); ISS: idiopathic short stature; SD: standard deviation; CDGP: constitutional delay of growth and puberty; GH: growth hormone.<br />* Short stature is defined as height that is 2 SD or more below the mean (Z-score ≤–2) for children of the same sex and chronologic age in a given population. This corresponds to a height that is below the 2.3rd percentile.<br />¶ Decreased height velocity (HV) is indicated by a growth rate &lt;5.5 cm/year from 2 to 4 years of age; &lt;5 cm/year from 4 to 6 years of age; &lt;4 cm/year from age 6 years to puberty; or crossing two major percentile lines on a standard height-by-age chart.<br />Δ Systemic diseases may present with signs and symptoms either before or after they affect height or height velocity. This is especially true for inflammatory diseases (Crohn disease, juvenile idiopathic arthritis) or any disorder that affects nutrition.<br /><FONT class=lozenge>◊</FONT> Bone age determination requires expert interpretation of the hand radiograph using the Greulich and Pyle Atlas. If bone age is delayed or advanced, the HV percentile and projected height should be recalculated based on bone age.<br />§ Delayed or advanced bone age (BA) is defined as a BA that is 2 SD or more below or above the mean, respectively. This translates to difference beween BA and chronological age (CA) of approximately 12 months between 2 and 4 years of CA, 18 months between 4 and 12 years, and 24 months after age 12.<br />¥ Evaluation for systemic, endocrine, or genetic disorder includes a focused history and physical examination (refer to topic review on evaluation for short stature). In addition, patients with growth failure usually should have laboratory screening including a complete blood count (CBC), erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), tissue transglutaminase (tTG), creatinine, electrolytes, bicarbonate, calcium, phosphate, alkaline phosphatase, albumin, thyroid stimulating hormone (TSH), free thyroxine (T4) and insulin-like growth factor-I (IGF-I), and insulin-like growth factor binding protein-3 (IGFBP-3). A karyotype should be performed in all girls with unexplained short stature, and in short boys with associated genital abnormalities<SUP>[1]</SUP>. Some or all of this evaluation is typically performed by a pediatric subspecialist, but varies with the child's presenting symptoms and the clinical setting.<br />‡ Constitutional delay of growth and puberty (CDGP) is particularly likely if there is a family history of this growth pattern (eg, relatively late puberty).</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: A summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93:4210.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 94743 Version 4.0</div></div></div>"},"94745":{"type":"graphic_figure","displayName":"Huntington procedure ","title":"Huntington procedure for correction of puerperal uterine inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Huntington procedure for correction of puerperal uterine inversion</div><div class=\"cntnt\"><img style=\"width:447px; height:462px;\" src=\"images/OBGYN/94745_Huntington_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Huntington procedure, the&nbsp;cup formed by the inversion is located. A clamp, such as an Allis or Babcock clamp, is placed on each round ligament entering the cup, about 2 cm deep in the cup. Gently pulling on the clamps exerts upward traction on the inverted fundus. Clamping and traction are repeated until the inversion is corrected. The myometrium can be clamped if the round ligaments cannot be identified.</div><div id=\"graphicVersion\">Graphic 94745 Version 1.0</div></div></div>"},"94746":{"type":"graphic_figure","displayName":"Manual replacement of uterine inversion","title":"Manual replacement of puerperal uterine inversion","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Manual replacement of puerperal uterine inversion</div><div class=\"cntnt\"><img style=\"width:543px; height:477px;\" src=\"images/OBGYN/94746_Manual_replacement_of_uterine_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inverted uterus is replaced by placing a hand inside the vagina and pushing the fundus along the long axis of the vagina toward the umbilicus.&nbsp;If a constriction ring is palpable, pressure should be applied to the part of the fundus nearest the ring to ease it through from bottom to top.</div><div id=\"graphicVersion\">Graphic 94746 Version 2.0</div></div></div>"},"94752":{"type":"graphic_table","displayName":"CHADS2 and CHA2DS2-VASc risk stratification nonvalvular AF","title":"Comparison of the CHADS2 and CHA2DS2-VASc risk stratification scores for subjects with nonvalvular AF","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of the CHADS2 and CHA2DS2-VASc risk stratification scores for subjects with nonvalvular AF</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Definition and scores for CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc</td> </tr> <tr> <td class=\"subtitle2_left\">CHADS<sub>2</sub> acronym</td> <td class=\"subtitle2 divider_bottom\">Score</td> </tr> <tr> <td class=\"indent1\">Congestive HF</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Age &#8805;75 years</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Stroke/TIA/TE</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Maximum score</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"subtitle2_left\">CHA<sub>2</sub>DS<sub>2</sub>-VASc acronym</td> <td class=\"subtitle2 divider_bottom\">Score</td> </tr> <tr> <td class=\"indent1\">Congestive HF</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Age &#8805;75 years</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Stroke/TIA/TE</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Vascular disease (prior MI, PAD, or aortic plaque)</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Age 65 to 74 years</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Sex category (ie, female sex)</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maximum score</td> <td class=\"centered\">9</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Stroke risk stratification with the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores</td> </tr> <tr> <td class=\"subtitle2_left\">CHADS<sub>2</sub> acronym</td> <td class=\"subtitle2 divider_bottom\">Unadjusted ischemic stroke rate (% per year)*</td> </tr> <tr> <td class=\"indent1\">0</td> <td class=\"centered\">0.6%</td> </tr> <tr> <td class=\"indent1\">1</td> <td class=\"centered\">3.0%</td> </tr> <tr> <td class=\"indent1\">2</td> <td class=\"centered\">4.2%</td> </tr> <tr> <td class=\"indent1\">3</td> <td class=\"centered\">7.1%</td> </tr> <tr> <td class=\"indent1\">4</td> <td class=\"centered\">11.1%</td> </tr> <tr> <td class=\"indent1\">5</td> <td class=\"centered\">12.5%</td> </tr> <tr> <td class=\"indent1\">6</td> <td class=\"centered\">13.0%</td> </tr> <tr> <td class=\"subtitle2_left\">CHA<sub>2</sub>DS<sub>2</sub>-VASc acronym</td> <td class=\"subtitle2 divider_bottom\">Unadjusted ischemic stroke rate (% per year)*</td> </tr> <tr> <td class=\"indent1\">0</td> <td class=\"centered\">0.2%</td> </tr> <tr> <td class=\"indent1\">1</td> <td class=\"centered\">0.6%</td> </tr> <tr> <td class=\"indent1\">2</td> <td class=\"centered\">2.2%</td> </tr> <tr> <td class=\"indent1\">3</td> <td class=\"centered\">3.2%</td> </tr> <tr> <td class=\"indent1\">4</td> <td class=\"centered\">4.8%</td> </tr> <tr> <td class=\"indent1\">5</td> <td class=\"centered\">7.2%</td> </tr> <tr> <td class=\"indent1\">6</td> <td class=\"centered\">9.7%</td> </tr> <tr> <td class=\"indent1\">7</td> <td class=\"centered\">11.2%</td> </tr> <tr> <td class=\"indent1\">8</td> <td class=\"centered\">10.8%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">9</td> <td class=\"centered\">12.2%</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AF: atrial fibrillation; CHADS<sub>2</sub>: Congestive heart failure, Hypertension, Age &ge;75 years, Diabetes mellitus, Prior Stroke or TIA or Thromboembolism (doubled); CHA<sub>2</sub>DS<sub>2</sub>-VASc: Congestive heart failure, Hypertension, Age &ge;75 years (doubled), Diabetes mellitus, Prior Stroke or TIA or thromboembolism (doubled), Vascular disease, Age 65-74 years, Sex category; HF: heart failure; LV: left ventricular; MI: myocardial infarction; PAD: peripheral artery disease; TE: thromboembolic; TIA: transient ischemic attack.<br />* These unadjusted (not adjusted for possible use of aspirin) stroke rates were published in 2012<sup>[1]</sup>. Actual rates of stroke in contemporary cohorts might vary from these estimates.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33:1500.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original figure modified for this publication. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014. DOI: 10.1016/j.jacc.2014.03.022. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94752 Version 6.0</div></div></div>"},"94753":{"type":"graphic_diagnosticimage","displayName":"Perinephric abscess associated with staghorn calculus ","title":"Perinephric abscess associated with staghorn calculus on imaging","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Perinephric abscess associated with staghorn calculus on imaging</div><div class=\"cntnt\"><img style=\"width:598px; height:205px;\" src=\"images/ID/94753_Perineprhic_absces_staghorn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perirenal suppration complicating a staghorn calculus. This severely infected kidney is not functional. Successful treatment consisted&nbsp;of en-bloc nephrectomy and excision of all perirenal infected fat. (A)&nbsp;Plain radiograph:&nbsp;A staghorn calculus&nbsp;is visualized&nbsp;in the pelvicaliceal system. (B) Computed tomography:&nbsp;The abscess (asterisk) progressed to the lumboabdominal wall with an inflammatory cutaneous reaction (arrowhead). The staghorn calculus is visible (arrow).</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 94753 Version 3.0</div></div></div>"},"94754":{"type":"graphic_algorithm","displayName":"Airway Approach Algorithm for anesthesia","title":"Airway Approach Algorithm for anesthesia","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Airway Approach Algorithm for anesthesia</div><div class=\"cntnt\"><img style=\"width:588px; height:344px;\" src=\"images/ANEST/94754_Arwyapprchalgoanesthesia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A decision tree approach to entry in the American Society of Anesthesiologists Difficult Airway Algorithm.</div><div class=\"graphic_footnotes\">TTJV: transtracheal jet ventilation.</div><div class=\"graphic_reference\">Modified with permission from: Rosenblatt WH, Sukhupragarn W. Airway Management. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 94754 Version 9.0</div></div></div>"},"94755":{"type":"graphic_algorithm","displayName":"Algorithm for management of puerperal uterine inversion","title":"Algorithm for management of puerperal uterine inversion in a hemodynamically unstable patient","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of puerperal uterine inversion in a hemodynamically unstable patient</div><div class=\"cntnt\"><img style=\"width:604px; height:789px;\" src=\"images/OBGYN/94755_puerperal_uterine_inversion.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count.</div><div id=\"graphicVersion\">Graphic 94755 Version 1.0</div></div></div>"},"94756":{"type":"graphic_figure","displayName":"Classification of puerperal uterine inversion","title":"Classification of puerperal uterine inversion","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Classification of puerperal uterine inversion</div><div class=\"cntnt\"><img style=\"width:536px; height:520px;\" src=\"images/OBGYN/94756_Classification_of_puerperal_uterine_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) 1st. degree (incomplete) inversion: the fundus is within the endometrial cavity; (B) 2nd. degree (complete) inversion: the fundus protrudes through the cervical os; (C)&nbsp;3rd. degree inversion (uterine prolapse): the fundus protrudes to or beyond the introitus; (D) 4th. degree (total uterine and vaginal) inversion: both the uterus and vagina are inverted.</div><div id=\"graphicVersion\">Graphic 94756 Version 1.0</div></div></div>"},"94757":{"type":"graphic_figure","displayName":"Hydrostatic method for correction of puerperal uterine inversion","title":"Hydrostatic method for correction of puerperal uterine inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydrostatic method for correction of puerperal uterine inversion</div><div class=\"cntnt\"><img style=\"width:424px; height:442px;\" src=\"images/OBGYN/94757_Hydrostatic_method_for_correction_of_puerperal_uterine_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hydrostatic reduction of acute uterine inversion is an option if all other interventions have failed and surgical intervention is not possible. The patient is placed in reversed Trendelenburg lithotomy position. A bag of warmed fluid is hung at least one meter above the patient and allowed to flow by gravity or with light pressure through tubing connected to a silastic ventouse cup in the vagina; the seal between the perimeter of the cup and the vagina prevents significant leakage. The resulting intravaginal hydrostatic pressure may force the inverted fundus back to its normal position. Two to five liters of fluid may be needed.</div><div id=\"graphicVersion\">Graphic 94757 Version 1.0</div></div></div>"},"94758":{"type":"graphic_figure","displayName":"Haultain procedure","title":"Haultain procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Haultain procedure</div><div class=\"cntnt\"><img style=\"width:404px; height:395px;\" src=\"images/OBGYN/94758_Haultain_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Haultain procedure for&nbsp;management of uterine inversion&nbsp;involves making an incision in the posterior surface of the uterus to bisect the constriction ring in the myometrium, which is&nbsp;preventing reduction of the inversion.</div><div id=\"graphicVersion\">Graphic 94758 Version 1.0</div></div></div>"},"94760":{"type":"graphic_picture","displayName":"Papular purpuric gloves and socks syndrome - palm","title":"Papular-purpuric gloves and socks syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Papular-purpuric gloves and socks syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94760_Pap_purp_gloves_socks_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palmar erythema in a patient with parvovirus B19 infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94760 Version 2.0</div></div></div>"},"94768":{"type":"graphic_table","displayName":"Neurodegenerative diseases and their effect on deglutition","title":"Neurodegenerative diseases and their effect on deglutition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurodegenerative diseases and their effect on deglutition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Incidence in general population</td> <td class=\"subtitle1\">Prevalence of dysphagia (%)</td> <td class=\"subtitle1\">Aspect of deglutition affected</td> <td class=\"subtitle1\">Risk of aspiration</td> </tr> <tr> <td>Muscular dystrophy</td> <td>17 to 28:100,000</td> <td>18</td> <td>Oral&#62;pharyngeal</td> <td>Low early stages, high late stages</td> </tr> <tr> <td>MG</td> <td>1.7 to 10.4:1,000,000</td> <td>40</td> <td>Pharyngeal&#62;oral</td> <td>High (35%)</td> </tr> <tr> <td>MS</td> <td>2 to 7:100,000</td> <td>24 to 65</td> <td>Oral/pharyngeal, cortical</td> <td>High</td> </tr> <tr> <td>ALS</td> <td>2:100,000</td> <td>83</td> <td>Oral&#62;pharyngeal, cortical</td> <td>High</td> </tr> <tr> <td>Parkinson disease</td> <td>13:100,000</td> <td>82</td> <td>Esophageal&#62;oral/pharyngeal, cortical</td> <td>High</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MG: myasthenia gravis; MS: multiple sclerosis; ALS: amyotrophic lateral sclerosis.</div><div class=\"graphic_reference\">Reproduced from: Altman KW, Richards A, Goldberg L, et al. Dysphagia in stroke, neurodegenerative disease, and advanced dementia. Otolaryngol Clin N Am 2013; 46:1137. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94768 Version 2.0</div></div></div>"},"94769":{"type":"graphic_picture","displayName":"Meningococcemia","title":"Meningococcemia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Meningococcemia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94769_Meningococcemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous macules and papules resembling a viral exanthem may be the early manifestation of meningococcemia in some patients.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94769 Version 1.0</div></div></div>"},"94770":{"type":"graphic_picture","displayName":"Rocky Mountain spotted fever-palm","title":"Rocky Mountain spotted fever","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Rocky Mountain spotted fever</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/DERM/94770_Rocky_Mtn_spotted_feverpalm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The maculopapular rash of Rocky Mountain spotted fever typically starts on the ankles, palms, wrists, and forearm, and then spreads centripetally to the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94770 Version 1.0</div></div></div>"},"94771":{"type":"graphic_waveform","displayName":"Acute IV antiepileptic drug trial in suspected NCSE","title":"EEG before and after acute IV antiepileptic drug trial in a patient with suspected nonconvulsive status epilepticus","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">EEG before and after acute IV antiepileptic drug trial in a patient with suspected nonconvulsive status epilepticus</div><div class=\"cntnt\"><img style=\"width:582px; height:760px;\" src=\"images/NEURO/94771_Case_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Generalized spike-and-wave (GSW) complexes (some with polyspike-and-wave) in a patient with penetrating brain injury to the right parietal lobe who presented with pulseless cardiac arrest and myoclonic status epilepticus, treated successfully with IV and oral antiepileptic drugs and continuous midazolam. This EEG was obtained several days after midazolam was tapered, when the patient was exhibiting new nystagmus and frequent eye blinks.<br />(B) Resolution of GSW after administration of IV midazolam. The patient's nystagmus and eye blinks also disappeared. Although the EEG did not return to a normal awake background, the disappearance of both GSW and clinical manifestations confirms their ictal nature.</div><div id=\"graphicVersion\">Graphic 94771 Version 3.0</div></div></div>"},"94772":{"type":"graphic_picture","displayName":"Henoch-Schonlein purpura","title":"Henoch-Schonlein purpura","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Henoch-Schonlein purpura</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94772_Henoch_Schonlein_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple purpuric, nonblanchable, raised lesions (palpable purpura) are present on the leg and foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94772 Version 1.0</div></div></div>"},"94773":{"type":"graphic_waveform","displayName":"Generalized periodic discharges","title":"Generalized periodic discharges (GPDs)","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Generalized periodic discharges (GPDs)</div><div class=\"cntnt\"><img style=\"width:624px; height:385px;\" src=\"images/NEPH/94773_Generalized_periodic_charge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-pass filter: 1Hz; low-pass filter: 70Hz; notch filter: off.</div><div id=\"graphicVersion\">Graphic 94773 Version 2.0</div></div></div>"},"94774":{"type":"graphic_waveform","displayName":"Lateralized periodic discharges","title":"Lateralized periodic discharges (LPDs), also known as periodic lateralized epileptiform discharges (PLEDs)","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Lateralized periodic discharges (LPDs), also known as periodic lateralized epileptiform discharges (PLEDs)</div><div class=\"cntnt\"><img style=\"width:623px; height:390px;\" src=\"images/NEURO/94774_Lateralized_periodic_disch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-pass filter: 1Hz; low-pass filter: 70Hz; notch filter: off.</div><div id=\"graphicVersion\">Graphic 94774 Version 2.0</div></div></div>"},"94775":{"type":"graphic_waveform","displayName":"Bilateral independent periodic discharges","title":"Bilateral independent periodic discharges (BIPDs), also known as bilateral independent lateralized epileptiform discharges (BIPLEDs)","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Bilateral independent periodic discharges (BIPDs), also known as bilateral independent lateralized epileptiform discharges (BIPLEDs)</div><div class=\"cntnt\"><img style=\"width:623px; height:390px;\" src=\"images/NEURO/94775_Bilat_indep_period_discharg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-pass filter: 1Hz; low-pass filter: 70Hz; notch filter: off.</div><div id=\"graphicVersion\">Graphic 94775 Version 2.0</div></div></div>"},"94776":{"type":"graphic_waveform","displayName":"Lateralized periodic discharges with fast rhythmic activity","title":"Lateralized periodic discharges with superimposed fast rhythmic activity (LPDs+), also known as PLEDs plus","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Lateralized periodic discharges with superimposed fast rhythmic activity (LPDs+), also known as PLEDs plus</div><div class=\"cntnt\"><img style=\"width:624px; height:392px;\" src=\"images/NEURO/94776_Lat_disch_superimp_fast_rhy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-pass filter: 1Hz; low-pass filter: 70Hz; notch filter: off.</div><div id=\"graphicVersion\">Graphic 94776 Version 2.0</div></div></div>"},"94777":{"type":"graphic_waveform","displayName":"Stimulus-induced rhythmic delta activity","title":"Stimulus-induced rhythmic delta activity (a subtype of stimulus-induced rhythmic, periodic or ictal-appearing discharges [SIRPIDs])","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Stimulus-induced rhythmic delta activity (a subtype of stimulus-induced rhythmic, periodic or ictal-appearing discharges [SIRPIDs])</div><div class=\"cntnt\"><img style=\"width:623px; height:393px;\" src=\"images/NEURO/94777_Stim_induced_rhythmic_delta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-pass filter: 1Hz; low-pass filter: 70Hz; notch filter: off.</div><div id=\"graphicVersion\">Graphic 94777 Version 2.0</div></div></div>"},"94778":{"type":"graphic_table","displayName":"Treatment of nonconvulsive status epilepticus","title":"Treatment of nonconvulsive status epilepticus (NCSE) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of nonconvulsive status epilepticus (NCSE) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Re-loading dose</td> <td class=\"subtitle1\">Maintenance dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Parenteral benzodiazepine choices (initial regimen)</td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td>0.1 mg/kg (up to 4 mg) IV bolus (up to 2 mg/min)</td> <td>0.1 mg/kg (up to 4 mg)</td> <td>N/A</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td>0.15 mg/kg (up to 10 mg) IV bolus (up to 5 mg/min)</td> <td>0.15 mg/kg (up to 10 mg)</td> <td>N/A</td> </tr> <tr> <td class=\"indent1\">Midazolam</td> <td>0.2 mg/kg (up to 10 mg) intramuscularly</td> <td>0.2 mg/kg (up to 10 mg) intramuscularly</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Clonazepam*</td> <td>0.015 mg/kg (up to 1 mg) slow IV bolus (0.5 mg/min)</td> <td>0.015 mg/kg (up to 1 mg)</td> <td>N/A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Non-sedating antiseizure choices (initial regimen)</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> <td>20 mg/kg IV (up to 50 mg/min)</td> <td>5 to 10 mg/kg up to a maximum cumulative dose of 30 mg/kg<sup>&#182;</sup></td> <td>5 to 7 mg/kg/d orally/IV, divided every 8 h</td> </tr> <tr> <td class=\"indent1\">Fosphenytoin</td> <td>20 mg PE/kg IV (up to 150 mg PE/min)</td> <td>5 to 10 mg PE/kg up to a maximum cumulative dose of 30 mg/kg<sup>&#182;</sup></td> <td>5 to 7 mg PE/kg/d IV, divided every 8 h</td> </tr> <tr> <td class=\"indent1\">Valproate</td> <td>20 to 40 mg/kg IV (up to 5 mg/kg/min)</td> <td>20 mg/kg</td> <td>30 to 60 mg/kg/d, orally/IV divided every 6 to 12 h<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Levetiracetam</td> <td>2500 mg IV (up to 5 mg/kg/min, typically given over 15 min)</td> <td>1000 to 2000 mg</td> <td>2 to 4 g/d orally/IV, divided every 6 to 12 h<sup>&#916;</sup><sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lacosamide</td> <td>200 to 400 mg IV (over 15 min)</td> <td>200 mg</td> <td>200 to 600 mg/d orally/IV, divided every 12 h<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Potential oral or nasogastric add-on non-anesthetic options</td> </tr> <tr> <td class=\"indent1\">Topiramate</td> <td>100 mg orally every 12 h</td> <td>N/A</td> <td>300 to 800 mg/d orally, divided every 8-12 h</td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> <td>300 mg orally every 8 h</td> <td>N/A</td> <td>1800 to 3600 mg/d orally, divided every 6-8 h</td> </tr> <tr> <td class=\"indent1\">Pregabalin</td> <td>75 mg orally every 12 h</td> <td>N/A</td> <td>150 to 600 mg/d orally, divided every 8-12 h</td> </tr> <tr> <td class=\"indent1\">Clobazam</td> <td>10 to 20 mg orally every 12 h</td> <td>N/A</td> <td>Up to 60 mg/d orally, divided every 12 h</td> </tr> <tr> <td class=\"indent1\">Perampanel</td> <td>6 to 12 mg orally every 24 h</td> <td>N/A</td> <td>Up to 12 mg orally every 24 h</td> </tr> <tr> <td class=\"indent1\">Oxcarbazepine</td> <td>300 to 600 mg orally every 12 h</td> <td>N/A</td> <td>Up to 2400 mg/d orally, divided every 12 h</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> <td>300 to 800 mg orally in two to four divided doses (product dependent)</td> <td>N/A</td> <td>Up to 1600 mg/d orally, divided every 12 h (tablets) or every 6 h (liquid)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vigabatrin</td> <td>500 to 750 mg orally every 12 h</td> <td>N/A</td> <td>Up to 3000 mg/d orally, divided every 12 h<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Continuous infusion anesthetic options in critically ill mechanically ventilated patients<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Midazolam</td> <td>0.2 mg/kg IV (up to 2 mg/min) every 5 min until seizures controlled or maximum dose of 2 mg/kg; followed by continuous infusion</td> <td>N/A</td> <td>0.05 to 2.9 mg/kg/h continuous IV infusion</td> </tr> <tr> <td class=\"indent1\">Propofol</td> <td>1 to 2 mg/kg IV every 5 min until seizures controlled or maximum dose 10 mg/kg; followed by continuous infusion</td> <td>N/A</td> <td>1.8 to 12 mg/kg/h continuous IV infusion (limit to 5 mg/kg/h for treatment &#62;48 h)</td> </tr> <tr> <td class=\"indent1\">Pentobarbital</td> <td>5 mg/kg IV (up to 50 mg/min) every 5 min until seizures controlled up to a maximum of 25 mg/kg; followed by continuous infusion</td> <td>N/A</td> <td>0.5 to 10 mg/kg/h continuous IV infusion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketamine</td> <td>1.5 mg/kg IV every 5 min until seizures controlled or up to a maximum dose of 4.5 mg/kg; followed by continuous infusion</td> <td>N/A</td> <td>1.2 to 7.5 mg/kg/h continuous IV infusion</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other potential treatments</td> </tr> <tr> <td class=\"indent1\">Ketogenic diet</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> <td>1 g/d for 3 days</td> <td>N/A</td> <td>1 mg/kg/d then taper</td> </tr> <tr> <td class=\"indent1\">IVIG</td> <td>0.4 g/kg/d for 5 days</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td class=\"indent1\">Plasma exchange</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Electroconvulsive therapy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>For the initial treatment of NCSE in most adults, we suggest an IV benzodiazepine (eg, lorazepam) combined or sequenced with a non-sedating IV antiseizure drug (eg, fosphenytoin, valproate, levetiracetam, lacosamide) under closely monitored conditions with continuous EEG. Treatment choices and sequence must be individualized based upon clinical features. Refer to accompanying text.</li>&#xD;&#xA;    <li>Critically ill patients often exhibit altered drug pharmacokinetics due to organ dysfunction, reduced protein binding, and/or hypermetabolic state. Adjustment of dose guided by serum drug concentration may be necessary, particularly for levetiracetam, (fos)phenytoin, and valproate.<sup>&Delta;</sup></li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">D: day; EEG: electroencephalography; g: gram; h: hour; IV: intravenous; IVIG: intravenous immunoglobulin; kg: kilogram; min: minutes; mg: milligram; N/A: not applicable; PE: phenytoin equivalent.<br />* Clonazepam is not available in IV formulation in the United States.<br />¶ In patients receiving phenytoin chronically the maximum re-loading dose is determined by assessment of serum concentration.<br />Δ Oral/enteral bioavailability may be limited in critically ill patients due to ileus, intestinal wall edema, and visceral hypoperfusion; IV formulations are preferred when available.<br /><FONT class=lozenge>◊</FONT> Higher doses and more frequent dosing may be necessary in some critically ill patients.<br />§ Vigabatrin has been associated with vision loss and availability in the United States is restricted. The US Food and Drug administration recommends baseline and serial monitoring of visual fields every three months in patients treated with vigabatrin.<br />¥ Anesthetic agents are titrated to seizure termination by an experienced intensivist in a critical care unit.</div><div class=\"graphic_reference\">Courtesy of authors with additional data from Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3 and Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 94778 Version 4.0</div></div></div>"},"94779":{"type":"graphic_algorithm","displayName":"Algorithm for determining impairment rating","title":"Algorithm for determining impairment rating","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Algorithm for determining impairment rating</div><div class=\"cntnt\"><img style=\"width:478px; height:702px;\" src=\"images/PULM/94779_AMA_algo_impairment_rating.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IC: impairment class; PFT: pulmonary function tests; VO<sub>2</sub>: oxygen uptake; BHR: bronchial hyperresponsiveness; FEV<sub>1</sub>: forced expiratory volume in one second.<br />* This algorithm is designed to accompany the American Medical Association table for assessment of pulmonary dysfunction.</div><div class=\"graphic_reference\">Adapted from: American Medical Association. Guides to the Evaluation of Permanent Impairment, 6th ed, American Medical Association, Chicago 2008.</div><div id=\"graphicVersion\">Graphic 94779 Version 1.0</div></div></div>"},"94780":{"type":"graphic_table","displayName":"Assessment of pulmonary dysfunction","title":"American Medical Association assessment of pulmonary dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Medical Association assessment of pulmonary dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup><colgroup span=\"5\" width=\"3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Class 0</td> <td class=\"subtitle1\" colspan=\"5\">Class 1</td> <td class=\"subtitle1\" colspan=\"5\">Class 2</td> <td class=\"subtitle1\" colspan=\"5\">Class 3</td> <td class=\"subtitle1\" colspan=\"5\">Class 4</td> </tr> <tr class=\"divider_bottom\"> <td>Whole person impairment rating (%)</td> <td class=\"centered\">0</td> <td class=\"centered\" colspan=\"5\">2 to 10</td> <td class=\"centered\" colspan=\"5\">11 to 23</td> <td class=\"centered\" colspan=\"5\">24 to 40</td> <td class=\"centered\" colspan=\"5\">45 to 65</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"22\">Severity grade</td> </tr> <tr> <td class=\"indent1\">Percent impairment</td> <td>&nbsp;</td> <td class=\"centered\">2</td> <td class=\"centered\">4</td> <td class=\"centered\">6</td> <td class=\"centered\">8</td> <td class=\"centered\">10</td> <td class=\"centered\">11</td> <td class=\"centered\">14</td> <td class=\"centered\">17</td> <td class=\"centered\">20</td> <td class=\"centered\">23</td> <td class=\"centered\">24</td> <td class=\"centered\">28</td> <td class=\"centered\">32</td> <td class=\"centered\">36</td> <td class=\"centered\">40</td> <td class=\"centered\">45</td> <td class=\"centered\">50</td> <td class=\"centered\">55</td> <td class=\"centered\">60</td> <td class=\"centered\">65</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Grade</td> <td>&nbsp;</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">E</td> </tr> <tr class=\"divider_bottom\"> <td>History</td> <td>No symptoms currently <strong>and/or</strong> intermittent dyspnea that does not require treatment</td> <td colspan=\"5\">Dyspnea controlled with intermittent or continuous treatment <strong>or</strong> intermittent mild dyspnea despite continuous treatment</td> <td colspan=\"5\">Constant mild dyspnea despite continuous treatment <strong>or</strong> intermittent moderate dyspnea despite continuous treatment</td> <td colspan=\"5\">Constant moderate dyspnea despite continuous treatment <strong>or</strong> intermittent severe dyspnea despite continuous treatment</td> <td colspan=\"5\">Constant severe dyspnea despite continuous treatment <strong>or</strong> intermittent extreme dyspnea despite continuous therapy</td> </tr> <tr class=\"divider_bottom\"> <td>Physical findings</td> <td>No current signs of disease</td> <td colspan=\"5\">Physical findings not present with continuous treatment <strong>or</strong> intermittent mild physical findings</td> <td colspan=\"5\">Constant mild physical findings despite continuous treatment <strong>or</strong> intermittent moderate findings</td> <td colspan=\"5\">Constant moderate physical findings despite continuous treatment <strong>or</strong> intermittent severe findings</td> <td colspan=\"5\">Constant severe physical findings despite continuous treatment <strong>or</strong> intermittent extreme findings</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"22\">Objective tests</td> </tr> <tr> <td class=\"indent1\">FVC</td> <td class=\"centered\"> <p>&#8805;80% of predicted</p> <strong>and</strong></td> <td class=\"centered\" colspan=\"5\"> <p>70 to 79% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>60 to 69% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>51 to 59% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>Below 50% of predicted</p> <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">FEV<sub>1</sub></td> <td class=\"centered\"> <p>&#8805;80% of predicted</p> <strong>and</strong></td> <td class=\"centered\" colspan=\"5\"> <p>65 to 79% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>55 to 64% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>45 to 54% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>Below 45% of predicted</p> <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">FEV<sub>1</sub>/FVC</td> <td class=\"centered\"> <p>FEV<sub>1</sub>/FVC &#62;LLN or &#62;75% of predicted</p> <strong>and</strong></td> <td class=\"centered\" colspan=\"5\">&nbsp;</td> <td class=\"centered\" colspan=\"5\">&nbsp;</td> <td class=\"centered\" colspan=\"5\">&nbsp;</td> <td class=\"centered\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">DLCO</td> <td class=\"centered\"> <p>DLCO &#8805;75% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>65 to 74% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>55 to 64% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>45 to 54% of predicted</p> <strong>or</strong></td> <td class=\"centered\" colspan=\"5\"> <p>Below 45% of predicted</p> <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">VO<sub>2</sub> max</td> <td class=\"centered\"> <p>&#62;25 mL/kg/min</p> <p><strong>or</strong></p> &#62;7.1 METs</td> <td class=\"centered\" colspan=\"5\"> <p>22 to 25 mL/kg/min</p> <p><strong>or</strong></p> 6.3 to 7.1 METs</td> <td class=\"centered\" colspan=\"5\"> <p>18 to 21 mL/kg/min</p> <p><strong>or</strong></p> 5.1 to 6.2 METs</td> <td class=\"centered\" colspan=\"5\"> <p>15 to 17 mL/kg/min</p> <p><strong>or</strong></p> 4.3 to 5 METs</td> <td class=\"centered\" colspan=\"5\"> <p>&#60;15 mL/kg/min</p> <p><strong>or</strong></p> &#60;4.3 METs</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FVC: forced vital capacity; FEV<sub>1</sub>: forced expiratory volume in one second; LLN: lower limit of normal; DLCO: diffusion capacity for carbon monoxide; VO<sub>2</sub> max: maximum oxygen consumption; METS: metabolic equivalents (multiples of resting oxygen uptake).</div><div class=\"graphic_reference\">Reprinted from AMA's Guides to the Evaluation of Impairment, 6th Edition with the permission of the American Medical Association, Copyright © 2008. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 94780 Version 2.0</div></div></div>"},"94789":{"type":"graphic_picture","displayName":"Pustules in pustular psoriasis close view","title":"Generalized pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Generalized pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94789_Pustules_pustular_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules, erythema, and scale in generalized&nbsp;pustular psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94789 Version 1.0</div></div></div>"},"94790":{"type":"graphic_picture","displayName":"Pustular psoriasis erythema and scale","title":"Pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94790_Pustu_psoriasis_eryth_scale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread erythematous patches, desquamation, and pustules in pustular psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94790 Version 1.0</div></div></div>"},"94791":{"type":"graphic_picture","displayName":"Acrodermatitis continua of Hallopeau multiple digits","title":"Acrodermatitis continua of Hallopeau","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acrodermatitis continua of Hallopeau</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94791_Acroderm_continua_Hallopeau.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules, erythema, scale, and nail dystrophy involving the distal fingers.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94791 Version 1.0</div></div></div>"},"94792":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94792_Palmoplantar_pustulosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules, scale, and erythema on the palm of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94792 Version 1.0</div></div></div>"},"94793":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis on hands","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94793_Palmoplant_pustulosis_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, scale, pustules, and brown macules on the palms.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94793 Version 1.0</div></div></div>"},"94798":{"type":"graphic_diagnosticimage","displayName":"CT T1aN0M0 NSCLC","title":"T1aN0M0 non-small cell lung cancer on CT","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">T1aN0M0&nbsp;non-small cell lung cancer on CT</div><div class=\"cntnt\"><img style=\"width:609px; height:497px;\" src=\"images/RADIOL/94798_CT_stage_1A_NSCLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through chest shows a T1aN0M0, 9 mm adenocarcinoma in the right upper lobe (arrow). The tumor is surrounded by lung.</div><div class=\"graphic_footnotes\">CT: computed tomography; NSCLC: non small cell lung cancer.</div><div id=\"graphicVersion\">Graphic 94798 Version 2.0</div></div></div>"},"94799":{"type":"graphic_diagnosticimage","displayName":"Imaging T1cN0M0 NSCLC","title":"T1cN0M0 non-small cell lung cancer on CT and PET scans","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">T1cN0M0&nbsp;non-small cell lung cancer on CT and PET scans</div><div class=\"cntnt\"><img style=\"width:594px; height:360px;\" src=\"images/RADIOL/94799_Imaging_stage_1A_NSLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal reconstruction of a chest CT scan (A) shows a T1cN0M0, 2.3 cm carcinoma in the right upper lobe (arrow). Image B shows an FDG avid nodule (arrow) without metastatic disease.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography; PET: positron emission tomography; FDG: fluorodeoxyglucose.</div><div id=\"graphicVersion\">Graphic 94799 Version 2.0</div></div></div>"},"94800":{"type":"graphic_diagnosticimage","displayName":"CT stage M1c NSCLC","title":"M1c non-small cell lung cancer on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">M1c non-small cell lung cancer on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:243px;\" src=\"images/RADIOL/94800_CT_stage_4_NSLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the chest (A) shows two satellite nodules (arrows) peripheral to the large primary NSCLC (arrowhead). Image B demonstrates M1c disease with multiple metastases in the left lobe of the liver (arrows) and the left adrenal gland (arrowhead).</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 94800 Version 2.0</div></div></div>"},"94801":{"type":"graphic_diagnosticimage","displayName":"Imaging stage 1B II NSLC","title":"Stage 1B II non small cell lung cancer on CT and PET","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Stage 1B II non small cell lung cancer on CT and PET</div><div class=\"cntnt\"><img style=\"width:598px; height:334px;\" src=\"images/RADIOL/94801_Imaging_stage_1B_II_NSLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the chest (A) shows a 4.2 cm stage 1B/II squamous carcinoma in the right upper lobe (arrow). Image B shows an FDG avid mass (arrow) without metastatic disease. The relative lack of avidity suggests necrosis of the tumor.</div><div class=\"graphic_footnotes\">NSCLC: non small cell lung cancer; CT: computed tomography; PET: positron emission tomography; FDG: fluorodeoxyglucose.</div><div id=\"graphicVersion\">Graphic 94801 Version 1.0</div></div></div>"},"94802":{"type":"graphic_diagnosticimage","displayName":"Imaging T3N3M0 NScLC","title":"T3N3M0 NSCLC on CT and PET","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">T3N3M0 NSCLC on CT and PET</div><div class=\"cntnt\"><img style=\"width:598px; height:281px;\" src=\"images/RADIOL/94802_Imaging_stage_3A_NSLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal reconstruction of a chest CT scan (A) shows&nbsp;a 3 cm tumor in the left upper lobe (arrow) with small left hilar nodes (arrowhead). Image B shows an FDG avid nodule (arrow) with ipsilateral hilar and mediastinal disease (arrowhead).</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography; PET: positron emission tomography; FDG: fluorodeoxyglucose.</div><div id=\"graphicVersion\">Graphic 94802 Version 2.0</div></div></div>"},"94803":{"type":"graphic_diagnosticimage","displayName":"CT stage T3N3M0 NSLC","title":"Stage T3N3M0 non-small cell lung cancer on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Stage&nbsp;T3N3M0 non-small cell lung cancer on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:416px;\" src=\"images/RADIOL/94803_CT_stage_3B_NSLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal reconstruction of a chest CT scan (A) shows a 5.1 cm, cavitating left lower squamous carcinoma (arrow). Image B is an axial scan through the upper chest and shows ipsilateral lymphadenopathy (arrows) and image C shows contralateral lymphadenopathy (arrow). EBUS-guided fine needle aspiration biopsy of the mediastinal nodes confirmed&nbsp;T3N3M0 status.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography; EBUS: endobronchial ultrasound.</div><div id=\"graphicVersion\">Graphic 94803 Version 2.0</div></div></div>"},"94816":{"type":"graphic_algorithm","displayName":"Evaluation microcephaly children","title":"Evaluation of microcephaly in infants and children","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Evaluation of microcephaly in infants and children</div><div class=\"cntnt\"><img style=\"width:608px; height:623px;\" src=\"images/PEDS/94816_Eval_microcephaly_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SD: standard deviation; MRI: magnetic resonance imaging; US: ultrasonography; CMV: cytomegalovirus.<br />* Consultation with a specialist in pediatric infectious diseases, pediatric genetics, pediatric neurology, and/or pediatric radiology may be helpful in planning the evaluation.<br />¶ Consultation with a pediatric radiologist may be helpful in planning neuroimaging.<br />Δ Additional testing may include evaluation for genetic or metabolic studies, ophthalmology evaluation, and/or tests for congenital infection. Consultation with a specialist in pediatric infectious diseases, pediatric genetics, or pediatric neurology may be helpful in planning the evaluation.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ashwal S, Michelson D, Plawner L, et al. Practice parameter: Evaluation of the child with microcephaly (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2009; 73:887.</li>&#xD;&#xA;    <li>von der Hagen M, Pivarcsi M, Liebe J, et al. Diagnostic approach to microcephaly in childhood: a two-center study and review of the literature. Dev Med Child Neurol 2014; Epub ahead of print.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 94816 Version 2.0</div></div></div>"},"94837":{"type":"graphic_figure","displayName":"Laid-back breastfeeding PI","title":"Laid-back breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Laid-back breastfeeding</div><div class=\"cntnt\"><img style=\"width:526px; height:360px;\" src=\"images/PI/94837_Laid-back_breastfeeding_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The laid-back breastfeeding position facilitates the natural breastfeeding behaviors with the full body skin-to-skin contact between the mother and baby. It promotes a strong letdown of breast milk from the mother and allows the baby to have more control over the milk flow. </div><div id=\"graphicVersion\">Graphic 94837 Version 2.0</div></div></div>"},"94838":{"type":"graphic_table","displayName":"Functional classification of PCOS","title":"Functional classification of PCOS according to source of androgen excess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional classification of PCOS according to source of androgen excess</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PCOS functional type</td> <td class=\"subtitle1\">Source of androgen</td> <td class=\"subtitle1\">GnRHag test:<br /> 17OHP response</td> <td class=\"subtitle1\">DAST testosterone response</td> <td class=\"subtitle1\">ACTH test:<br /> DHEA response</td> <td class=\"subtitle1\">Prevalence among PCOS</td> </tr> <tr class=\"divider_bottom\"> <td>Typical PCOS (PCOS-T)</td> <td>Primary functional ovarian hyperandrogenism (typical FOH)</td> <td class=\"centered\">High<sup>&#182;</sup></td> <td class=\"centered\">High in 92.5%</td> <td class=\"centered\">High in 28% (associated FAH)</td> <td class=\"centered\">67%<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"3\">Atypical PCOS (PCOS-A)</td> <td>Primary functional ovarian hyperandrogenism (atypical FOH)</td> <td class=\"centered\">Normal<sup>&#182;</sup></td> <td class=\"centered\">High</td> <td class=\"centered\">High in 30% (associated FAH)</td> <td class=\"centered\">20%</td> </tr> <tr> <td>Isolated primary functional adrenal hyperandrogenism (isolated FAH)</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">High</td> <td class=\"centered\">5%</td> </tr> <tr> <td>PCOS without FOH or FAH (atypical PCOS of obesity or idiopathic atypical PCOS)</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">8%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The functional ovarian hyperandrogenism (FOH) seen in two-thirds of PCOS cases is distinguished by 17-hydroxyprogesterone (17OHP) hyper-responsiveness to stimulation testing with gonadotropin-releasing hormone agonist (GnRHag). However, in one-third it is detected only by an elevated testosterone in response to a dexamethasone androgen-suppression test (DAST). Functional adrenal hyperandrogenism (FAH) is distinguished by DHEA hyper-response to ACTH, which correlates with the DHEAS level. FAH occurs most often concomitantly with FOH, but it can also occur in the absence of FOH (isolated FAH). Text (high versus normal) indicates defining characteristics; percentages indicate experimentally determined prevalence of abnormality.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; ACTH: adrenocorticotropic hormone (corticotropin); DHEA: dehydroepiandrosterone.<br />* Based on data of Rosenfield RL, et al. Determination of the source of androgen excess in functionally atypical PCOS by a short DAST and a low-dose ACTH test.<SUP>[1]</SUP><br />¶ \"High\" versus \"normal\" denotes defining characteristics; percentages indicate experimentally determined prevalence of abnormality.<br />Δ Prevalence determined from an age-matched subgroup (n = 60) of an original cohort (n = 99) in which 69% had PCOS-T.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011; 26:3138.</LI></OL>Modified from: Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews 2016; 37:467, by permission of Oxford University Press on behalf of The Endocrine Society. Copyright © 2016.</div><div id=\"graphicVersion\">Graphic 94838 Version 6.0</div></div></div>"},"94853":{"type":"graphic_figure","displayName":"Lateral wall LV aneurysm","title":"Lateral wall left ventricular aneurysm","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Lateral wall left ventricular aneurysm</div><div class=\"cntnt\"><img style=\"width:474px; height:708px;\" src=\"images/CARD/94853_Lateral_wall_LV_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral wall left ventricular aneurysm. Preoperative axial (A) and 3-D (B) cardiac CT demonstrating a large lateral-wall LV aneurysm. The arrow in the axial image (A) points to the neck. Intraoperative image of the aneurysm with the apex of the heart lifted to expose the obtuse margin (C) and a large clot removed from within the aneurysm (D). Follow-up cardiac CT (E, F) performed six months after endoaneurysmorrhaphy shows restoration of the LV contour to normal and a bioprosthetic mitral valve.</div><div class=\"graphic_footnotes\">CT: computed tomography; LV: left ventricular.</div><div class=\"graphic_reference\">Courtesy of Oz Shapira, MD.</div><div id=\"graphicVersion\">Graphic 94853 Version 1.0</div></div></div>"},"94855":{"type":"graphic_figure","displayName":"Functional categorization of PCOS pathophysiology","title":"Functional categorization of polycystic ovary syndrome pathophysiology","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Functional categorization of polycystic ovary syndrome pathophysiology</div><div class=\"cntnt\"><img style=\"width:545px; height:528px;\" src=\"images/PEDS/94855_Funct_categ_PCOS_pathophys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">About two-thirds of PCOS cases have the typical type of functional ovarian hyperandrogenism (FOH), in which there is hypersensitivity to luteinizing hormone (LH), as indicated by 17-hydroxyprogesterone (17-OHP) hyper-responsiveness to stimulation testing with gonadotropin-releasing hormone (GnRH) agonist or human chorionic gonadotropin (hCG). The remaining one-third of PCOS cases have a functionally atypical type of PCOS, characterized by lack of 17-OHP hyper-responsiveness to gonadotropins. A component of functional adrenal hyperandrogenism (FAH) may be present in either typical PCOS or atypical PCOS. A minority of cases of atypical PCOS are characterized by isolated FAH (without FOH) or by an unknown mechanism, possibly obesity itself, causing androgen excess.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome.</div><div class=\"graphic_reference\">Illustration based on data from: Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum reprod 2011; 26:3138.</div><div id=\"graphicVersion\">Graphic 94855 Version 2.0</div></div></div>"},"94856":{"type":"graphic_figure","displayName":"Coagulation cascade anticoagulant effects","title":"Coagulation cascade: Anticoagulant effects","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coagulation cascade: Anticoagulant effects</div><div class=\"cntnt\"><img style=\"width:365px; height:326px;\" src=\"images/HEME/94856_Coagulation_cascade_anticoagulant_effects.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LMW heparins include enoxaparin, dalteparin, and tinzaparin. Unfractionated heparin and LMW heparin inihbit both factor Xa and thrombin; the effect of LMW heparins on thrombin is less than that of unfractionated heparin. Fondaparinux is a synthetic pentasaccharide based on the minimal antithrombin-binding region of heparin that inhibits factor Xa. LMW heparins, unfractionated heparin, and fondaparinux inhibit clotting factors by binding to antithrombin.<br />Oral direct factor Xa inhibitors include apixaban, rivaroxaban, and edoxaban. Parenteral direct thrombin inhibitors include argatroban and lepirudin. Oral direct thrombin inhibitors include dabigatran.<br />Coagulation factors are shown as Roman numerals. Only the activated forms (with the suffix \"a\") are shown for simplicity. Thrombin is also known as factor IIa.</div><div class=\"graphic_footnotes\">LMW: low molecular weight.</div><div id=\"graphicVersion\">Graphic 94856 Version 3.0</div></div></div>"},"94861":{"type":"graphic_figure","displayName":"Bones of upper limb","title":"Bones of upper limb","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Bones of upper limb</div><div class=\"cntnt\"><img style=\"width:638px; height:632px;\" src=\"images/EM/94861_Bonesupperlimb.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94861 Version 3.0</div></div></div>"},"94862":{"type":"graphic_figure","displayName":"Deep veins of upper limb","title":"Deep veins of upper limb","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Deep veins of upper limb</div><div class=\"cntnt\"><img style=\"width:619px; height:543px;\" src=\"images/EM/94862_Deepveinsupperlimb.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The deep veins bear the same name as the arteries they accompany.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94862 Version 3.0</div></div></div>"},"94863":{"type":"graphic_figure","displayName":"Arteries of proximal upper limb - Anterior view","title":"Arteries of proximal upper limb: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Arteries of proximal upper limb: Anterior view</div><div class=\"cntnt\"><img style=\"width:721px; height:669px;\" src=\"images/EM/94863_Artrprxmlupprlmbantrr.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94863 Version 3.0</div></div></div>"},"94865":{"type":"graphic_figure","displayName":"Relationship of arteries and nerves of arm to humerus","title":"Relationship of arteries and nerves of arm to humerus and compartments of arm","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Relationship of arteries and nerves of arm to humerus and compartments of arm</div><div class=\"cntnt\"><img style=\"width:559px; height:798px;\" src=\"images/EM/94865_Rltnshpartrnrvarmhmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radial nerve and accompanying profunda brachii artery wind posteriorly around, and directly on the surface of, the humerus in the radial groove. The radial nerve and radial collateral artery then pierce the lateral intermuscular septum to enter the anterior compartment. The ulnar nerve pierces the medial intermuscular septum to enter the posterior compartment and then lies in the groove for the ulnar nerve on the posterior aspect of the medial epicondyle of the humerus. The median nerve and brachial artery descend in the arm to the medial side of the cubital fossa, where it is well protected and rarely injured.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94865 Version 4.0</div></div></div>"},"94870":{"type":"graphic_picture","displayName":"Ultrathin bronchoscopy","title":"Size of ultrathin bronchoscope compared to routine diagnostic and therapeutic bronchoscope","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Size of ultrathin bronchoscope compared to routine diagnostic and therapeutic bronchoscope</div><div class=\"cntnt\"><img style=\"width:712px; height:455px;\" src=\"images/PULM/94870_Ultrathin_bronchoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure shows an ultrathin bronchoscope (right) compared with therapeutic (left) and diagnostic (middle) bronchoscopes. The ultrathin bronchoscope allows access to small airways or through tight endobronchial obstructions.</div><div id=\"graphicVersion\">Graphic 94870 Version 1.0</div></div></div>"},"94871":{"type":"graphic_picture","displayName":"Narrow band image","title":"Narrow band image on bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Narrow band image on bronchoscopy</div><div class=\"cntnt\"><img style=\"width:448px; height:444px;\" src=\"images/PULM/94871_Narrow_band_image.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 94871 Version 1.0</div></div></div>"},"94872":{"type":"graphic_picture","displayName":"Normal white light bronchoscopy","title":"Image of normal bronchus on white light bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Image of normal bronchus on white light bronchoscopy</div><div class=\"cntnt\"><img style=\"width:445px; height:444px;\" src=\"images/PULM/94872_Normal_white_light_bronch.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 94872 Version 1.0</div></div></div>"},"94873":{"type":"graphic_diagnosticimage","displayName":"Alveolus pCLE","title":"Normal alveolus on confocal laser endomicroscopy","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Normal alveolus on confocal laser endomicroscopy</div><div class=\"cntnt\"><img style=\"width:484px; height:343px;\" src=\"images/PULM/94873_Alveolus_pCLE.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Dr. David Wilson and Dr. Adam Wellikoff, Louisiana State University Health - Shreveport, LA. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94873 Version 1.0</div></div></div>"},"94874":{"type":"graphic_diagnosticimage","displayName":"Bronchus pCLE","title":"Normal bronchus on confocal laser endomicroscopy","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Normal bronchus on confocal laser endomicroscopy</div><div class=\"cntnt\"><img style=\"width:484px; height:343px;\" src=\"images/PULM/94874_Bronchus_pCLE.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Dr. David Wilson and Dr. Adam Wellikoff, Louisiana State University Health - Shreveport, LA. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94874 Version 1.0</div></div></div>"},"94875":{"type":"graphic_picture","displayName":"Brachytherapy catheter","title":"Brachytherapy catheter in right lower lobe bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachytherapy catheter in right lower lobe bronchus</div><div class=\"cntnt\"><img style=\"width:447px; height:444px;\" src=\"images/PULM/94875_Brachytherapy_catheter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 94875 Version 1.0</div></div></div>"},"94876":{"type":"graphic_picture","displayName":"Bronchial thermoplasty","title":"Endobronchial thermoplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial thermoplasty</div><div class=\"cntnt\"><img style=\"width:430px; height:440px;\" src=\"images/PULM/94876_Bronchial_thermoplasty.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 94876 Version 1.0</div></div></div>"},"94877":{"type":"graphic_picture","displayName":"Scapular assistance test","title":"Scapular assistance test","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Scapular assistance test</div><div class=\"cntnt\"><img style=\"width:584px; height:720px;\" src=\"images/EM/94877_Scapular_assistance_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scapular assistance test is used to help determine whether scapular dyskinesis is contributing to shoulder impingement.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 94877 Version 1.0</div></div></div>"},"94878":{"type":"graphic_picture","displayName":"Scapular repositioning test","title":"Scapular repositioning test","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Scapular repositioning test</div><div class=\"cntnt\"><img style=\"width:581px; height:724px;\" src=\"images/EM/94878_Scapular_repositioning_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scapular repositioning test is used to help determine whether weakness of the muscles that stabilize the scapula is contributing to the patient's shoulder dysfunction.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 94878 Version 2.0</div></div></div>"},"94887":{"type":"graphic_picture","displayName":"Crohn genital ulcer","title":"Genital ulcers in Crohn's disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Genital ulcers in Crohn's disease</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94887_Crohn_genital_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Knife cut\" vulvar ulcerations are pathognomonic of Crohn's disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94887 Version 1.0</div></div></div>"},"94888":{"type":"graphic_picture","displayName":"Genital herpes ulcers","title":"Genital herpes simplex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genital herpes simplex</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/94888_Genital_herpes_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple superficial vulvar ulcers, some with a polycyclic border, in a patient with genital herpes.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94888 Version 1.0</div></div></div>"},"94889":{"type":"graphic_picture","displayName":"Vulvar ulcers kissing","title":"Acute vulvar ulceration","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute vulvar ulceration</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94889_Vulvar_ulcers_kissing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute ulceration of the labia minora with a partially symmetrical appearance (\"kissing pattern\")</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94889 Version 1.0</div></div></div>"},"94890":{"type":"graphic_picture","displayName":"Primary syphilis ulcer","title":"Primary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary syphilis</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/94890_Primary_syphilis_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-delimited vulvar ulceration with raised, indurated borders and a clean base in a patient with primary syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94890 Version 1.0</div></div></div>"},"94892":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum vulva","title":"Genital pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Genital pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:708px; height:528px;\" src=\"images/DERM/94892_Pyodermagangrenosumvulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large ulcers with undermined borders and coverd with a purulent exudate involve labia majora and labia minora in this patient with vulvar pyoderma gangrenosum.</div><div class=\"graphic_reference\">From: Sripathi H, Rao R, Prabhu S, Singh M. Pyoderma gangrenosum affecting the vulva. Indian J Dermatol Venereol Leprol 2008; 74:506. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2008 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94892 Version 2.0</div></div></div>"},"94894":{"type":"graphic_table","displayName":"ASCO guidelines for treatment and care of cancer fatigue","title":"American Society of Clinical Oncology (ASCO) guidelines for treatment and care of fatigue in adult cancer survivors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Clinical Oncology (ASCO) guidelines for treatment and care of fatigue in adult cancer survivors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Target population</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>This practice guideline pertains to cancer survivors diagnosed at age &#8805;18 years who have completed primary cancer treatment with curative intent and are in clinical remission off therapy as well as patients who are disease free and have transitioned to maintenance or adjuvant therapy (eg, patients with breast cancer receiving hormonal therapy, patients with chronic myelogenous leukemia receiving tyrosine kinase inhibitors) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Target audience</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>This guidance is intended to inform health care professionals (eg, medical, surgical, and radiation oncologists, psychosocial and rehabilitation professionals, primary care providers, nurses, and others involved in the delivery of care for survivors) as well as patients, family members, and caregivers of patients who have survived cancer </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment and care options</td> </tr> <tr> <td class=\"subtitle2_single\">Education and counseling</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>All patients should be offered specific education about fatigue after treatment (eg, information about the difference between normal and cancer-related fatigue, persistence of fatigue after treatment, and causes and contributing factors) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients should be offered advice on general strategies that help manage fatigue </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If treated for fatigue, patients should be observed and re-evaluated on a regular basis to determine whether treatment is effective or needs to be reassessed </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Contributing factors</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Address all medical and treatable contributing factors first (eg, pain, depression, anxiety, emotional distress, sleep disturbance, nutritional deficit, activity level, anemia, medication adverse effects, and comorbidities) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Physical activity</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Initiating/maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment survivors </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Actively encourage all patients to engage in a moderate level of physical activity after cancer treatment (eg, 150 minutes of moderate aerobic exercise [such as fast walking, cycling, or swimming] per week with an additional two to three strength training [such as weight lifting] sessions per week, unless contraindicated) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Walking programs are generally safe for most cancer survivors; the American College of Sports Medicine recommends that cancer survivors can begin this type of program after consulting with their physicians but without any formal exercise testing (such as a stress test) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Survivors at higher risk of injury (eg, those living with neuropathy, cardiomyopathy, or other long-term effects of therapy) and patients with severe fatigue interfering with function should be referred to a physical therapist or exercise specialist. Breast cancer survivors with lymphedema should also consider meeting with an exercise specialist before initiating upperbody strength training. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Psychosocial interventions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cognitive behavioral therapy/behavioral therapy can reduce cancer-related fatigue in post-treatment survivors </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Psychoeducational therapies/educational therapies can reduce cancer-related fatigue in post-treatment survivors </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Survivors should be referred to psychosocial service providers who specialize in cancer and are trained to deliver empirically based interventions. Psychosocial resources that address fatigue may also be available through the National Cancer Institute and other organizations. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Mind-body interventions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>There is some evidence that mindfulness-based approaches, yoga, and acupuncture can reduce fatigue in cancer survivors </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Additional research, particularly in the post-treatment population, is needed for biofield therapies (touch therapy), massage, music therapy, relaxation, reiki, and qigong </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Survivors should be referred to practitioners who specialize in cancer and who use protocols that have been empirically validated in cancer survivors </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Pharmacologic interventions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evidence suggests that psychostimulants (eg, methylphenidate) and other wakefulness agents (eg, modafinil) can be effectively used to manage fatigue in patients with advanced disease or those receiving active treatment. However, there is limited evidence of their effectiveness in reducing fatigue in patients after active treatment who are currently disease free. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Small pilot studies have evaluated the impact of supplements, such as ginseng, vitamin D, and others, on cancer-related fatigue. However, there is no consistent evidence of their effectiveness. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Bower JE, et al: J Clin Oncol 2014. DOI: 10.1200/JCO.2013.53.4495. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94894 Version 2.0</div></div></div>"},"94900":{"type":"graphic_figure","displayName":"Posterior leads V7 to V9","title":"Posterior leads V7 to V9","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Posterior leads V7 to V9</div><div class=\"cntnt\"><img style=\"width:528px; height:350px;\" src=\"images/CARD/94900_Posterior_leads_V7_to_V9.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 94900 Version 1.0</div></div></div>"},"94903":{"type":"graphic_table","displayName":"Pan-Canadian guidelines on care and rx cancer-related fatigue","title":"Pan-Canadian guidelines on care and treatment for patients with cancer-related fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pan-Canadian guidelines on care and treatment for patients with cancer-related fatigue</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">1. Screening for cancer-related fatigue<sup>*</sup></td> </tr> <tr> <td class=\"indent2\">All health care providers should routinely screen for the presence of fatigue from the point of diagnosis onward.</td> </tr> <tr> <td class=\"indent2\">All patients should be screened for fatigue at their initial visit, at appropriate intervals (for example, daily for inpatients, routine and follow-up visits for outpatients, and self-monitoring during post-treatment) and as clinically indicated, especially with changes in disease status.</td> </tr> <tr> <td class=\"indent2\">Screen with a valid and reliable tool that includes reportable scores (dimensions) that are clinically meaningful and have established cut-offs-for example, Screening for Distress Tool, which includes the Edmonton Symptom Assessment System (ESAS) and the Canadian Problem Checklist (CPC).</td> </tr> <tr> <td class=\"indent2\">For inpatients unable to assign a numeric value to rate their fatigue, a rating of mild, moderate, or severe may be used.</td> </tr> <tr> <td class=\"subtitle1_left\">2. Comprehensive and focused assessment of cancer-related fatigue<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Screen for fatigue, and if moderate or severe fatigue is detected through screening (ESAS tiredness greater than 4), individuals should have a comprehensive and a focused assessment to identify the nature and extent of the fatigue symptoms.</td> </tr> <tr> <td class=\"indent2\">Medical and substance-induced causes of fatigue should be ruled out (for example, anemia, infection, nutrition deficiencies, medication, or treatment side effects).</td> </tr> <tr> <td class=\"indent2\">Assessments should be a shared responsibility of the clinical team, with designation of those who are expected to conduct assessments based on scope of practice.</td> </tr> <tr> <td class=\"indent2\">Assessment should include a history of fatigue (for example, disease status, pretreatment activity levels, fatigue onset, pattern, duration, changes over time, interference with function and daily living), contributing risk factors (for example, depression, anemia, pain, nausea, sleep disturbance, comorbidities), a physical exam, a review of symptoms, and a self-assessment of causes contributing to fatigue.</td> </tr> <tr> <td class=\"indent2\">Promote open communication between the patient, family members, and the clinical team to facilitate discussions about the experience of fatigue and its effects on daily functioning.</td> </tr> <tr> <td class=\"indent2\">As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional is needed (that is, all patients with an&nbsp;ESAS score in the severe range, or with certain accompanying factors or symptoms, or with a cut-off score identified using valid and reliable tools for assessment of symptoms of fatigue).</td> </tr> <tr> <td class=\"subtitle1_left\">3. Treatment and care options for cancer-related fatigue<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Address all medical and substance-induced treatable contributing factors first (for example, pain, depression, anxiety, anemia, sleep disturbance, nutrition, activity level, medication side effects, and comorbidities). </td> </tr> <tr> <td class=\"indent2\">Actively encourage all patients to engage in a moderate level of physical activity during and after cancer treatment (for example, 30 minutes of moderate-intensity activity most days) unless contraindicated. Moderate activity includes aerobic (for example, fast walking, cycling, or swimming) and resistance (for example, weights) training.</td> </tr> <tr> <td class=\"indent2\">Additional nonpharmacologic interventions include nutrition consultation, optimizing sleep quality, psychosocial interventions to improve coping with fatigue (for example, cognitive behavioural therapy, stress management, or support groups), relaxation, massage and attention-restoring therapy (for example, exposure to natural environments).</td> </tr> <tr> <td class=\"indent2\">For patients on active treatment or on long-term follow-up post treatment who have moderate-to-severe fatigue, consider referral to rehabilitation (for example, physical or occupational therapy, and physical medicine).</td> </tr> <tr> <td class=\"indent2\">All patients should be offered specific education about fatigue before the start of treatment and when fatigue is identified, plus advice on strategies (for example, physical activity, energy conservation, stress reduction, and distraction) to manage fatigue.</td> </tr> <tr> <td class=\"indent2\">At this time, the use of pharmacologic agents to treat cancer-related fatigue is considered experimental and is therefore not recommended (for example, psychostimulants, sleep medications, trials of low-dose corticosteroids such as prednisone or dexamethasone), except for selected patients at the end of life with severe fatigue.</td> </tr> <tr> <td class=\"indent2\">Promote ongoing self-monitoring of fatigue levels as a late or long-term cancer or treatment problem in post-treatment survivors.</td> </tr> <tr> <td class=\"indent2\">For those on active treatment and those with advanced, progressive disease, repeat ESAS screening and assessment as needed to determine any change in both subjective and objective aspects of fatigue.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on the expert consensus of the National Advisory Group and informed by National Comprehensive Cancer Network category 2A, Oncology Nursing Society expert opinion.<br />¶&nbsp;Based on the expert consensus of the National Advisory Group and informed by National Comprehensive Cancer Network category 2A,&nbsp;Oncology Nursing Society category \"likely to be effective\", Oncology Nursing Society expert opinion.<br />Δ Based on the expert consensus of the National Advisory Group and informed by National Comprehensive Cancer Network categories 1 and 2A, Oncology Nursing Society categories \"recommended for practice\" and \"likely to be effective\", Oncology Nursing Society expert opinion.</div><div class=\"graphic_reference\">Reproduced with permission from: Howell D, Keller-Olaman S, Oliver TK, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol 2013; 20:e233. Published in Peritoneal Dialysis International. Copyright &copy; 2013 Peritoneal Dialysis International.</div><div id=\"graphicVersion\">Graphic 94903 Version 1.0</div></div></div>"},"94904":{"type":"graphic_table","displayName":"Topical camphor products","title":"Some camphor-containing medications available over-the-counter","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some camphor-containing medications available over-the-counter</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Camphor concentration</td> <td class=\"subtitle1\">Volume (mL) containing 500 mg camphor</td> </tr> <tr> <td>Tiger Balm</td> <td class=\"centered\">11%</td> <td class=\"centered\">4.6</td> </tr> <tr> <td class=\"sublist1_start\">Campho-Phenique</td> <td class=\"centered\">10.8%</td> <td class=\"centered\">4.6</td> </tr> <tr> <td class=\"indent1\">Cold sore treatment</td> <td class=\"centered\">10.8%</td> <td class=\"centered\">4.6</td> </tr> <tr> <td class=\"indent1\">Pain-relieving antiseptic liquid</td> <td class=\"centered\">10.8%</td> <td class=\"centered\">4.6</td> </tr> <tr> <td class=\"indent1\">Liquid/gel</td> <td class=\"centered\">10.8%</td> <td class=\"centered\">4.6</td> </tr> <tr> <td>Vick's VapoSteam</td> <td class=\"centered\">6.2%</td> <td class=\"centered\">8.1</td> </tr> <tr> <td>CVS Hot Steam Liquid</td> <td class=\"centered\">6.2%</td> <td class=\"centered\">8.1</td> </tr> <tr> <td>Vick's VapoRub Cream</td> <td class=\"centered\">5.2%</td> <td class=\"centered\">9.6</td> </tr> <tr> <td>Vick's VapoRub</td> <td class=\"centered\">4.8%</td> <td class=\"centered\">10.4</td> </tr> <tr> <td>SuperG Medicated Chest Rub</td> <td class=\"centered\">4.8%</td> <td class=\"centered\">10.4</td> </tr> <tr> <td>RiteAid Chest Rub</td> <td class=\"centered\">4.8%</td> <td class=\"centered\">10.4</td> </tr> <tr> <td>CVS Medicated Chest Rub</td> <td class=\"centered\">4.8%</td> <td class=\"centered\">10.4</td> </tr> <tr> <td>TheraFlu Vapor Stick</td> <td class=\"centered\">4.8%</td> <td class=\"centered\">10.4</td> </tr> <tr> <td>Family Pharmacy Medicated Chest Rub</td> <td class=\"centered\">4.73%</td> <td class=\"centered\">10.6</td> </tr> <tr> <td>Triaminic Vapor Patch</td> <td class=\"centered\">4.7%</td> <td class=\"centered\">10.6</td> </tr> <tr> <td>Bayer Muscle &#38; Joint Cream</td> <td class=\"centered\">4.0%</td> <td class=\"centered\">12.5</td> </tr> <tr> <td>BenGay UltraStrength Nongreasy Pain Relieving Formula</td> <td class=\"centered\">4.0%</td> <td class=\"centered\">12.5</td> </tr> <tr> <td>Heet</td> <td class=\"centered\">3.6%</td> <td class=\"centered\">13.9</td> </tr> <tr> <td>Maximum Strength Flexall Plus</td> <td class=\"centered\">3.1%</td> <td class=\"centered\">16.1</td> </tr> <tr> <td>Flexall Plus Gel</td> <td class=\"centered\">3.1%</td> <td class=\"centered\">16.1</td> </tr> <tr> <td>JointFlex Ironman Gel</td> <td class=\"centered\">3.1%</td> <td class=\"centered\">16.1</td> </tr> <tr> <td>Anbesol Cold Sore Therapy Ointment</td> <td class=\"centered\">3.0%</td> <td class=\"centered\">16.7</td> </tr> <tr> <td>Orajel Cold Sore Medication</td> <td class=\"centered\">3.0%</td> <td class=\"centered\">16.7</td> </tr> <tr> <td>Chap Stick Medicated Cold Sore Therapy</td> <td class=\"centered\">3.0%</td> <td class=\"centered\">16.7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Love JN, Sammon M, Smereck J. Are one or two dangerous? Camphor exposure in toddlers. J Emerg Med 2004; 27:49. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94904 Version 2.0</div></div></div>"},"94909":{"type":"graphic_picture","displayName":"Bronchoscopy facemask","title":"Bronchoscopy facemask","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Bronchoscopy facemask</div><div class=\"cntnt\"><img style=\"width:612px; height:498px;\" src=\"images/ANEST/94909_Bronchoscopy_face_mask.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oxygen or mask ventilation may be delivered via an endoscopy facemask with a port that allows passage of a bronchoscope without air escaping from the mask. Alternatively, a standard facemask with a bronchoscopic adapter may be used.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 VBM Medical Inc.</div><div id=\"graphicVersion\">Graphic 94909 Version 4.0</div></div></div>"},"94910":{"type":"graphic_figure","displayName":"Effect of HF and CAD on operative mortality","title":"Effect of heart failure and coronary artery disease, compared to neither, on operative mortality by procedure","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Effect of heart failure and coronary artery disease, compared to neither, on operative mortality by procedure</div><div class=\"cntnt\"><img style=\"width:481px; height:652px;\" src=\"images/ANEST/94910_EffectHFCADoperatmortal.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Procedure-specific models include indicators for disease group, age, sex, race, admission characteristics, comorbidities, and hospital teaching status.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.</div><div class=\"graphic_reference\">Reproduced with permission from: Hammill BD, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology 2008; 108:559. DOI: <A spellcheck=true href=\"http://journals.lww.com/anesthesiology/pages/articleviewer.aspx?year=2008&amp;issue=04000&amp;article=00006&amp;type=abstract\" target=_blank>10.1097/ALN.0b013e31816725ef</A>. Copyright © 2008 American Society of Anesthesiologists, Inc. Unauthorized reproduced of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94910 Version 5.0</div></div></div>"},"94913":{"type":"graphic_picture","displayName":"Epiglottis and larynx bronchoscopic view","title":"Epiglottis and larynx bronchoscopic view ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epiglottis and larynx bronchoscopic view </div><div class=\"cntnt\"><img style=\"width:383px; height:367px;\" src=\"images/ANEST/94913_Epiglottis_larynx_bronchoscopic_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A view of the epiglottis, with the larynx in the background, as seen through a flexible fiberoptic bronchoscope.</div><div id=\"graphicVersion\">Graphic 94913 Version 1.0</div></div></div>"},"94915":{"type":"graphic_picture","displayName":"Trachea bronchoscopic view","title":"Trachea bronchoscopic view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trachea bronchoscopic view</div><div class=\"cntnt\"><img style=\"width:308px; height:313px;\" src=\"images/ANEST/94915_Trachea_bronchoscopic_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of the trachea after passing through the larynx during fiberoptic bronchoscopy.</div><div id=\"graphicVersion\">Graphic 94915 Version 2.0</div></div></div>"},"94916":{"type":"graphic_picture","displayName":"Carina bronchoscopic view","title":"Carina bronchoscopic view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carina bronchoscopic view</div><div class=\"cntnt\"><img style=\"width:310px; height:314px;\" src=\"images/ANEST/94916_Carina_bronchoscopic_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of the carina during flexible fiberoptic bronchoscopy.</div><div id=\"graphicVersion\">Graphic 94916 Version 2.0</div></div></div>"},"94917":{"type":"graphic_diagnosticimage","displayName":"Apical 4-chamber echo of LVNC with color Doppler","title":"Apical four-chamber echocardiogram of left ventricular non-compaction","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Apical four-chamber echocardiogram of left ventricular non-compaction</div><div class=\"cntnt\"><img style=\"width:598px; height:315px;\" src=\"images/CARD/94917_Apical_4_ch_echo_LVNC_Doppl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic apical four-chamber two-dimensional echocardiogram (A) without and (B) with color flow Doppler. The arrows indicate deep recesses that are filled by color flow in the right panel.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium.</div><div class=\"graphic_reference\">Courtesy of Christine H Attenhofer Jost, MD.</div><div id=\"graphicVersion\">Graphic 94917 Version 1.0</div></div></div>"},"94918":{"type":"graphic_diagnosticimage","displayName":"Four-chamber echo and CMR of LVNC","title":"Apical four-chamber echocardiogram and cardiac magnetic resonance image of left ventricular non-compaction","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Apical four-chamber echocardiogram and cardiac magnetic resonance image of left ventricular non-compaction</div><div class=\"cntnt\"><img style=\"width:596px; height:347px;\" src=\"images/CARD/94918_Four_chamber_echo_CMR_LVNC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transthoracic apical four-chamber echocardiographic image from a patient with features of left ventricular non-compaction. Striking non-compacted myocardium is present, particularly at the apex (arrow).<br />(B) Cardiac magnetic resonance image (steady state free precession sequence) from the same patient depicts deep recesses and pronounced trabeculations (arrow) with no distinct papillary muscle.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; RV: right ventricle; RA: right atrium.</div><div class=\"graphic_reference\">Courtesy of Christine H Attenhofer Jost, MD.</div><div id=\"graphicVersion\">Graphic 94918 Version 2.0</div></div></div>"},"94919":{"type":"graphic_diagnosticimage","displayName":"Short-axis echo view of LVNC","title":"Short-axis echocardiographic end-systolic view consistent with left ventricular noncompaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short-axis echocardiographic end-systolic view consistent with left ventricular noncompaction</div><div class=\"cntnt\"><img style=\"width:405px; height:369px;\" src=\"images/CARD/94919_Short_axis_echo_view_LVNC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal-short-axis echocardiographic end-systolic view of the left ventricle. The ratio of noncompacted myocardium (spanned by the red line [top section]) to compacted myocardium (spanned by the yellow line [bottom section]) is 3:1. Thickened left ventricular wall with a ratio ≥2:1 of non-compacted to compacted myocardium at end-systole and prominent trabecular meshwork in the LV apex or midventicle (along with color Doppler evidence of flow within the deep intertrabecular recesses) are the criteria for left ventricular noncompaction proposed by Jenni et al.</div><div class=\"graphic_reference\">Courtesy of Christine H Attenhofer Jost, MD.</div><div id=\"graphicVersion\">Graphic 94919 Version 2.0</div></div></div>"},"94921":{"type":"graphic_figure","displayName":"Skeletal structure of the leg, ankle, and foot - Medial view","title":"Skeletal structure of the leg, ankle, and foot: Medial view","html":"<div class=\"graphic\"><div style=\"width: 895px\" class=\"figure\"><div class=\"ttl\">Skeletal structure of the leg, ankle, and foot: Medial view</div><div class=\"cntnt\"><img style=\"width:875px; height:417px;\" src=\"images/EM/94921_Skltstrctlganklftmdvw.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Leg, ankle, foot. In: Functional Anatomy: Muscoloskeletal Anatomy, Kinesiology, and Palpation for Manuel Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94921 Version 4.0</div></div></div>"},"94922":{"type":"graphic_figure","displayName":"Skeletal structure of the leg, ankle, and foot - Lateral view","title":"Skeletal structure of the leg, ankle, and foot: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 823px\" class=\"figure\"><div class=\"ttl\">Skeletal structure of the leg, ankle, and foot: Lateral view</div><div class=\"cntnt\"><img style=\"width:803px; height:518px;\" src=\"images/EM/94922_Skltlstrctlganklftltrl.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Leg, ankle, foot. In: Functional Anatomy: Muscoloskeletal Anatomy, Kinesiology, and Palpation for Manuel Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94922 Version 4.0</div></div></div>"},"94923":{"type":"graphic_table","displayName":"ASCO guidelines for screening and assessment of cancer fatigue","title":"American Society of Clinical Oncology (ASCO) guidelines for screening and assessment of of fatigue in adult cancer survivors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Clinical Oncology (ASCO) guidelines for screening and assessment of of fatigue in adult cancer survivors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Target population</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>This practice guideline pertains to cancer survivors diagnosed at age &#8805;18 years who have completed primary cancer treatment with curative intent and are in clinical remission off therapy as well as patients who are disease free and have transitioned to maintenance or adjuvant therapy (eg, patients with breast cancer receiving hormonal therapy, patients with chronic myelogenous leukemia receiving tyrosine kinase inhibitors) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Target audience</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>This guidance is intended to inform health care professionals (eg, medical, surgical, and radiation oncologists, psychosocial and rehabilitation professionals, primary care providers, nurses, and others involved in the delivery of care for survivors) as well as patients, family members, and caregivers of patients who have survived cancer </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Recommendations</td> </tr> <tr> <td class=\"subtitle2_single\">Screening</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>All health care providers should routinely screen for the presence of fatigue from the point of diagnosis onward, including after completion of primary treatment </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>All patients should be screened for fatigue as clinically indicated and at least annually </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Screening should be performed and documented using a quantitative or semiquantitative assessment </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Comprehensive and focused assessment</td> </tr> <tr> <td class=\"subtitle2_single\">History and physical</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform a focused fatigue history </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evaluate disease status </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess treatable contributing factors </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>As a shared responsibility, the clinical team must decide when referral to an appropriately trained professional (eg, cardiologist, endocrinologist, mental health professional, internist, and so on) is needed </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Laboratory evaluation</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Consider performing laboratory evaluation based on presence of other symptoms and onset and severity of fatigue </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Bower JE, et al: J Clin Oncol 2014. DOI: 10.1200/JCO.2013.53.4495. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94923 Version 2.0</div></div></div>"},"94925":{"type":"graphic_picture","displayName":"Keratosis pilaris atrophicans histo","title":"Histologic features of keratosis pilaris atrophicans","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Histologic features of keratosis pilaris atrophicans</div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/DERM/94925_Kerato_pilaris_atroph_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The follicle is plugged with compact orthokeratin that protrudes above the skin surface.</div><div class=\"graphic_reference\">Reproduced with permission from: Elder DE. Lever's Histopathology of the Skin, 10th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 94925 Version 3.0</div></div></div>"},"94928":{"type":"graphic_waveform","displayName":"Posterior MI leads V7-V9","title":"Posterior myocardial infarction leads V7-V9","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Posterior myocardial infarction leads V7-V9</div><div class=\"cntnt\"><img style=\"width:658px; height:312px;\" src=\"images/CARD/94928_Posterior_MI_leads_V7_V9.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Burns E. ECG Library: Posterior Myocardial Infarction. Life in the Fastlane. Available at: <a href=\"http://lifeinthefastlane.com/ecg-library/pmi/\" target=\"_blank\">http://lifeinthefastlane.com/ecg-library/pmi/</a> (Accessed on April 22, 2014).</div><div id=\"graphicVersion\">Graphic 94928 Version 1.0</div></div></div>"},"94931":{"type":"graphic_table","displayName":"BEARS screening tool for assessment of sleep in children","title":"BEARS screening tool for assessment of sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">BEARS screening tool for assessment of sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Preschool<br /> (2-5 years)</td> <td class=\"subtitle1\">School-aged<br /> (6-12 years)</td> <td class=\"subtitle1\">Adolescent<br /> (13-18 years)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>B</strong>edtime problems</td> <td> <p>Does your child have any problems going to bed?</p> Falling asleep?</td> <td> <p>Does your child have any problems at bedtime? (P)</p> Do you have any problems going to bed? (C)</td> <td>Do you have any problems falling asleep at bedtime? (C)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>E</strong>xcessive daytime sleepiness</td> <td> <p>Does your child seem over tired or sleepy a lot during the day?</p> Does she still take naps?</td> <td> <p>Does your child have difficulty waking in the morning, seem sleepy during the day or take naps? (P)</p> Do you feel tired a lot? (C)</td> <td>Do you feel sleepy a lot during the day? In school? While driving? (C)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>A</strong>wakenings during the night</td> <td>Does your child wake up a lot at night?</td> <td> <p>Does your child seem to wake up a lot at night? Any sleepwalking or nightmares? (P)</p> Do you wake up a lot at night? Have trouble getting back to sleep? (C)</td> <td> <p>Do you wake up alot at night?</p> Have trouble getting back to sleep? (C)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>R</strong>egularity and duration of sleep</td> <td> <p>Does your child have a regular bedtime and wake time?</p> What are they?</td> <td> <p>What time does your child go to bed and get up on school days? Weekends?</p> Do you think he/she is getting enough sleep? (P)</td> <td> <p>What time do you usually go to bed on school nights?</p> Weekends? How much sleep do you usually get? (C)</td> </tr> <tr> <td><strong>S</strong>leep-disordered breathing</td> <td>Does your child snore a lot or have difficulty breathing at night?</td> <td>Does your child have loud or nightly snoring or any breathing difficulties at night? (P)</td> <td>Does your teenager snore loudly or nightly? (P)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The BEARS instrument prompts screening questions in five major sleep domains, represented by the acronym B-E-A-R-S: <strong>B</strong>edtime problems, <strong>E</strong>xcessive daytime sleepiness, <strong>A</strong>wakenings during the night, <strong>R</strong>egularity and duration of sleep, and <strong>S</strong>leep-disordered breathing. The table above shows examples of trigger questions for each age group.</div><div class=\"graphic_footnotes\">P: questions addressed to parent; C: questions addressed to child.</div><div class=\"graphic_reference\">Reproduced with permission from Judith Owens, MD, MPH. Originally published in: Owens JA, Dalzell V. Use of the 'BEARS' sleep screening tool in a pediatric residents' continuity clinic: a pilot study. Sleep Med 2005; 6:63.</div><div id=\"graphicVersion\">Graphic 94931 Version 1.0</div></div></div>"},"94933":{"type":"graphic_table","displayName":"Possible treatable causes cancer fatigue and diagnostic workup","title":"Potentially treatable causes of cancer-related fatigue and examples of the diagnostic evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potentially treatable causes of cancer-related fatigue and examples of the diagnostic evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatable contributing factor</td> <td class=\"subtitle1\">Examples of possible diagnostic evaluation*</td> </tr> <tr> <td>Cardiac dysfunction (eg, arrhythmia, hypertension, coronary artery disease, heart failure)</td> <td>Consider echocardiogram, exercise test for cardiopulmonary reserve</td> </tr> <tr> <td>Endocrine dysfunction (eg, diabetes, hypothyroidism, hypogonadism, adrenal insufficiency)</td> <td>Consider measuring HgbA1C, TSH, glucose, and testosterone, conduct dexamethasone suppression test</td> </tr> <tr> <td>Pulmonary dysfunction</td> <td>Consider chest x-ray, six-minute walk test, pulmonary function tests, oxygen saturation</td> </tr> <tr> <td>Renal dysfunction</td> <td>Consider kidney and electrolyte chemistries</td> </tr> <tr> <td>Anemia</td> <td>Consider CBC</td> </tr> <tr> <td>Arthritis</td> <td>Consider erythrocyte sedimentation rate (ESR), serologies</td> </tr> <tr> <td>Neuromuscular complications (neuromuscular degerative disease, neuropathy)</td> <td>Consider grip strength test, neuropathy sensory testing, electromyography</td> </tr> <tr> <td>Sleep disturbances (eg, insomnia, sleep apnea, vasomotor symptoms, restless leg syndrome)</td> <td>Consider assessing sleep with standardized questionnaire, possible sleep study</td> </tr> <tr> <td>Pain</td> <td>Evaluate with standardized assessment tool</td> </tr> <tr> <td>Emotional distress (eg, anxiety, depression)</td> <td>Evaluate with standardized assessment tool or diagnostic interview</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: This list is not meant to be exhaustive.</div><div class=\"graphic_footnotes\">CBC: complete blood cell count; HgbA1C: hemoglobin A1C; TSH: thyroid-stimulating hormone.<br />* Should be undertaken only when clinically appropriate.</div><div class=\"graphic_reference\">From: Bower JE, et al: J Clin Oncol 2014. DOI: 10.1200/JCO.2013.53.4495. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94933 Version 1.0</div></div></div>"},"94934":{"type":"graphic_table","displayName":"Parameters of assessment for cancer-related fatigue","title":"Pan-Canadian guidelines on parameters of assessment for cancer-related fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pan-Canadian guidelines on parameters of assessment for cancer-related fatigue</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td><strong>1. Pattern of fatigue</strong></td> <td>Onset, duration, change over time, relationship to treatment</td> </tr> <tr> <td><strong>2. Description of fatigue in patient's own words and intensity</strong></td> <td>Use a valid tool for assessing intensity of fatigue-that is, the Brief Fatigue Inventory</td> </tr> <tr> <td><strong>3. Factors that alleviate or aggregate fatigue</strong></td> <td> <p>Disease status, treatment history, treatment-related symptoms</p> <p>Sleep or rest patterns, relaxation habits</p> <p>Current medications, including alcohol and other risk substances</p> <p>Possible stressors (for example, life events: recent bereavement or loss; change in home setting, financial resources, or support systems)</p> <p>Nutrition intake and any appetite or weight changes, muscle wasting</p> Level of activity or exercise</td> </tr> <tr> <td><strong>4. Effects of fatigue on daily living and lifestyle</strong></td> <td>Determine the activities with which fatigue interferes; impact on work, participation in social life, and other leisure activities; work; concentration; short-term memory</td> </tr> <tr> <td><strong>5. Possible contributing factors</strong></td> <td>Consider anemia, depression, anxiety, pain, dehydration, nutritional deficiencies (for example, protein, calories, vitamins), sedating medications (for example, opioids, benzodiazepines), neurotoxic therapies, infection, fever, sleep disturbances, inactivity, or other symptoms ( for example, dyspnea)</td> </tr> <tr> <td><strong>6. Physical exam</strong></td> <td>Check for signs of nutritional deficiencies, gait and posture, muscle wasting</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Howell D, Keller-Olaman S, Oliver TK, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol 2013; 20:e233. Published in Peritoneal Dialysis International. Copyright &copy; 2013 Peritoneal Dialysis International.</div><div id=\"graphicVersion\">Graphic 94934 Version 1.0</div></div></div>"},"94935":{"type":"graphic_table","displayName":"DDx FAS","title":"Differential diagnosis of syndromes similar to FAS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of syndromes similar to FAS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Overlapping features</td> <td class=\"subtitle1\">Differentiating features</td> </tr> <tr> <td> <p>Aarskog syndrome</p> <p>MIM <a href=\"http://omim.org/entry/100050\" spellcheck=\"true\" target=\"_blank\">100050</a></p> </td> <td>Small nose with anteverted nares, broad philtrum, maxillary hypoplasia, and wide-spaced eyes</td> <td>Rounded face, down-slant to palpebral fissures, widow's peak, crease, below lower lip, incomplete out folding of upper helices, and dental eruption problems</td> </tr> <tr> <td> <p>Williams syndrome</p> <p>MIM <a href=\"http://omim.org/entry/194050\" spellcheck=\"true\" target=\"_blank\">#194050</a></p> </td> <td>Short palpebral fissures, anteverted nares, long philtrum, depressed nasal bridge, and epicanthal folds</td> <td>Wide mouth with full lips, stellate pattern of the iris, periorbital fullness, and connective tissue disorders</td> </tr> <tr> <td> <p>Noonan syndrome</p> <p>MIM <a href=\"http://omim.org/entry/163950\" spellcheck=\"true\" target=\"_blank\">#163950</a></p> </td> <td>Low nasal bridge, wide-spaced eyes, and epicanthal folds</td> <td>Down-slant to palpebral fissures, keratoconus, wide mouth, and protruding upper lip</td> </tr> <tr> <td> <p>Dubowitz syndrome</p> <p>MIM <a href=\"http://omim.org/entry/223370\" spellcheck=\"true\" target=\"_blank\">%223370</a></p> </td> <td>Short palpebral fissures, wide-spaced eyes, and epicanthal folds</td> <td>Shallow supraorbital ridge with nasal bridge near the level of the forehead, and broad nasal tip</td> </tr> <tr> <td> <p>Chromosome 15q11-q13 duplication syndrome</p> <p>MIM <a href=\"http://omim.org/entry/608636\" spellcheck=\"true\" target=\"_blank\">#608636</a></p> </td> <td> <p>Cognitive impairment, neurobehavioral manifestations</p> </td> <td>Lacks facial dysmorphisms</td> </tr> <tr> <td> <p>Cornelia de Lange syndrome 1</p> <p>(Brachmann-de Lange syndrome)</p> <p>MIM <a href=\"http://omim.org/entry/122470\" spellcheck=\"true\" target=\"_blank\">#122470</a></p> </td> <td>Long philtrum, thin vermillion border, anteverted nares, and depressed nasal bridge</td> <td>Single, bushy eyebrow extending across forehead, long eyelashes, downturned mouth, high-arched palate, and short limbs (yielding short stature)</td> </tr> <tr> <td> <p>Chromosome 22q11.2 deletion syndromes</p> <p>(eg, DiGeorge syndrome MIM <a href=\"http://omim.org/entry/188400\" spellcheck=\"true\" target=\"_blank\">#188400</a>; velocardiofacial syndrome, MIM <a href=\"http://omim.org/entry/192430\" spellcheck=\"true\" target=\"_blank\">#192430</a>)</p> </td> <td>Short palpebral fissures, wide-spaced eyes</td> <td>Micrognathia, low-set ears, strabismus, short philtrum, high-arched palate, cleft palate, bifid uvula</td> </tr> <tr> <td>Toluene embryopathy</td> <td>Short palpebral fissures, mid-face hypoplasia, smooth philtrum, and thin vermillion border</td> <td>Micrognathia, large anterior fontanel, down-turned mouth corners, hair patterning abnormalities, bifrontal narrowing, and ear abnormalities</td> </tr> <tr> <td>Fetal hydantoin syndrome<br /> (Fetal dilantin syndrome)</td> <td>Wide-spaced eyes and depressed nasal bridge</td> <td>Short nose with bowed upper lip</td> </tr> <tr> <td>Fetal valproate syndrome</td> <td>Epicanthal folds, anteverted nares, long philtrum with thin vermilion border, and wide-spaced eyes</td> <td>High forehead, infraorbital crease or groove, and small mouth</td> </tr> <tr> <td>Maternal PKU fetal effects</td> <td>Epicanthal folds, short palpebral fissures, long underdeveloped philtrum, and thin vermillion border</td> <td>Small upturned nose, round facies, and prominent glabella</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FAS: fetal alcohol syndrome; PKU: phenylketonuria.</div><div class=\"graphic_reference\">Adapted&nbsp;from:<br /><OL>&#xD;&#xA;<LI>Fetal Alcohol Syndrome: Guidelines for Referral and Diagnosis. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, and Department of Health and Human Services. Available at:&nbsp;<A href=\"http://www.cdc.gov/ncbddd/fasd/documents/fas_guidelines_accessible.pdf\" target=_blank>www.cdc.gov/ncbddd/fasd/documents/fas_guidelines_accessible.pdf</A> (Accessed on April 22, 2014).</LI>&#xD;&#xA;<LI>Hoyme HE, Kalberg WO, Elliott AJ, et al. Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders. Pediatrics 2016; 138.</LI></OL></div><div id=\"graphicVersion\">Graphic 94935 Version 3.0</div></div></div>"},"94936":{"type":"graphic_picture","displayName":"Torus palatinus","title":"Torus palatinus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Torus palatinus</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/94936_Torus_palatinus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bony, lobulated protuberance on the midline of the hard palate of a patient with torus palatinus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94936 Version 1.0</div></div></div>"},"94938":{"type":"graphic_diagnosticimage","displayName":"Crown rump length","title":"Crown rump length","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Crown rump length</div><div class=\"cntnt\"><img style=\"width:621px; height:555px;\" src=\"images/OBGYN/94938_Crown_rump_length.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRL: crown rump length; w: weeks of gestation; d: days; GA: gestational age.</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO.</div><div id=\"graphicVersion\">Graphic 94938 Version 2.0</div></div></div>"},"94941":{"type":"graphic_table","displayName":"PERC rule","title":"The pulmonary embolism rule out criteria (PERC rule)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The pulmonary embolism rule out criteria (PERC rule)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age &#60;50 years</td> </tr> <tr> <td>Heart rate &#60;100 bpm</td> </tr> <tr> <td>Oxyhemoglobin saturation &#8805;95%</td> </tr> <tr> <td>No hemoptysis</td> </tr> <tr> <td>No estrogen use</td> </tr> <tr> <td>No prior DVT or PE</td> </tr> <tr> <td>No unilateral leg swelling</td> </tr> <tr> <td>No surgery/trauma requiring hospitalization within the prior four weeks</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DVT: deep venous thrombosis; PE: pulmonary embolus; bpm: beats per minute.<br />* This rule is only valid in patients with a low clinical probability of PE (gestalt estimate &lt;15 percent). In patients with a low probability of PE who fullfil all eight criteria, the likelihood of PE is low and no further testing is required. All other patients should be considered for further testing with sensitive D-dimer or imaging.</div><div class=\"graphic_reference\">Source: Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost 2008; 6:772.</div><div id=\"graphicVersion\">Graphic 94941 Version 1.0</div></div></div>"},"94942":{"type":"graphic_table","displayName":"Causes of overgrowth or tall stature","title":"Causes of overgrowth or tall stature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of overgrowth or tall stature</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Bone age</td> <td class=\"subtitle1\">Child height</td> <td class=\"subtitle1\">Adult height</td> <td class=\"subtitle1\">Key features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Overgrowth in infancy</td> </tr> <tr> <td class=\"indent1\">Infant of a diabetic mother</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Long-term risks for metabolic disease (obesity, diabetes).</td> </tr> <tr> <td class=\"indent1\">Cerebral gigantism (Sotos syndrome)</td> <td>Advanced</td> <td>Tall</td> <td>Normal</td> <td>Macrocephaly, high forehead, frontal bossing, hypertelorism, prominent jaw, high arched palate, intellectual disability (mental retardation), hypotonia, poor coordination.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Beckwith-Wiedemann syndrome</td> <td>Advanced</td> <td>Tall</td> <td>Tall</td> <td>Macrosomia, hemihypertrophy, visceromegaly, embryonal tumors (Wilm's tumor, hepatoblastoma), characteristic facies, renal and cardiac anomalies.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Overgrowth in childhood and adolescence</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Normal variant</td> </tr> <tr> <td class=\"indent2\">Familial (constitutional) tall stature</td> <td>Normal</td> <td>Tall</td> <td>Tall</td> <td>One or both parents are tall; child's growth is within the range predicted by the mid-parental \"target\" height.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Endocrine disorders</td> </tr> <tr> <td class=\"sublist3_start\">Precocious puberty (multiple causes)</td> <td class=\"sublist_other_start\">Advanced</td> <td class=\"sublist_other_start\">Tall</td> <td class=\"sublist_other_start\">Normal or short (if untreated)</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"sublist3\">Gonadotropin-dependent (central)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Most cases in girls are idiopathic. CNS lesions should be excluded, especially in boys.</td> </tr> <tr> <td class=\"sublist3\">Gonadotropin-independent (peripheral)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">May be caused by ovarian or testicular tumors, exogenous estrogens or androgens, or adrenal pathology. McCune-Albright syndrome is suggested by caf&#233;-au-lait skin pigmentation and fibrous dysplasia of bone. A familial form affects only boys.*</td> </tr> <tr> <td class=\"indent2\">Growth hormone excess (pituitary gigantism)</td> <td>Normal (or delayed)<sup>&#182;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Causes gigantism in growing children, or acromegaly in adults.</td> </tr> <tr> <td class=\"indent2\">Hyperthyroidism</td> <td>Advanced</td> <td>Tall</td> <td>Normal or short (if untreated)</td> <td>Increased linear growth normalizes with treatment of the hyperthyroidism.</td> </tr> <tr> <td class=\"indent2\">Sex hormone deficiency or insensitivity</td> <td>Delayed</td> <td>Tall</td> <td>Tall</td> <td>Long limbs compared with trunk.</td> </tr> <tr> <td class=\"indent2\">Familial glucocorticoid deficiency, type 1</td> <td>Advanced</td> <td>Tall</td> <td>Normal or short</td> <td>Hyperpigmentation, muscle weakness, hypoglycemia, and seizures. Some patients also have features of Allgrove syndrome (adrenal insufficiency, achalasia, and alacrima [absence of tears]).</td> </tr> <tr> <td class=\"indent2\">Familial glucocorticoid resistance</td> <td>Advanced</td> <td>Tall</td> <td>Normal</td> <td>Females present with hirsutism, male pattern baldness, menstrual abnormalities and infertility. Males present with isosexual precocious puberty, abnormal spermatogenesis and infertility. Males and females have hypertension and hypokalemic alkalosis in both sexes.</td> </tr> <tr> <td class=\"indent2\">Congenital total lipodystrophy</td> <td>Advanced</td> <td>Tall</td> <td>Normal or tall</td> <td>Generalized absence of subcutaneous fat and muscular hypertrophy presenting in infancy, with overgrowth and acromegaloid changes. Patients also develop hyperpigmentation, enlargement of the penis or clitoris, advanced bone age, insulin resistance, hyperinsulinemia, hyperlipidemia, and nonketotic hyperglycemia.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Non-endocrine disorders</td> </tr> <tr> <td class=\"indent2\">Exogenous obesity</td> <td>Normal or advanced</td> <td>Tall</td> <td>Normal</td> <td>High weight-for-height and BMI; family history of obesity. May have mild Cushingoid features.</td> </tr> <tr> <td class=\"indent2\">Melanocortin 4 receptor (MC4R)&nbsp;mutation&nbsp;</td> <td>Advanced&nbsp;</td> <td>Tall</td> <td>Tall</td> <td>About 4 percent of individuals with early-onset obesity have an MC4R mutation.&nbsp;Height tends to be taller than expected for those with exogenous obesity, and GH pulsatility is increased.<sup>[1]</sup></td> </tr> <tr> <td class=\"indent2\">Klinefelter syndrome</td> <td>Normal (or delayed)<sup>&#916;</sup></td> <td>Normal or tall</td> <td>Normal</td> <td>Relatively long legs; may have learning disabilities, mainly in expressive language. May have gynecomastia, hypogonadism, small testes and phallus, hypospadias, and cryptorchidism. The most common karyotype is 47,XXY.</td> </tr> <tr> <td class=\"indent2\">47,XYY</td> <td>Normal</td> <td>Normal or tall</td> <td>&nbsp;</td> <td>Mild abnormalities, including possible delay in motor and language development, macrocephaly, macroorchidism, hypotonia, hypertelorism, and tremor.</td> </tr> <tr> <td class=\"indent2\">Marfan syndrome</td> <td>Usually normal</td> <td>Tall</td> <td>Tall</td> <td>Long thin fingers (arachnodactyly), increased arm span compared with height, hyperextension of joints, and lens subluxation. May have pectus excavatum, scoliosis, aortic or mitral regurgitation, and aortic root dilatation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; CNS: central nervous system; LH: luteinizing hormone; GH: growth hormone.<br />* Familial male-limited precocious puberty (testotoxicosis) is caused by an activating mutation in the LH receptor gene.<br />&para; Bone age in patients with growth hormone excess (pituitary gigantism) may be delayed if the disease also interferes with pituitary secretion of gonadotropins.<br />&Delta; Bone age in patients with Klinefelter syndrome may be normal or delayed, depending on the level of testosterone secretion.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Martinelli CE, Keogh JM, Greenfield JR, et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab 2011; 96:E181.</LI></OL></div><div id=\"graphicVersion\">Graphic 94942 Version 4.0</div></div></div>"},"94944":{"type":"graphic_picture","displayName":"Macular amyloidosis","title":"Macular amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Macular amyloidosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94944_Macular_amyloidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A characteristic rippled pattern of pigmentation in a patient with macular amyloidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94944 Version 1.0</div></div></div>"},"94945":{"type":"graphic_picture","displayName":"Macular amyloidosis leg","title":"Macular amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Macular amyloidosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94945_Macular_amyloidosis_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A characteristic rippled pattern of pigmentation on the leg of a patient with macular amyloidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94945 Version 1.0</div></div></div>"},"94964":{"type":"graphic_picture","displayName":"Distal villous hypoplasia","title":"Distal villous hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Distal villous hypoplasia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/OBGYN/94964_Distal_villous_hypoplas_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to a long thin villi and a small round villi. The asterisk is in the expanded intervillous space.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 94964 Version 1.0</div></div></div>"},"94965":{"type":"graphic_picture","displayName":"Intravillous hemorrhage","title":"Intravillous hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Intravillous hemorrhage</div><div class=\"cntnt\"><img style=\"width:590px; height:441px;\" src=\"images/OBGYN/94965_Intravillous_hemorrhage_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to villi with blood filled stroma. An asterisk indicates red blood cells located appropriately within the villous vascular space.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 94965 Version 1.0</div></div></div>"},"94969":{"type":"graphic_picture","displayName":"Lichen amyloidosis legs","title":"Lichen amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lichen amyloidosis</div><div class=\"cntnt\"><img style=\"width:590px; height:380px;\" src=\"images/DERM/94969_Lichen_amyloidosis_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented plaques on the extensor surfaces of the legs in a patient with lichen amyloidosis. The plaques, which result from coalescing papules, are persistent and intensely pruritic.</div><div id=\"graphicVersion\">Graphic 94969 Version 1.0</div></div></div>"},"94971":{"type":"graphic_picture","displayName":"Lichen amyloidosis buttocks","title":"Lichen amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lichen amyloidosis</div><div class=\"cntnt\"><img style=\"width:590px; height:390px;\" src=\"images/DERM/94971_Lichen_amyloidosis_buttocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Firm, hyperpigmented papules, some of which coalesce into plaques, on the buttocks of a patient with lichen amyloidosis.</div><div id=\"graphicVersion\">Graphic 94971 Version 1.0</div></div></div>"},"94972":{"type":"graphic_picture","displayName":"Macular amyloidosis histopathology","title":"Clinical and histologic features of macular amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical and histologic features of macular amyloidosis</div><div class=\"cntnt\"><img style=\"width:379px; height:812px;\" src=\"images/DERM/94972_Macularamyloidosishisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Rippled hyperpigmentation on the upper back.<br />(B) Distended dermal papillae filled with eosinophilic material (H&amp;E, &times;100).<br />(C) Orange-pink amyloid (Congo red stain, &times;100).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">From: Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hyperpigmentary disorders. Indian J Dermatol Venereol Leprol 2013;79:367. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2013;volume=79;issue=3;spage=367;epage=375;aulast=Patel\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.110798</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2013 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94972 Version 3.0</div></div></div>"},"94973":{"type":"graphic_table","displayName":"ICU handoff","title":"Protocol for \"handoff\" in the intensive care unit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for \"handoff\" in the intensive care unit</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Phase 1: Equipment and technology handoff</td> </tr> <tr> <td class=\"indent1\">Monitoring transferred to ICU equipment</td> </tr> <tr> <td class=\"indent1\">Ventilator function initiated</td> </tr> <tr> <td class=\"indent1\">Infusions and fluids checked</td> </tr> <tr> <td class=\"indent1\">Chest drains secured and on suction</td> </tr> <tr> <td class=\"indent1\">Vital signs confirmed to be stable, ventilator functioning well, infusions running appropriately</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anesthesiologist, nurse, surgeon, and intensivist&nbsp;confirm that they are ready for information transfer</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2: Information handoff</td> </tr> <tr> <td class=\"subtitle2_single\">Anesthesiologist presents:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Patient-specific information (age, weight, medical and surgical history, allergy status, baseline vital signs, pertinent laboratory results, diagnosis, current condition and vital signs) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Anesthetic information (intraoperative course and any complications, lines present, blood transfusion and fluid totals, doses of paralytic and opioids, antibiotics, current infusions, vital sign parameters and limits, pain relief plan, laboratory values) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Surgeon presents:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Surgical course (diagnosis, operation performed, surgical findings, complications, blood loss, drains) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>If no intensivist present or if surgeon provides ICU care: Further plans (antibiotic plan, deep vein thrombosis [DVT] prophylaxis medication plan, tests to be done, nutrition, key goals for the next 6 to 12 hours) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Intensivist presents:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Further plans (antibiotic plan, deep vein thrombosis [DVT] prophylaxis medication plan, tests to be done, nutrition, key goals for the next 6 to 12 hours) </li> </ul> </td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\"><strong>Phase 3: Questions and discussion</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICU: intensive care unit.</div><div id=\"graphicVersion\">Graphic 94973 Version 5.0</div></div></div>"},"94974":{"type":"graphic_figure","displayName":"Port placement ventral hernia repair","title":"Port placement ventral hernia repair","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Port placement ventral hernia repair</div><div class=\"cntnt\"><img style=\"width:529px; height:713px;\" src=\"images/SURG/94974_Port_placement_ventral_hernia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Possible port placement for laparoscopic ventral hernia repair. Ports are placed away from the hernia defect(s).&nbsp;One 12 mm trocar is used to facilitate mesh entry into the peritoneal cavity.</div><div id=\"graphicVersion\">Graphic 94974 Version 1.0</div></div></div>"},"94975":{"type":"graphic_picture","displayName":"Congenital cutaneous candidiasis 2","title":"Congenital cutaneous candidiasis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Congenital cutaneous candidiasis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/94975_Congencutancandidiasis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized eruption of erythematous macules and pustules in a neonate with congenital cutaneous candidiasis. Diffuse, fine scaling is also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94975 Version 2.0</div></div></div>"},"94977":{"type":"graphic_diagnosticimage","displayName":"CMR of LVNC","title":"Cardiovascular magnetic resonance images showing left ventricular noncompaction","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Cardiovascular magnetic resonance images showing left ventricular noncompaction</div><div class=\"cntnt\"><img style=\"width:598px; height:301px;\" src=\"images/RADIOL/94977_CMR_of_LVNC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiovascular magnetic resonance images (steady state free precession sequence) of a 22-year-old man diagnosed with heart failure at age three. Images are at end-diastole.<br />(A) Four-chamber image showing hypertrabeculation in the left ventricle. There are also increased trabeculations in the right ventricle. The thickness of noncompacted myocardium (blue) is greater than 2.3 times the thickness of compacted myocardium (red).<br />(B) Apical short-axis image also shows hypertrabeculation.</div><div class=\"graphic_reference\">Courtesy of Yuchi Han, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 94977 Version 1.0</div></div></div>"},"94979":{"type":"graphic_diagnosticimage","displayName":"Cine CMR of LVNC","title":"Apical two-chamber cine cardiac magnetic resonance imaging of left ventricular noncompaction","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Apical two-chamber cine cardiac magnetic resonance imaging of left ventricular noncompaction</div><div class=\"cntnt\"><img style=\"width:510px; height:510px;\" src=\"images/RADIOL/94979_Cine_CMR_of_LVNC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical two-chamber cine (bSSFP) cardiovascular magnetic resonance images of a 22-year-old man diagnosed with heart failure at age three. Note the marked hypertrabeculation in this end-diastolic image.</div><div class=\"graphic_reference\">Courtesy, Yuchi Han, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 94979 Version 2.0</div></div></div>"},"94980":{"type":"graphic_diagnosticimage","displayName":"CMR of myocarditis","title":"Cardiovascular magnetic resonance images of coxsackievirus-induced myocarditis","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Cardiovascular magnetic resonance images of coxsackievirus-induced myocarditis</div><div class=\"cntnt\"><img style=\"width:597px; height:597px;\" src=\"images/RADIOL/94980_CMR_of_myocarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiovascular magnetic resonance images of a 58-year-old woman with coxsackievirus-induced myocarditis and ventricular tachycardia. Late gadolinium enhancement is seen in a basal to mid anterior and anterolateral distribution (arrows). Note the epicardial to transmural distribution of the enhancement, which is more consistent with myocarditis than myocardial infarction.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; A: anterior; AL: anterolateral.</div><div class=\"graphic_reference\">Courtesy Yuchi Han, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 94980 Version 1.0</div></div></div>"},"94981":{"type":"graphic_waveform","displayName":"Early deceleration","title":"Early deceleration","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Early deceleration</div><div class=\"cntnt\"><img style=\"width:730px; height:194px;\" src=\"images/OBGYN/94981_Earlydeceleration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early decelerations are uniform, mirror the contractions, and decelerate only 10 to 20 beats per minute.</div><div class=\"graphic_reference\">Reproduced with permission from: Freeman RK, Garite TJ, Nageotte MP, Miller LA. Basic Pattern Recognition. In: Fetal Heart Rate Monitoring. Lippincott, Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 94981 Version 4.0</div></div></div>"},"94985":{"type":"graphic_diagnosticimage","displayName":"CT of hepatic sarcoid","title":"Computed tomography of hepatic sarcoid","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Computed tomography of hepatic sarcoid</div><div class=\"cntnt\"><img style=\"width:588px; height:419px;\" src=\"images/PULM/94985_CT_hepatic_sarcoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with hepatic sarcoidosis, computed tomography (CT) of the liver demonstrates multiple hypodense, irregular nodules of varying size.</div><div class=\"graphic_reference\">Reproduced with permission from: Koyama T, Ueda H, Togashi K, et al. Radiologic manifestations of sarcoidosis in various organs. Radiographics 2004; 24:87. Copyright &copy; 2004 Radiological Society of North America (RSNA).</div><div id=\"graphicVersion\">Graphic 94985 Version 2.0</div></div></div>"},"94989":{"type":"graphic_table","displayName":"Alarm signs suggesting organic cause of constipation","title":"Alarm signs or physical findings that suggest an organic cause of constipation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alarm signs or physical findings that suggest an organic cause of constipation in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Symptoms or history</td> </tr> <tr> <td class=\"subtitle2_single\">Acute signs</td> </tr> <tr> <td class=\"indent1\">Delayed passage of meconium (after 48 hours of life)</td> </tr> <tr> <td class=\"indent1\">Fever, vomiting, or diarrhea</td> </tr> <tr> <td class=\"indent1\">Rectal bleeding (unless attributable to an anal fissure)</td> </tr> <tr> <td class=\"indent1\">Severe abdominal distension</td> </tr> <tr> <td class=\"subtitle2_single\">Chronic signs</td> </tr> <tr> <td class=\"indent1\">Constipation present from birth or early infancy</td> </tr> <tr> <td class=\"indent1\">Ribbon stools (very narrow in diameter)</td> </tr> <tr> <td class=\"indent1\">Urinary incontinence or bladder disease</td> </tr> <tr> <td class=\"indent1\">Weight loss or poor weight gain</td> </tr> <tr> <td class=\"indent1\">Delayed growth (eg, decreasing height percentiles)</td> </tr> <tr> <td class=\"indent1\">Extraintestinal symptoms (especially neurologic deficits)</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies or syndrome associated with Hirschsprung disease (eg, Down syndrome)</td> </tr> <tr> <td class=\"indent1\">Family history of Hirschsprung disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Physical findings</td> </tr> <tr> <td class=\"indent1\">Severe abdominal distension</td> </tr> <tr> <td class=\"indent1\">Pelvic mass (eg, sacral teratoma)</td> </tr> <tr> <td class=\"indent1\">Lower spine abnormalities</td> </tr> <tr> <td class=\"indent1\">Lumbosacral dimple, hair tuft or lipoma, or deviation of the gluteal cleft</td> </tr> <tr> <td class=\"indent1\">Anal scars</td> </tr> <tr> <td class=\"indent1\">Anteriorly displaced anus</td> </tr> <tr> <td class=\"indent1\">Patulous anus</td> </tr> <tr> <td class=\"indent1\">Perianal fistula</td> </tr> <tr> <td class=\"indent1\">Tight anal canal with empty rectum</td> </tr> <tr> <td class=\"indent1\">Explosive expulsion of stool after digital examination of the rectum</td> </tr> <tr> <td class=\"indent1\">Absent anal wink</td> </tr> <tr> <td class=\"indent1\">Absent cremasteric reflex</td> </tr> <tr> <td class=\"indent1\">Decreased lower extremity tone or strength</td> </tr> <tr> <td class=\"indent1\">Abnormal lower extremity deep tendon reflex: absence of delay in relaxation phase</td> </tr> <tr> <td class=\"indent1\">Abnormal thyroid gland</td> </tr> <tr> <td class=\"indent1\">Extreme fear during the anal inspection</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Based on information in Tabbers MM, Dilorenzo C, Berger MY, et al. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:265.</div><div id=\"graphicVersion\">Graphic 94989 Version 3.0</div></div></div>"},"94990":{"type":"graphic_picture","displayName":"Nevus of Ito","title":"Nevus of Ito","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nevus of Ito</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/DERM/94990_NevusIto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus of Ito presenting as a blue-gray patch on the scapular area. Note the mottled appearance of the pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94990 Version 1.0</div></div></div>"},"94991":{"type":"graphic_figure","displayName":"Efficacy of 5-grass sublingual tablet","title":"Efficacy of 5-grass sublingual tablet","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Efficacy of 5-grass sublingual tablet</div><div class=\"cntnt\"><img style=\"width:714px; height:728px;\" src=\"images/ALLRG/94991_5_grass_SLIT_efficacy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Mean daily&nbsp;combined score&nbsp;and pollen count. (B) Daily&nbsp;combined score&nbsp;(least-squares&nbsp;mean ± standard error) overall and in subgroups based on Timothy grass-specific serum IgE at baseline. The number of participants per group is displayed in each bar. NOTE: IgE data were not obtained for&nbsp;one placebo-treated subject.</div><div class=\"graphic_footnotes\">IR: index of reactivity; IgE: immunoglobulin E; D0: day&nbsp;0 (first day of pollen period).<br />* p&lt;0.001 versus placebo.</div><div class=\"graphic_reference\"><FONT size=2>Reproduced from: Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012; 130:1327. Illustration used with the permission of Elsevier Inc. All rights reserved.</FONT></div><div id=\"graphicVersion\">Graphic 94991 Version 3.0</div></div></div>"},"94992":{"type":"graphic_figure","displayName":"Efficacy of ragweed sublingual tablet","title":"Efficacy of ragweed sublingual tablet","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Efficacy of ragweed sublingual tablet</div><div class=\"cntnt\"><img style=\"width:713px; height:732px;\" src=\"images/ALLRG/94992_Ragweed_SLIT_efficacy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) TCS plotted against pollen count (averaged across all regions). A lower TCS corresponds to fewer symptoms and less need for medications.<br />(B) TCS.</div><div class=\"graphic_footnotes\">TCS: total combined score; RS: ragweed season.</div><div class=\"graphic_reference\">Reproduced from: Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North America and European adults. J Allergy Clin Immunol 2013; 131:1342. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 94992 Version 2.0</div></div></div>"},"94993":{"type":"graphic_picture","displayName":"Nevus of Ota 2","title":"Nevus of Ota","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevus of Ota</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/94993_NevusOta2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A mottled, gray-blue patch involving the skin, conjunctiva, and sclera in the areas innervated by the first and second divisions of the trigeminal nerve in a patient with nevus of Ota.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 94993 Version 1.0</div></div></div>"},"94994":{"type":"graphic_picture","displayName":"Dyschromatosis symmetrica hereditaria 2","title":"Dyschromatosis symmetrica hereditaria","html":"<div class=\"graphic\"><div style=\"width: 755px\" class=\"figure\"><div class=\"ttl\">Dyschromatosis symmetrica hereditaria</div><div class=\"cntnt\"><img style=\"width:735px; height:861px;\" src=\"images/DERM/94994_Dyschrmtssymmtrchrdtr2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented and hypopigmented macules on the back of hands and feet of patients with dyschromatosis symmetrica hereditaria.</div><div class=\"graphic_reference\">From: Yuan C, Liu H, Fu X, et al. Two novel mutations of the ADAR1 gene in Chinese patients with dyschromatosis symmetrica hereditaria. Indian J Dermatol Venereol Leprol 2012; 78:746. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=6;spage=746;epage=748;aulast=Yuan\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.102375</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2012 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94994 Version 2.0</div></div></div>"},"94996":{"type":"graphic_picture","displayName":"Amyloidosis cutis dyschromica","title":"Amyloidosis cutis dyschromica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloidosis cutis dyschromica</div><div class=\"cntnt\"><img style=\"width:432px; height:249px;\" src=\"images/DERM/94996_Amyloidosiscutisdyschromc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hypopigmented and depigmented macules are visible on the upper back of a 26-year-old woman with amyloidosis cutis dyschromica.</div><div class=\"graphic_reference\">From: Kurian SS, Rai R, Madhukar ST. Amyloidosis cutis dyschromica. Indian Dermatol Online J 2013; 4:344. DOI: <a href=\"http://www.idoj.in/article.asp?issn=2229-5178;year=2013;volume=4;issue=4;spage=344;epage=346;aulast=Kurian\" target=\"_blank\">10.4103/2229-5178.120678</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2013 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 94996 Version 2.0</div></div></div>"},"94998":{"type":"graphic_table","displayName":"Causes of constipation in children","title":"Causes of constipation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of constipation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiologic causes of constipation</td> </tr> <tr> <td class=\"indent1\">Functional constipation* (may have dietary or behavioral triggers, exacerbated by painful defecation and stool withholding)</td> </tr> <tr> <td class=\"indent1\">Cow's milk or other dietary protein intolerance*</td> </tr> <tr> <td class=\"indent1\">Low dietary fiber*</td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Slow transit constipation</span>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Inadequate fluid intake (fever, hot weather)</td> </tr> <tr> <td class=\"indent1\">Immobility</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa</td> </tr> <tr> <td class=\"indent1\">Starvation</td> </tr> <tr> <td class=\"subtitle1_single\">Neurogenic causes</td> </tr> <tr> <td class=\"indent1\">Hirschsprung disease<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Cerebral palsy</td> </tr> <tr> <td class=\"indent1\">Myelomeningocele</td> </tr> <tr> <td class=\"indent1\">Spinal cord injury</td> </tr> <tr> <td class=\"indent1\">Closed spinal dysraphism<sup>&#182;</sup><sup>&#9674;</sup> (eg, tethered cord, sacral agenesis, split spinal cord malformation [diastematomyelia])</td> </tr> <tr> <td class=\"indent1\">Sacral teratoma<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Neurofibromatosis</td> </tr> <tr> <td class=\"indent1\">Muscular weakness (may be generalized, as in Down syndrome, or due to abnormal abdominal musculature,<sup>&#916;</sup> as in prune belly syndrome or gastroschisis)</td> </tr> <tr> <td class=\"indent1\">Infantile botulism<sup>&#182;</sup><sup>&#916;</sup> (constipation an early complaint, facial and ocular palsies, poor suck and hypotonia are other features)</td> </tr> <tr> <td class=\"indent1\">Pseudoobstruction (eg, visceral neuropathies, myopathies, mitochondrial disorders)</td> </tr> <tr> <td class=\"indent1\">Intestinal neuronal dysplasia</td> </tr> <tr> <td class=\"indent1\">Familial or acquired dysautonomia</td> </tr> <tr> <td class=\"indent1\">Duchenne muscular dystrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine and metabolic causes</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis<sup>&#182;</sup> (with meconium ileus in neonates,<sup>&#916;</sup> or distal intestinal obstruction syndrome in older children)</td> </tr> <tr> <td class=\"indent1\">Hypokalemia</td> </tr> <tr> <td class=\"indent1\">Lead poisoning<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Vitamin D intoxication</td> </tr> <tr> <td class=\"indent1\">Hypo- or hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">Multiple endocrine neoplasia type 2B (MEN2B)</td> </tr> <tr> <td class=\"indent1\">Polyuria (leading to dehydration)</td> </tr> <tr> <td class=\"indent1\">Juvenile systemic sclerosis (scleroderma) or mixed connective tissue disease</td> </tr> <tr> <td class=\"indent1\">Acute intermittent porphyria</td> </tr> <tr> <td class=\"subtitle1_single\">Anatomic causes</td> </tr> <tr> <td class=\"indent1\">Anorectal anomalies (imperforate anus,<sup>&#916;</sup> anteriorly displaced anus)</td> </tr> <tr> <td class=\"indent1\">Intestinal obstruction<sup>&#182;</sup> (in neonates, consider atresia, webs or volvulus)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Small left colon syndrome<sup>&#916;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Other causes</td> </tr> <tr> <td class=\"indent1\">Celiac disease*</td> </tr> <tr> <td class=\"indent1\">Drugs (opiates, anticholinergics, antidepressants, chemotherapy, aluminum containing antacids)</td> </tr> <tr> <td class=\"indent1\">Generalized joint hypermobility&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Relatively common cause.<br />¶ Prompt diagnosis is important to the outcome.<br />Δ Generally presents during infancy.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topic reviews on closed spinal dysraphism (spina bifida occulta).<br />§ Similar findings may occur in infants with Hirschsprung disease.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.</LI>&#xD;&#xA;<LI>Tabbers MM, Dilorenzo C, Berger MY, et al. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:265.</LI>&#xD;&#xA;<LI>Kajbafzadeh AM, Sharifi-Rad L, Seyedian SS, et al. Generalized joint hypermobility and voiding dysfunction in children: is there any relationship? Eur J Pediatr 2014; 173:197.</LI>&#xD;&#xA;<LI>Kraus D, Wong BL, Horn PS, Kaul A. Constipation in Duchenne Muscular Dystrophy: Prevalence, Diagnosis, and Treatment. J Pediatr 2016; 171:183.</LI></OL></div><div id=\"graphicVersion\">Graphic 94998 Version 5.0</div></div></div>"}};